Document:

Collaboration Agreement, dated October 29, 2004

 EXHIBIT 10.1 
 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
 COLLABORATION AGREEMENT 
 This
COLLABORATION AGREEMENT (the “Agreement”), having a date of October 29, 2004 (the “Effective Date”), is made by and between, on the one hand, F. HOFFMANN-LA ROCHE LTD, a Swiss corporation, having its principal place of
business at Grenzacherstrasse 124, CH-4070, Basel, Switzerland and HOFFMANN-LA ROCHE INC., a New Jersey corporation, having its principal place of business at 340 Kingsland Street, Nutley, New Jersey 07110 (collectively “Roche”) and, on
the other hand, PHARMASSET, INC., a Delaware corporation, having its principal place of business at 1860 Montreal Road, Tucker, Georgia 30084 (“Pharmasset”). 
 RECITALS 
 WHEREAS, Pharmasset has a discovery and development program relating to
2’-fluoronucleoside compounds, and owns related intellectual property rights; 
 WHEREAS, Roche has expertise in the research,
development, manufacture and commercialization of pharmaceutical products; 
 WHEREAS, Roche desires to secure rights to further develop and
commercialize products developed and to be developed pursuant to the Collaboration (as defined below); 
 NOW THEREFORE, in consideration of
the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Pharmasset and Roche agree as follows: 
 ARTICLE 1. DEFINITIONS 
 As used in
this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 
  

	1.1	“Affiliate” means (a) a business entity which owns, directly or indirectly, more than fifty percent (50%) of the voting shares or other means of control of a
Party; or (b) a business entity in which more than fifty percent (50%) of the voting shares or other means of control are owned by a Party, either directly or indirectly; or (c) a business entity, the majority ownership of which is
directly or indirectly common to the majority ownership of a Party. Anything to the contrary in this paragraph notwithstanding, [***], a [***] corporation (“[***]”), and [***], a [***] corporation (“[***]”), shall not be deemed
an Affiliate of Roche until the existing [***] agreements pursuant to which Roche has relinquished [***] rights in [***] and [***], respectively, expire or are earlier terminated or otherwise are in relevant part no longer of force or effect or
earlier if Roche provides written notice to Pharmasset of its intent to have [***] and/or [***] treated as an Affiliate under this Agreement. 

  

 1 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	1.2	“Agreement Term” means the term of this Agreement, as more fully described in Section 17.1. 

  

	1.3	“API” means active pharmaceutical ingredient. 

  

	1.4	“Bundled Product” means Product(s) sold to a Third Party for use with one or more other products or services, wherein the Product(s) and the other product or services are
sold for one unit price, even though packaged separately. 

  

	1.5	“Claim” shall have the meaning given in Section 19.1(a). 

  

	1.6	“CMC Derisking Activities” shall have the meaning given in Schedule 8. 

  

	1.7	“CMC Subcommittee” shall have the meaning given in Section 8.1(e). 

  

	1.8	“Collaboration” means discovery and development by the Parties of Primary Compounds and Potential Licensed Compounds during the Collaboration Period, and thereafter
development and commercialization of Licensed Compounds by Roche and Pharmasset, in each case pursuant to this Agreement. 

  

	1.9	“Collaboration Period” means the period of time commencing January 1, 2005 and ending [***], unless extended by Roche as per Section 4.4.

  

	1.10	“Combination Product” means any co-formulated product containing both a pharmaceutically active agent that causes it to be considered a Product and one or more other
pharmaceutically active agents that are not Licensed Compounds. 

  

	1.11	“Compound Claim” shall mean, for a given Product, a claim in a Pharmasset Patent Right, Joint Patent Right or Roche Patent Right Covering the molecule per se of a Licensed
Compound that is contained, in whole or as a component thereof, as an active ingredient of such Product. 

  

	1.12	“Control” or “Controlled” means, with respect to any intellectual property right, possession by a Party of the ability (whether by ownership, license or
otherwise) to grant access, a license or a sublicense to such intellectual property right without violating the terms of any agreement or other arrangement with any Third Party. 

  

	1.13	“Cost of Goods” means the manufacturing cost of either (a) [***], or (b) [***] made from [***], as the case may be, calculated in accordance with [***] methods
[***] applied by [***] for [***], provided that such methods (x) in the case of Roche, comply with [***] and consistent with [***], and (y) in the case of Pharmasset, comply with [***]. Cost of Goods shall include direct labor (including [***]),
direct materials (including [***] and [***]), and a [***] allocation of [***] and [***], [***] expense (including [***] costs and [***] of [***], [***] and [***]), [***] costs and other costs allocable to the [***]. Notwithstanding the foregoing, in
the event that (a) [***], or (b) [***] made from [***], as the case may be, is manufactured by a Third Party supplier, the “Cost of Goods” shall be the [***] for [***] by [***] to [***]. For clarity, the “Cost of Goods” shall be
the [***] of [***] of such goods [***] or [***] of such goods [***], and shall not be the [***] of such goods between or among [***]. 

  

	1.14	 “Cover” (including the variations such as “Covered”, “Coverage” or “Covering”) means that the selling of a given compound or
product would infringe a Patent Right (including pending claims that, if issued, would be infringed so long as the pendency of the patent application and any parent applications to which such patent application claim priority have not been pending
for more than ten (10)

  

 2 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
years) in the absence of a license under such Patent Right. The determination of whether a compound or product is Covered by a particular Patent Right shall
be made on a country-by-country basis. 

  

	1.15	“Development Plan” means the plan of development for a Licensed Compound developed by the Parties, outlining the global development of such Licensed Compound through
Regulatory Approval. The initial Development Plan for the Primary Compound is attached as Schedule 1. The Parties may amend each Development Plan from time to time through the Joint Development and Marketing Committee in accordance with
Section 9.3. 

  

	1.16	“Dispute” shall have the meaning given in Section 18.2. 

  

	1.17	“Effective Date” shall have the meaning given in the first paragraph hereof. 

  

	1.18	“End of Phase 1” means, for a given Potential Licensed Compound, the completion of all the criteria listed in Schedule 5 during the Collaboration Period.

  

	1.19	“EU MAA Filing” means an application for marketing authorization filed in any country in the European Union or Switzerland for a given Product. 

 

	1.20	“European Approval” means all Regulatory Approvals necessary for selling and marketing a Product in an European Major Market Country. 

  

	1.21	“European Major Market Country” means [***], or [***]. 

  

	1.22	“European Union” means the countries comprising the European Union as of the Effective Date. 

  

	1.23	“Executives” shall have the meaning given in Section 8.1(c). 

  

	1.24	“Expiration Date” shall have the meaning given in Section 17.1. 

  

	1.25	“FDA” means the US Food and Drug Administration. 

  

	1.26	“Field” means human healthcare for all indications, including the HCV Indication. 

  

	1.27	“GLP Tox Completion” means, for a given Potential Licensed Compound, the transmittal to Roche of all of the data from all of the studies and activities criteria listed in
Schedule 4, in the form of a final report, including statistical analysis of such data. 

  

	1.28	“HCV Indication” means treatment or prevention of hepatitis C virus infection in humans. 

  

	1.29	 “HCV Target Screening Patent License” means any license to a Patent Right Covering an assay, technology platform or research tool for screening drug

  

 3 

	 	 
candidates that inhibit HCV polymerase, but shall not include any Pre-existing Pharmasset Third Party License. 

  

	1.30	“IND” means an Investigational New Drug Application filed with the FDA, or the foreign equivalent, for human clinical testing of a drug. 

  

	1.31	“Initiation of Phase 1” means the date that a patient is first dosed with a Product in a Phase 1 clinical trial. 

  

	1.32	“Initiation of Phase 2” means the date that a patient is first dosed with a Product in a Phase 2 clinical trial whose interim assessment, as decided by the Joint
Development and Marketing Committee, will be used to support a Phase 3 clinical trial. 

  

	1.33	“Initiation of Phase 3” means the date that a patient is first dosed with a Product in a Phase 3 clinical trial. In the event a Phase 2 clinical trial and a Phase 3
clinical trial constitute component parts of a combined trial, “Initiation of Phase 3” means the formal commencement date pursuant to the applicable protocol of the Phase 3 clinical trial component part. 

  

	1.34	“Japan Approval” means all Regulatory Approvals necessary for selling and marketing a Product in Japan. 

  

	1.35	“Japan NDA Filing” means an application for marketing authorization filed in Japan for a given Product. 

  

	1.36	“JDMC” shall have the meaning given in Section 8.1. 

  

	1.37	“Joint Inventions shall have the meaning given in Section 14.1(a). 

  

	1.38	“Joint Patent Rights” shall have the meaning given in Section 14.1(c). 

  

	1.39	“JRC” shall have the meaning given in Section 8.2. 

  

	1.40	“Know-How” means data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical data,
assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or commercialization of Licensed Compounds or Products. 

  

	1.41	“Launch” means, with respect to a Product in a country, the date of the first commercial sale to a Third Party of the given Product following Regulatory Approval in the
given country. 

  

	1.42	“Licensed Collaboration Compound” means a Licensed Compound other than a Primary Compound. 

  

 4 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	1.43	“Licensed Compound” means Primary Compound, and if Roche exercises its Option for a given Potential Licensed Compound, then also the given Potential Licensed Compound and
its pro-drugs. 

  

	1.44	“Major Market Countries” means the [***] and any European Major Market Country. 

  

	1.45	“Option” shall have the meaning given in Section 2.1(c). 

  

	1.46	“Option Exercise Period” means the period commencing on the Effective Date and ending ninety (90) days after the end of the Collaboration Period.

  

	1.47	“Party” means Roche or Pharmasset, and “Parties” means Roche and Pharmasset. 

  

	1.48	“Patent” means any patent or patent application, in any country, including any patents issuing on such patent application, and further including any substitution,
extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuation-in-part of any of the foregoing and any independently patentable improvements to any of the foregoing.

  

	1.49	“Patent Rights” means all rights under any Patent. 

  

	1.50	“Pharmasset Adjusted Gross Sales” means the amount of gross sales of the Product [***] by [***] and [***] to [***] less [***] consistent in all respects with [***], [***]
with respect to [***] (if not previously [***] the amount [***]), of (i) [***] and [***] (including [***] for [***], [***], [***], [***], [***] Product [***], [***] and [***]), (ii) [***] ([***] to [***] and [***] and similar types of [***] e.g.,
[***]), (iii) [***] and [***] ([***]) [***], (iv) [***] and [***], and (v) [***] ([***] or [***], [***] and other [***] linked to the [***] amount), [***] and [***] will be adjusted for actual [***] and [***]. For avoidance of doubt, the cost of
[***] to [***] at [***] charge shall not be [***] from [***]. The calculation for Pharmasset Adjusted Gross Sales shall be consistently applied and made in accordance with financial and accounting standards used by Pharmasset in preparing its
audited financial statements. 

  

	1.51	“Pharmasset Indemnified Parties” shall have the meaning given in Section 19.1(a). 

  

	1.52	“Pharmasset Inventions” shall have the meaning given in Section 14.1(b). 

  

	1.53	“Pharmasset Know-How” means all Know-How that Pharmasset owns, or otherwise has the right to grant rights to use, during the Agreement Term. 

  

	1.54	“Pharmasset Net Sales” means Pharmasset Adjusted Gross Sales [***] of [***] on a [***] (e.g. [***]). The calculation for Pharmasset Net Sales shall be consistently applied
and made in accordance with financial and accounting standards used by Pharmasset in preparing its audited financial statements. 

  

	1.55	“Pharmasset Patents” means Patents included in the Pharmasset Patent Rights. 

  

	1.56	“Pharmasset Patent Rights” means all Patent Rights that are necessary or useful for the discovery, manufacture, development or commercialization of Licensed Compounds or
Products, that Pharmasset owns or otherwise Controls, and has the right to grant rights under, during the Agreement Term, including without limitation, those Patent Rights arising from Pharmasset Inventions. 

  

 5 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	1.57	“Pharmasset Territory” means Latin America (i.e., Mexico, the Caribbean, and Central and South America) and the Korean peninsula (i.e., North Korea and South Korea).

  

	1.58	“Phase 1” means the first phase of human clinical trials of a drug required by the FDA or other equivalent regulatory authority to gain evidence of safety in enrollees, as
described in 21 C.F.R. Part 312, as it may be amended. 

  

	1.59	“Phase 2” means the second phase of human clinical trials of a drug required by the FDA or other equivalent regulatory authority to gain evidence of efficacy in the target
population, determine optimal dosage, and obtain expanded evidence of safety for Product(s), as described in 21 C.F.R. Part 312, as it may be amended. 

  

	1.60	“Phase 3” means the third phase of human clinical trials of a drug required by the FDA or other equivalent regulatory authority to gain evidence of efficacy in the target
population and obtain expanded evidence of safety for Product(s), as described in 21 C.F.R. Part 312, as it may be amended. 

  

	1.61	“POC Study” means a [***] Phase 1 study designed to show clinical proof of concept in a multiple-ascending-dose study. 

  

	1.62	“Potential Licensed Compound” means any [***] (excluding any [***]) owned or Controlled by Pharmasset, other than a Primary Compound, which has been screened for HCV
polymerase inhibition and has been shown to have activity against HCV polymerase, in accordance with Schedule 1.62. Potential Licensed Compound shall not include Gemcitibine or derivatives or pro-drugs thereof. For clarity, no [***] shall, at any
time [***], be deemed [***]. 

  

	1.63	“Pre-Existing Pharmasset Third Party Licenses” means the Third-Party licenses obtained by Pharmasset on or before the Effective Date of this Agreement listed in Schedule
7A hereto. 

  

	1.64	“Pre-Existing Roche Third Party Licenses” means the Third-Party licenses obtained by Roche on or before the Effective Date of this Agreement listed in Schedule 7B hereto.

  

	1.65	“Primary Compound” means the compound known as PSI-6130 and its pro-drugs. 

  

	1.66	“Primary Product” means any and all products that include, in whole or as a component thereof, Primary Compound. 

  

	1.67	“Product” means any and all products that include, in whole or as a component thereof, Licensed Compound or Licensed Collaboration Compound. 

  

	1.68	 “Reasonable Diligence” means the [***] standard of effort as used by such Party, or in [***] case [***] then [***] in the [***] for [***], for the
activities to be undertaken pursuant to this Agreement for a [***] of [***] and [***]. It is understood that such [***] may change from time to time based upon changing [***] and [***], as measured as of the time of [***]. The Parties acknowledge
that [***] and [***] do not always [***] to [***] in [***] or [***] to [***] in [***] for [***] or [***] that has [***]. 

  

 6 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
Whether [***] has exercised Reasonable Diligence (i) with respect to any [***] is to be determined by judging [***]’s efforts in such [***] on a
[***] basis, and (ii) with respect to any [***] other than the [***] is to be determined by judging [***]’s efforts in [***] ([***]) [***]. 

  

	1.69	“Regulatory Approval” means any approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations of any national or international or
local regulatory authority, department, bureau or other governmental entity, necessary for the manufacture, marketing and sale of a Product in a regulatory jurisdiction in the Territory. 

  

	1.70	“Relinquished Compound” means a Potential Licensed Compound for which Roche has relinquished rights in accordance with Sections 2.1(h), 4.2(a)(iii) or 4.2(b)(ii).

  

	1.71	“Relinquished Product” shall have the meaning given in Section 2.1(h). 

  

	1.72	“Research Plan” means the plan of research attached as Schedule 2, developed by the Parties, outlining the work expected to be performed with respect to a Potential
Licensed Compound or a pro-drug of the Primary Compound as part of the Collaboration, as such plan may be updated from time to time as provided in this Agreement. 

  

	1.73	“Rights” shall have the meaning given in Section 2.1(h). 

  

	1.74	“Roche Adjusted Gross Sales” means the amount of gross sales of the Product [***] by [***] and [***] to [***] less [***] consistent in all respects with [***], [***] with
respect to [***] (if not previously [***] the amount [***]), of (i) [***] and [***] (including [***] for [***] Product [***] and [***]), (ii) [***] ([***] to [***] and [***] and similar types of [***] e.g., [***]), (iii) [***] ([***]) [***], (iv)
[***] and [***], and (v) [***] ([***] and other [***] linked to the [***]), [***] and [***] will be adjusted for [***] and [***]. For avoidance of doubt, the cost of [***] to [***] shall not be [***] from [***]. The calculation for Roche Adjusted
Gross Sales shall be [***] and made in accordance with [***] used by [***] in [***]. 

  

	1.75	“Roche Indemnified Parties” shall have the meaning given in Section 19.1(b). 

  

	1.76	“Roche Inventions” shall have the meaning given in Section 14.1(a). 

  

	1.77	“Roche Know-How” means all Know-How that Roche owns, or otherwise has the right to grant rights to use, during the Agreement Term. 

  

	1.78	“Roche Net Sales” means Roche Adjusted Gross Sales [***] a [***] of (i) [***] ([***]) of [***] with respect to the [***], or (ii) [***] ([***]) of [***] with
respect to [***] of the [***], in each case in lieu of those [***] which Roche [***] on a [***] basis (e.g. [***], and [***] at the time of [***]). The calculation for Roche Net Sales shall be [***] and made in [***] used by [***] in [***].

  

	1.79	“Roche Patents” means Patents included within the Roche Patent Rights. 

  

	1.80	 “Roche Patent Rights” means all Patent Rights that are necessary or useful for the discovery, manufacture, development or commercialization of Licensed
Compounds or Products, that Roche owns or otherwise Controls, and has the right 

  

 7 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
to grant rights under, during the Agreement Term, including without limitation, those Patent Rights arising from Roche Inventions.

  

	1.81	“Roche Territory” means all countries and territories in the world other than the Pharmasset Territory. 

  

	1.82	“Third Party” means a person or entity other than (i) Pharmasset or any of its Affiliates or (ii) Roche or any of its Affiliates. 

  

	1.83	“US” means the United States of America and its possessions and territories. 

  

	1.84	“US Launch” means Launch in the US. 

  

	1.85	“US NDA Filing” means a New Drug Application filed with the FDA for a Product. 

  

	1.86	“Valid Claim” means a claim in a Patent that Covers a Product and (i) has not been held permanently revoked, unenforceable or invalid by a final unappealable decision
of a court or government agency of competent jurisdiction over such claim, (ii) has not been admitted to be invalid or unenforceable through disclaimers, consent decrees or otherwise or (iii) in the case of a patent application, has not
been pending for more than [***] ([***]) years after the filing of its first priority application. 

  

	1.87	“Valid Compound Claim” means a Valid Claim that is a Compound Claim. 

 ARTICLE 2. GRANTS 
  

	2.1	License Grants; Option. 

  

	 	(a)	Subject to the terms and conditions of this Agreement, Pharmasset hereby grants to Roche, with respect to Primary Compound, an exclusive license, including the right to grant
sublicenses in accordance with Section 2.3, under the Pharmasset Patent Rights, and to use the Pharmasset Know-How, solely to make, use, offer for sale, sell and import such Products containing a Primary Compound in the Roche Territory.

  

	 	(b)	Subject to the terms and conditions of this Agreement, Roche hereby grants to Pharmasset, with respect to each Licensed Compound, an exclusive license, including the right to grant
sublicenses in accordance with Section 2.3, under the Roche Patent Rights, and to use the Roche Know-How, solely to make, use, offer for sale, sell and import Products containing such Licensed Compounds in the Pharmasset Territory.

  

	 	(c)	 Subject to the terms and conditions of this Agreement, commencing on the Effective Date and ending at the conclusion of the Option Exercise Period, Pharmasset
hereby grants to Roche, with respect to each Potential Licensed Compound, the right to exercise an option (“Option”) to obtain an exclusive license, including the right to grant sublicenses in 

  

 8 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
accordance with Section 2.3, under the Pharmasset Patent Rights, and to use the Pharmasset Know-How, in each case solely to make, use, offer for sale,
sell and import Products containing such Potential Licensed Compound in the Roche Territory. 

  

	 	(d)	If Roche has exercised its Option for a particular Potential Licensed Compound, then, subject to the terms and conditions of this Agreement, Roche shall thereby have, with respect
to such designated Potential Licensed Compound, an exclusive license, including the right to grant sublicenses in accordance with Section 2.3, under the Pharmasset Patent Rights, and to use the Pharmasset Know-How, in each case solely to make,
use, offer for sale, sell and import Products containing Potential Licensed Compound in the Roche Territory. 

  

	 	(e)	Notwithstanding anything else contained herein to the contrary, Pharmasset at all times reserves such rights in the Pharmasset Patents and the Pharmasset Know-How as is necessary to
allow Pharmasset to research and develop Potential Licensed Compounds, and manufacture Licensed Compounds and Products, anywhere in the world. 

  

	 	(f)	Roche may exercise its Option for a given Potential Licensed Compound by giving Pharmasset written notice to such effect prior to the conclusion of the Option Exercise
Period, and by (i) making payment to Pharmasset of either (A) the payment specified in Section 4.2(a)(i) or (B) the payment specified in Section 4.2(a)(ii), or (ii) taking such other actions to exercise its Option as
provided in Sections 3.1(d), 4.2(c), or 4.2(d). 

  

	 	(g)	Prior to [***] but after [***] has been [***], Pharmasset may, in writing, request that [***], which [***] shall be [***] to Pharmasset [***] no later than [***] ([***]) [***] after
[***] of Pharmasset’s request. 

  

	 	(h)	If Roche declines to exercise its Option pursuant to Section 2.1(c) for a given Potential Licensed Compound, either pursuant to Section 4.2, or in response to
Pharmasset’s request pursuant to Section 2.1(g), Roche shall relinquish its right to license that particular Potential Licensed Compound and any Products containing such Potential Licensed Compound as a Licensed Compound; and any such
relinquished Potential Licensed Compound shall be deemed a Relinquished Compound. During the [***] if Pharmasset wishes to [***], then the following procedures must be followed and the following conditions must be satisfied before Pharmasset may
[***]: 

  

	 	(i)	[***] shall, prior to [***] with any [***] with respect to the [***], deliver to [***] of [***] interest in [***] such a [***]; 

  

	 	(ii)	[***] shall not, unless [***] indicates otherwise in a written notice to [***] to the contrary, [***] in any [***] with any [***] with respect to the [***] for a period of [***]
([***]) [***] following [***] by [***] of the [***] referred to in Section [***]; 

  

	 	(iii)	If, on or before the expiration of such [***] ([***]) [***] period specified in Section 2.1(h)(ii), [***] provides to [***] written notice of [***]’s interest in [***] a [***]
to the [***], [***] and [***] shall [***], for a period not to exceed [***] ([***]) [***] from [***]’s receipt of the notice from [***], to [***] for the [***]. Nothing in this Section 2.1(h)(iii) shall require [***]; and

  

	 	(iv)	[***]. 

  

 9 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	2.2	Pharmasset’s Rights to Grant Licenses to Third Parties. Pharmasset shall not, without Roche’s prior written consent, grant a right or license to any Third Party,
under any Pharmasset Patent Right, in the Roche Territory, to make, use, offer for sale, sell or import any [***] (excluding any [***]) for an HCV Indication, except as otherwise provided in Section 2.1(h). Pharmasset may, without Roche’s
prior consent, grant a right or license to any Third Party under any Pharmasset Patent Right, to make, use, offer for sale, sell or import any [***], which is not a Licensed Compound or Potential Licensed Compound, for any other indication, except
as provided in Section 2.1(h). 

  

	2.3	Sublicense Rights. 

  

	 	(a)	Subject to the restriction set forth in Section 2.3(b) below, the rights and licenses granted to Roche shall include the right of Roche to grant sublicenses to its Affiliates
and Third Parties to make, use, offer for sale, sell or import Products in the Territory for use in the Field. If Roche grants such a sublicense, Roche shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the
Affiliate or Third Party sublicensee to the same extent as they apply to Roche for all purposes. Roche assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such Affiliate or Third Party
sublicensee and shall itself account to Pharmasset for all payments due under this Agreement by reason of such sublicense. 

  

	 	(b)	Notwithstanding Section 2.3(a), [***]. 

  

	2.4	Pharmasset Co-Promotion Right. Pharmasset shall have the right to co-promote any Product in the US, as specified in this Section 2.4. For purposes of this Agreement,
“co-promote” and “co-promotion” shall mean the marketing, promotion, detailing and advertisement of Product by or on behalf of Pharmasset, or any of its Affiliates, under the relevant Regulatory Approvals and the then existing
trademarks. “Co-promote” and “co-promotion” shall not mean the sale or distribution of a Product. Pharmasset may exercise its co-promotion right with regard to a Product by giving written notice thereof to Roche at any time
during the period commencing upon NDA Filing in the US for such Product and ending three (3) months following such date, provided that at the time of such exercise Pharmasset has an established sales force in the US directed to sales to HIV
treatment providers. Upon Pharmasset’s exercise of its co-promotion right, the Parties shall negotiate in good faith and enter into a written co-promotion agreement (the “Co-Promotion Agreement”) to be executed reasonably prior to the
anticipated first Launch of such Product. In addition to any other terms agreed to by the Parties, the Co-Promotion Agreement shall contain the terms set forth in Schedule 3 hereto. 

  

 10 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 ARTICLE 3. DILIGENCE 
  

	3.1	Diligence. 

  

	 	(a)	Pharmasset shall use Reasonable Diligence in proceeding with the discovery and development of the Potential Licensed Compounds, except that Pharmasset’s obligation hereunder
shall expire upon the expiration of the Option Exercise Period. 

  

	 	(b)	From and after (i) the Effective Date with regard to the Primary Compound, and (ii) the effective date of Roche’s exercise of its Option with regard to a given
Potential Licensed Compound, Roche shall use Reasonable Diligence in the development and commercialization of such Primary Compound (and Primary Products containing the Primary Compound), or Potential Licensed Compound (and Products containing such
Potential Licensed Compound), as the case may be, including [***]. 

  

	 	(c)	[***] shall [***], as applicable. 

  

	 	(d)	If Pharmasset fails to use Reasonable Diligence in the performance of GLP Tox Completion activities for a Potential Licensed Compound (unless the JRC determines that such activities
are not necessary for development of such Potential Licensed Compound), then Roche shall have the right to exercise its Option for such Potential Licensed Compound at no cost to Roche. If Roche fails to use Reasonable Diligence in the performance of
the Development Plan with respect to a Licensed Compound (including, in the case of early exercise of an Option, any remaining GLP Tox Completion activities to the extent that the JDMC determines that such activities are necessary for development of
such Potential Licensed Compound), then Pharmasset shall have the right to reversion of such Licensed Compound in accordance with the provisions of Section 17.4. 

  

	 	(e)	With respect to [***], if [***], prior to [***] in [***], ceases [***] to achieve [***] in such [***] for a period of [***] ([***]) [***], then [***] shall have the right of a [***]
of [***] to [***] in such [***] in accordance with Section [***]. With respect to each [***], if [***], after receiving [***] for a [***] in a [***], ceases [***] in [***] for a period of [***] ([***]) [***], then [***] shall have the right of a
[***] of [***] to such [***] in [***] in accordance with Section [***]. For clarity, this Section 3.1(e) does not apply, and [***] shall not have any [***] of [***], if the reason for [***] to [***] or [***] is attributable to a [***] or some other
[***] by a [***] that prevents [***] from continuing [***] or [***] activities. 

 ARTICLE 4. PAYMENTS TO PHARMASSET

  

	4.1	Research and Development Payments. 

  

	 	(a)	Within ten (10) business days after the Effective Date, Roche shall make a payment to Pharmasset of eight million dollars ($800,000,000) [***]. This upfront payment represents
reimbursement of Pharmasset’s research and development expenses relating to its HCV research program, which were incurred by Pharmasset prior to the Effective Date or, except with respect to payments otherwise contemplated by this Agreement to
be made to Pharmasset, are incurred by Pharmasset after the Effective Date through and including December 31, 2004. 

  

	 	(b)	During each year of the Collaboration Period, Roche shall make a payment of [***] dollars ($[***]), due and payable within fifteen (15) business days after the first day of
each calendar year (January 1) during the Collaboration Period, with the first such payment being due and payable by January 23, 2005. 

  

 11 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(c)	During each year of the Collaboration Period, Roche shall make aggregate payments totaling [***] dollars ($[***]), payable in four (4) equal quarterly installments of [***]
dollars ($[***]). Each installment is due and payable within fifteen (15) business days after the first day of each calendar quarter, with the first such payment being due and payable by January 23, 2005. 

  

	 	(d)	These installment payments set forth in Sections 4.1(b) and 4.1(c) are intended to partially reimburse Pharmasset’s internal FTE costs. 

  

	4.2	Option Exercise. 

  

	 	(a)	Within thirty (30) days after GLP Tox Completion for a given Potential Licensed Compound, provided another Product is also under development and/or commercialization at the
same time, Roche shall have the option of: 

  

	 	(i)	[***]; 

  

	 	(ii)	[***]; or 

  

	 	(iii)	[***] 

  

	 	(b)	If Roche makes the election provided for under Section 4.2(a)(ii) above, then upon the completion of the first clinical study to assess the multiple ascending dose in HCV
infected patients, provided that another Product is also under development and/or commercialization at the same time, Roche shall have the further option of: 

  

	 	(i)	[***]; or 

  

	 	(ii)	[***]. 

  

	 	(c)	Roche may exercise its Option for any given Potential Licensed Compound during the Collaboration Period and prior to GLP Tox Completion for such compound. If, at such time
(i) another Product is also under development and/or commercialization or (ii) there is no Product under development and/or commercialization but Roche has not met its diligence obligations under Article 3 with respect thereto, then
Roche’s exercise of its Option shall be on the terms and conditions set forth in Section 4.2(a). 

  

	 	(d)	If, at any time during the Collaboration Period, there is no Licensed Compound or Product then under development and/or commercialization but Roche has met its diligence obligations
under Article 3 with respect to such compound, then Roche may, upon written notice to Pharmasset, exercise its Option for the Potential Licensed Compound of Roche’s choice at no cost to Roche. After Roche exercises its Option, the designated
Potential Licensed Compound shall be deemed a Licensed Compound, and any products containing such compound shall be deemed Products. 

  

 12 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(e)	From and after the exercise of its Option with respect to a Potential Licensed Compound, Roche shall assume responsibility for all of the activities, costs and expenses related to
the further development and commercialization of the corresponding Licensed Compound and related Products. In the event that Roche exercises its Option earlier than GLP Tox Completion, Pharmasset shall have no responsibility for any GLP Tox
Completion activities that were not initiated prior to Roche’s exercise of its Option, and Roche shall assume such responsibility for the remaining GLP Tox Completion activities, to the extent that the JDMC determines that such activities are
necessary for development of such Potential Licensed Compound. For clarity, in the event that Roche does not exercise its Option at GLP Tox Completion, Pharmasset shall not be required to conduct further development of such Potential Licensed
Compound. 

  

	4.3	Development Event Fees. 

  

	 	(a)	Primary Compound. Roche shall pay to Pharmasset the following nonrefundable payments (shown in millions of US Dollars) upon the first occurrence of the following events for
the Primary Compound: 

  

			
	 Event
	  	Payment
	 Initiation of Phase 1 MAD/POC Study
	  	5.0
	 The earlier of (i) [***], or (ii) successful conclusion of the fourteen (14) day patient POC study for a Primary Compound (as defined in
Schedule 2B and agreed upon by the JDMC) or (iii) [***]
	  	7.5
	 [***]
	  	[***]

  

 13 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(b)	Licensed Compounds. Roche shall pay to Pharmasset the following nonrefundable payments (shown in [***] of US dollars) upon the first occurrence of the following events for
Licensed Compound: 

  

					
	 Event
	  	Payment for First
Achievement of
Event	  	Payment for Second
and Each Subsequent
Achievement of Event
	 [***]
	  	[***]	  	[***]

  

	 	(c)	Timing of Payments. Each payment in Section 4.3(a) and (b) shall be due and payable by Roche within fifteen (15) business days after the later of (i) the
occurrence of the applicable event and (ii) receipt by Roche of an invoice from Pharmasset for such amount. 

  

	 	(d)	Payment Occurrences. 

  

	 	(i)	Roche shall make each of the payments set forth in Section 4.3(a) only once for the first occurrence of each event, regardless of how many times such event may be subsequently
achieved. 

  

 14 

	 	(ii)	Roche shall make each of the payments set forth in the second column of Section 4.3(b) captioned “Payment for First Achievement of Event” only once for the first
occurrence of each event, regardless of how many times such event may be subsequently achieved for the same or another compound. Roche shall make each of the payments set forth in the third column of Section 4.3(b) captioned “Payment for
Second and Each Subsequent Achievement of Event” once for each of the second or any subsequent achievement(s) of such event, provided, however, that such payments shall be made only once per compound, regardless of how many times such event may
be subsequently achieved for the same compound (i.e., such payment shall be made multiple times for multiple compounds but only once per compound). Furthermore, Roche shall make the payments set forth in the third column of Section 4.3(b) only
if it has previously made the payment in the second column for the corresponding event for a different compound. 

  

	 	(iii)	In Section 4.3(b), if event 2 is achieved prior to achievement of event 1A or 1B for the same compound, then the corresponding payment for event 1A or 1B, as the case may be,
shall become due and payable upon the achievement of event 2 as if event 1A or 1B, as the case may be, had then been achieved. If any of events 3, 4 or 5 are achieved prior to achievement of event 2 for the same compound, then the corresponding
payment for event 2 shall become due and payable upon the achievement of event 3, 4 or 5 as if event 2 had then been achieved. Other than as described in this Section 4.3(d)(iii), the achievement of a later event shall not trigger the payment
corresponding to any earlier event. 

  

	 	(iv)	For clarity, Roche shall make the payment in the 3rd column of Section 4.3(b) for event 1B upon the first achievement of event 1B, which shall be triggered only in the event
there are at least two Licensed Compounds in development at that time. Also for clarity, Roche shall make the payment in the 3rd column of Section 4.3(b) for event 12 upon the first achievement of event 12, which shall be triggered only in the
event there is US Regulatory Approval for a Licensed Compound and a Licensed Collaboration Compound to be used in combination. 

  

 15 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(e)	Credits. If, during the Agreement Term, the development and/or commercialization of all Licensed Compounds have been terminated (other than for breach by Roche), then Roche
may, at its option and discretion, designate one Potential Licensed Compound to be a Licensed Collaboration Compound at no additional cost to Roche under the terms of Section 4.2(d). If Roche has already made the payment required under Sections
4.2(a) or 4.2(b) to exercise such Option (the “Option Exercise Fee”), then Roche may credit the Option Exercise Fee against any milestone payments for such Licensed Collaboration Compound owed to Pharmasset in the future.

  

	4.4	Payment for Extension of Collaboration Period. Roche shall have the right, but not the obligation, to extend the Collaboration Period as follows: 

  

	 	(a)	If Roche provides written notice to Pharmasset, no later than [***], of Roche’s election to have the Collaboration Period extended for an additional year, until [***], then the
Collaboration Period shall be so extended (“First Extension”), and Roche must then make the research funding payments specified in Sections 4.1(b) and 4.1(c) for such additional year under the terms and conditions set forth in
Section 4.1. 

  

	 	(b)	If Roche has elected to exercise its right to First Extension, then Roche shall have the further right, but not the obligation, to extend the Collaboration Period by another year.
Roche may exercise its right to such an extension by providing written notice to Pharmasset, no later than [***], of Roche’s election to have the Collaboration Period extended for an additional year, until [***] (“Second Extension”).
If the Collaboration Period is extended for a second year, Roche must then make the research funding payments specified in Sections 4.1(b) and 4.1(c) for such additional year under the terms and conditions set forth in Section 4.1.

 ARTICLE 5. ROYALTIES 
  

	5.1	Royalties to Pharmasset. Roche shall pay to Pharmasset the following royalty payments based on the Roche Net Sales for a given Product, which payments shall be subject to
adjustment as provided in this Article 5. 

  

	 	(a)	For any year in which annual Roche Net Sales of a Product is less than or equal to [***] dollars ($[***]), such royalty payments shall be calculated by multiplying the royalty rates
specified below by the incremental annual Roche Net Sales of such Product: 

  

			
	 Annual Roche Net Sales
	  	 Royalty Rate (%)

	(in [***] of US Dollars)	  	 
	[***]	  	[***]
	[***]	  	[***]

  

 16 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	  	For example, if in [***], the [***] shall be [***]. The [***] may be [***]. 

  

	 	(b)	For any [***] in which [***], [***] shall pay to [***]. 

  

	 	(c)	For any [***] in which [***], [***] shall pay to [***]. 

  

	 	(d)	Notwithstanding the above, commencing on the date that is the [***] ([***]) anniversary of the first commercial sale of Product in the Roche Territory, for any calendar year
(January through December) in which annual Roche Net Sales of a Product is less than or equal to [***] dollars ($[***]), such royalty payments shall be calculated by multiplying the percentages specified below by the incremental annual Roche Net
Sales of such Product: 

  

			
	 Annual Roche Net Sales
	  	 Royalty Rate (%)

	(in [***] of US Dollars)	  	 
	[***]	  	[***]
	[***]	  	[***]

  

	 	  	For example, if in [***], the [***] shall be [***]. The [***] may be [***]. 

  

	 	(e)	Term of Royalty Payments. Roche’s obligation to make royalty payments to Pharmasset under Section 5.1 with respect to a Product shall commence on the Launch of such
Product in any country of the Roche Territory. The Roche Net Sales in a given country shall be included for purposes of calculating royalties under Section 5.1 from such Launch date until the later of (a) expiration of the last to expire
Valid Compound Claim of a Patent Covering such Product in such country, or (b) [***] ([***]) years from the Launch of such Product in such country. 

  

	 	(f)	 Adjustments Related to Absence of Valid Claims. If there is no Valid Claim in a Pharmasset Patent, Roche Patent or any Patent contained in the Joint Patent
Rights, Covering the sale of a given Product in a country of the Roche Territory or if in a country, the only such Valid Claim Covers only a synthesis method and/or a manufacturing process, then Roche may calculate royalties in such country for such
Product for any time period in which there is no such Valid Claim (or in which the only 

  

 17 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
such Valid Claim Covers only a synthesis method and/or manufacturing process) as if Roche Net Sales were equal to [***] percent ([***]%) of the actual amount
of Roche Net Sales for that time period. 

  

	5.2	Royalty Reduction. 

  

	 	 (a)
	 Cost of Goods Protection. Commencing on January 1st after the first full year of Net Sales after the Launch of a Primary Product in the Roche Territory, if Pharmasset is the single source of API supply of such
Primary Product and if, in a given calendar year, Roche’s Cost of Goods for such Primary Product exceed [***] percent ([***]%) of Roche Net Sales for such Primary Product, Roche shall be entitled to deduct from its royalty payments to
Pharmasset [***] of the amount by which Roche’s Cost of Goods exceed such [***] percent ([***]%) threshold. For clarity, there shall be no royalty reduction by reason of Roche’s Cost of Goods (i) if Roche is the single source of API
supply of Primary Product, or (ii) on any Product that contains a Licensed Collaboration Compound. 

  

	 	(b)	Third Party Royalties. If Roche, based upon advice by independent legal counsel, determines in good faith that it is in the economic best interests of the Parties in the
Collaboration to obtain a license under Patent Rights of a Third Party for a Valid Compound Claim, then Roche may deduct from its royalty payments to Pharmasset in a given calendar year [***] of the amount of any royalty payment (other than any
royalty payment associated with Pre-Existing Roche Third Party Licenses) made by Roche to such Third Party in such calendar year for such license. If Roche, based upon advice by independent legal counsel, determines in good faith that it is in the
economic best interests of the Parties in the Collaboration to obtain a license under Patent Rights of a Third Party for a Valid Claim (other than one Covering a synthesis method and/or manufacturing process), then Roche may deduct from its royalty
payments to Pharmasset in a given calendar year [***] of the amount of any royalty payment (other than any royalty payment associated with Pre-Existing Roche Third Party Licenses) made by Roche to such Third Party in such calendar year for such
license. Any permitted royalty reduction shall be applied giving effect to any stacking credit or other allowance for a reduction in royalty payments by Roche to such Third Party. Notwithstanding the above, Roche shall be solely responsible for any
HCV Target Screening Patent License royalties. 

  

	 	(c)	 Floor on Royalty Reduction. In no event shall the reduction required by this Section 5.2 cause Roche’s royalty payments to Pharmasset for a given
Product in a given calendar year to be lower than [***] percent [***]% of Roche Net Sales of such Product. If any royalty reduction is not fully deducted in any calendar year because of the royalty floor, any remaining royalty reduction shall be
carried forward to the succeeding calendar year. At the end of the Term of this Agreement (i.e., upon 

  

 18 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
expiration of Roche’s royalty obligations), any unused carryforward royalty reductions shall be extinguished. 

  

	5.3	Royalties to Roche. Pharmasset shall pay to Roche the following royalty payments based on the Pharmasset Net Sales for a given Product, which payments shall be subject to
adjustment as provided in this Article 5. 

  

	 	(a)	For any year in which annual Pharmasset Net Sales of a Product is less than or equal to [***] dollars ($[***]), such royalty payments shall be calculated by multiplying the royalty
rates specified below by the incremental annual Pharmasset Net Sales of such Product: 

  

			
	 Annual Pharmasset Net Sales
	  	 Royalty Rate (%)

	(in [***] of US Dollars)	  	 
	[***]	  	[***]
	[***]	  	[***]

  

	 	  	For example, if in [***], the [***] shall be [***]. The [***] may be [***]. 

  

	 	(b)	For any [***] in which [***], [***] shall pay to [***]. 

  

	 	(c)	For any [***] in which [***], [***] shall pay to [***]. 

  

	 	(d)	Notwithstanding the above, commencing on the date that is the [***] ([***]) anniversary of the first commercial sale of Product in the Pharmasset Territory, for any calendar year
(January through December) in which annual Pharmasset Net Sales of a Product is less than or equal to [***] dollars ($[***]), such royalty payments shall be calculated by multiplying the percentages specified below by the incremental annual
Pharmasset Net Sales of such Product: 

  

			
	 Annual Pharmasset Net Sales
	  	 Royalty Rate (%)

	(in Millions of US Dollars)	  	 
	[***]	  	[***]
	[***]	  	[***]

  

	 	  	For example, if in [***], the [***] shall be [***]. The [***] may be [***]. 

  

	 	(e)	 Term of Royalty Payments. Pharmasset’s obligation to make royalty payments to Roche under this Section 5.3 with respect to a Product shall commence
on the Launch of such Product in any country of the 

  

 19 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
Pharmasset Territory. The Pharmasset Net Sales in a given country shall be included for purposes of calculating royalties under this Section 5.3 from
such Launch date until the later of (a) expiration of the last to expire Valid Compound Claim in a Patent Covering such Product in such country, or (b) [***] ([***]) years from the Launch of such Product in such country.

  

	 	(f)	Adjustments Related to Absence of Valid Claims. If there is no Valid Claim in a Pharmasset Patent, Roche Patent or in any Patent contained in the Joint Patent Rights,
Covering the sale of a given Product in a country of the Pharmasset Territory or if in a country the only such Valid Claim Covers only a synthesis method and/or a manufacturing process, then Pharmasset may calculate royalties in such country for
such Product for any time period in which there is no such Valid Claim (or in which the only such Valid Claim Covers only a synthesis method and/or manufacturing process) as if Pharmasset Net Sales were equal to [***] percent ([***]%) of the actual
amount of Pharmasset Net Sales for that time period. 

  

	 	(g)	Third Party Royalties. If Pharmasset, based on advice by independent legal counsel, determines in good faith that it is in the economic best interests of the Parties in the
Collaboration to obtain a license under Patent Rights of a Third Party for a Valid Compound Claim, then Pharmasset may deduct from its royalty payments to Roche in a given calendar year [***] of the amount of any royalty payment (other than any
royalty payment associated with Pre-Existing Pharmasset Third Party Licenses) made by Pharmasset to such Third Party in such calendar year for such license. If Pharmasset, based on advice by independent legal counsel, determines in good faith that
it is in the economic best interests of the Parties in the Collaboration to obtain a license under Patent Rights of a Third Party for a Valid Claim (other than one Covering a synthesis method or manufacturing process) in a country in the Pharmasset
Territory, then Pharmasset may deduct from its royalty payments to Roche in a given calendar year [***] of the amount of any royalty payment (other than any royalty payment associated with Pre-Existing Pharmasset Third Party Licenses) made by
Pharmasset to such Third Party in such calendar year for such license. Any permitted royalty reduction shall be applied giving effect to any stacking credit or other allowance for a reduction in royalty payments by Pharmasset to such Third Party.

  

	5.4	 Bundled Products. In the event that either Party or any of its Affiliates or sublicensees intends to sell a Bundled Product, the Parties shall meet
approximately one (1) year prior to the anticipated commercial launch of such Bundled Product to negotiate in good faith and agree to an appropriate adjustment to the calculation of Roche or Pharmasset Adjusted Gross Sales (whichever is
appropriate) (the “Adjusted Gross Sales”) to reflect the relative significance and 

  

 20 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
value (including consideration of relative market share, sales potential and price potential) of the Product and the other pharmaceutically active product(s)
bundled with the Product. If, after good faith negotiations (not to exceed [***] ([***]) [***]), the Parties [***] to an [***], the Adjusted Gross Sales for the Product shall be calculated by [***] of the [***], the [***] is the [***] value of the
[***] and the [***] is the [***] value in the [***] included in the [***]. If the Parties cannot agree to the [***] values for purposes of this provision, such disagreement shall be resolved in accordance with the [***]. The Parties agree that [***]
and [***] and [***] shall not, in the event [***] is [***] to a [***], [***] allocate such [***] to any [***] as a part of the [***]. 

  

	5.5	Combination Products. 

  

	 	(a)	Roche Sales. In the event Roche or any of its Affiliates or sublicensees sells a Combination Product,[***] shall equal [***] of the [***] a [***], the [***] the [***] (e.g.,
[***]) of the [***] and the [***] the [***] in the [***] of [***] in the [***]. 

  

	 	(b)	Pharmasset Sales. In the event Pharmasset or any of its Affiliates or sublicensees sells a Combination Product, [***] shall equal [***] of the [***] a [***], the [***] the
[***] (e.g., [***]) of the [***] and the [***] the [***] in the [***] of [***] in the [***]. 

 ARTICLE 6. COMMERCIALIZATION
PAYMENTS 
  

	6.1	Net Sales Event Payments. Roche shall pay to Pharmasset the following one-time payments for each Product, payable the first time the applicable sales threshold is met based
upon the annual Roche Net Sales for such Product. 

  

			
	 Annual Roche Net Sales
	  	 Payment

	(In [***] of US Dollars)	  	(In [***] of US Dollars)
	[***]	  	[***]
	[***]	  	[***]

  

	6.2	For clarity, if the [***] is made, without [***] having been made, then [***] shall make [***]. 

 ARTICLE 7. PAYMENT, REPORTING, AUDITING 
  

	7.1	Currency and Conversion. 

  

	 	(a)	Method and Currency of Payment. All payments under this Agreement are stated and shall be payable in US dollars by wire transfer to a bank in the United States designated in
writing by the party to which the payment is due. 

  

 21 

	 	(b)	Currency Conversion for Roche Net Sales. Whenever calculation of Roche Net Sales requires conversion from any foreign currency, Roche shall convert the monthly amount of
Roche Net Sales in such foreign currency into US dollars as computed in the central Roche currency conversion system, using the YTD average monthly rate of exchange at the time for such currencies as retrieved from the Reuters System used by Roche
(or some other source agreed upon by the Parties for any particular country) for each month of the reporting period. If convenient for Roche, such conversion may be made initially into Swiss Francs and then into U.S. Dollars for purposes of
calculating royalties, provided that Pharmasset is not disadvantaged by reason of such multiple conversions (e.g., that the conversion rates used by Roche do not reflect transaction costs of conversion). The currency conversion system used by Roche
shall be subject to audit by Pharmasset as described in Section 7.4 and, if it is determined that the conversion system does not reflect the fair market value of the currencies in question, the above currency conversion process shall be
modified as necessary to effect currency conversion at fair market value. 

  

	 	(c)	Roche Sublicensees. For sublicensees in a country, when calculating the Roche Net Sales, Roche shall require the sublicensee to report to Roche the amount of such sales
within thirty (30) days from the end of the reporting period. 

  

	 	(d)	Currency Conversion for Pharmasset Net Sales. Whenever calculation of Pharmasset Net Sales requires conversion from any foreign currency, Pharmasset shall convert the monthly
amount of Pharmasset Net Sales in such foreign currency into US dollars using the average rate of exchange using the average rate of exchange published in the Wall Street Journal (or some other source agreed upon by the Parties for any particular
country) for each month of the reporting period. 

  

	7.2	Payments. 

  

	 	(a)	After the Launch of a Product in any country of the Roche Territory: 

  

	 	(i)	Roche shall calculate royalty payments set forth in Article 5 and milestone payments set forth in Article 6 quarterly as of March 31, June 30, September 30
and December 31 (each being the last day of an accounting period). 

  

	 	(ii)	 Following the quarter ended December 31 in each year in which royalties are calculated on an annualized (i.e., not incremental) basis, Roche shall determine
the royalties due for the immediately preceding calendar year, and adjust the payment due to Pharmasset for the quarter ended December 31 

  

 22 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
by the amount necessary to make the aggregate payments made for the four quarters of such year equal the amount due for the entire year; provided, however,
that if [***] shall determine the [***]. 

  

	 	(iii)	Roche shall pay such payments quarterly within forty-five (45) days after the end of each reporting period in which Roche Net Sales occur during the Agreement Term.

  

	 	(b)	With each such payment under Section 7.2(a), Roche shall deliver to Pharmasset the following information, and methodology for its calculation, stated separately for the US and
the rest of the Roche Territory: 

  

	 	(i)	Roche Net Sales for each Product; and 

  

	 	(ii)	the royalty payments and milestone payments due to Pharmasset for such reporting period. 

  

	 	(c)	If [***] requests [***] thereto, [***] agrees to [***]. 

  

	 	(d)	After the Launch of a Product in any country of the Pharmasset Territory: 

  

	 	(i)	Pharmasset shall calculate royalty payments set forth in Article 5 and milestone payments set forth in Article 6 quarterly as of
March 31, June 30, September 30 and December 31 (each being the last day of an accounting period). 

  

	 	(ii)	Following the quarter ended December 31 in each year in which royalties are calculated on an annualized (i.e., not incremental) basis, Pharmasset shall determine the royalties
due for the immediately preceding calendar year, and adjust the payment due to Roche for the quarter ended December 31 by the amount necessary to make the aggregate payments made for the four quarters of such year equal the amount due for the
entire year; provided, however, that if [***] of a [***] shall determine [***], and [***] for such [***]. 

  

	 	(iii)	Pharmasset shall pay such payments quarterly within forty-five (45) days after the end of each reporting period in which Pharmasset Net Sales occur during the Agreement Term.

  

	 	(e)	With each such payment under Section 7.2(c), Pharmasset shall deliver to Roche the following information, and methodology for its calculation, stated for the Pharmasset
Territory: 

  

	 	(i)	Pharmasset Net Sales for each Product; and 

  

	 	(ii)	the royalty payments due to Roche for such reporting period. 

  

 23 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(f)	In the event that a Party (the “Payor”) does not pay to the other Party (the “Payee”) any amounts due under this Agreement within the applicable time period set
forth herein, such payment shall bear interest, to the extent permitted by applicable law, at an annual rate of interest equal to the average [***] calculated based on the number of [***] such a [***]. 

  

	7.3	Taxes. 

  

	 	(a)	If the laws or regulations of any country require withholding of taxes of any type, levies on Pharmasset or its Affiliates, or other charges against Pharmasset or its Affiliates
with respect to any amounts payable under this Agreement to Pharmasset, Roche shall promptly pay such tax, levy or charge for and on behalf of Pharmasset or its Affiliates to the proper governmental authority, and shall promptly furnish Pharmasset
with a receipt evidencing such payment. Roche shall have the right to deduct any such tax, levy or charge actually paid from payment due Pharmasset hereunder or to be promptly reimbursed by Pharmasset if no further payments are due Pharmasset
hereunder. 

  

	 	(b)	If the laws or regulations of any country require withholding of taxes of any type, levies on Roche or its Affiliates, or other charges against Roche or its Affiliates with respect
to any amounts payable under this Agreement to Roche, Pharmasset shall promptly pay such tax, levy or charge for and on behalf of Roche or its Affiliates to the proper governmental authority, and shall promptly furnish Roche with a receipt
evidencing such payment. Pharmasset shall have the right to deduct any such tax, levy or charge actually paid from payment due Roche hereunder or to be promptly reimbursed by Roche if no further payments are due Roche hereunder.

  

	 	(c)	Notwithstanding anything contained herein to the contrary, all amounts payable under this Collaboration Agreement are exclusive of any applicable value added tax or other sales
taxes (“VAT”). If a Party determines that it must account for VAT in respect of any payments made to it hereunder (the “Responsible Party”), it shall notify the other Party as soon as practicable, and the other Party shall, in
addition to the amounts payable by it hereunder, pay to the Responsible Party the amount of an such VAT within thirty (30) days of its receipt of proof of payment of such VAT by the Responsible Party. 

  

	 	(d)	Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in
force and in minimizing the amount required to be so withheld or deducted. 

  

 24 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	7.4	Accounting. 

  

	 	(a)	During the Agreement Term and for a period of three years thereafter, each Party shall, and shall cause its Affiliates and sublicensees to, maintain at their respective principal
places of business records and books of account containing all particulars that may be necessary for the purpose of calculating all payments due under this Agreement. During the Agreement Term and for a period of three (3) years thereafter, a
Party (the “Auditing Party”) shall have the right to engage on its own behalf the other Party’s (the “Audited Party”) independent, certified public accountant, to perform, on behalf of the Auditing Party, during the
Agreement Term and for a period of three years thereafter, an audit of such books and records of the Audited Party and its Affiliates and sublicensees as may be necessary to confirm any amounts payable to the Auditing Party under this Agreement for
the period or periods requested by the Auditing Party or to confirm the accuracy of any report made under this Agreement. 

  

	 	(b)	Such audits shall be conducted during normal business hours upon reasonable prior written notice from the Auditing Party (minimum of thirty (30) days) in such a manner as to
not unnecessarily interfere with the Audited Party’s normal business activities, and shall be permitted with respect to records and books covering the three (3) years immediately preceding the date of notification of the audit.

  

	 	(c)	The Auditing Party shall use all information, data, documents and abstracts obtained during an audit conducted pursuant to this Section 7.4 solely for the purposes described in
Section 7.4(a). The Auditing Party shall treat all such information, data, documents and abstracts as the Audited Party’s Confidential Information subject to Article 16 of this Agreement and, except in the event of a dispute between the
Parties regarding amounts payable hereunder or the results of any audit, the Auditing Party shall not retain such information, data, documents and abstracts for more than three (3) years from the end of the calendar year to which each shall
pertain. Audit results shall be shared by the Parties. 

  

	 	(d)	If any audit hereunder reveals an underpayment, the Audited Party shall promptly make up such underpayment. If any audit hereunder reveals an overpayment, the Auditing Party shall
promptly reimburse such overpayment. The Auditing Party shall bear the full cost of any audit under this Section 7.4, unless such audit discloses an underpayment by the Audited Party of more than [***] of the amount owed hereunder in which case
the Audited Party shall bear the full cost of such audit, together with interest on any such underpayment from the date otherwise due through the date of payment at the rate set forth in Section 7.2(e). 

  

 25 

	 	(e)	The failure of a Party to request verification of any payment calculation within the three (3) year period following receipt of such payment shall be considered acceptance of
such calculation by the Party. 

 ARTICLE 8. GOVERNANCE 
  

	8.1	Primary Compound and Licensed Collaboration Compound. A joint development and marketing committee (the “JDMC”) shall oversee all matters relating to the research,
global development and marketing of Primary Compounds and Licensed Collaboration Compounds in the Roche Territory, after completion of GLP tox studies for such compounds. 

  

	 	(a)	Organization. The JDMC shall be formed within thirty (30) days after the Effective Date. The JDMC shall consist of six (6) members – three (3) members to
be designated by Roche and three (3) members to be designated by Pharmasset. Each Party shall notify the other Party in writing of the members designated by such Party within thirty (30) days after the Effective Date. Any Party may
withdraw the designation of any of its members of the JDMC and designate a replacement at any time by giving prior written notice of the withdrawal and identifying the replacement to the other Party. The chairperson of the JDMC shall be from Roche.
Initially Roche will try to ensure that one member of the JDMC is a member of the standard Roche decision making bodies (Research Development Committee, Life Cycle Committee). 

  

	 	(b)	Meetings. The JDMC shall hold meetings at least quarterly during the Collaboration Period and semi-annually thereafter, on mutually agreeable dates, with the location of the
meetings to alternate between Pharmasset’s facilities and Roche’s facilities in Nutley, New Jersey, or Basel, Switzerland (or such other locations as may be mutually agreed to by the Parties). The frequency and location of such meetings
may be modified by mutual agreement of the Parties. Each Party shall pay its own expenses associated with meetings. Each Party may, in its discretion, invite employees of such Party who are not members of the JDMC and consultants who have entered
appropriate confidentiality agreements to attend meetings of the JDMC. The Roche Global Alliance Director shall attend the JDMC meetings and will serve as the primary contact person for all non-scientific matters. 

  

	 	(c)	Responsibilities: The JDMC will have the following responsibilities: 

  

	 	(i)	Discuss and agree upon the Development Plan, material changes and amendments which cause a material delay in the US NDA Filing and/or the EU MAA Filing; 

  

 26 

	 	(ii)	Review the progress of the project teams and discuss and agree upon their annual goals; 

  

	 	(iii)	Review, discuss and agree upon presentations to be given to the Roche internal decision making bodies; 

  

	 	(iv)	Discuss the reports on development submitted by Roche and the progress of material activities in the Development Plan; 

  

	 	(v)	Discuss and agree upon the clinical and non-clinical study protocols; 

  

	 	(vi)	Discuss all draft study reports of the Phase 1 POC study performed by Pharmasset and the final reports of these studies; 

  

	 	(vii)	Discuss material submissions to the FDA and the EMEA and reasonable ways to expedite these submissions; 

  

	 	(viii)	Facilitate and coordinate the exchange of information; 

  

	 	(ix)	Ensure communication to the project teams of decisions made by the JDMC; 

  

	 	(x)	Inform the other party on up-coming major internal events and decisions and communicate to the other party on the results of such events and the decisions taken;

  

	 	(xi)	Ensure communication to Pharmasset by Roche of any major issues, plans and/or expected decisions discussed by Roche’s internal development teams; 

  

	 	(xii)	Discuss Pharmasset’s plans of its development activities in the Pharmasset territories and material changes and amendments thereof with the Development Plan in order to align
such activities with the Roche’s global development strategy; and 

  

	 	(xiii)	Discuss the progress of Pharmasset’s development in the Pharmasset territories. 

  

	 	(d)	Decision-Making. Decisions of the JDMC shall be by consensus, with each Party getting one vote. 

  

	 	(i)	If the JDMC is unable to decide a matter by consensus, the Parties shall refer such matter for resolution to the Global Head of Roche Pharma (or a designee) and the Chief Executive
Officer of Pharmasset (or a designee) (the “Executives”). 

  

 27 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(ii)	If after sixty (60) days the Executives are unable to resolve any such matter after good faith discussions, then each [***] shall have [***] as to [***], except (A) with
respect to [***] issues, for which decisions will be based on [***] and [***] shall [***], and (B) in the event that [***] and [***] enter into a [***] in accordance with Section [***], with respect to the [***] of the [***] in the [***], for
which decisions will be made in accordance with the [***] set forth in the [***]. 

  

	 	(e)	Roche Internal Project Team. A Roche internal project team will be formed to manage the day-to-day activities of the Collaboration subject to the terms and conditions of this
Agreement. This internal team will be responsible for implementing the recommendations of the JDMC and will be subject to the governance of the standard Roche decision-making bodies. 

  

	 	(f)	CMC Subcommittee. The JDMC shall appoint a subcommittee comprised of representatives from both Pharmasset and Roche (the “CMC Subcommittee”) to handle day-to-day
issues relating to chemistry/manufacturing/control technical development (“CMC”) and technical regulatory issues (e.g., synthetic route, market formulation and supply chain structure). This CMC Subcommittee shall report to the JDMC and
shall meet regularly as needed, but no less often than quarterly. Schedule 6 of this Agreement provides guidance as to the issues and matters to be considered by the CMC Subcommittee. 

  

	 	(g)	Progress Reports. At each JDMC meeting, both Parties shall provide a report to the JDMC, summarizing in reasonable detail the results to date of the Collaboration. After each
meeting, the JDMC shall prepare a report summarizing the discussions held and conclusions reached and setting forth plans for the Collaboration for the next six (6) months. 

  

	8.2	Potential Licensed Compounds. A joint research committee (the “JRC”) shall monitor the progress of the research program for Potential Licensed Compounds, and permit
collaboration, wherever possible, during compound discovery through GLP Tox Completion or End of Phase 1, as applicable, for any given Potential Licensed Compound. The JRC shall be responsible for overseeing the research and development of Potential
Licensed Compounds for which Roche has not yet exercised its Option. Upon Roche’s exercise of its Option to a Potential Licensed Compound, the JDMC shall take over responsibility for such Potential Licensed Compound; and governance for such
compound shall be in accordance with Section 8.1 above. 

  

	 	(a)	 Organization. The JRC shall be formed within thirty (30) days after the Effective Date. The JRC shall consist of four (4) members – two
(2) members to be designated by Roche and two (2) members to be 

  

 28 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
designated by Pharmasset. Each Party shall notify the other Party in writing of the members designated by such Party within thirty (30) days after the
Effective Date. Any Party may withdraw the designation of any of its members of the JRC and designate a replacement at any time by giving prior written notice of the withdrawal and identifying the replacement to the other Party. The chairperson of
the JRC shall be from Pharmasset. 

  

	 	(b)	Meetings. The JRC shall hold meetings at least quarterly during the Collaboration Period, with the location of the meetings with the location of the meetings to alternate
between Pharmasset’s facilities and Roche’s facilities in Nutley, New Jersey, and Basel, Switzerland (or such other locations as may be mutually agreed to by the Parties). The frequency and location of such meetings may be modified by
mutual agreement of the Parties. Each Party shall pay its own expenses associated with meetings. Each Party may, in its discretion, invite employees of such Party and consultants who have entered into appropriate confidentiality agreements who are
not members of the JRC to attend meetings of the JRC. The Roche Global Alliance Director shall attend the JRC meetings and will serve as the primary contact person for all non-scientific matters. 

  

	 	(c)	Decision-Making. Decisions of the JRC shall be by consensus, with each Party getting one vote. If the JRC is unable to decide a matter by consensus, the Parties shall refer
such matter for resolution to the Global Head of Roche Pharma Research (or a designee) and the Chief Executive Officer of Pharmasset (or a designee) (the “Executives”). If the Executives are unable to resolve any such matter after [***],
then [***] shall have [***] with respect to [***] so long as such [***]. 

  

	 	(d)	Progress Reports. Within thirty (30) days after the end of each calendar quarter, Pharmasset shall prepare and deliver to Roche and the JRC a written progress report,
summarizing in reasonable detail the results to date of the Collaboration. After each meeting, the JRC shall prepare a report summarizing the discussions held and conclusions reached and setting forth plans for the Collaboration for the next six
(6) months. 

  

	8.3	PSI-6130 Pro-Drugs. The JRC shall monitor the progress of the research program for potential pro-drugs of PSI-6130 through completion of GLP tox studies for each potential
pro-drug. After completion of GLP tox studies, the JDMC shall have responsibility for such pro-drugs in accordance with the governance process outlined in Section 8.1. 

  

	 	(a)	 Decision-Making. Decisions of the JRC shall be by consensus, with each Party getting one vote. However, if the JRC is unable to decide a matter by consensus,
the Parties shall refer such matter for resolution to the Global Head of Roche Pharma Research (or a designee) and the Chief Executive Officer of Pharmasset (or a designee) (the 

  

 29 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
“Executives”). If the Executives are unable to resolve any such matter after sixty (60) days, then [***] shall have final say.

  

	 	(b)	Transition to JDMC for Decision-Making. After completion of GLP tox studies, the JDMC shall have responsibility for such pro-drugs in accordance with the governance process
outlined in Section 8.1. 

  

	 	(c)	Prodrug Team. A joint project team will be formed to manage the day-to-day activities required for the prodrug and subject to the terms and conditions of this Agreement. This
internal team will be responsible for implementing the recommendations of the JRC. 

  

	8.4	Compound Reports. 

  

	 	(a)	In addition to the progress reports of Section 8.2(d), Pharmasset shall prepare and deliver to Roche, at least once per quarter, a report containing the following:

  

	 	(i)	the data from the activities listed in Schedule 4 (defining GLP Tox Completion) for each Potential Licensed Compound; and 

  

	 	(ii)	if Roche has not exercised its Option for a given Potential Licensed Compound within sixty (60) days after GLP Tox Completion for such Potential Licensed Compound, the data
from the activities listed in Schedule 5 for each such Potential Licensed Compound. 

  

	8.5	Effect of Option Exercise on Governance. Notwithstanding anything to the contrary in Section 8.2, once Roche exercises its Option for a Potential Licensed Compound, the
JDMC shall have purview over Potential Licensed Compound as a Licensed Collaboration Compound in accordance with Section 8.1. 

  

	8.6	Sublicense of Obligations. 

  

	 	(a)	Roche acknowledges that Pharmasset may subcontract Pharmasset’s obligations under this Agreement. However, prior to entering into any significant subcontracts relating to
activities under the Research Plan or the development activities listed in Section 9.1(a), Pharmasset shall first solicit the advice and input of Roche with respect to such subcontract. 

  

	 	(b)	Pharmasset acknowledges that Roche may subcontract Roche’s obligations under this Agreement. However, prior to entering into any significant subcontracts under the Research
Plan, Roche shall first solicit the advice and input of Pharmasset with respect to such subcontract. 

 ARTICLE 9. RESEARCH
AND DEVELOPMENT 
  

	9.1	Primary Compounds. 

  

	 	(a)	For Primary Compound, the Parties have established a Development Plan, attached to this Agreement as Schedule 1. Under the Development Plan for Primary Compound, Pharmasset shall
conduct the following activities in support of development in the Roche Territories: 

  

	 	(i)	[***]; 

  

 30 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(ii)	[***]; and 

  

	 	(iii)	[***]. 

  

	 	(b)	Other than activities completed by Pharmasset pursuant to 9.1(a) above, Pharmasset shall not have any obligation for any other studies relating to the Primary Compound to achieve
(i) [***], and (ii) [***]. Roche may undertake some or all of these studies for the Primary Compound as determined by the JDMC. 

  

	 	(c)	Subject to Article 11 and pursuant to the Development Plan, Roche shall conduct all other activities in support of obtaining Regulatory Approval in the Roche Territory pursuant to
the Development Plan. 

  

	 	(d)	Each Party shall bear its own costs for the above activities except that Roche shall reimburse Pharmasset for its external expenses that are incurred after the Effective Date of
this Agreement and are associated with the activities listed in Section 9.1(a) above, up to a maximum of four and one-half million US dollars (US $4,500,000). If Roche has the resources available, Roche will be Pharmasset’s preferred provider
of external services for the activities listed in Section 9.1(a), assuming that Roche’s costs are competitive with the cost of Third Party providers for the same services. If Roche undertakes any of the activities listed in Section 9.1(a) on
behalf of Pharmasset, the four and one-half million US dollars (US $4,500,000) million cap described above shall be reduced by Roche’s actual costs for providing such services (including employee costs) in lieu of any payments by Pharmasset to
Roche for such services. 

  

	 	(e)	If the JDMC determines to pursue development of the pro-drug of PSI-6130, then a Development Plan shall be established and certain of the activities contemplated by
Section 9.1(a) and the reimbursement provided for in Section 9.1(d) may be allocated toward such pro-drug as the JDMC may determine. If Pharmasset is required to perform activities for the pro-drug that Pharmasset previously performed for
PSI-6130 (as listed in 9.1(a)), then Pharmasset shall be reimbursed for its actual expenses incurred to perform such activities, including the cost of any API manufactured, at the request of the JDMC, by Pharmasset, its Affiliates or a Third Party
(at Pharmasset’s direction) whether or not such API has been used. 

  

	 	(f)	The Parties contemplate that Pharmasset will participate in process research and process development activities (including formulation, analytical, QC and the like) to such extent
as defined by the CMC Committee as sanctioned by the JDMC. Roche shall reimburse Pharmasset for its internal and external costs that are incurred after the Effective Date of this Agreement and are associated with such activities. The FTE
reimbursement rate shall be $[***] per year. Pharmasset shall invoice all FTE costs to Roche, and Roche shall pay each such invoice within thirty (30) days of the date that such invoice is received by Roche. 

  

	 	(g)	Subject to Article 11 and the Pharmasset development plan for the Pharmasset Territory, Pharmasset shall, at its own cost, conduct all activities in support of obtaining Regulatory
Approval in the Pharmasset Territory. 

  

	9.2	 Potential Licensed Compounds. Pharmasset will undertake to discover and develop Potential Licensed Compounds during the Collaboration Period pursuant to the
Research Plan. Pharmasset shall have final say regarding compound design, although Roche may participate in design of compounds through the JRC. For a given Potential Licensed Compound, prior to exercise of its Option but during the Collaboration
Period, Roche, at its expense, shall have the right, but not the obligation, to conduct activities with respect to the Potential Licensed Compounds in accordance with the Research Plan. If Roche conducts an activity, it shall provide Pharmasset with
the data and results of such activity, and 

  

 31 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
Pharmasset shall own such data and results to the extent that Roche has the right and ability to grant Pharmasset ownership rights in such data and results;
provided, however, Pharmasset shall not allow a Third Party to use or access such data and results without prior written consent from Roche unless and until the Potential Licensed Compound becomes a Relinquished Compound.

  

	9.3	Licensed Compounds. The Development Plan for the Primary Compound is attached hereto as Schedule 1. For a given Potential Licensed Compound, promptly following the exercise
by Roche of its Option designated such Potential Licensed Compound as a Licensed Collaboration Compound, the Parties shall, through JDMC, develop and adopt a Development Plan for such Licensed Collaboration Compound. Each Development Plan shall
specify, among other things, that Roche shall conduct, at its own cost and expense, all activities in support of obtaining Regulatory Approval in the Roche Territory. Such Development Plan may be amended from time to time in accordance with Article
8. 

  

	9.4	Existing [***] Programs. Any existing [***] compounds (excluding any [***]) [***], whether [***] or including or using [***], shall [***]; and any such [***] shall be [***].
For clarity, Roche shall retain rights to such compounds and products whether or not it chooses to develop such products and shall retain rights to such compounds and products upon termination or expiration of this Agreement.

 ARTICLE 10. REGULATORY MATTERS 
  

	10.1	Regulatory Approvals. 

  

	 	(a)	 Roche, at its sole cost, shall pursue all Regulatory Approvals related to Products in the Roche Territory, including the preparation and filing of applications for
clinical trials and Regulatory Approvals, as well as any and all governmental approvals required to manufacture, have manufactured and sell Products in the Roche Territory. Without limiting the generality of the foregoing, Roche shall be responsible
for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory authorities, for all Products in all countries in the Roche Territory. During such time, Roche or its Affiliates shall own and file, at
its cost, all regulatory filings and Regulatory Approvals for all Products in all countries of the Roche Territory. Roche shall supply Pharmasset with a copy of all material communications related to any Product to and from any regulatory authority
for all Major Market Countries, promptly after receipt of such communication from such 

  

 32 

	 	 
authority or concurrently with sending such communication to such authority, as applicable. Upon request of Pharmasset, Roche shall supply Pharmasset with a
copy of all such communications in all other countries in the Roche Territory. 

  

	 	(b)	Pharmasset, at its sole cost, shall pursue all Regulatory Approvals (other than manufacturing) related to Products in the Pharmasset Territory, including the preparation and filing
of applications for Regulatory Approvals, as well as any and all governmental approvals required to sell Products in the Pharmasset Territory. Without limiting the generality of the foregoing, Pharmasset shall be responsible for pursuing, compiling
and submitting all regulatory filing documentation, and for interacting with regulatory authorities, for all Products in all countries in the Pharmasset Territory. During such time, Pharmasset or its Affiliates shall own and file, at its cost, all
regulatory filings and Regulatory Approvals for all Products in all countries of the Pharmasset Territory. Upon request of Roche, Pharmasset shall supply Roche with a copy of all such communications in all countries in the Pharmasset Territory.

  

	10.2	Pharmacovigilance. 

  

	 	(a)	The Parties agree to inform each other about adverse events occurring or having occurred in connection with the use of Products in sufficient time to allow all Parties to comply
with all applicable laws, rules and regulations in their respective territories. 

  

	 	(b)	No later than the initiation of the first clinical trial of a Product, the Parties shall execute a separate detailed pharmacovigilance agreement specifying the procedure for
exchange of information relating to adverse drug reactions which may occur (i) during development and (ii) after Launch. 

  

	 	(c)	Roche, at its sole cost, shall report to appropriate authorities in the Roche Territory in accordance with and as required by all applicable laws, rules and regulations all adverse
events, adverse drug reactions, serious adverse events and serious adverse drug reactions related to use of Products anywhere in the Roche Territory. 

  

	 	(d)	Pharmasset, at its sole cost, shall report to appropriate authorities in the Pharmasset Territory in accordance with and as required by all applicable laws, rules and regulations
all adverse events, adverse drug reactions, serious adverse events and serious adverse drug reactions related to use of Products anywhere in the Pharmasset Territory. 

  

	 	(e)	 Both Parties shall maintain a safety database that allows them to manage safety data collected and to fulfill their regulatory responsibilities in 

  

 33 

	 	 
their respective territories. After transfer of the historical clinical safety data to Roche, Roche shall maintain the global safety database for each
Product, which shall be searched to provide answers to safety queries for the preparation of Analyses of Similar Events (ASIMEs) and for safety reports. Transfer of historical clinical safety data from Pharmasset to Roche shall occur as soon as
possible but, in any event, no later than Roche’s initiation of clinical trial enrollment activities. 

  

	10.3	Transfer of Regulatory Responsibilities in the Roche Territory. The JDMC shall agree upon a process for transferring regulatory responsibilities to Roche. If, at Roche’s
request, Pharmasset continues to hold the IND for a Product after completion of the POC Study, then Roche shall reimburse Pharmasset for its reasonable expenses incurred in connection with activities relating to holding the IND, including direct
internal labor costs, which shall be reimbursed at a rate of $150 per hour. 

  

	10.4	Data Access. Except with respect to the global safety database, each Party shall permit the other Party access to, and grant the other Party the right to reference and use,
all clinical and manufacturing data associated with any submissions for approvals or other issues associated with any Licensed Compound at no cost. Such data shall include, but is not limited to, preclinical and clinical data, regulatory filings,
Regulatory Approvals, CMC data and any adverse event reports or information. In furtherance of the foregoing, each Party shall, promptly upon the request of the other Party, deliver a letter to the FDA (or the relevant regulatory authority)
authorizing the other Party to reference the drug master files and other regulatory filings of the authorizing Party related to Products. For clarity, Roche shall not provide Pharmasset with direct access to Roche’s global safety database;
rather, Roche shall allow Pharmasset to submit database queries for the purpose of generating ASIMEs and required safety reports. 

 ARTICLE 11. MANUFACTURE AND SUPPLY 
  

	11.1	Primary Compound and Primary Product. 

  

	 	(a)	For clinical supply of a Primary Compound, Pharmasset will establish a single source of API for both the Roche Territory and the Pharmasset Territory, and shall be responsible for
providing clinical supply at Cost of Goods until the Initiation of Phase 2. 

  

	 	(b)	For clinical supply of a Primary Compound after Initiation of Phase 2 and for commercial supply of Primary Product, the JDMC shall decide, at least twelve (12) months prior to
the anticipated Initiation of Phase 2, whether Roche or Pharmasset shall establish a single source of API for both the Roche Territory and the Pharmasset Territory. 

  

 34 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(i)	If Pharmasset is selected as the single source of supply, then Pharmasset shall provide: (1) Phase 2 and Phase 3 clinical supply of API to Roche for the Roche Territory at
Pharmasset’s Cost of Goods, not to exceed $[***]/kg ([***]); and (2) commercial supply of API to Roche for the Roche Territory (including samples) at a transfer price equal to Pharmasset’s Cost of Goods plus [***]%, the total price to
Roche not to exceed $[***]/kg ([***]). 

  

	 	(ii)	If the JDMC decides that Pharmasset shall have responsibility and authority for establishing a single source of API for both the Roche Territory and the Pharmasset Territory, then
Roche shall have a right to establish itself (or a Third Party) as the secondary source of API supply, provided however, Roche may not supply in excess of [***]% of the requirements for the global supply (unless Roche becomes the primary source, as
set forth in Section 11.1(b)(iii) below). 

  

	 	(iii)	If Roche is selected as the single source of supply, then Roche shall provide: (1) Phase 2 and Phase 3 clinical supply of API to Pharmasset for the Pharmasset Territory at
Roche’s Cost of Goods, not to exceed $[***]/kg ([***]); and (2) commercial supply of API to Pharmasset for the Pharmasset Territory (including samples) at a transfer price of (A) [***] during such time period as Pharmasset is
paying a royalty to Roche pursuant to Section 5.3, or (B) [***]%, the total price to Pharmasset not to exceed $[***]/kg ([***]). 

  

	 	(iv)	If the JDMC decides that Roche shall have responsibility and authority for establishing a single source of API for both the Roche Territory and the Pharmasset Territory, then
Pharmasset shall have a right to establish itself (or a Third Party) as the secondary source of API supply, provided however, Pharmasset may not supply in excess of [***]% of the requirements for the global supply (unless Pharmasset becomes the
primary source, as set forth in Section 11.1(b)(i)). 

  

	 	(v)	In the event that Roche is a source of API, it may contract with Pharmasset for certain processes, or supply intermediates at a reasonable mark-up, to be negotiated in good faith,
to Pharmasset’s Cost of Goods for such intermediates. 

  

	 	(c)	 The Party manufacturing and supplying API hereunder shall use Reasonable Diligence to improve the efficiency of the manufacturing 

  

 35 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
process, including without limitation, cost of API, yield and delivery timing, in order to reduce the Cost of Goods. 

  

	 	(d)	Each Party shall be responsible for manufacturing and packaging of finished goods containing Product for its own territory based upon common formulation for both clinical and
commercial supply. 

  

	11.2	Technology Transfer to Roche; Transfer Deliverables. Upon a determination by the JDMC, in accordance with Section 11.1(b)(iii), that Roche will establish a single source
of supply for API, then Pharmasset shall, as promptly as practicable following such determination, transfer to Roche and its designated supplier the physical embodiment of the Pharmasset Know-How as necessary to enable Roche or such designated
supplier to manufacture the Licensed Compound(s). 

  

	11.3	GMP Audits by Roche. Pharmasset shall use reasonable efforts to ensure that Roche has the right to conduct GMP audits upon reasonable notice of any Third Party suppliers used
by Pharmasset to supply Roche with Products, Licensed Compounds, API or intermediates. If Pharmasset itself acts as a supplier, then Roche shall have a right to conduct GMP audits of Pharmasset’s facilities upon reasonable notice.

  

	11.4	GMP Audits by Pharmasset. Roche shall use reasonable efforts to ensure that Pharmasset has the right to conduct GMP audits upon reasonable notice of any Third Party suppliers
used by Roche to supply Pharmasset with Products, Licensed Compounds, API or intermediates. If Roche itself acts as a supplier, then Pharmasset shall have a right to conduct GMP audits of Roche’s facilities upon reasonable notice.

  

	11.5	Licensed Collaboration Compounds. The JDMC shall determine the optimal manufacturing and supply chain arrangements for each Licensed Collaboration Compound.

 ARTICLE 12. COMMERCIALIZATION 
  

	12.1	Decision Making. Roche shall have sole responsibility and decision-making authority for the marketing, promotion, sale and distribution of Products in the Roche Territory,
except as expressly set forth in any Co-Promotion Agreement entered into between the Parties pursuant to Section 2.4. Pharmasset shall have sole responsibility and decision-making authority for the marketing, promotion, sale and distribution of
Products in the Pharmasset Territory, subject to Section 12.2. 

  

	12.2	Grant of Rights in the Pharmasset Territory. Pharmasset may grant rights to a Third Party to distribute, promote, market or sell a Product in the Pharmasset Territory
(“Pharmasset Commercialization Rights”). However, prior to offering such Pharmasset Commercialization Rights to a Third Party (with the exception of [***] or [***]). Pharmasset shall first notify Roche in writing of its intent to offer
such Pharmasset Commercialization Rights to a Third Party and provide Roche the first opportunity to obtain such rights and negotiate an agreement with respect thereto with Pharmasset. If, after good faith negotiations, the Parties are unable to
reach such agreement, then Pharmasset shall be free to offer such rights to a Third Party, provided that the terms offered to the Third Party are not more favorable to such Third Party than the last offer made by Pharmasset to Roche.

  

	12.3	Cross-Border Sales. To the extent permitted by law, each of the Parties shall take reasonable measures to prevent any re-sales of Products originally sold by such Party or
its Affiliates, sublicensees or distributors in such Party’s territory into the other Party’s territory. 

  

 36 

 ARTICLE 13. TRADEMARKS 
  

	13.1	Ownership of Trademarks. 

  

	 	(a)	Roche shall own all trademarks used in connection with Products in the Roche Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and
defense of all trademarks used in connection with Products in the Roche Territory. 

  

	 	(b)	Pharmasset shall own all trademarks used in connection with Products in the Pharmasset Territory, and shall, at its sole cost, be responsible for procurement, maintenance,
enforcement and defense of all trademarks used in connection with Products in the Pharmasset Territory. 

  

	13.2	Single Trademark. It is the intent of the Parties that the Parties shall select a single trademark to be used for each given Licensed Compound throughout the world; provided
that a different trademark may be used in a particular country if the single trademark is not appropriate. 

 ARTICLE 14.
PATENT RIGHTS 
  

	14.1	Ownership of Patent Rights. Title to inventions, discoveries, improvements and other technology, whether or not patentable (collectively, “Inventions”), and any
patent or patent application claiming such Inventions, shall be as set forth below. Inventorship shall be determined under the patent laws of the country in which the relevant patent application was filed. 

  

	 	(a)	Roche shall own Inventions and any patent or patent applications claiming such Inventions wherein the inventors consist of employees, agents or consultants of Roche (but no
Pharmasset employees, agents or consultants) (“Roche Inventions”). 

  

	 	(b)	Pharmasset shall own Inventions and any patent or patent applications claiming such Inventions wherein the inventors consist of employees, agents or consultants of Pharmasset (but
no Roche employees, agents or consultants) (“Pharmasset Inventions”). 

  

	 	(c)	Pharmasset and Roche shall own jointly Inventions invented jointly by employees, agents or consultants of Pharmasset and Roche (“Joint Inventions”) and any patent or
patent applications claiming such Inventions (“Joint Patent Rights”). 

  

	 	(d)	Roche shall grant to Pharmasset a fully paid-up, non-exclusive, worldwide license to any Joint Patent Rights for all fields; and Pharmasset shall likewise grant to Roche a fully
paid-up, non-exclusive, worldwide license to any Joint Patent Rights for all fields. 

  

 37 

	14.2	Patent Prosecution and Maintenance. 

  

	 	(a)	Pharmasset shall have the right, but not the obligation, at its own cost, to prepare, file, prosecute and maintain all Pharmasset Patents (including prior Pharmasset Patents and
patent applications in respect of Pharmasset Inventions) using outside patent counsel of Pharmasset’s choice with strategic input on such choice of counsel from Roche. 

  

	 	(b)	If Pharmasset does not wish to prepare, file, prosecute or maintain any Pharmasset Patent in a country on the list of designated countries specified in Schedule 9A (the
“Pharmasset Designated Countries”), then Pharmasset shall so notify Roche and Roche shall have the right to prepare, file, prosecute, and maintain any such patent at its own costs and at its own discretion in such country. Roche shall copy
Pharmasset on all material correspondence relating to the prosecution and maintenance of such Pharmasset Patent in such country. 

  

	 	(c)	Roche shall have the right, but not the obligation, at its own cost, to prepare, file, prosecute and maintain all Roche Patents (including patents and patent applications in respect
of Roche Inventions) using outside patent counsel of Roche’s choice with strategic input on such choice of counsel from Pharmasset. 

  

	 	(d)	If Roche does not wish to prepare, file, prosecute or maintain any such patent, in a country on the list of designated countries specified in Schedule 9B (the “Roche Designated
Countries”), then Roche shall so notify Pharmasset and Pharmasset shall have the right to prepare, file, prosecute, and maintain any such patent at its own costs and at its own discretion in such country. Pharmasset shall copy Roche on all
material correspondence relating to the prosecution and maintenance of such patent in such country. 

  

	 	(e)	Roche shall be responsible for the preparation, filing, prosecution, and maintenance of all Joint Patent Rights in the Roche Territory, using patent counsel of Roche’s choice
with strategic input on such choice of counsel from Pharmasset. All costs associated with filing, prosecution, and maintenance of Joint Patent Rights in the Roche Territory shall be borne by Roche. 

  

	 	(f)	Pharmasset shall be responsible for the preparation, filing, prosecution, and maintenance of all Joint Patent Rights in the Pharmasset Territory, using patent counsel of
Pharmasset’s choice with strategic input on such choice of counsel from Roche. 

  

	 	(g)	 If the Party bearing the costs of patent prosecution and maintenance of Joint Patents in accordance with subsections (e) and (f) above (the
“Cost-Bearing Party”) does not intend to cover such costs as to a 

  

 38 

	 	 
particular country, it shall promptly notify the other Party. Upon such notification, (i) the Cost-Bearing Party shall assign its right and interest in
such Joint Patent Rights to the other Party at no cost, and (ii) if the Cost-Bearing Party is Roche, Pharmasset shall have the right to prepare, file, prosecute and maintain such Joint Patent Right in such country. 

 

	14.3	Enforcement of Pharmasset Patents. Each Party shall inform the other Party promptly upon learning of any infringement of the Pharmasset Patents. Pharmasset shall have the
right to enforce and defend, at its own cost, all Pharmasset Patents (excluding the Third Party patents licensed to Pharmasset as of the Effective Date). Roche shall cooperate with and assist Pharmasset in the enforcement of the Pharmasset Patents
upon the reasonable request of Pharmasset, including joining as a party to any enforcement action, provided, however, that Pharmasset shall reimburse Roche for its reasonable litigation expenses (including legal fees charged by Roche’s
independent counsel, not including any internal costs associated with activities performed by Roche employees). In the event that Pharmasset does not pursue an enforcement action within a period of one hundred twenty (120) days following
reasonable notification of the infringement of the Pharmasset Patents, then Roche shall have the right to bring such action at its own cost. Roche may join Pharmasset as a party in such actions, provided, however, that Roche shall reimburse
Pharmasset for its reasonable litigation expenses (including legal fees charged by Pharmasset’s independent counsel, not including any internal costs associated with activities performed by Pharmasset employees). 

  

	14.4	Enforcement of Roche Patents. Each Party shall inform the other Party promptly upon learning of any infringement of the Roche Patents. Roche shall have the right to enforce
and defend, at its own cost, all Roche Patents. Pharmasset shall cooperate with and assist Roche in the enforcement of the Roche Patents upon the reasonable request of Roche, including joining as a party to any enforcement action, provided, however,
that Roche shall reimburse Pharmasset for its reasonable litigation expenses (including legal fees charged by Pharmasset’s independent counsel, not including any internal costs associated with activities performed by Pharmasset employees). In
the event that Roche does not pursue an enforcement action within a period of one hundred twenty (120) days following reasonable notification of the infringement of the Roche Patents, then Pharmasset shall have the right to bring such actions
at its own cost. Pharmasset may join Roche as a party in such actions, provided, however, that Pharmasset shall reimburse Roche for its reasonable litigation expenses (including legal fees charged by Roche’s independent counsel, not including
internal costs associated with activities performed by Roche’s employees). 

  

 39 

	14.5	Enforcement of Joint Patent Rights. 

  

	 	(a)	Roche shall inform Pharmasset promptly upon learning of any infringement to the Joint Patents in the Roche Territory. Roche shall have the right to enforce and defend, at its own
cost, all Joint Patents in Roche Territory. Pharmasset shall cooperate with and assist Roche in the enforcement of the Joint Patents upon the reasonable request of Roche, including joining as a party to any enforcement action, provided, however,
that Roche shall reimburse Pharmasset for its reasonable litigation expenses (including legal fees charged by Pharmasset’s independent counsel, not including any internal costs associated with activities performed by Pharmasset employees). In
the event that Roche does not pursue an enforcement action within a period of one hundred twenty (120) days following reasonable notification of the infringement of the infringement of Joint Patent Rights, then Pharmasset shall have the right
to bring such action at its own cost. Pharmasset may join Roche as a party in such actions provided, however, that Pharmasset shall reimburse Roche for its reasonable litigation expenses (including legal fees charged by Roche’s independent
counsel not including any internal costs associated with activities performed by Roche employees). 

  

	 	(b)	Pharmasset shall inform Roche promptly upon learning of any infringement to the Joint Patents in the Pharmasset Territory. Pharmasset shall have the right to enforce and defend, at
its own cost, all Joint Patents in Pharmasset Territory. Roche shall cooperate with and assist Pharmasset in the enforcement of the Joint Patents upon the reasonable request of Pharmasset, including joining as a party to any enforcement action,
provided, however, that Pharmasset shall reimburse Roche for its reasonable litigation expenses (including legal fees charged by Roche’s independent counsel, not including any internal costs associated with activities performed by Roche
employees). In the event that Pharmasset does not pursue an enforcement action within a period of one hundred twenty (120) days following reasonable notification of the infringement of the infringement of the Joint Patents, then Roche shall
have the right to bring such action at its own cost. Roche may join Pharmasset as a party in such actions, provided, however, that Roche shall reimburse Pharmasset for its reasonable litigation expenses (including legal fees charged by
Pharmasset’s independent counsel, not including any internal costs associated with activities performed by Pharmasset employees). 

  

 40 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	14.6	Recoveries. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken under
Sections 14.3, 14.4 or 14.5 shall first be applied to reimburse the Parties for their respective costs and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such action or conducting such settlement. Any amounts
remaining shall be allocated between the Parties as follows: 

  

	 	(a)	For any Joint Patents, regardless of which Party brings the enforcement action, the amounts remaining shall be allocated [***] ([***]%/[***]%]) between the Parties;

  

	 	(b)	If a Party enforces its own Patent in its own territory (i.e., Roche enforcing a Roche Patent in the Roche Territory, or Pharmasset enforcing a Pharmasset Patent in the Pharmasset
Territory), then the Party enforcing its own Patent shall retain [***] amounts, except that to the extent any such recovery is attributable to [***] with respect to Products, such amounts shall be treated as [***] for purposes of this Agreement and
the other Party shall be entitled to [***] on such [***] as if such [***] had occurred during the time period of infringement. 

  

	 	(c)	If a Party enforces its own Patent in the other Party’s territory (i.e., Roche enforcing a Roche Patent in the Pharmasset Territory, or Pharmasset enforcing a Pharmasset Patent
in the Roche Territory), then the Party enforcing its own Patent shall retain the greater of (i) fifty percent (50%) of any remaining amounts, or (ii) the royalties that it would have been entitled if such remaining amounts were treated as Net
Sales under this Agreement. 

  

	 	(d)	If a Party enforces the other Party’s Patent in the other Party’s territory (i.e., Roche enforcing a Pharmasset Patent in the Pharmasset Territory, or Pharmasset enforcing
a Roche Patent in the Roche Territory), the Party enforcing the other Party’s Patent shall retain [***] percent ([***]%) of any remaining amounts. 

  

	14.7	Patent Licenses From Third Parties. 

  

	 	(a)	Pre-existing Pharmasset Third Party Licenses. Pharmasset shall maintain all Pre-existing Pharmasset Third Party Licenses at [***] cost. If a Third Party claims a payment is
due from under a Pre-Existing Pharmasset Third Party License, related to any Product, and Pharmasset does not agree to make such payment, Pharmasset shall immediately advise Roche in writing of such disagreement. 

  

	 	(b)	HCV Target Screening Patent Licenses. Roche shall obtain and maintain any HCV Target Screening Patent License at [***] cost, if Roche determines such license is required,
except that [***] will be responsible for milestone and royalty payments associated with such license that are specific to the [***] Territory. For clarity, [***] shall have no responsibility for any HCV Target Screening Patent Licenses with respect
to Relinquished Compounds. 

  

	 	(c)	 Pre-existing Roche Third Party Licenses; Other Third Party Licenses. Roche shall maintain all Pre-existing Roche Third Party Licenses at [***] cost. If a
Third Party claims a payment is due from under a Pre-existing Roche Third Party License, related to any Product, and Roche does not agree to make such payment, Roche shall immediately advise 

  

 41 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
Pharmasset in writing of such disagreement. In addition, except as provided for in Sections 14.7(a) or 14.7(b), [***] shall bear the cost of all other patent
licenses required to sell a Product in the [***] Territory. Notwithstanding the preceding sentence, [***] shall be responsible for a pro rata share ([***] percent ([***]%)) of (i) any up-front amounts, and (ii) all milestone and royalty
payments that are specific to the [***] Territory, but only if the patent license required to sell a Licensed Compound is a license to a Patent Right containing a Valid Claim Covering the Product in a country in the [***] Territory and such patent
license is not a Pre-existing Roche Third Party License. 

  

	 	(d)	Process for Entering into Third Party Patent License Agreements. Roche shall consider in good faith Pharmasset’s input in any negotiations for Third Party patent
licenses; and [***] shall not [***] without [***]. Any disputes over whether to enter into a particular Third Party patent license agreement shall be subject to the arbitration procedure specified in Article 18. 

  

	 	(e)	Future Third Party [***] Licenses. If, during the Collaboration Period, either Party or its Affiliates (the “Identifying Party”) identify a [***] compounds
(excluding any [***] technology) not Controlled by a Party (“Related Technology”), the Identifying Party shall notify and disclose to the other Party all available information concerning such Related Technology. After such notice has been
provided, the Party receiving such notice shall have thirty (30) days from the date of such notice to notify the Identifying Party of its interest in such Related Technology. If both Parties are interested in such Related Technology, then,
regardless of which Party is the Identifying Party, Pharmasset shall, together with Roche, negotiate with the relevant Third Party to obtain rights to the Related Technology and bring it within the scope of the license grant to Roche under
Section 2.1 as part of Pharmasset Patent Rights. In furtherance thereof, [***] shall [***], and otherwise [***], except that [***] shall be [***]. In the event Pharmasset is the Identifying Party and Roche (i) notifies Pharmasset that it
does not desire to bring such Related Technology within the scope of the license grant to Roche, or (ii) fails to notify Pharmasset within such thirty (30) day period of its desire to include the Related Technology as part of the license
grant under Section 2.1, Pharmasset may acquire the rights to such Related Technology outside the collaboration and such rights shall not be subject to this Agreement. In the event Roche is the Identifying Party and Pharmasset (i) notifies
Roche that it does not desire to enter into a license agreement for such Related Technology, or (ii) fails to notify Roche of its interest in such Related Technology, then Roche may acquire the rights to such Related Technology outside the
collaboration and such rights shall not be subject to this Agreement. For clarity, this Section does not apply to any pre-existing licenses and agreements entered into prior to the Effective Date of this Agreement. 

  

 42 

 ARTICLE 15. REPRESENTATIONS AND WARRANTIES 
  

	15.1	Mutual Representations and Warranties. Each Party warrants and represents to the other Party that: 

  

	 	(a)	it has the full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit its ability to perform the obligations imposed on it
by this Agreement; 

  

	 	(b)	all corporate action on the part of such Party, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of this Agreement and
(ii) the performance of all obligations of such Party hereunder has been taken, and this Agreement constitutes the legal and binding obligation of such Party, enforceable against such Party in accordance with its terms;

  

	 	(c)	the execution of this Agreement and the performance of the transactions contemplated by this Agreement by such Party will not conflict with or result in a breach of any of the
terms, conditions or provisions of, or constitute a default under any agreement or other instrument to which such Party is a party or by which it or any of its property is bound; 

  

	 	(d)	it has the right to grant the licenses granted under this Agreement; and 

  

	 	(e)	it has not intentionally failed to disclose any information within its knowledge that would materially affect the other Party’s decision to enter into this Agreement, and that
no information provided by it in connection with this Agreement contains any untrue statement of material fact or omits to state a material fact. 

  

	15.2	Additional Representations and Warranties. 

  

	 	(a)	Pharmasset represents and warrants to Roche that, as of the Effective Date, the only Pharmasset Pre-existing Third Party Licenses are those listed in Schedule 7A.

  

	 	(b)	Roche represents and warrants to Pharmasset that, as of the Effective Date, Roche has not intentionally failed to disclose the existence of any Roche Pre-existing Third Party
Licenses needed for this Collaboration. 

  

	 	(c)	Pharmasset represents and warrants to Roche that, as of the Effective Date, that no Third Parties, including any governmental agencies or authorities, have asserted that any Third
Parties have rights to any Pharmasset Patent Rights or Pharmasset Know-How. 

  

 43 

	 	(d)	Pharmasset represents and warrants to Roche that, as of the Effective Date, it is not involved in any litigation, arbitration or other dispute that could adversely affect its
ability to grant the licenses and rights granted in Section 2.1 or to fulfill its obligations under this Agreement. 

  

	15.3	Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. EACH OF PHARMASSET AND ROCHE
DISCLAIM ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THEIR RESPECTIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED,
AND THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS OR ANY RESEARCH. EXCEPT WITH RESPECT TO ANY CLAIM BY A THIRD
PARTY FOR INDEMNIFICATION PURSUANT TO SECTION 19.1, IN NO EVENT SHALL EITHER PHARMASSET OR ROCHE BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL
THEORY. 

 ARTICLE 16. CONFIDENTIAL INFORMATION 
  

	16.1	Treatment of Confidential Information. In carrying out its obligations under this Agreement, each Party will be sharing confidential and proprietary data and information
(“Confidential Information”) with the other Party. Except as expressly permitted by this Agreement, each Party shall, and shall cause its Affiliates to, treat Confidential Information received from the other Party (the “Disclosing
Party”) or its Affiliates as it treats its own proprietary information of like nature and importance. During the Agreement Term and for a period of five (5) years thereafter, the Party in receipt of the Disclosing Party’s Confidential
Information (the “Receiving Party”) shall not disclose, divulge or otherwise communicate such Confidential Information to any Third Party, or use it for any purpose except pursuant to and in order to carry out its obligations under this
Agreement. Notwithstanding the foregoing, the Receiving Party may disclose Confidential Information of the Disclosing Party to the Receiving Party’s directors, officers, employees, Affiliates, consultants, subcontractors, sublicensees or agents
to the extent reasonably necessary to carry out its obligations under this Agreement, provided that such directors, officers, employees, Affiliates, consultants, subcontractors, sublicensees or agents have been advised of the confidential nature of
such information and have agreed to maintain such information as confidential to the same extent required by this Article 16. 

  

 44 

	16.2	Exceptions to Definition of Confidential Information. Confidential Information shall not include information that the Receiving Party can demonstrate:

  

	 	(a)	was known by the Receiving Party or its Affiliates prior to the date it was disclosed to the Receiving Party or its Affiliates by the Disclosing Party or its Affiliates, as
evidenced by the prior written records of the Receiving Party or its Affiliates; 

  

	 	(b)	is lawfully disclosed to the Receiving Party or its Affiliates by a Third Party rightfully in possession of such information, either before or after the date of the disclosure to
the Receiving Party or its Affiliates; 

  

	 	(c)	becomes generally known to the public through no act or omission on the part of the Receiving Party or its Affiliates, either before or after the date of the disclosure to the
Receiving Party or its Affiliates; 

  

	 	(d)	is independently developed by the Receiving Party or its Affiliates without reference to or reliance upon any Confidential Information of the Disclosing Party or its Affiliates; or

  

	 	(e)	is required to be disclosed by the Receiving Party or its Affiliates pursuant to a judicial or governmental order, provided that the Receiving Party gives the Disclosing Party
sufficient notice to permit Disclosing Party to seek a protective order or other similar order with respect to such Information. 

  

	16.3	Exceptions. The restrictions set forth in this Article 16 and Section 19.2 shall not prevent either Party from (i) disclosing Confidential Information in connection
with preparing, filing, prosecuting or maintaining a patent application or its resulting patents related to a Product in accordance with Article 14, (ii) disclosing Confidential Information to governmental agencies to the extent required or
desirable to obtain a Regulatory Approval, (iii) disclosing Confidential Information to potential private investors (under a confidentiality agreement at least as restrictive as the provisions of this Article 16) in connection with fundraising
activities, (iv) disclosing Confidential Information to underwriters and financial advisors (under an obligation of confidentiality) in connection with the public offering of securities, or (v) disclosing Confidential Information that is
reasonably determined is required to be disclosed by the Receiving Party (to comply with applicable securities or other laws) to public investors or governmental agencies in connection with the public offering of securities, provided that in all of
the above cases, the Party disclosing Confidential Information of the Disclosing Party shall use all reasonable efforts to provide prior written notice of such disclosure to the Disclosing Party and to take reasonable and lawful actions to avoid or
limit such disclosure or to assist the Disclosing Party in avoiding or limiting such disclosure. 

  

 45 

	16.4 	Previous Non-Disclosure Agreement. Notwithstanding anything contained herein to the contrary, that certain Mutual Non-Disclosure Agreement, dated as of May 25, 2004, by
and between the Parties shall remain in full force and effect as to the information disclosed between the Parties prior to the date hereof. 

  

	16.5 	Publications. The following provisions shall apply to the Parties with respect to all publications, presentations and other public disseminations of any information relating
to Licensed Compounds or to scientific work performed as part of the Collaboration: 

  

	 	(a)	The Party desiring to publish, present or otherwise publicly disseminate such information (the “Publishing Party”) shall provide the other Party with a copy of any
proposed publication, presentation or other public dissemination at least thirty (30) days prior to submission for publication, presentation or other public dissemination so as to provide such other Party an opportunity to recommend any changes
it reasonably believes are necessary to preserve the Confidential Information belonging in whole or in part to such other Party or to preserve such other Party’s ability to obtain a patent or patents Covering any Invention. The incorporation of
such recommended changes shall not be unreasonably refused. 

  

	 	(b)	If such other Party provides written notice (“Notice”) to the Publishing Party within fifteen (15) days of receipt of the copy of the proposed publication,
presentation or other public dissemination that such publication, presentation or other public dissemination in its reasonable judgment (i) discloses information about an Invention for which the other Party desires patent protection or
(ii) discloses Confidential Information of the other Party, the Publishing Party shall prevent such publication or delay such publication, presentation or other dissemination until the Parties have agreed on mutually acceptable modifications
thereto so as not to prejudice the other Party’s right to obtain a patent and not to disclose the other Party’s Confidential Information. In the case of Inventions, a delay shall be for a period reasonably sufficient to permit the timely
preparation and filing of a patent application(s) or application(s) on the Invention, and in no event less than sixty (60) days from the date of Notice. 

 ARTICLE 17. TERM AND TERMINATION 
  

	17.1 	 Agreement Term. The Agreement Term shall commence on the Effective Date and expire, unless earlier terminated upon the mutual written agreement of the
Parties or in accordance with the provisions of this Article 17, on the date of expiration of all royalty and other payment obligations (the “Expiration Date”) under this Agreement. Upon the Expiration Date, (i) the licenses granted
to Roche by Pharmasset under this Agreement and (ii) the licenses granted to Pharmasset by Roche, shall become fully paid-up and irrevocable, subject to any 

  

 46 

	 	 
obligations which have accrued prior to the Expiration Date, except for any payments for commercial supply of Product pursuant to Article 11 or the terms of
any applicable supply agreement. 

  

	17.2 	Termination for Breach. 

  

	 	(a)	Each Party (the “Non-Breaching Party”) shall be entitled to terminate this Agreement (i) on a Product-by-Product, country-by-country basis, by written notice to the
other Party (the “Breaching Party”) in the event that the Breaching Party is in default of any of its material obligations hereunder relating to such Product and such country and fails to remedy such default within sixty (60) days
(or, in the case of payment defaults, within thirty (30)) days after provision of written notice thereof by the Non-Breaching Party identifying the alleged breach in reasonable detail. Notwithstanding the foregoing, the non-Breaching Party
shall be entitled to terminate this Agreement in its entirety in the event that, as a result of such breach, the non-Breaching Party is unable to recognize substantially all financial benefits of this Agreement when taken as a whole.

  

	 	(b)	The effective date of termination of this Agreement in its entirety under this Section 17.2 for an unremedied breach of a material obligation shall be the date sixty
(60) days (or, in the case of an unremedied payment default, thirty (30) days) after provision of written notice thereof by the Non-Breaching Party. 

  

	17.3 	Roche’s Rights to Terminate. Roche shall have the unilateral right to terminate this Agreement, on a Product-by-Product basis, either on a worldwide basis or on a
country-by-country basis, by providing six (6) months prior written notice to Pharmasset. Such termination pursuant to this Section 17.3 shall be effective six (6) months after Roche provides such written notice to Pharmasset.

  

	17.4 	Consequences of Termination or Reversion. 

  

	 	(a)	Reversion of License and Assignment of Roche Rights. Upon any termination of this Agreement pursuant to this Article 17 or other reversion or relinquishment as contemplated
by Sections 2.1(h), 3.1(d), 3.1(e), 4.2(a)(iii) or 4.2(b)(ii), any and all licenses granted by Pharmasset to Roche under this Agreement shall terminate with respect to the Product(s) and country(ies) to which the termination relates on the effective
date of such termination, and the following provisions shall apply: 

  

	 	(i)	 Roche shall, upon Pharmasset’s written request, assign and transfer to Pharmasset, or its Affiliates as requested by Pharmasset, at no expense to Pharmasset or
its Affiliates, and free of any liens, pledges, security interests or other 

  

 47 

	 	 
financial encumbrances other than those incurred in accordance with this Agreement and in the commercialization of the Product, all of Roche’s right,
title and interest in and to: 

  

	 	(1)	all regulatory filings (such as INDs and drug master files), Regulatory Approvals, and clinical trial agreements (to the extent assignable and not cancelled) for such Product(s) in
such country(ies), 

  

	 	(2)	all trademarks specific to such Product(s) in such country(ies), not including any housemarks or trademarks used in connection with any products other than such Product(s), and

  

	 	(3)	all data, including clinical data, materials and information of any kind or nature whatsoever, in Roche’s possession or in the possession of its Affiliates or its or their
respective agents related to such Product(s) in such country(ies). All such filings, approvals and data transferred to Pharmasset pursuant to this Section 17.4 shall be deemed to be Pharmasset Confidential Information. 

 

	 	(ii)	In addition, for each (A) Licensed Compound for which rights have reverted to Pharmasset in accordance with Sections 3.1(d) or 3.1(e) and (B) Product for which
Roche’s rights have been terminated pursuant to Sections 17.2 or 17.3, Roche shall grant to Pharmasset a sole and exclusive, fully paid-up right and license under Roche Patent Rights and Roche Know-How, to make, have made, use, offer for sale,
sell and import such terminated Product(s) in such terminated countries; provided, however that Pharmasset shall be responsible for the payment of all royalty and milestone payments owed by Roche to any Third Party as a result of the development or
commercialization by Pharmasset of compounds or Products for which rights have been obtained by Pharmasset in accordance with Sections 3.1(d), 3.1(e), 17.2 or 17.4. 

  

	 	(iii)	 If Roche is responsible for clinical or commercial supply of Product at the time of termination, then Roche shall supply, or cause to be supplied, to Pharmasset,
upon Pharmasset’s written request, Pharmasset’s or its licensee’s clinical or commercial requirements of Product and Licensed Compounds, pursuant to a supply agreement to be 

  

 48 

	 	 
negotiated in good faith by the Parties, provided that (1) any and all or part of Roche’s remaining supply and inventory of Product(s) and Licensed
Compound(s), and any intermediates useful for the synthesis of Product(s) and Licensed Compound(s), shall be provided to Pharmasset at no cost, (2) any additional requirements for Product and Licensed Compound shall be supplied to Pharmasset or
its licensee at Roche’s Cost of Goods, and (3) Roche’s supply obligation shall not continue for more than twenty-four (24) months after the termination of this Agreement, and (4) Roche shall maintain the same quality and
specifications for manufacturing Product and/or Licensed Compounds as immediately prior to notice of termination, and (5) Pharmasset shall effect a transfer as soon as practicable of Product(s) and Licensed Compound(s) manufacturing activities
from Roche to another supplier. Roche shall also transfer to Pharmasset or its designated supplier a manufacturing transfer package that will enable Pharmasset or such designated supplier to manufacture the Product(s) and Licensed Compound(s) in a
timely manner. 

  

	 	(iv)	If Roche is supplying Product pursuant to any ongoing or completed clinical trial or for a compassionate use program or similar supply of Product, Roche shall continue to supply
Product to any patients who are already enrolled and receiving Product in such clinical trial or compassionate use program, and Pharmasset shall not assume any such obligations. 

  

	 	(v)	Other than in Section 17.4(a)(iii) above, Roche shall cease manufacturing, processing, producing and selling Products. 

  

	 	(b)	Royalty and Payment Obligations. Termination of this Agreement by either Party for any reason will not release Roche from any obligation to pay royalties or milestones or to
make any payments to Pharmasset which were accrued prior to the effective date of termination (including for sales made and events achieved under Articles 5 and 6, prior to the date of termination) or that relate to Product(s) or country/countries
to which such termination does not relate. However, termination of this Agreement by either Party for any reason will release Roche from any obligation to pay royalties or make any payments to Pharmasset which would have otherwise become accrued
after the effective date of termination (provided that Roche shall be obligated to pay royalties and milestones for payments received after the effective date of termination for Products sold prior to such effective date). 

 

 49 

	 	(c)	Non-Exclusive Remedy for Breach. The provisions of this Section 17.4 are not intended to be exclusive and are without prejudice to the rights of the Parties to seek any
other rights and remedies that they may have under this Agreement or otherwise. 

  

	17.5 	Survival of Obligations. Sections 5.2(c), 14.1, 14.5, 14.6(a), 17.4, 17.5, 19.1, 19.2 and 19.6 and Articles 7, 16 and 18, and any definitions used in any such Section or
Article, shall survive the termination of this Agreement in its entirety. Except for obligations which clearly are not intended to continue in respect of a partial termination pursuant to Section 17.4 (including the applicable diligence
obligation), with respect to the country or Product terminated, all obligations in this Agreement shall survive such partial termination. 

 ARTICLE 18. LAW AND ARBITRATION 
  

	18.1 	Governing Law. This Agreement shall be governed by the laws of the State of Delaware without regard to its conflict of laws rules or principles. 

  

	18.2 	Arbitration. All disputes, controversies or claims (each a “Dispute”) arising out of this Agreement shall be settled by arbitration conducted in accordance with the
rules then in effect of the American Arbitration Association (“AAA”). Either Party may submit a Dispute to arbitration if the Parties are not able to settle such Dispute amicably within forty-five (45) days after appropriate officers
of the Parties have had good faith discussions to resolve the Dispute. Any such arbitration shall take place in Wilmington, Delaware, or in a venue mutually agreed by the Parties. Any such arbitration shall be conducted by a panel of three
(3) arbitrators. Each Party shall designate one (1) arbitrator, and the two (2) arbitrators designated by the Parties shall select the third arbitrator, all within the time limits established by the then existing rules of the AAA. If
scientific or technical matters are a central issue of the Dispute, at least one of the arbitrators chosen hereunder shall have educational training and/or experience sufficient to demonstrate a reasonable level of knowledge in the Field and
pharmaceutical drug development. If the two (2) arbitrators designated by the Parties are unable to agree upon a third arbitrator within two (2) months after submission of the matter to arbitration, the AAA shall select such third
arbitrator within three (3) months of such original submission. The written decision of the panel of arbitrators shall be final and binding on the Parties and may be enforced in any court having jurisdiction over the Parties or their current
assets. 

 ARTICLE 19. MISCELLANEOUS 
  

	19.1 	Indemnification. 

  

	 	(a)	 Roche shall defend Pharmasset and its Affiliates and its and their respective directors, officers, employees and agents (the “Pharmasset Indemnified
Parties”) at Roche’s cost and expense, and shall indemnify and hold Pharmasset and the Pharmasset Indemnified Parties harmless 

  

 50 

	 	 
from and against any claims, losses, costs, damages, fees or expenses (including reasonable attorney’s fees) (each a “Claim”) to the extent
arising out of or otherwise relating to (1) acts or omissions of Roche or its Affiliates in the conduct of the Collaboration, (2) the development, manufacture, use, offer for sale, sale or other disposition of any product by Roche, its
Affiliates or sublicensees, and each of their respective distributors, representatives or anyone in privity therewith (other than Pharmasset and its Affiliates and licensees), (3) any breach by Roche of a representation, warranty or covenant
contained in this Agreement, or (4) the gross negligence or willful misconduct of Roche, its Affiliates or sublicensees and each of their respective distributors, representatives or anyone in privity therewith. In the event of a Claim against
the Pharmasset Indemnified Parties by a Third Party, Pharmasset shall promptly notify Roche in writing of the Claim (provided that any failure or delay to so notify Roche shall not excuse any obligation of Roche except to the extent Roche is
actually prejudiced thereby) and Roche solely shall manage and control, at its sole expense, the defense of the Claim and its settlement; provided further that Roche shall not settle any Claim without the prior written consent of Pharmasset. The
Pharmasset Indemnified Parties shall cooperate with Roche and, at their option and expense, may be represented in any such action or proceeding by counsel of their choice. The Pharmasset Indemnified Parties shall provide Roche with access to any and
all documents and information in their possession relating to the Claim. Roche shall not be liable for any litigation costs or expenses incurred by the Pharmasset Indemnified Parties without Roche’s written authorization. Notwithstanding the
foregoing, Roche shall not be obligated to indemnify Pharmasset against any Claims to the extent that Pharmasset would be obligated to indemnify Roche against such Claims in accordance with Section 19.1(b). 

  

	 	(b)	 Pharmasset shall defend Roche and its Affiliates and its and their respective directors, officers, employees and agents (the “Roche Indemnified Parties”)
at Pharmasset’s cost and expense, and shall indemnify and hold Roche and the Roche Indemnified Parties harmless from and against any Claim to the extent arising out of or otherwise relating to (1) acts or omissions of Pharmasset in the
conduct of the Collaboration, (2) the development, manufacture, use, offer for sale, sale or other disposition of any product by Pharmasset, its Affiliates, licensees other than Roche, sublicensees and each of their respective distributors,
representatives or anyone in privity therewith, (3) any breach by Pharmasset of a representation, warranty or covenant contained in this Agreement, or (4) the gross negligence or willful misconduct of Pharmasset, its Affiliates, licensees
other than Roche, sublicensees and each of their respective distributors, representatives or anyone in privity therewith. In the event of a Claim against the Roche Indemnified Parties by a Third Party, Roche shall promptly notify 

  

 51 

	 	 
Pharmasset in writing of the Claim (provided that any failure or delay to notify shall not excuse any obligation of Pharmasset except to the extent
Pharmasset is actually prejudiced thereby) and Pharmasset solely shall manage and control, at its sole expense, the defense of the Claim and its settlement; provided further that Pharmasset shall not settle any Claim without the prior written
consent of Roche. The Roche Indemnified Parties shall cooperate with Pharmasset and, at their option and expense, may be represented in any such action or proceeding by counsel of their choice. The Roche Indemnified Parties shall provide Pharmasset
with access to any and all documents and information in their possession relating to the Claim. Pharmasset shall not be liable for any litigation costs or expenses incurred by the Roche Indemnified Parties without Pharmasset’s written
authorization. Notwithstanding the foregoing, Pharmasset shall not be obligated to indemnify Roche against any Claims to the extent that Roche would be obligated to indemnify Pharmasset against such Claims in accordance with Section 19.1(a).

  

	19.2 	Publicity. Neither Party shall issue any news release or make any other public announcement, written or oral, relating to this Agreement, including its terms, without the
prior approval of the other Party, except solely to the extent a Party is advised by its legal counsel that the same is required by law. Each Party shall limit any legally required public disclosure of the financial terms set forth in this Agreement
to the minimum extent required by law (by, for example, requesting confidential treatment of such terms in documents required to be filed with the US Securities and Exchange Commission). Notwithstanding the foregoing, any Party may, upon
consultation with the other Party, disclose from time-to-time the general economic structure of and results from the transactions contemplated hereby to its shareholders, creditors or ratings agencies as it deems necessary or appropriate.

  

	19.3 	Force Majeure. Neither Party shall be responsible to the other Party for nonperformance or delay in performance of the terms or conditions of this Agreement due to acts of
God, acts of governments, war (declared or undeclared), acts of terrorism, riots, strikes, accidents in transportation, or other causes beyond the reasonable control of such Party, but such force majeure shall toll any and all obligations (other
than payment obligations) and time periods for so long as such force majeure continues. Upon the occurrence of an event of force majeure, the Party whose performance is affected thereby shall notify the other Party promptly of such event. Upon the
cessation of such event, such Party shall take all reasonable steps within its power to resume with the least possible delay compliance with its obligations hereunder. 

  

	19.4 	 Bankruptcy. Any licenses or rights granted under or pursuant to this Agreement by Pharmasset to Roche are, and shall otherwise be deemed to be, for purposes
of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that during the Agreement Term,
each Party, as a 

  

 52 

	 	 
licensee of rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the
continued performance of its obligations under this Agreement. 

  

	19.5 	Waiver. The waiver by a Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any subsequent breach of
the same or any other provision hereof, nor shall any delay or omission on the part of a Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of that or any other right, power or
privilege of such Party hereunder. 

  

	19.6 	Notices. Any notice or other communication required or permitted to be given in connection with this Agreement must be in writing and may be given by any of the following
methods: (i) personal delivery with a signed acknowledgement of receipt; (ii) registered or certified mail, postage prepaid, return receipt requested; or (iii) by overnight delivery service with a signed acknowledgement of receipt.
Notice shall be effective when delivered to the addressee at the address listed below or such other address as the addressee shall have specified in a written notice actually received by the addresser. 

 If to Pharmasset: 
 Pharmasset, Inc.

 1860 Montreal Road 
 Tucker,
Georgia 30084 
 Attn: Legal Affairs 
 and 
 Morgan, Lewis & Bockius LLP 
 502 Carnegie Center 
 Princeton, NJ 08540 
 Attn: Randall B. Sunberg, Esq. 
 If to Roche:

 F. Hoffmann-La Roche Ltd 
 Grenzacherstrasse 124 
 CH-4070 
 Basel, Switzerland 
 Attn: Legal Department 
 and 
 Hoffmann La-Roche Inc. 
 340 Kingsland Street 
 Nutley, NJ 07110 
 Attn.: Corporate Secretary 
  

 53 

	19.7 	Relationship of the Parties. The Parties are independent contractors. Nothing herein is intended, or shall be deemed, to constitute a partnership, agency, joint venture or
employment relationship between the Parties. Neither Party shall be responsible for the other Party’s acts or omissions; and neither Party shall have authority to speak for, represent or obligate the other Party in any way without prior written
authority from the other Party. 

  

	19.8 	Entire Agreement. This Agreement and the Schedules attached hereto (which Schedules are incorporated herein by reference and are deemed to be a part of this Agreement for all
purposes) constitute the entire agreement of the Parties with respect to the subject matter hereof and supersede all prior understandings and writings between the Parties relating thereto. No amendment, waiver, alteration or modification of any of
the provisions of this Agreement shall be binding unless made in writing and signed by the Parties. 

  

	19.9 	Headings. The headings contained in this Agreement are for convenience of reference only and shall not be considered in interpreting this Agreement. 

 

	19.10 	Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any
law of any relevant jurisdiction, the validity of the remaining provisions of this Agreement shall not be affected thereby, and the Parties shall negotiate a substitute provision that, to the extent possible, accomplishes the original business
purpose of the unenforceable provision. During the period of such negotiation, and thereafter if no substituted provision is agreed upon in writing by the Parties, any such provision which is enforceable in part but not in whole shall be enforced to
the maximum extent permitted by law. 

  

	19.11 	Assignment. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party, except
to an Affiliate of the assigning Party or to any other party who acquires all or substantially all of the pharmaceutical business of the assigning Party by merger, sale of assets or otherwise, in each case so long as such Affiliate or other party
agrees in writing to be bound by all the terms of this Agreement. 

  

	19.12 	Successors and Assigns. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their successors and
permitted assigns. 

  

	19.13 	 Interpretation. The words “include,” “includes” and “including” when used in this Agreement shall be deemed to be followed by
the phrase “without limitation.” All references herein to Articles, Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall otherwise require. Except as
otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with International Financial Reporting Standards (“IFRS”), as in effect from time to time. Unless the context otherwise
requires, countries shall 

  

 54 

	 	 
include all territories thereof. A Licensed Compound and all of its pro-drugs shall be deemed to the same for the purposes of payments under Articles 4, 5, 6
and 9 of this Agreement. 

  

	19.14 	Rights and Obligations of Roche. The obligations of “Roche” hereunder shall be joint and several as to both F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The
rights of “Roche” hereunder shall be applicable to either F. Hoffmann-La Roche Ltd or Hoffmann-La Roche Inc. 

  

	19.15 	Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same
instrument. 

 [Remainder of Page Intentionally Left Blank] 
  

 55 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in their names by their
properly and duly authorized officers or representatives as of the date first written above. 
  

									
	 PHARMASSET, INC.
	 		 	 HOFFMANN-LA ROCHE INC.

					
	By:	 	 /s/ P. Schaefer Price
	 		 	 By:
	 	 /s/ Dennis E. Burns

	 Title:
	 	 President and CEO
	 		 	 Title:
	 	 Vice President

		 		 		 		 	 Global Head of Business Development

			
		 		 	 F. HOFFMANN-LA ROCHE LTD

					
		 		 		 	 By:
	 	 /s/ Peter Huang

		 		 		 	 Title:
	 	 Global Head

		 		 		 		 	 Pharma Partnering

					
		 		 		 	 By:
	 	 /s/ Stephan Arnold

		 		 		 	 Title:
	 	 Deputy Director

  

 56 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 1 
 [***] 
  

					
	 [***]
	 	Task Name	  	[***]

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 1.62 
 SCREENING PRINCIPLES 
 [***] will screen [***]. [***]. 
  

	**	The procedures set forth in this Schedule 1.62 are intended to clarify [***]. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 2A 
 [***] 
 The parties will [***] for [***]. [***] will focus their efforts on [***] and [***]. [***] are listed below. It is
anticipated that [***], but will exclude [***]. This [***] will be [***] on [***] basis. Both [***] and [***] will be [***]. 
 [***] 
 [***] will [***] in accord with [***]. [***] will establish [***]. 
 [***]

 As a [***] strategy for [***], the first objective of [***] is [***]. 
 The activities required to [***] will be [***] and allocated as [***]. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 2B 
 [***] 
 Mean [***] from [***]. 
 [***], activity [***]. 
 [***] that [***] should be [***], and not preclude [***] with (i) [***], or (ii) [***]. 
 [***] that [***] should be not [***]. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 3 
 SUMMARY TERMS FOR CO-PROMOTION OF PRODUCT 
  

	1.	CO-PROMOTION TERRITORY. The “Co-Promotion Territory” shall be the US. 

  

	2.	ASSIGNMENT. Pharmasset may not assign its co-promotion rights without Roche’s express written consent; provided, however, that Pharmasset may assign such rights to any
Affiliate of Pharmasset. 

  

	3.	MARKETING. The Co-Promotion Agreement shall provide that Pharmasset shall detail Product to HIV treating physicians in the US, which may or may not be exclusive to Roche
detailing Product to HIV treating physicians. If Pharmasset exercises its right to detail Product to HIV treating physicians in the US, the Parties’ respective rights and obligations with respect to detailing and marketing shall be set forth in
the Co-Promotion Agreement. Such detailing shall commence on the date Roche commences detailing of the Product and shall expire on the first date Roche no longer details such Product. The HIV treatment providers to which Pharmasset shall provide
details may be either HIV treating physicians that Roche is targeting for Product (“Targeted Providers”), or may be HIV treating physicians that are not Targeted Providers (“Non-Target Providers”). For Targeted Providers, both
Parties shall provide details in a manner to be decided by the JPT (see below), except that Pharmasset shall have sole discretion, after JPT discussion, to determine the number of details or the specific Targeted Providers to be detailed by
Pharmasset. For Non-Targeted Providers, solely Pharmasset shall provide details in a manner to be decided by the JPT, except that Pharmasset shall have sole discretion, after JPT discussion, to determine the number of details or the specific
Non-Targeted Providers to be detailed by Pharmasset. Pharmasset may subcontract its sales employees to fulfill its detail obligations only upon prior written consent of Roche, not to be unreasonably withheld. [***]. 

  

	4.	REVENUE SPLIT. For so long as Pharmasset is detailing to Non-Target Providers, Pharmasset shall receive a royalty on Net Sales attributable to prescriptions from the
Non-Target Providers, to be set forth in the Co-Promotion Agreement, in addition to the royalties otherwise provided for under Article 5 of the Collaboration Agreement. Pharmasset may also detail Targeted Providers without additional compensation,
as otherwise provided for under Article 5 of the Collaboration Agreement. [***] . 

  

	5.	GOVERNANCE. Within ninety (90) days after Pharmasset’s notice to Roche that it wishes to co-promote, the Parties shall form a Joint Promotional Team
(“JPT”), which shall oversee the co-promotional activities of the Parties with respect to Target Providers and Non-Target Providers. The JPT shall consist of six (6) members, three (3) members to be designated by Roche and three
(3) members to be designated by Pharmasset. Any Party may withdraw the designation of any of its members of the JPT and designate a replacement at any time by giving prior written notice of the withdrawal and identifying the replacement to the
other Party. 

 Decisions of the JPT shall be by consensus. The chairperson of the JPT shall be from Roche. If the JPT is
unable to decide a matter by consensus, the Parties shall refer such matter for resolution to the Executives. If the Executives are unable to resolve a matter after good faith discussions, the final decision shall rest with Roche, provided such
decision shall not commit Pharmasset to incur an expense that it had not previously agreed to incur or that would increase any expense that Pharmasset is otherwise responsible for or that would limit Pharmasset’s ability to obtain payment under
Section 4 above, with obtaining Pharmasset’s prior written consent. 
 The Co-Promotion Plan shall set forth the detailed plan for
commercialization of Product in the US on a calendar-year basis, including: (a) strategies for detailing and co-promoting, as applicable, of Products, including recommended target doctors for such activities; (b) allocation between the
Parties of responsibilities for marketing activities; (c) anticipated marketing, sales and promotion efforts by each Party (or its Affiliates) (including number and position of details, and sampling activities); (d) market and sales
forecasts in a form to be agreed between the Parties via the JDMC; (e) advertising, public relations and other promotional programs and sampling, to be used in co-promotion; (f) medical affairs programs, including professional symposia and
other educational activities, and medical affairs studies based upon JDMC-approved protocols; (g) Phase 4 clinical trials (based upon JDMC-approved protocols) in the US relating to Products; and (h) as appropriate, a training plan for the
Parties’ sales representatives. In addition to the detailed plan and budget for the current calendar year, an outline of the projected plan and estimated budget for the next calendar year shall be included. 
 Roche shall be responsible for the distribution and sale of Product and for invoicing and booking sales in the US. 
  

	6.	ROCHE’S OBLIGATIONS AND AUTHORITY. Roche shall be ultimately responsible for establishing and modifying the terms and conditions with respect to the sale of the Product,
including pricing for the relevant Product. Roche shall provide Pharmasset, without charge, with a master copy of the same training materials as Roche uses to train its own sales force regarding the detailing and promotion of the Product, and with a
master copy of such promotional materials as may be specified in the Co-Promotion Plan. Pharmasset shall then supply, at its own cost, copies of such training and/or promotional materials to its sales force. At Pharmasset’s request, Roche shall
make available sales and training personnel to assist Pharmasset in training Pharmasset’s sales force to detail and promote the Product. For avoidance of doubt, each Party has final responsibility for the adequate training of its own sales
force. Roche shall provide Pharmasset proportional allocation of samples as Roche provides to its own sales force. 

  

	7.	INDEMNIFICATION. Each Party shall indemnify the other Party for all Third Party claims relating to the marketing or promotion of the Product to the extent that such
indemnifying Party or its representatives are negligent or fail to promote the Product in accordance with applicable federal, state and local laws, rules and regulations. 

	8.	DEFINITIVE AGREEMENT. In addition to terms described in this Heads of Agreement, the Co-Promotion Agreement shall contain ordinary and customary terms for an agreement in
which a pharmaceutical product of like nature is co-promoted in the US, such as insurance, warranties and the like. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 4 
 [***] 
 [***] to be [***]: 
 [***] 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 5 
 [***] 
 [***] to be [***]: 
 [***] 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 6 
 [***] 
  

							
	 	    	[***]	    	[***]	    	[***]
	 Regulatory [***]
	    		    		    	
				
	 Process [***]
	    		    		    	
				
	 [***]
	    		    		    	
				
	 Early [***]
	    		    	[***]	    	
				
	 [***] Characterization
	    		    		    	
				
	 [***] Support
	    		    		    	
				
	 [***] Support
	    		    		    	
				
	 [***] Support
	    		    		    	

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 7A 
 PRE-EXISTING PHARMASSET LICENSES 
 License Agreement between Apath, LLC and Pharmasset,
Ltd. (now Pharmasset, Inc.) dated October 18, 2000, regarding [***]. 
 License Agreement among [***], [***], and Pharmasset, Ltd. (now Pharmasset,
Inc.) dated [***], regarding [***]. 

 SCHEDULE 7B 
 PRE-EXISTING ROCHE LICENSES 
 None. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 8 
 [***] 
  

	1.	Upon [***] for [***]; 

  

	2.	[***]; and 

  

	3.	[***] regarding [***] are fulfilled; or 

  

	4.	In the event that [***], then [***] will [***]. 

  

	5.	In the event [***], [***] will [***]. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 9A 
 PHARMASSET DESIGNATED COUNTRIES 
 [***] 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 SCHEDULE 9B 
 ROCHE DESIGNATED COUNTRIES 
 [***]License Agreement, dated June 23, 2005

 EXHIBIT 10.2 
 Execution Copy 
 LICENSE AGREEMENT 
 BETWEEN 
 BUKWANG PHARM. CO., LTD. 
 AND 
 PHARMASSET, INC. 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page
	 ARTICLE 1.
	 	 DEFINITIONS
	  	2
			
	 ARTICLE 2.
	 	 LICENSES
	  	9
			
	 ARTICLE 3.
	 	 LICENSE FEE, ROYALTIES, AND MILESTONE PAYMENTS
	  	13
			
	 ARTICLE 4.
	 	 REPORTS AND ACCOUNTING
	  	17
			
	 ARTICLE 5.
	 	 PAYMENTS
	  	20
			
	 ARTICLE 6.
	 	 DEVELOPMENT PROGRAM
	  	22
			
	 ARTICLE 7.
	 	 JOINT PROJECT COMMITTEE
	  	23
			
	 ARTICLE 8.
	 	 PATENT PROSECUTION & TRADEMARK
	  	26
			
	 ARTICLE 9.
	 	 INFRINGEMENT
	  	30
			
	 ARTICLE 10.
	 	 TRANSFER OF KNOW-HOW; TECHNICAL ASSISTANCE
	  	31
			
	 ARTICLE 11.
	 	 WARRANTIES AND REPRESENTATIONS; LIMITATION OF LIABILITY; AND DISCLAIMERS
	  	34
			
	 ARTICLE 12.
	 	 INDEMNIFICATION
	  	41
			
	 ARTICLE 13.
	 	 CONFIDENTIALITY
	  	42
			
	 ARTICLE 14.
	 	 CONDITIONS PRECEDENT
	  	45
			
	 ARTICLE 15.
	 	 TERM AND TERMINATION
	  	46
			
	 ARTICLE 16.
	 	 ASSIGNMENT
	  	51
			
	 ARTICLE 17.
	 	 REGISTRATION OF LICENSE
	  	51
			
	 ARTICLE 18.
	 	 NOTIFICATION AND AUTHORIZATION UNDER DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT
	  	51
			
	 ARTICLE 19.
	 	 DISPUTE RESOLUTION AND ARBITRATION
	  	53
			
	 ARTICLE 20.
	 	 GENERAL PROVISIONS
	  	55
			
	 ARTICLE 21.
	 	 SUPPLY OF COMPOUND
	  	60

  

 i 

 LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT is executed as of June 23, 2005, by and between BUKWANG PHARM. CO., LTD., with its principal offices at 398-1, Daebang-Dong, Dongjak-Ku, Seoul 156-020, Korea (“Bukwang”),
and PHARMASSET, INC., with principal offices located at 1860 Montreal Road, Tucker, Georgia 30084, U.S.A. (“Pharmasset”). 
 WITNESSETH: 
 WHEREAS, Bukwang has evidenced the in vitro and in vivo activity of an L- nucleoside compound known
generically as “L-FMAU” OR “CLV” or “Clevudine”; 
 WHEREAS, L-FMAU is covered by patents and patent
applications filed in various countries throughout the world; 
 WHEREAS, Bukwang has entered into that certain license agreement, dated
December 28, 1995, as amended effective September 1, 1997, December 1, 1997, February 27, 1998 (now ineffective) and July 15, 2001 (collectively the “Primary License Agreement”) with Yale
University (“Yale”) and University of Georgia Research Foundation, Inc. (“UGARF”) (Yale and UGARF collectively, the “Primary Licensors”), a copy of which Primary License Agreement is attached hereto
as Exhibit A, pursuant to which Bukwang has obtained an exclusive worldwide license under the Primary Licensors’ patents and patent applications and has acquired the right to grant licenses under such patents and patent applications;

 WHEREAS, effective February 2, 1998, Bukwang entered into a License Agreement with Triangle Pharmaceuticals covering the Compound
(the “Triangle License Agreement”), which Triangle License Agreement was terminated effective August 6, 2003, in accordance with that certain Termination Procedure Letter dated July 5, 2003 attached hereto as Exhibit
B. 
 WHEREAS, Bukwang possesses certain technology and know-how relating to L-FMAU and has the right to grant licenses in respect of
such technology and know-how; and 
 WHEREAS, Pharmasset desires to obtain, and Bukwang desires to grant, an exclusive license for the
Territory under such patents, patent applications, technology and know-how. 
  

 1 

 NOW, THEREFORE, in consideration of the premises and the covenants herein contained, the parties agree as
follows: 
 ARTICLE 1. DEFINITIONS 
 The following terms as used herein, when written with an initial capital letter, shall have the meanings ascribed to them below: 
 1.1 “Acquisition Cost” shall mean the actual invoiced price paid by a party to any non-Affiliate third party for acquiring any item (e.g., a Compound or other active ingredient), including but not
limited to, shipping and handling costs and customs duties incurred and paid by such party in connection with the acquisition of such item. 
 1.2 “Affiliate” shall mean any corporation or non-corporate business entity which controls, is controlled by, or is under common control with a party to this Agreement. A corporation or non-corporate business entity shall
be regarded as in control of another corporation if it owns, or directly or indirectly controls, at least fifty (50%) percent of the voting stock of the other corporation, or (a) in the absence of the ownership of at least fifty
(50%) percent of the voting stock of a corporation or (b) in the case of a non-corporate business entity, or non-profit corporation, if it possesses, directly or indirectly, the power to direct or cause the direction of the management and
policies of such corporation or non-corporate business entity, as applicable. 
 1.3 “Agreement” shall mean this Agreement,
including all Exhibits attached hereto. 
 1.4 “Bukwang Know-How” shall mean all Know-How that is necessary or useful for
the development, manufacture, use, sale, offer for sale, import, export and/or registration of the Compounds or the Licensed Products that is Controlled by Bukwang as of the Effective Date (including, but not limited to, any Know-How licensed to
Bukwang under the Primary License Agreement), or which is not Joint Know-How or Joint Inventions, or at anytime during the term of this Agreement including, but not limited to, all manufacturing and synthesis Know-How. 
 1.5 “Bukwang Patents” shall mean all Patents in the Territory Controlled by Bukwang as of the Effective Date (including, but not limited
to, all Patents licensed to Bukwang 

  

 2 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
under the Primary License Agreement (the “Primary License Patents”) and under the Triangle License Agreement) or during the term of this
Agreement and that claim the development, registration, manufacture, use or sale, offer for sale, import and/or export of the Compounds or Licensed Products. All Bukwang Patents as of the Effective Date are listed in Exhibit C attached hereto
(all Bukwang Patents coming into existence after the Effective Date shall be listed on amendments to Exhibit C and attached hereto by the parties hereto within ten (10) days from the date such Patent comes into existence). For the
avoidance of doubt, Pharmasset acknowledges that the Primary License Patents do not include certain patents related to delta hepatitis virus applications, specifically, the patent family identified by U.S. patent number [***] and U.S. patent
application serial number [***] and all foreign counterpart patents and patent applications thereto. 
 1.6 “Bulk Drug
Substance” shall mean the Compound in bulk form which, if appropriately formulated and finished, would be suitable for preclinical or clinical use. 
 1.7 “cGMP” shall mean all applicable standards relating to manufacturing practices for fine chemicals, active pharmaceutical ingredients, intermediates, bulk products or finished pharmaceutical
products, including (i) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 210 and 211 and The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for
Medicinal Products as each may be amended from time to time, (ii) the principles detailed in the ICH Q7A guidelines, (iii) laws promulgated by any governmental authority having jurisdiction over the manufacture of Compound or Licensed
Product within the Territory, and (iv) publicly available guidance documents promulgated by any governmental authority having jurisdiction over the manufacture of Compound or Licensed Product (including but not limited to publicly available
advisory opinions, compliance policy guides and guidelines), which guidance documents are being implemented within the pharmaceutical manufacturing industry. 
 1.8 “Combination Product” shall mean any Licensed Product that contains Compound and one or more pharmaceutically active ingredients in addition to Compound. 
  

 3 

 1.9 “Compounds” shall mean the compound known as L-FMAU, with the chemical name
2’-fluoro-5-methyl-ß-L-arabinofuranosyluracil, including any salts, esters, isomers, solutes, polymorphs and derivatives thereof. 
 1.10 “Control” shall mean, with respect to any intellectual property right or other intangible property, that a party or one of its Affiliates owns or has a license or sublicense to such item or right, and has the ability
to grant access, license or sublicense in or to such right without violating the terms of any agreement or other arrangement with any third party. 
 1.11 “Development Program” shall mean the research and development program described in Article 6 of this Agreement. 
 1.12 “Dollars” shall mean United States dollars. 
 1.13 “Effective Date” shall mean the later of
(a) the date first written above and (b) the date, if any, that all of the conditions set forth in Section 14.1 shall have been satisfied or, if applicable, waived. 
 1.14 “FDA” shall mean the United States Food and Drug Administration or any successor entity thereto and any domestic equivalent within
the Territory. 
 1.15 “Field” shall mean all human antiviral applications and uses. 
 1.16 “First Commercial Sale” shall mean, with respect to a Licensed Product and on a country-by-country basis, the first commercial sale
after receipt of Registration of such Licensed Product in such country. Sales for clinical studies, compassionate use, named patient programs, or under a treatment IND, where the Licensed Product is supplied with or without charge shall not
constitute a First Commercial Sale. 
 1.17 “HBV” shall mean hepatitis B virus. 
 1.18 “IND” shall mean an Investigational New Drug Application, and any domestic equivalent within the Territory, filed with the FDA.

  

 4 

 1.19 “Indemnitees” shall mean (a) in the case of the indemnity set forth in
Sections 12.1, Bukwang, its Affiliates and sublicensees, the Primary Licensors, the Primary Licensors’ officers and directors, the University of Georgia and its employees, the Inventors (as that term is defined in the Primary License Agreement)
and their heirs, executors, administrators, and legal representatives; (b) in the case of the indemnity set forth in Section 12.2, Pharmasset, its Affiliates and sublicensees, and their directors, officers and employees; and (c) in
the case of the Indemnitees referenced in Section 12.3, the parties identified in Subsections 1.19(a) and 1.19 (b) above, as applicable. 
 1.20 “Invention” shall mean any discovery (whether patentable or not) conceived during the term of this Agreement and necessary or useful for the manufacture, use, development, import and/or export of Compounds or Licensed
Products or the sale or offer for sale of Licensed Products. 
 1.21 “Joint Inventions” shall mean any Inventions that are
jointly made by at least one (1) Bukwang employee or permitted contractor and at least one (1) Pharmasset employee or permitted contractor. 
 1.22 “Joint Know-How” shall mean all Know-How that is necessary or useful for the development, registration, manufacture, use, sale, offer for sale, import and/or export of the Compounds or the
Licensed Products that is developed jointly by at least one (1) Bukwang employee or permitted contractor and at least one (1) Pharmasset employee or permitted contractor during the term of this Agreement. All Joint Know-How shall be owned
jointly by the parties hereto. 
 1.23 “Joint Project Committee” shall mean the committee described in Article 7 hereof.

 1.24 “Know-How” shall mean any non-public information, results and data of any type whatsoever, in any tangible or
intangible form whatsoever, including without limitation, databases, ideas, discoveries, inventions, trade secrets, practices, methods, tests, assays, techniques, specifications, processes, formulations, formulae, knowledge, know-how, skill,
experience, materials, including pharmaceutical, chemical and biological materials, products and 

  

 5 

 
compositions, scientific, technical or test data (including pharmacological, biological, chemical, biochemical, toxicological and clinical test data),
analytical and quality control data, stability data, studies and procedures, drawings, plans, designs, diagrams, sketches, technology, documentation, and patent-related and other legal information or descriptions. 
 1.25 “Licensed Product(s)” shall mean any pharmaceutical product containing one or more Compounds as an active ingredient, alone or in
combination with other active ingredients. 
 1.26 “Manufacturing Cost” shall mean, with respect to a particular item (e.g.,
a Compound or other active ingredient), the costs of direct labor (including allocable employee benefits and employment taxes), direct material, direct energy, direct utilities and other charges incurred directly by a party in the manufacture by it
of such item and, without duplication, normal production overhead (i.e., indirect labor, utilities, maintenance, depreciation of the manufacturing equipment and facilities and other allocable overhead of the manufacturing facility), all determined
in accordance with U.S. GAAP. 
 1.27 “NDA” shall mean a New Drug Application, and any domestic equivalent within the
Territory, filed with the FDA. 
 1.28 “NDA Acceptance” shall mean the written notification without qualification by the FDA
that the NDA has met all the criteria for filing acceptance pursuant to 21 C.F.R. § 314.101. 
 1.29 “Net Sales” shall
mean, with respect to a Licensed Product, the gross sales price of such Licensed Product billed by Pharmasset, its Affiliates or sublicensees to independent customers less (to the extent actually given, paid or allowed, as appropriate, without
duplication): (a) normal and customary trade, quantity and cash discounts, all rebates (including those paid to third party payors), price reductions, reimbursements, credits or chargebacks, including any credits, volume rebates, charge-back
and prime vendor rebates, fees, fees for services or reimbursements granted or given to wholesalers and other distributors, buying groups, health care insurance carriers, pharmacy benefit management companies, health maintenance organizations or
other institutions or health care organizations; (b) sales, value added, use, or other similar taxes, and tariffs, custom duty, excise or other duty and any other official 

  

 6 

 
governmental charges; (c) transportation, freight, insurance and handling charges; (d) adjustments, allowances or credits (calculated on a per unit
basis) to customers, including without limitation on account of price adjustments, official governmental requirements, billing errors, rejection, damage, recalls, or returns (including allowances actually given for spoiled damaged, out-dated,
rejected, returned Licensed Product sold, withdrawals and recalls) of such Licensed Product; (e) payments or rebates paid in connection with sales of Licensed Products to any governmental or regulatory authority in respect of any state or
federal Medicare, Medicaid, P.P.R.S., or similar programs or to social or welfare systems, and (f) any item in the future substantially similar in character/substance to the foregoing, all determined in accordance with U.S. GAAP. For purposes
hereof, a sale shall be deemed to occur when a Licensed Product is billed. 
 In the event that Pharmasset or its Affiliates or sublicensees
distribute any Licensed Products to a third party for non-monetary consideration (e.g., barter or exchange), such distribution shall be considered a sale for accounting and royalty purposes; provided, however, the disposition of a Licensed Product
or the use of the Licensed Product in clinical studies, compassionate use, named patient programs, under a treatment IND, introduction, without sales, into a formulary or equivalent thereof, any nonregistrational non-commercial studies, patient
assistance program or any similar instance shall not result in any Net Sales. Net Sales for any such distributions shall be determined on a country-by-country basis and shall be the average price of “arm’s length” sales by Pharmasset
or its Affiliates or sublicensees in such country in the Territory during the royalty period in which such sale occurs or, if no such “arm’s length” sales occurred in such country in the Territory during such royalty period, during
the last royalty period in which such “arm’s length” sales occurred. If no “arm’s length” sales have occurred in a particular country in the Territory, Net Sales for any such distributions in such country in the
Territory, shall be the average price of “arm’s length” sales in all countries in the Territory during such royalty period. 
 For purposes of determining Net Sales of a Licensed Product that is sold as a Combination Product, the Net Sales of any such Combination Product shall be determined in any accounting period by multiplying the Net Sales of the Combination
Product by the fraction A/(A+B), where A is the average invoiced price per unit of the Licensed Product when sold as a 

  

 7 

 
stand-alone Licensed Product in finished form in the applicable country in the Territory and B is the average invoice price of the other product(s) sold as
stand-alone product(s) in finished form in the applicable country in the Territory. In the event that such average invoiced price cannot be determined for the Licensed Product or the other product(s), the fraction applied to Net Sales in the
applicable country in the Territory for purposes of determining royalties shall be one-half (1/2). In the event that a Combination Product containing a Compound and two or more other compound as active ingredients is sold in a country before a
Licensed Product containing only one or more Compounds is sold in that country, the portion of gross sales price of such Combination Products attributable to Compounds until a Licensed Product containing only one or more Compounds as active
ingredients is sold in that country shall be the percentage determined by dividing one by the number of active ingredients in that Combination Product. 
 1.30 “Patent” shall mean (i) patents, re-examinations, reissues, renewals, extensions, supplementary protection certificates and term restorations, any confirmation patent or registration patent
or patent of addition based on any such patent, (ii) pending applications for patents, including without limitation continuations, continuations-in-part, divisional, provisional and substitute applications, and inventors’ certificates,
(iii) all foreign counterparts of any of the foregoing, and (iv) all priority applications of any of the foregoing. 
 1.31
“Pharmasset Know-How” shall mean all Know-How Controlled by Pharmasset and arising solely out of the Development Program or the manufacture, use or sale of the Compounds that is useful for the development, registration,
manufacturing, using or selling of the Compounds that is not Joint Know-How or Joint Inventions during the term of this Agreement. For the avoidance of doubt, the Pharmasset Know-How shall not include any Know-How covering the development,
registration, manufacturing, using or selling of Racivir. 
 1.32 “Pharmasset Patents” shall mean all Patents Controlled by
Pharmasset claiming the development, registration, manufacturing, using or selling of the Compounds. As of the Effective Date, there are no Pharmasset Patents. All Pharmasset Patents coming into existence after the Effective Date shall be listed on
amendments to Exhibit D and attached hereto by the parties hereto within ten (10) days from the date such Patent comes into existence. For the 

  

 8 

 
avoidance of doubt, the Pharmasset Patents shall not include any Patent claiming the development, registration, manufacturing, using or selling of Racivir.

 1.33 “Registration” shall mean, in relation to any Licensed Product, such approvals by the regulatory authorities in a
given country (including pricing and reimbursement approvals, if any) as may be legally required before such Licensed Product may be commercialized or sold in such country. 
 1.34 “Retained Territory” shall mean all countries of the world other than those in the Territory. 
 1.35 “Territory” shall mean all the countries in Central America, North America, South America, Europe, the Caribbean and Israel,
including those countries set forth on Exhibit E, and any and all territories and possessions of any such countries. 
 1.36
“U.S. GAAP” shall mean generally accepted accounting principles in the United States, consistently applied. 
 1.37
“Valid Claim” shall mean an issued or granted claim of any issued and unexpired patent included among the Bukwang Patents that is listed on Exhibit C and that has not been held unenforceable, unpatentable or invalid by a
decision of a court or governmental body of competent jurisdiction, which is unappealable or unappealed within the time allowed for appeal, which has not been rendered unenforceable through disclaimer or otherwise or which has not been lost through
an interference or opposition proceeding. 
 ARTICLE 2. LICENSES 
 2.1 License Under Bukwang Patents and Bukwang Know-How. Bukwang hereby grants Pharmasset the exclusive right and license under the Bukwang Patents
and the Bukwang Know-How to develop, have developed, make, have made, use, import and export Compounds and Licensed Products for the purposes of offering for sale, selling and having sold Licensed Products (including, but not limited to, Bulk Drug
Substance) in the Territory in the Field during the term of this Agreement. 
  

 9 

 2.2 Extension to Affiliates. Pharmasset shall have the right to extend its rights under the
license granted in Section 2.1 to one or more of its Affiliates; provided, that Pharmasset (a) gives Bukwang at least thirty (30) days’ prior written notice of such extension and (b) shall remain responsible for such
Affiliate’s compliance with all Pharmasset’s obligations under this Agreement which apply to such Affiliate. 
 2.3 Sublicenses
to Third Parties. Pharmasset may grant sublicenses to non-Affiliate third parties without any consent; provided, however, in the event that Pharmasset proposes to grant a sublicense to a prospective non-Affiliate sublicensee which is not listed
among the top one hundred (100) pharmaceutical companies (based solely on pharmaceutical sales) by IMS, Pharmasset must first obtain the prior written consent of Bukwang and the Primary Licensors, which consent shall not be unreasonably
withheld or delayed; provided, further, however, the grant of rights to a third-party distributor authorized to import Licensed Product (“Distributor”) to distribute a Licensed Product shall not be considered a sublicense and,
therefore, Pharmasset shall not be required to obtain the prior consent of either Bukwang or the Primary Licensors prior to granting such rights to such Distributor. No sublicense granted by Pharmasset shall relieve it of any obligation hereunder.
With respect to any sublicense for which Bukwang’s consent is not required pursuant to this Section 2.3, Pharmasset shall provide Bukwang with notice of its intention to grant a sublicense at least fifteen (15) days prior to entering
into the applicable sublicense agreement. Pharmasset shall promptly provide Bukwang with a copy of any executed sublicense agreement subject to any third party confidentiality obligations. 
 2.4 License Under Pharmasset Patents and Pharmasset Know-How. Pharmasset hereby grants Bukwang a non-exclusive right and license under the
Pharmasset Patents and Pharmasset Know-How to make, have made, use, import, offer for sale, sell and have sold Licensed Products, with a right to sublicense, in the Retained Territory in the Field and in the event Pharmasset’s license granted
under Section 2.1 is terminated in a given country within the Territory (other than by expiration or by Pharmasset pursuant to Section 15.2 hereof) in such country from and after the date of termination. The license granted pursuant to
this Section 2.4 shall be royalty free; provided that if Pharmasset would be required to pay any amounts to any third party under the Pharmasset Patents and/or Pharmasset Know-How in the Retained 

  

 10 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
Territory, Bukwang shall be responsible for any and all such amounts solely with respect to the Retained Territory. 
 2.5 Covenant Not to Sue. Pharmasset and Bukwang agree that, during the term of this Agreement, neither it nor any of its Affiliates will assert
against the other party (a “licensed party”) or its Affiliates or sublicensees any patent not included in the Bukwang Patents or Pharmasset Patents, as applicable, that is or might be infringed by reason of such licensed party’s or
its Affiliates’ or sublicensees’ exercise of the license granted to it hereunder. 
 2.6 Right of First Refusal for Racivir.
Subject to any rights of third parties, including Gilead Sciences, Inc. or its successors (“Gilead”), as of the Effective Date, Pharmasset hereby grants Bukwang a right of first refusal to license under existing and future Patents
and Know-How Controlled by Pharmasset relating to the development, making, using, marketing and selling of Racivir for the treatment of HBV in Korea with no license fee or milestone payment obligations and with a royalty of [***] percent ([***]%) of
net sales of pharmaceutical product containing Racivir as an active ingredient. For purposes of this Section, “Racivir” means (±)-FTC, with the chemical name (±)-ß-2’,3’-dideoxy-5-fluoro-3’-thiacytosine.
In the event that Bukwang determines to exercise such right of first refusal it shall so notify Pharmasset (“Bukwang Notice”) and Pharmasset shall, within five (5) days of its receipt of the Bukwang Notice, notify each third
party with rights to Racivir of Bukwang’s election to exercise its right of first refusal hereunder, and Pharmasset shall notify Bukwang within five (5) days of a third party’s timely exercise or failure to timely exercise its right
of first refusal such that Bukwang may exercise its right without giving effect to an additional opportunity of such third party to exercise its right of first refusal. If a third party has not exercised its right of first refusal, the parties shall
negotiate in good faith for a period of ninety (90) days a separate agreement for the license rights contemplated by this Section 2.6. If the parties are unable to reach agreement during such time period, Pharmasset shall have no further
obligation to Bukwang under this Section 2.6. 
 2.7 Retained License. Pharmasset acknowledges that, pursuant to paragraph 2.2 of
the Primary License Agreement, the Primary Licensors have retained on their behalf and on the behalf of any of their research collaborators a royalty-free right and license to make and use 

  

 11 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
Compounds and Licensed Products and to practice the Licensed Technology (as defined therein) for research and educational purposes only. 
 2.8 United States Government Rights. Pharmasset acknowledges that the Bukwang Patents licensed under the Primary License Agreement, Bukwang
Know-How licensed under the Primary License Agreement, or portions thereof were developed with financial or other assistance through grants or contracts funded by the United States government. Pharmasset acknowledges that, in accordance with Public
Law 96-517, other applicable statutes, regulations and Executive Orders now in existence or as may be amended or subsequently enacted, the United States government has certain rights in the Bukwang Patents licensed under the Primary License
Agreement and Bukwang Know-How licensed under the Primary License Agreement. Pharmasset shall take all reasonable actions necessary to enable the Primary Licensors to satisfy their obligations of which Pharmasset is notified under any federal law
relating to the Bukwang Patents or Bukwang Know-How. If, at any time during the term of this Agreement, the United States government should take action which terminates the Primary License Agreement or requires that the Primary License Agreement be
terminated, Pharmasset acknowledges that, upon such termination, Pharmasset shall become a direct licensee with the Primary Licensors for the Territory pursuant to paragraph 2.5 of the Primary License Agreement and this Agreement shall continue with
respect to any Bukwang Patents and Bukwang Know-How that are not licensed under the Primary License Agreement. If, due to such government action, Pharmasset becomes a direct licensee with the Primary Licensors, the parties hereto shall negotiate in
good faith, in light of amendments, if any, to the Primary License Agreement, as to a reduction of royalty obligations hereunder as may then be necessary to ensure that the royalty due to Bukwang shall not be more than [***] percent ([***]%) and the
total royalty due to both the Primary Licensors and Bukwang shall not be more than [***] percent ([***]%). In the event that the Primary License Agreement is terminated and Pharmasset becomes a direct licensee with the Primary Licensors and the
royalty due to Bukwang immediately prior to such termination of the Primary License Agreement is less than [***] percent ([***]%) for any country in the Territory, the royalty due to Bukwang for such country shall decrease proportionately and shall
not be more than [***] percent ([***]%) of the royalty due to Bukwang before such termination. As an example, in the event that the Primary License Agreement is terminated and Pharmasset becomes a direct licensee with the Primary Licensors and the
royalty payable by Pharmasset to Bukwang 

  

 12 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
in a given country immediately prior to such termination was [***] percent ([***]%), then the royalty due to Bukwang for such country shall not be more than
[***] percent ([***]%). 
 2.9 No Implied License. The license and rights granted in this Agreement to Pharmasset shall not be
construed to confer any rights upon Pharmasset by implication, estoppel or otherwise as to any technology, know-how or any other intellectual property not specifically identified as Bukwang Patents or Bukwang Know-How. The license and rights granted
in this Agreement to Bukwang shall not be construed to confer any rights upon Bukwang by implication, estoppel or otherwise as to any technology, know-how or any other intellectual property not specifically identified as Pharmasset Patents or
Pharmasset Know-How. 
 2.10 Joint Know-How. During the term of this Agreement, with respect to Compounds or Licensed Products,
Pharmasset shall have the exclusive right to use all Joint Know-How in the Territory, and Bukwang and its sublicensee shall have the exclusive right to use all Joint Know-How within the Retained Territory. 
 ARTICLE 3. LICENSE FEE, ROYALTIES, AND MILESTONE PAYMENTS 
 3.1 License Fee. As partial consideration for entering into this Agreement, Pharmasset shall pay Bukwang a license fee of six million United States Dollars (USD $6,000,000) (“License Fee”),
provided that one million United States Dollars (USD $1,000,000) of the License Fee shall be paid within ten (10) days after the full execution hereof (“Initial Payment”) and the remaining five million United States Dollars
(USD $5,000,000) shall be paid within fifteen days after receipt of an invoice specifying the satisfaction or waiver of all conditions precedent contained in Article 14; provided, further, that in the event that any such condition precedent remains
unsatisfied and is not waived at the close of business on the forty-fifth (45th) day following the date of full execution hereof (subject to one fifteen (15) day extension at the election of either party if the only such condition then
remaining unsatisfied and not waived is the condition set forth in Section 14.1(a) hereof), then the Initial Payment shall be returned to Pharmasset forthwith, no further payment of the remaining License Fee shall be payable and the Effective
Date shall be deemed not to have occurred, such that this Agreement shall be of no further force and effect. 
  

 13 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 3.2 Milestone Payments. So long as the Primary License Agreement is then in effect, Pharmasset
shall pay Bukwang the milestone payments (each, a “Milestone Payment”) in the amounts specified below no later than thirty (30) days after the occurrence of the corresponding event designated below, unless Pharmasset has given
Bukwang notice of termination of this Agreement in the entire Territory prior to such due date. 
  

					
	 	  	 Milestone
	  	 Milestone Payment

			
	 (a)
	  	The earlier of (i) first patient dosed in the first FDA accepted pivotal (i.e., used for registration purposes in the Territory) Phase III clinical study wherever located or (ii) first patient
dosed after designation of a Phase II clinical study as a FDA accepted pivotal Phase III clinical study wherever located used for registration purposes in the Territory.	  	 USD $1,000,000

			
	 (b)
	  	NDA Acceptance in the Territory	  	 USD $ [***]

			
	 (c)
	  	FDA Approval of the NDA in the Territory	  	 USD $ [***]

			
	 (d)
	  	First Commercial Sale in the United States	  	 USD $ [***]

			
	 (e)
	  	First Commercial Sale in Europe	  	 USD $ [***]

			
	 (f)
	  	First time achievement of USD $[***] in annual Net Sales in the Territory	  	 USD $ [***]

			
	 (g)
	  	First time achievement of USD $[***] in annual Net Sales in the Territory	  	 USD $ [***]

			
	 (h)
	  	First time achievement of USD $[***] in annual Net Sales in the Territory	  	 USD $ [***]

			
		  	Total Milestone Payments	  	 USD $ [***]

 3.3 Earned Royalties; Duration and Reduction. 
 (a) Pharmasset shall pay Bukwang a royalty equal to [***] percent ([***]%) of the Net Sales of Licensed Products sold in the Territory by
Pharmasset and its Affiliates and sublicensees; provided, however, if a sublicensee is listed among the top one hundred (100) pharmaceutical companies (based solely on pharmaceutical sales) by IMS, then Pharmasset shall only pay Bukwang a
royalty equal to [***] percent ([***]%) of the Net Sales of Licensed Products sold in the Territory by any such sublicensee. 
 (b) Royalties under this Article 3 shall be paid in respect of Licensed Products in a given country for a period of [***] ([***]) years after the First Commercial Sale of a Licensed Product in such country in case that, in such particular
country, no Valid Claim is 

  

 14 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
granted. For the countries where a Valid Claim is granted, royalties shall be paid in respect of a given Licensed Product in such country only so long as the
manufacture (excluding packaging), use, offer for sale, sale or importation of such Licensed Product in such country would, in the absence of this license, infringe a Valid Claim in such country. 
 (c) Subject to Article 9 of this Agreement, if at any time during the term of this Agreement, (i) a third party or third parties
commence selling a product in a country of the Territory and (ii) such product contains any Compound (“Unlicensed Unit Sales”), then (A) if such Unlicensed Unit Sales for any royalty period amount to more than [***]
percent ([***]%) and less than [***] percent ([***]%) of Pharmasset’s Unit Sales of Licensed Product containing such Compound in such country in such royalty period, determined in accordance with Section 3.3(d) below, then
Pharmasset’s royalty obligation in such country with respect to such Licensed Product shall be reduced by [***] percent ([***]%) of the Net Sales, or (B) if such Unlicensed Unit Sales for any royalty period amount to more than [***]
percent ([***]%) of Pharmasset’s Unit Sales of Licensed Product containing such Compound in such country in such royalty period, determined in accordance with Section 3.3(d) below, then Pharmasset’s royalty obligation in such country
with respect to such Licensed Product shall be reduced by [***] percent ([***]%) of the Net Sales. Notwithstanding the foregoing, in no event shall the royalty due to Bukwang be reduced to less than [***] percent ([***]%); provided that, it will not
be deemed to be commercially unreasonable for Pharmasset not to sell Product in any country in which Unlicensed Unit Sales for any royalty period amount to more than [***] percent ([***]%) of Pharmasset’s Unit Sales in such country in the last
prior royalty period, determined in accordance with Section 3.3(d) below. 
 (d) For purposes of this Section 3.3,
(i) “Unlicensed Unit Sales” and “Pharmasset’s Unit Sales” shall be deemed to mean the Compound contained in the third party products (irrespective of dosage form) and the Licensed Product (irrespective of dosage form),
respectively, as reflected on the label of each such unit; and (ii) Unlicensed Unit Sales shall be determined by the sales reports of IMS or any successor to IMS or any other independent marketing auditing firm selected by Pharmasset and
reasonably acceptable to Bukwang. If Pharmasset is entitled to a royalty reduction based on Unlicensed Unit Sales pursuant to Section 3.3(c) for any royalty period, Pharmasset shall submit the sales report of IMS or such other 

  

 15 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
independent firm, as applicable for the relevant royalty period to Bukwang, together with Pharmasset’s sales report for the relevant royalty period.
Such sales reports for each royalty period in which Pharmasset is entitled to such royalty reduction shall be submitted with the royalty report for such royalty period submitted pursuant to Section 4.1. 
 3.4 Annual Minimum Royalties. In the event that, during the [***] full calendar year following the year during which the FDA Registration for an
HBV indication is granted for a Licensed Product or any calendar year thereafter for as long as royalty obligations exist in at least [***] Major Market Countries (as defined below), Pharmasset’s total annual royalty payments to Bukwang
pursuant to Section 3.3 above are less than $[***] (the “Annual Minimum”), Pharmasset shall make a payment to Bukwang together with the royalty report for the fourth quarter of such year required in Section 4.1 of this
Agreement equal to the difference between such Annual Minimum and the royalties paid to Bukwang for the preceding year pursuant to Section 3.3 above. As used in this Section 3.4, “Major Market Countries” shall mean the
United States, Italy, Spain, France and Germany. 
 3.5 Accrual of Royalties. No royalty shall be payable on a Licensed Product made,
sold, or used for tests or development purposes, or distributed as samples. No royalties shall be payable on sales of Licensed Products among Pharmasset, its Affiliates and sublicensees, but royalties shall be payable on subsequent sales by
Pharmasset, its Affiliates or sublicensees to a third party. No multiple royalty shall be payable because the manufacture, use or import of Compounds or a Licensed Product or offer for sale or sale of a Licensed Product is covered by more than one
Valid Claim or by at least one Valid Claim and the Bukwang Know-How. 
 3.6 Compulsory Licenses. Should a compulsory license be
granted to any third party in any country of the Territory to make, have made, use, import, offer for sale or sell Licensed Products, the royalty rate payable hereunder for sales of the Licensed Products by Pharmasset in such country shall be
adjusted to match any lower royalty rate granted to the third party for such country. 
 3.7 Third Party Patents. If Pharmasset, due
to a claim of infringement by a third party, is required, after consultation with Bukwang, to obtain a license from any third party under any patent in order to use, make, have made, offer for sale or sell a Licensed Product, or if 

  

 16 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
Pharmasset is required, after consultation with Bukwang, to pay a royalty under such license calculated on sales of a Licensed Product in any country, and
the infringement of such third party patent cannot reasonably be avoided by Pharmasset, or if Pharmasset is required by a court of competent jurisdiction to pay such a royalty, then Pharmasset’s obligation to pay royalties to Bukwang based on
sales of the same Licensed Product in such country under this Article 3 shall be reduced by [***] percent ([***]%) of the amount of the royalty paid to such third party. In addition, if Pharmasset is required to pay upfront payments, license fees,
milestone payments or other similar payments to such third party in consideration for such license, then Pharmasset may amortize the amount of such other payment equally over a [***] period and apply such amounts as a credit against its royalty
payment obligations. Notwithstanding the foregoing, in no event shall the royalty due to Bukwang pursuant to Section 3.3(a) be reduced to less than [***] percent ([***]%). 
 ARTICLE 4. REPORTS AND ACCOUNTING 
 4.1 Royalty Reports and
Records. 
 (a) During the term of this Agreement commencing with the First Commercial Sale of the first Licensed Product,
Pharmasset shall furnish, or cause to be furnished to Bukwang, written reports governing each of Pharmasset’s fiscal quarters showing: 
 (i) the gross sales of all Licensed Products sold by Pharmasset, its Affiliates and sublicensees during the reporting period, together with the calculations of Net Sales in accordance with Sections 1.29; and

 (ii) the royalties payable in Dollars, which shall have accrued hereunder in respect of such Net Sales; and 
 (iii) the exchange rates used, if any, in determining the amount of Dollars; and 
 (iv) any Withholding Taxes (as defined below). 
  

 17 

 (b) With respect to sales of the Licensed Product invoiced in Dollars, the gross sales,
Net Sales, and royalties payable shall be expressed in Dollars. With respect to sales of the Licensed Product invoiced in a currency other than Dollars, the gross sales, Net Sales, and royalties payable shall be expressed in the domestic currency of
the party making the sale together with the Dollar equivalent of the royalty payable, calculated using the simple average of the exchange rates published in the Wall Street Journal on the last day of each month during the reporting period. If any
Pharmasset Affiliate or sublicensee makes any sales invoiced in a currency other than its domestic currency, the gross sales and Net Sales shall be converted to its domestic currency in accordance with the Affiliate’s or sublicensee’s
normal accounting practices. 
 (c) Reports shall be made on a quarterly basis. Quarterly reports shall be due within sixty
(60) days after the close of every Pharmasset fiscal quarter and shall be prepared in accordance with U.S. GAAP. Pharmasset shall keep accurate records in sufficient detail to enable royalties and other payments payable hereunder to be
determined. Pharmasset shall be responsible for all royalties and late payments that are due to Bukwang that have not been paid by Pharmasset’s Affiliates and sublicensees. Pharmasset’s Affiliates and sublicensees shall have, and shall be
notified by Pharmasset that they have, the option of making any royalty payment directly to Bukwang. 
 (d) Withholding
Taxes. Bukwang will be responsible for any and all income or other taxes owed by Bukwang and required by applicable law to be withheld or deducted from any of the royalty and other payments made by or on behalf of Pharmasset to Bukwang hereunder
(“Withholding Taxes”), and Pharmasset may deduct from any amounts that Pharmasset is required to pay hereunder an amount equal to such Withholding Taxes. Pharmasset will provide Bukwang with reasonable advance notice of tax
withholding obligations to which it reasonably believes that it is subject. Bukwang will provide Pharmasset any information available to Bukwang that is necessary to determine the Withholding Taxes. Such Withholding Taxes will be paid by Pharmasset
to the proper taxing authority for Bukwang’s account and evidence of such payment will be secured and sent to Bukwang within one (1) month of such payment. 
  

 18 

 4.2 Records of Sales. In order to enable Bukwang to exercise its audit rights pursuant to Section
4.3, Pharmasset, its Affiliates and sublicensees shall keep at their respective principal place of businesses true and accurate records of all sales hereunder in accordance with generally accepted accounting principles in such form and manner so
that all royalties owed to Bukwang may be readily and accurately determined. Pharmasset shall furnish Bukwang copies of such records upon Bukwang’s request, which request shall not be made more often than once per calendar year. 
 4.3 Right to Audit. Bukwang (or the Primary Licensors on Bukwang’s behalf if authorized in writing to Pharmasset by Bukwang and provided they
agree to be bound by the provisions of Sections 4.3 and 4.4) shall have the right, upon prior notice to Pharmasset, not more than once in each Pharmasset fiscal year nor more than once in respect of any calendar year, through an independent
certified public accountant selected by Bukwang or the Primary Licensors, as applicable, and acceptable to Pharmasset, which acceptance shall not be unreasonably refused, to have access during normal business hours to those records of Pharmasset as
may be reasonably necessary to verify the accuracy of the royalty reports required to be furnished by Pharmasset pursuant to Section 4.1 of the Agreement. Such accountant may report only the accuracy or inaccuracy of the royalty reports furnished by
Pharmasset and, in the event they are determined to be inaccurate, the corrections in the amounts which need to be made to such reports. Pharmasset shall include in any sublicenses granted pursuant to this Agreement a provision requiring the
sublicensee to keep and maintain records of sales made pursuant to such sublicense in accordance with U.S. GAAP and to grant access to such records by Bukwang’s or the Primary Licensors’ independent certified public accountant, as
applicable, under the same terms that Bukwang has access to Pharmasset’s records. If such independent certified public accountant’s report shows any underpayment of royalties by Pharmasset its Affiliates or sublicensees, within thirty (30)
days after Pharmasset’s receipt of such report, Pharmasset shall remit or shall cause its sublicensees to remit to Bukwang: 
 (a) the amount of such underpayment; and 
  

 19 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 (b) if such underpayment exceeds [***] percent ([***]%) of the total royalties owed
for the fiscal year then being reviewed, the reasonably necessary fees and expenses of such independent certified public accountant performing the audit. 
 Otherwise, Bukwang’s accountant’s fees and expenses shall be borne by Bukwang. Any overpayment of royalties shall be fully creditable against future royalties payable in any subsequent royalty periods or if
this Agreement terminates or expires before such overpayment is fully credited, Bukwang agrees to refund the uncredited portion of such overpayment within thirty (30) days after receipt of the final royalty payment hereunder. Upon the expiration of
[***] ([***]) months following the end of any fiscal year during the term of this Agreement or until the end of Pharmasset’s next subsequent fiscal year after the termination or expiration of this Agreement, the calculation of royalties payable
with respect to such fiscal year shall be binding and conclusive on Bukwang and Pharmasset, unless an audit for such fiscal year is initiated before expiration of such period. Pharmasset shall retain, and shall cause its Affiliates and sublicensees
to retain, those records required to be maintained pursuant to this Section 4.3 in respect of each fiscal year for a period of [***] ([***]) months after the end of such fiscal year during the term of this Agreement and until the end of
Pharmasset’s next subsequent fiscal year thereafter. If Pharmasset disputes the findings generated pursuant to this Section 4.3, the parties shall meet and discuss such dispute. If such dispute is not resolved within forty-five (45) days, then
it shall be subject to Article 19. 
 4.4 Confidentiality of Records. All information subject to review under this Article 4 shall be
confidential. Except where otherwise required by law, Bukwang and its accountant shall retain all such information in confidence. 
 ARTICLE 5. PAYMENTS 
 5.1 Payments and Due Dates. Except as otherwise provided herein, royalties and other
amounts payable to Bukwang as a result of activities occurring during the period covered by each royalty report provided for under Article 4 of this Agreement shall be due and payable on the date such royalty report is due. Payments of royalties and
other amounts in whole or in part may be made in advance of such due date. Bukwang and Pharmasset agree that unless otherwise agreed by the parties, Pharmasset will remit all royalties and other amounts due 

  

 20 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
pursuant to Article 3 of this Agreement to Bukwang and Bukwang shall, in turn, be responsible for paying any amounts owed to the Primary Licensors pursuant
to the Primary License Agreement. 
 In the event the Primary License Agreement is terminated (including as contemplated by Section 2.8
hereof), Pharmasset and Bukwang acknowledge and agree that, upon such termination, Pharmasset shall become a direct licensee with the Primary Licensors and this Agreement shall continue with respect to any Bukwang Patents and Bukwang Know-How that
are not licensed under the Primary License Agreement. If Pharmasset becomes a direct licensee with the Primary Licensors, the parties hereto shall negotiate in good faith, in light of the royalties to be paid by Pharmasset directly to the Primary
Licensors, as to a reduction of royalty obligations hereunder as may then be necessary to ensure that the royalty due to Bukwang shall not be more than [***] percent ([***]%) and the total royalty due to both the Primary Licensors and Bukwang shall
not be more than [***] percent ([***]%). In the event that the Primary License Agreement is terminated and Pharmasset becomes a direct licensee with the Primary Licensors and the royalty due to Bukwang immediately prior to such termination of the
Primary License Agreement is less than [***] percent ([***]%) for any country in the Territory, the royalty due to Bukwang for such country shall decrease proportionately and shall not be more than [***] percent ([***]%) of the royalty due to
Bukwang before such termination. As an example, in the event that the Primary License Agreement is terminated and Pharmasset becomes a direct licensee with the Primary Licensors and the royalty payable by Pharmasset to Bukwang in a given country
immediately prior to such termination was [***] percent ([***]%), then the royalty due to Bukwang for such country shall not be more than [***] percent ([***]%). 
 5.2 Wire Transfer. All payments to Bukwang shall be made by wire transfer to an account of Bukwang designated by Bukwang from time to time; provided, however, that in the event that Bukwang fails to designate
such account, Pharmasset or its Affiliates and sublicensees may remit payment to Bukwang to the address applicable for the receipt of notices hereunder; provided, further, that any notice by Bukwang of such account or change in such account, shall
not be effective until fifteen (15) days after receipt thereof by Pharmasset. 
  

 21 

 5.3 Currency Restrictions. Except as hereinafter provided in this Section 5.3, all royalties and
other amounts shall be paid in Dollars. If, at any time, legal restrictions prevent the prompt remittance of part of or all royalties with respect to any country in the Territory where Licensed Products are sold, Pharmasset or its sublicensee shall
have the right and option to make such payments by depositing the amount thereof in local currency to Bukwang’s accounts in a bank or depository in such country. 
 5.4 Overdue Payments. In the event any payment due hereunder is not made when due, the payment shall accrue simple interest (beginning on the date such payment is due) at the lower of (a) the US Prime Rate, as
reported in the Wall Street Journal, Eastern Edition, on the due date (or, if the due date is not a business day, on the last business day prior to such due date), or (b) the maximum rate permitted by applicable law, and such payment when made shall
be accompanied all interest so accrued; provided that such interest shall not be due to the extent that such payment is the subject of a good faith dispute by Pharmasset. The remittance of such interest shall not foreclose Bukwang from exercising
any other rights it may have pursuant to this Agreement because such payment is late. 
 ARTICLE 6. DEVELOPMENT PROGRAM

 6.1 Development Program. Within ninety (90) days following transfer by Gilead or Bukwang to Pharmasset of the IND for the
United States in respect of the Compound and Licensed Product (or, in the event that Pharmasset demonstrates that such time period is impracticable, then as such time period is extended by the parties hereto), Pharmasset will prepare a detailed
development plan with the objective of filing an NDA with the FDA in the United States and demonstrating that it has or will have the resources, marketing and medical expertise to attain such goal. Subject to Bukwang’s timely performance of its
obligations hereunder, and in complete fulfillment of Pharmasset’s diligence obligations hereunder and any such obligations implied by law, Pharmasset will undertake, or, if applicable, will cause its Affiliates and sublicensees to undertake,
the development activities described in this Article 6. Pharmasset shall, at its expense, use Commercially Reasonable Efforts (a) to conduct a development program (the “Development Program”) relating to the use of the Licensed
Product for HBV and (b) if the results of the Development Program so justify, to seek Registration for such Licensed Product in the United States and Europe. The Development Program shall be 

  

 22 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
mutually discussed by the parties hereto at the meetings of the Joint Project Committee held pursuant to Article 7 and shall take into consideration studies
and experiments carried out, or to be carried out by, Bukwang and its licensees, if any, outside the Territory, but the activities within the Territory comprising the Development Program shall be determined at Pharmasset’s sole discretion.
Anything in this Agreement to the contrary notwithstanding, Pharmasset shall be entitled to exercise prudent and justifiable business judgment in meeting its Commercially Reasonable Efforts obligations hereunder, provided, however, that (a)
Pharmasset shall initiate a clinical study no later than [***] ([***]) months after the above-referenced transfer of the IND to Pharmasset, or such longer period as may be required to address any FDA requirements, provided that Pharmasset is
actively addressing such requirements (it being understood that, if a clinical study has not been initiated within such [***] ([***]) month period, Pharmasset shall amend the Development Program in a manner reasonably satisfactory to Bukwang to
address Pharmasset’s response to any such FDA requirements); and (b) in no event shall Pharmasset’s filing of an NDA with the FDA in the United States occur later than the [***] ([***]) anniversary of such IND transfer to Pharmasset,
subject to extension, as negotiated in good faith by the parties hereto, in the event of regulatory actions beyond the control of the parties hereto or in the event that Bukwang fails to supply Pharmasset with sufficient quantities of clinical
supply to enable Pharmasset to conduct the development activities. For purposes of this Article 6, “Commercially Reasonable Efforts” shall mean the efforts and resources which would be used (including without limitation the
promptness in which such efforts and resources would be applied) by Pharmasset consistent with its normal business practices, with respect to a product or potential product at a similar stage in its development or product life taking into account
efficacy, safety, commercial value, the competitiveness of alternative products that are in the marketplace or under development, and the patent and other proprietary position of such product. 
 ARTICLE 7. JOINT PROJECT COMMITTEE 
 7.1 Appointment of
Coordinators. As soon as practicable after the Effective Date, Bukwang and Pharmasset shall each appoint an authorized representative (each, a “Coordinator”). Each party shall provide notice to the other as to the identity of
the individual so appointed. Each Coordinator shall be responsible for communications, other than legal notices, 

  

 23 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
between the parties with respect to the subject matter of this Agreement. Each party may replace its Coordinator at any time for any or no reason by
providing written notice to the other party. 
 7.2 Joint Project Committee. The Coordinators shall establish the Joint Project
Committee consisting of representatives of Pharmasset and Bukwang. The Joint Project Committee will consist of at least three (3) persons from each of Pharmasset and Bukwang, such persons having significant responsibility for the development and/or
marketing of the Licensed Product. The Joint Project Committee will meet from time to time at mutually agreeable times via teleconference or in-person, but no less than semi-annually during the term of this Agreement. The Coordinators shall set the
agenda for each meeting, and each Coordinator shall determine which regular members of Joint Project Committee and other representatives of such Coordinator’s party shall attend in light of the agenda. Each party shall bear its own costs
incurred in connection with participation in the Joint Project Committee. 
 7.3 Objective of the Joint Project Committee. The primary
objective of the Joint Project Committee will be to facilitate the expeditious Registration of a Licensed Product in the United States and Europe by Pharmasset and in Korea by Bukwang by, inter alia: 
 (a) subject to Section 7.5, facilitating the exchange of data and study results between the parties; 
 (b) providing a forum for protocol and development plan review; and 
 (c) coordinating the developmental efforts of the parties so as to avoid duplication and inconsistency of such efforts. 
 7.4 Due Consideration. Each party agrees to give due consideration to any input received from the other party at such Joint Project Committee
meetings; provided, however, that all final decisions relating to the development of Licensed Products in the [***] will be made by [***] and all final decisions relating to the development of Licensed Products in [***] will be made by [***].

 7.5 Exchange of Study Results. Each party shall submit a report detailing the results of each non-clinical and clinical study which
it performs to the other party within thirty (30) days 

  

 24 

 
after completion of the final statistical analyses of the results of such study. In addition, each party will provide the other party with semi-annual
progress reports summarizing its activities in respect of the development of Licensed Products during the relevant semi-annual period. Such reports shall cover the semi-annual periods ending each June 30 and December 31 and shall be due on or before
July 15 and January 15 of each year, respectively. 
 Each party shall permit the other party, including sublicensees of other party, access
to and grant such other party the right to reference and use for any purpose, all data, regulatory filings and regulatory communications associated with any submissions for regulatory approval or other issues associated with any Licensed Product. To
the extent that any such data, regulatory filings or regulatory communications are held by a third party, the Party shall arrange direct access to the portions of such data, regulatory filings or regulatory communications for the other party.
Notwithstanding the foregoing, in the event any such data, filings or communications of Pharmasset relate to a Combination Product, Bukwang shall only be entitled to reference such data, filings or communications in Korea and no other country in the
Retained Territory and shall not be entitled to share such data, filings or communications with any third party. 
 7.6 Publications.
Each party reserves the right to publish or publicly present the results of its own development activities in respect of the Licensed Products (the “Results”). The party proposing to publish or publicly present the Results (the
“publishing party”) will, however, submit a draft of any proposed manuscript, abstract, speech, transparencies, presentation materials and press releases to the other party (the “non-publishing party”) for comments
at least thirty (30) days prior to submission for publication or oral presentation, except, in the case of press releases, where applicable law, in the reasonable opinion of the publishing party, requires such press release to be issued within time
constraints which would make such review impractical. The non-publishing party shall notify the publishing party in writing within thirty (30) days of receipt of such draft whether such draft contains Information (as hereinafter defined) of the
non-publishing party which it considers to be confidential under the provisions of Article 13 hereof, or information that if published would have an adverse effect on a patent application for which non-publishing party has initial patent prosecution
responsibility pursuant to Article 8 of this Agreement. In the latter case, the non-publishing party shall have the right to request a 

  

 25 

 
delay and the publishing party shall delay such publication for a period not exceeding sixty (60) days. In any such notification the non-publishing party
shall indicate with specificity its suggestions regarding the manner and degree to which the publishing party may disclose such information. The publishing party shall have the final authority to determine the scope and content of any publication,
provided that such authority shall be exercised with reasonable regard for the interests of the non-publishing party, except that no publication will contain any Information disclosed by the non-publishing party to the publishing party without the
non-publishing party’s prior written permission. Each party shall cause its Affiliates, licensees or sublicensees, as the case may be, to comply with the requirements of this Section 7.5 with respect to any of their proposed publications.

 ARTICLE 8. PATENT PROSECUTION & TRADEMARK 
 8.1 Title to Inventions. Each party shall have and retain sole title in Inventions, whether or not patentable, made by it or on its behalf (as by its employees or agents) in the course of work performed under
this Agreement. 
 8.2 Bukwang Patents. 
 (a) During the period ending ninety (90) days after the Effective Date, Bukwang shall, in consultation with Pharmasset, file, prosecute and maintain all patent applications and patents included in the Bukwang Patents
which Bukwang owns, if any, at Bukwang’s sole expense. At the end of such ninety (90) day period, in the Territory, Pharmasset shall assume responsibility for filing, prosecution and maintenance of the Bukwang Patents owned by Bukwang, if any,
at Pharmasset’s expense. Bukwang and its patent counsel will cooperate fully with Pharmasset and its patent counsel to effect an orderly transfer of such prosecution and maintenance responsibilities. 
 (b) With respect to any Bukwang Patents licensed to it pursuant to the Primary License Agreement in the Territory, Pharmasset shall have
those rights relating to the prosecution and maintenance of such Bukwang Patents as are set forth in Article 7 of the Primary License Agreement. 
  

 26 

 (c) Except as otherwise expressly set forth in the first sentence of Section 8.2(a),
Pharmasset agrees to reimburse the Primary Licensors or Bukwang, as applicable, for all external fees, costs and expenses incurred by them after the period provided in Section 8.2(a) in filing, prosecuting and maintaining the Bukwang Patents in
the Territory. Invoices, including reasonable substantiation thereof, shall be submitted once in respect of each fiscal quarter as promptly as practicable after the end of such quarter. Payments shall be due net thirty (30) days from the date
of receipt of the invoice. If Pharmasset fails to reimburse Bukwang or the Primary Licensors, as applicable, for any undisputed patent prosecution expenses respecting any patent application or issued patent included in the Bukwang Patents within the
time allowed therefor, upon at least thirty (30) days’ prior written notice to Pharmasset, Bukwang or the Primary Licensors, as applicable, may remove such patent application or issued patent from the Bukwang Patents and Bukwang or the
Primary Licensors shall be free, at its or their election, to abandon or maintain the prosecution of such patent application or issued patent or grant rights to such patent application or issued patent to third parties. 
 (d) Pharmasset reserves the right to terminate its obligations pursuant to this Section 8.2 with respect to any patent application or
patent included in the Bukwang Patents in any country or countries upon at least ninety (90) days’ prior written notice to Bukwang and the Primary Licensors. After the date specified in such notice on which Pharmasset’s obligation to
pay further expenses terminates, such patent application or patent, as the case may be, shall no longer be included in the Bukwang Patents in those countries in which Pharmasset has exercised its rights to terminate such obligations. 
 8.3 Pharmasset Inventions. Pharmasset shall, in consultation with Bukwang, file such patent applications regarding any of the Pharmasset Patents
and thereafter shall diligently and in the exercise of its discretion in a manner reasonably consistent with the goals and expectations of the parties hereunder, giving due and reasonable consideration to Bukwang’s position, prosecute and
maintain in force the resulting Pharmasset Patents, all at Pharmasset’s expense. Pharmasset shall enable Bukwang to directly contact and confer with Pharmasset’s patent counsel, at Bukwang’s expense, with respect to the prosecution of
any patent applications constituting part of the Pharmasset Patents and shall use its reasonable efforts to amend, correct or refile any patent or patent application included in the Pharmasset Patents to include claims reasonably 

  

 27 

 
requested by Bukwang. The territorial scope of such filings shall be the subject of specific discussion between the parties. If for any reason Pharmasset
declines to file a patent application or, having filed, declines to prosecute or maintain any of the Pharmasset Patents in any country, Bukwang may so file, prosecute or maintain in Pharmasset’s name and at Bukwang’s expense in such
country, in which event, Pharmasset shall, at Bukwang’s request and expense, provide all reasonable assistance. 
 8.4 Joint
Inventions. With respect to Joint Inventions: (a) all patent applications and patents with respect thereto shall be jointly owned by Bukwang and Pharmasset; (b) Pharmasset and its sublicensees and assignees shall be free to use such
patent application and patents in the Territory and Bukwang and its licensees and assignees shall be free to use such patent applications and patents in the Retained Territory, in each event, without payment of royalty or accounting therefor;
(c) each party agrees to consult with the other party and to give due and reasonable consideration to the other party’s position in determining the territorial scope of patent filings within the Territory (in the case of Pharmasset) and
outside the Territory (in the case of Bukwang), and the prosecution and maintenance of resulting patent rights based on Joint Inventions; and (d) Pharmasset shall have the sole right and discretion to file within the Territory, and Bukwang
shall have the sole right and discretion to file within the Retained Territory, any patent application and prosecute and maintain any resulting patent rights on Joint Inventions, in which event, the non-filing party shall, at the filing party’s
request, provide all reasonable assistance and shall promptly reimburse the filing party with fifty percent (50%) of the reasonable out-of-pocket expenses so incurred by the filing party. 
 8.5 Further Obligations. 
 (a) Except as otherwise provided in Article 9 and 18, each party’s responsibilities for patent prosecution activities pursuant to this Article 8 shall also include all activities relating to the relevant patent applications and
patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to
give due consideration to the other party’s position with respect to any such patent prosecution activities (which term, as used herein, shall include without limitation, any 

  

 28 

 
activities of the type described in the first sentence of this Section 8.5(a)). In the event a party fails to initiate or pursue any patent prosecution
activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, the other party may initiate, pursue or assume such patent prosecution activities, at its sole
expense. 
 (b) In conducting its patent prosecution activities under this Agreement, each party may use patent attorneys
selected by it in its own discretion. In addition to the other obligations set forth in this Article 8, each party undertakes to keep the other party, throughout the term of this Agreement, regularly informed of the status and progress of the patent
prosecution activities it undertakes under this Agreement including, but not limited to, supplying the other, upon reasonable request and at reasonable intervals, with all correspondence with the United States and European patent office counterparts
with respect to the United States and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party in order to assist such other party in connection with any of its
activities or the exercise of any of its rights pursuant to Articles 8 and 9, such party shall provide the other party with such additional relevant documentation which such other party may reasonably request relating to such patent applications and
patents in the Bukwang Patents, Pharmasset Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party
decides to abandon or allow to lapse any patent application or patent or not to initiate any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 8, it shall give the other party notice
thereof in a sufficiently timely manner so as to enable such other party to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least sixty (60) days
before any abandonment, lapse or any other relevant deadline. 
 (c) Each party will require all of its and its
Affiliates’ employees to assign all Inventions that are the subject of patent applications claiming Inventions that are developed, made or conceived by such employees according to the ownership principles described in this Article 8. Each party
will require any agents or independent contractors performing an activity pursuant to this Agreement to assign all Inventions that are the subject of patent applications 

  

 29 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
claiming Inventions that are developed, made or conceived by such agents or independent contractors to Bukwang and/or Pharmasset according to the ownership
principles described in this Article 8. 
 8.6 Trademark. The Licensed Products shall be commercialized in the Territory under
trademarks and trade dress selected by Pharmasset (the “Pharmasset Trademarks”) in its sole discretion. With the prior approval of Bukwang, such approval not to be unreasonably withheld or delayed, Pharmasset may select a trademark
owned by Bukwang (a “Bukwang Trademark”) for use in connection with a Licensed Product in the Territory. If Pharmasset elects to utilize a Bukwang Trademark in connection with a Licensed Product, Bukwang hereby grants to Pharmasset
an exclusive license to use the Bukwang Trademark in the Territory during the term of this Agreement solely in conjunction with the Licensed Products. In the event of termination or expiration of this Agreement, Pharmasset may continue such use of
the Bukwang Trademark; provided that, for a period of [***] ([***]) years after the effective date of such termination or expiration, Pharmasset shall pay to Bukwang a royalty in the amount of [***] percent ([***]%) of Net Sales of Licensed Products
commercialized under the Bukwang Trademark. At the end of such [***] ([***]) year period, Pharmasset shall have a fully-paid, royalty-free, exclusive, perpetual and irrevocable right and license to use such Bukwang Trademark in connection with the
Products in the Territory. 
 ARTICLE 9. INFRINGEMENT 
 9.1 Third Party Infringement. If Pharmasset or Bukwang becomes aware of any activity that it believes represents an infringement of a Bukwang
Patent, Pharmasset Patent or a Patent relating to Joint Inventions, the party obtaining such knowledge shall promptly advise the other of all relevant facts and circumstances pertaining to the potential infringement. 
 9.2 Pharmasset’s Rights Against Third Party Infringers. Except to the extent otherwise provided in paragraph 8.1 of the Primary License
Agreement in respect of those Bukwang Patents licensed to Bukwang thereunder, Pharmasset shall have the first right to enforce or have enforced, at no expense to Bukwang, any Bukwang Patents or patent rights relating to Joint Inventions against
infringement by third parties and shall be entitled to retain recovery from such enforcement as prescribed by this Subsection 9.2. Upon Pharmasset’s 

  

 30 

 
undertaking to pay all expenditures reasonably incurred by Bukwang, Bukwang shall reasonably cooperate in any such enforcement and, as necessary, join as a
party therein. After first deducting its costs and expenses incurred in respect of enforcement (to the extent not otherwise awarded by settlement or a court), Pharmasset shall pay royalties (calculated per Section 3.3) on the balance of any
monetary recovery attributable to lost sales (provided that such monetary recovery shall, subject to Pharmasset demonstrating otherwise, be presumed attributable to lost sales). In the event that Pharmasset does not file suit against or commence
settlement negotiations with a substantial infringer of the Bukwang Patents or patent rights relating to Joint Inventions within six (6) months after receipt of a written demand from Bukwang that Pharmasset bring suit, then the parties will
consult with one another in an effort to determine whether a reasonably prudent licensee would institute litigation to enforce the patent in question in light of all relevant business and economic factors (including, but not limited to, the
projected cost of such litigation, the likelihood of success on the merits, the probable amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims against Pharmasset
and Bukwang, the diversion of Pharmasset’s human and economic resources, the impact of any possible adverse outcome on Pharmasset and the effect any publicity might have on Pharmasset’s and Bukwang’s respective reputations and
goodwill). If the parties cannot agree, the determination will be made by a mutually and reasonably acceptable third party consultant. If, after such process, it is determined that a suit should be filed and Pharmasset does not file suit or commence
settlement negotiations forthwith against the substantial infringer, then Bukwang shall have the right to enforce any patent not being enforced by Pharmasset that has been licensed hereunder on behalf of itself and Pharmasset (with Bukwang retaining
all recoveries from such enforcement). 
 ARTICLE 10. TRANSFER OF KNOW-HOW; TECHNICAL ASSISTANCE 
 10.1 Transfer by Bukwang. 
 (a) Within fifteen (15) days following the Effective Date and as far as it has not previously done so, Bukwang shall supply Pharmasset with all Bukwang Know-How, including, but not limited to pharmacology, toxicology, preclinical
testing, clinical testing, CMC data, batch records, trials and studies, safety and efficacy, manufacturing information, analytical and quality control. Bukwang shall also supply Pharmasset with copies of all study reports 

  

 31 

 
prepared with respect to the Compounds and/or Licensed Products. With respect to any Bukwang Know-How developed by Bukwang during the term of this Agreement,
such disclosure will be made at least on a quarterly basis or sooner, if practicable. 
 (b) Bukwang hereby agrees to assign,
and hereby does assign as of the Effective Date, to Pharmasset all INDs assignable by Bukwang relating to the Compound and/or Licensed Product in the Territory, upon which assignment all Bukwang obligations in respect of such INDs shall be assumed
by Pharmasset and shall terminate as obligations of Bukwang. Effective as of the Effective Date, Bukwang shall execute a letter in the form attached hereto as Exhibit F notifying the FDA of the transfer of such INDs to Pharmasset. In the
event that Bukwang obtains any INDs relating to the Compound and/or Licensed Product solely in the Territory after the execution of this Agreement, Bukwang hereby agrees to assign, and hereby does assign, to Pharmasset all such INDs obtained after
the Effective Date. 
 10.2 Technical Assistance. 
 (a) Bukwang shall, upon request by Pharmasset, provide Pharmasset with reasonable cooperation and assistance, consistent with the other
provisions hereof, in connection with the transfer of Bukwang Know-How. Such assistance may include, but is not limited to, development of the formulations of the Licensed Products; procurement of supplies and raw materials; initial developmental
and production batch manufacturing runs; process, specification and analytical methodology design and improvement; and, in general, such other assistance as may contribute to the efficient application by Pharmasset of the Bukwang Know-How. In this
regard, Bukwang agrees to make appropriate employees of Bukwang reasonably available to assist Pharmasset, and Bukwang agrees to provide reasonable numbers of appropriate Pharmasset personnel with access during normal business hours to the
appropriate personnel and operations of Bukwang for such periods of time as may be reasonable in order to familiarize Pharmasset personnel with the Bukwang Know-How as applied by Bukwang. At Pharmasset’s reasonable request, such assistance
shall be furnished at Pharmasset’s or its subcontractors’ or sublicensees’ facilities in the Territory, subject to a mutually agreed upon schedule. Such technical assistance shall include but not be limited to the following:

 (i) Bukwang shall: (A) provide Pharmasset with access to any and all Drug Master File(s) or counterparts thereof in
any countries of the Territory (“DMF”) of Bukwang relating to the manufacture of Bulk Drug Substance existing as of the Effective Date; (B) provide Pharmasset with letters of authorization to the FDA and other applicable
government authorities in other countries of the Territory to refer to Bukwang’s DMFs; and (C) reasonably cooperate with Pharmasset in obtaining access to and letters of authorization to refer to the DMFs of Bukwang’s subcontractors
which are, or will be, supplying any Bulk Drug Substance; and 
  

 32 

 (ii) Within fifteen (15) days after the Effective Date, Bukwang shall provide
Pharmasset with copies of all documentation in Bukwang’s possession reasonably necessary for Pharmasset to effectuate its Development Program. 
 (b) Subject to Article 21, in the event Bukwang supplies any Bulk Drug Substance to Pharmasset for the purpose of preclinical studies or clinical studies, Pharmasset will reimburse Bukwang for its Manufacturing Cost
or Acquisition Cost therefor, subject, however, to reasonable substantiation thereof. 
 10.3 Transfer by Pharmasset. With respect to
any Pharmasset Know-How developed by Pharmasset during the term of this Agreement, subject to the terms and conditions of this Agreement, Pharmasset shall supply Bukwang with such Pharmasset Know-How on at least a quarterly basis or sooner, if
practicable. 
 10.4 Language of Disclosures. All disclosures pursuant to this Agreement will be in English. 
 10.5 Pharmacovigilance. As soon as reasonably practicable following the date of this Agreement, the pharmacovigilance departments of each of
Pharmasset and Bukwang and any of their respective licensees of the Licensed Product shall meet and determine the approach to be taken for the collection, review, assessment, tracking and filing of information related to adverse events associated
with the Licensed Products. Such approach shall be documented in a separate and appropriate written pharmacovigilance agreement between each of Pharmasset and Bukwang. Bukwang agrees to share relevant information it receives (either directly or

  

 33 

 
indirectly) with Pharmasset in a timely manner so as to allow Pharmasset to comply with its responsibility to report pharmacovigilance information. Bukwang
shall be responsible for maintaining a global safety database for the Compound and the Licensed Products consistent with industry standard practices. Pursuant to the terms of the pharmacovigilance agreement, Bukwang shall provide Pharmasset access
to the global safety database. 
 ARTICLE 11. WARRANTIES AND REPRESENTATIONS; LIMITATION OF 
 LIABILITY; AND DISCLAIMERS 
 11.1 Warranties and Representations of Bukwang. Bukwang warrants and represents the following as of the Effective Date hereof: 
 (a) It possesses the rights and corporate authorizations necessary to enter into this Agreement; 
 (b) Exhibit A is a true, complete and accurate copy of the Primary License Agreement; 
 (c) Exhibit B
is a true, complete and accurate copy of the Termination Procedure Letter; 
 (d) Exhibit C is a complete list of all
Patents included in the Bukwang Patents as of the Effective Date; 
 (e) Exhibit G is a complete list of all persons or
entities to whom Bukwang has granted a license under the Bukwang Patents and/or Bukwang Know-How; 
 (f) It is not aware of
any material facts which it has not disclosed to Pharmasset regarding the development, manufacture or use of any Compounds or Licensed Products or the sale of any Licensed Product or the practice of any inventions included in the Bukwang Patents or
the use of the Bukwang Know-How by Pharmasset (except, potentially, details regarding the Bukwang Know-How to be provided under Article 10), including without limitation any material facts regarding the possibility that such development,
manufacture, use, sale or practice might infringe any third party’s Know-How, Patents or other intellectual property in the Territory; 
  

 34 

 (g) It is aware of no third party using or infringing all or any of the Bukwang Patents
in derogation of the rights granted pursuant to this Agreement; 
 (h) It is aware of no third party claim to any rights in
the Bukwang Patents or the Bukwang Know-How; 
 (i) It is aware of no pending interference or opposition proceeding or
litigation or any communication which threatens an interference or opposition proceeding or litigation before any patent and trademark office, court, or any other governmental entity or court in any jurisdiction in regard to the Bukwang Patent;

 (j) The Primary License Agreement is in full force and effect and Bukwang will: (i) use its reasonable best efforts to
fulfill all of its obligations under the Primary License Agreement, including, but not limited to any due diligence obligations outside the Territory set forth therein; (ii) take no action or fail to take any action which will cause it to be in
breach of any provision of the Primary License Agreement; (iii) immediately notify Pharmasset in the event that Bukwang receives written notice from the Primary Licensors (or their successors) that Bukwang is in default under the Primary
License Agreement or that the Primary Licensors (or their successors) have terminated or intend to terminate the Primary License Agreement; and (iv) not amend the Primary License Agreement in a manner which adversely affects Pharmasset’s
rights and obligations hereunder; 
 (k) It is not aware of any action or proceeding, pending or threatened, with respect to
Licensed Products and/or the Compound, including without limitation the conduct of any clinical trials, manufacturing activities or other activities, that questions the validity of this Agreement or any action taken by Bukwang in connection with the
execution of this Agreement. There are no material unsatisfied judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court, an administrative agency or by an arbitrator) against Bukwang with respect to
Licensed Products and/or the Compound, including without limitation the conduct of any clinical trials, manufacturing activities or other activities; 
  

 35 

 (l) Attached hereto as Exhibit H is a true, correct and complete list of all INDs
and drug approval applications filed with a governmental authority in the Territory relating to the Compound or a Licensed Product; 
 (m) Intellectual Property. 
 (i) Bukwang and, to its knowledge, the Primary Licensors have submitted all
information related to the Compound, Licensed Product and/or Bukwang Patents to the United States Patent and Trademark Office required to be submitted in accordance with 37 C.F.R. 1.56, 1.97 and 1.98; 
 (ii) The Bukwang Patents and Bukwang Know-How constitute all intellectual property Controlled by Bukwang that is necessary or useful to
manufacture, develop, use or commercialize the Compound and/or Licensed Product, and to the knowledge of Bukwang there is not any other intellectual property necessary for such purposes that is not Controlled by Bukwang; 
 (iii) Other than in respect of the Primary License, each of Bukwang and its Affiliates owns all right, title and interest in and to, or
has a license, sublicense or otherwise permission to use and license, all of the Bukwang Know-How or Bukwang Patents free and clear of all encumbrances and no person other than Bukwang (including any current or former employee or consultant of
Bukwang) has any proprietary, commercial or other interest in any of the Bukwang Know-How or Bukwang Patents; 
 (iv) To its
knowledge, all Patents within the Bukwang Patents are in full force and effect, valid, subsisting and, in the case of issued Patents, enforceable, and inventorship of the Bukwang Patents is properly identified on such Bukwang Patents. None of the
Bukwang Patents is currently involved in any interference, reissue, reexamination, or opposition proceeding, and neither Bukwang nor any of its Affiliates has received any written notice from any person, or has knowledge, of such actual or
threatened proceeding; 
 (v) It is aware of no actions or proceedings (including any inventorship challenges) pending or
threatened with respect to any of the Bukwang Know-How, Bukwang Patents, Compound or Licensed Products nor have any such actions or proceedings 

  

 36 

 
been brought or, to the knowledge of Bukwang, threatened during the past four (4) years, in each case which have not been resolved without impairment of
Bukwang’s rights in and to any of the Bukwang Know-How, Bukwang Patents, Compound or Licensed Products and without the obligation to pay any royalties or other amounts to any Third Party with respect to the use of such technology or the sale of
such products; 
 (vi) All official fees, maintenance fees and annuities for the Bukwang Patents have been paid through the
Effective Date; 
 (n) Compliance with Law. 
 (i) Bukwang and its Affiliates and, to its knowledge, any licensees, outsourcing company and contract research organization to which
Bukwang or its Affiliates have subcontracted activities in connection with Compound and Licensed Products (the “Contractors”) have complied in all material respects with all applicable laws, permits, governmental licenses,
registrations, approvals, concessions, franchises, authorizations, orders, injunctions and decrees in the research, development, manufacture and use of the Licensed Product and Compound, and neither Bukwang nor any of its Affiliates or, to the
knowledge of Bukwang, its Contractors, has received any written notice from any governmental authority claiming that any such activities as conducted by them are not in such compliance; 
 (ii) Since January 1, 2002, no governmental authority has served notice on Bukwang or any of its Affiliates that the Bukwang Know-How
or Bukwang Patents were or are in violation of any law or the subject of any investigation; 
 (iii) Since January 1,
2002, none of Bukwang or any of its Affiliates have received written notice from any governmental authority that there are any circumstances currently existing that might reasonably be expected to lead to any loss or refusal to renew any material
governmental licenses, permits, registrations, concessions, franchises and authorizations relating to the Licensed Product, Compound or any of the Bukwang Know-How or Bukwang Patents; 
 (iv) It is aware of no governmental authority (including the FDA) which has commenced or, to Bukwang’s knowledge, threatened to
initiate any action to enjoin 

  

 37 

 
production of the Compound or Licensed Product at any facility, nor has Bukwang or any of its Affiliates or, to the knowledge of Bukwang, any of its
Contractors, received any notice to such effect since January 1, 2002; 
 (v) All manufacturing operations conducted by
Bukwang and its Affiliates and, to its knowledge, Contractors since January 1, 2002 relating to the manufacturing of the Licensed Product and/or Compound have been conducted in material compliance with all applicable laws; 
 (vi) All development activities conducted by Bukwang and its Affiliates and, to its knowledge, Contractors since January 1, 2002
relating to the Licensed Product and/or Compound have been conducted in material compliance with all laws; 
 (vii) Bukwang
has delivered or otherwise made available to Pharmasset copies of any substantive or material (A) reports of FDA Form 483 inspection observations in its possession, (B) establishment inspection reports, (C) warning letters, and
(D) other documents that assert ongoing lack of compliance in any material respect with any applicable laws (including those of the FDA), in each case to the extent received by Bukwang or any of its Affiliates or, to the knowledge of Bukwang,
any of its Contractors from the FDA relating to a Licensed Product and/or Compound. Neither Bukwang nor any of its Affiliates has received any such reports, letters or other documents from any other governmental authority relating to a Licensed
Product and/or Compound; and 
 (viii) Bukwang and its Affiliates do not have any knowledge of any preliminary or other
results from any clinical trials relating to the lack of activity of the Compound or Licensed Product in human beings. 
 11.2 Warranties
and Representations by Pharmasset. Pharmasset represents and warrants the following as of the Effective Date: 
 (a) It
has or will obtain, the skill and expertise in the technical areas relating to the Bukwang Patents and Bukwang Know-How to make or have made an evaluation of the capabilities, safety, utility and commercial application of the Bukwang Patent and the
Bukwang Know-How. 
  

 38 

 (b) It possesses the rights and corporate authorizations necessary to enter into this
Agreement; 
 (c) There are currently no Pharmasset Patents; and 
 (d) It is not aware of any action or proceeding pending or threatened, with respect to the validity of this Agreement or any action taken
by Pharmasset in connection with the execution of this Agreement. 
 11.3 Warranties and Representations of Each Party. Each party
hereto warrants and represents the other that: (a) it is free to enter into this Agreement (including the receipt of all corporate authorizations) and to carry out all of the provisions hereof, including, its grant to the other of the licenses
described in Article 2; (b) to its knowledge, there is no failure to comply with, no violation of or any default under, any law, permit or court order applicable to it which might have a material adverse effect on its ability to execute,
deliver and perform this Agreement or on its ability to consummate the transactions contemplated hereby; and (c) it shall comply with laws and regulations relating to the performance of its obligations or the exercise of its rights hereunder
including, in the case of Pharmasset, those relating to the manufacture, processing, producing or use of Compounds and Licensed Products and the sale or distribution of Licensed Products; and that it shall not take any action which would cause it or
the other party to violate such laws and regulations. 
 11.4 Disclaimer and Limitation of Warranties. Bukwang makes no warranty as to
validity of the Bukwang Patents licensed hereunder and, except as expressly stated in Section 11.1, makes no representation whatsoever with regard to the scope of the Bukwang Patents or Bukwang Know-How, or that the Bukwang Patents or Bukwang
Know-How may be exploited by Pharmasset or its Affiliates or sublicensees without infringing intellectual property rights of third parties. EXCEPT AS OTHERWISE SET FORTH IN THIS ARTICLE 11, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY
KIND, INCLUDING WITH RESPECT TO THE BUKWANG PATENTS OR BUKWANG KNOW-HOW, AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY,
UTILITY, OR COMMERCIAL APPLICATION OF COMPOUNDS OR LICENSED PRODUCT, BUKWANG PATENTS OR BUKWANG KNOW-HOW. 
  

 39 

 11.5 Limitation of Liability. NEITHER BUKWANG AND THE PRIMARY LICENSORS, ON THE ONE HAND, NOR
PHARMASSET, ON THE OTHER HAND, SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT LIMIT EITHER PARTY’S OBLIGATIONS TO THE OTHER PARTY UNDER ARTICLE 12. 
 11.6 Insurance. Without limiting either party’s indemnity obligations under Article 12, each party shall maintain throughout the term of this
Agreement, and shall use its best efforts to maintain for a reasonable period of time thereafter, a commercial, general liability insurance policy, written by a reputable insurance company authorized to do business in the United States, that:

 (a) insures for all claims, damages, and actions mentioned in Section 12.1 and 12.2 of this Agreement; 
 (b) includes a contractual endorsement providing coverage for all liability arising out of bodily injury and property damage; 

(c) requires the insurance carrier to provide no less than thirty (30) days’ written notice of any change in the terms or
coverage of the policy or its cancellation; and 
 (d) provides product liability coverage in an amount no less than One
Million Dollars ($1,000,000) per occurrence for bodily injury and One Million Dollars ($1,000,000) per occurrence for property damage, subject to a reasonable aggregate amount. 
 Each party shall provide the other party with certificates of insurance evidencing the above insurance coverage. 
  

 40 

 11.7 Notice of Claims. Pharmasset shall promptly notify Bukwang and Primary Licensors of all
claims involving the Indemnitees and will advise Bukwang and Primary Licensors of the policy amounts that might be needed to defend and pay any such claims. 
 ARTICLE 12. INDEMNIFICATION 
 12.1 Pharmasset’s Indemnification. Subject to
compliance by the Indemnitees with the provisions set forth in Section 12.3, Pharmasset shall defend, indemnify, and hold harmless the Indemnitees, from and against any and all claims, demands, losses, liabilities, expenses, and damages
including investigative costs, court costs and reasonable attorneys’ fees (collectively, the “Liabilities”) arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations,
claims, demands, judgments, orders, decrees, stipulations or injunctions by a third party (each, a “Third Party Claim”) resulting from (a) any breach by Pharmasset of any of its representations, warranties, covenants or
obligations set forth in this Agreement, (b) the negligence, recklessness, or intentional acts or omissions of Pharmasset or its Affiliates, sublicensees or subcontractors and their respective directors, officers, employees and agents, or
(c) any and all personal injury (including death) and physical property damage caused or contributed to, in whole or in part, by manufacture, testing, design or use of any Compounds or Licensed Products, sale or labeling of any Licensed
Products or the practice of the Bukwang Patents or Bukwang Know-How by Pharmasset or Pharmasset’s Affiliates or sublicensees, except to the extent that such Liabilities result from the negligence or willful misconduct of Bukwang or are an item
for which Bukwang must indemnify Pharmasset pursuant to Section 12.2. Pharmasset’s obligations under this Article shall survive expiration or termination of this Agreement for any reason. 
 12.2 Bukwang’s Indemnification. Subject to compliance by the Indemnitees with the provisions set forth in Section 12.3, Bukwang shall
indemnify and hold harmless the Indemnitees from and against any and all Liabilities arising in connection with any Third Party Claim resulting from: (a) any breach by Bukwang of any of its representations, warranties, covenants or obligations
set forth in this Agreement; (b) any claims or suits asserted or commenced by the Primary Licensors regarding any payments owed by Bukwang pursuant to the Primary License Agreement, (c) Bukwang’s (or its agent’s,
contractor’s or other designee’s) failure to comply with applicable cGMP, applicable product specifications or applicable law in connection with the 

  

 41 

 
manufacture of Compound or any Licensed Product supplied to Pharmasset hereunder; or (d) the negligence, recklessness or intentional acts or omissions
of Bukwang or its Affiliates, sublicensees or subcontractors, and their respective directors, officers, employees and agents, except to the extent that same is an item for which Pharmasset must indemnify Bukwang pursuant to Section 12.1.
Bukwang’s obligations under this Article shall survive expiration or termination of this Agreement for any reason. 
 12.3
Indemnification Procedures. Any Indemnitee which intends to claim indemnification under this Article shall, promptly after becoming aware thereof, notify the party from whom it is seeking indemnification (the “Indemnitor”) in
writing of any matter in respect of which the Indemnitee or any of its employees intend to claim such indemnification. The Indemnitee shall permit, and shall cause its employees to permit, the Indemnitor, at its discretion, to settle any such matter
and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that such settlement does not adversely affect the Indemnitee’s rights hereunder or impose any obligations on the Indemnitee in addition to
those set forth herein in order for it to exercise such rights. No such matter shall be settled by such Indemnitor without the prior written consent of the Indemnitee and neither the Indemnitor nor the Indemnitee shall be responsible for any legal
fees or other costs incurred other than as provided herein. The Indemnitee and its employees shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of any matter covered by the applicable
indemnification. The Indemnitee shall have the right, but not the obligation, to be represented by counsel of its own selection and expense. 
 ARTICLE 13. CONFIDENTIALITY 
 13.1 Treatment of Confidential Information. Except as otherwise provided hereunder or
as required by law, during the term of this Agreement and for a period of five (5) years thereafter: 
 (a) Pharmasset
and its Affiliates and sublicensees shall retain in confidence and use only for purposes of this Agreement, any written information and data supplied by or on behalf of Bukwang under this Agreement and the Mutual Non-disclosure Agreement, dated
January 12, 2005, between Bukwang and Pharmasset (the “Confidentiality Agreement”); and 
  

 42 

 (b) Bukwang shall retain in confidence and use only for purposes of this Agreement any
written information and data supplied by or on behalf of Pharmasset to Bukwang under this Agreement. 
 For Purposes of this Agreement,
“Information” shall mean all information and materials received by either party from the other party pursuant to this Agreement and all information and materials developed in the course of the performance of the Development Program,
including, without limitation, information, data, know-how, and all other scientific, clinical, regulatory, marketing, financial and commercial information or data, whether communicated in writing or orally or otherwise, which is provided or
disclosed by one party to the other party in connection with this Agreement. 
 13.2 Right to Disclose. To the extent that it is
reasonably necessary to fulfill its obligations or exercise its rights under this Agreement, or any rights which survive termination or expiration hereof, each party may disclose Information to its Affiliates, sublicensees (actual or prospective),
consultants, outside contractors, actual or prospective investors (including, commercial banks, investment banks and venture capital firms), and clinical investigators on condition that such entities (other than the venture capital firms, as to
which Pharmasset will use its reasonable best efforts to obtain the venture capital firm’s execution of such nondisclosure agreement) or persons agree in writing: 
 (a) to keep the Information confidential for a period of at least five (5) years from the date of disclosure by such party to the
same extent as such party is required to keep the Information confidential; and 
 (b) to use the Information only for those
purposes for which the disclosing party is authorized to use the Information. 
 Each party or its Affiliates or sublicensees, as applicable,
may disclose Information to the extent that such disclosure (i) is for authorizations to conduct preclinical or clinical trials to commercially market Licensed Products, provided such party is then otherwise entitled to engage in such
activities in accordance with the provisions of this Agreement, (ii) is legally required, (iii) is necessary for the purpose of filing, prosecuting or maintaining patent applications, 

  

 43 

 
prosecuting, enforcing or defending litigation, (iv) is necessary to comply with applicable governmental regulations, submitting information to tax or
other governmental authorities (including regulatory authorities), or (v) is necessary to comply with applicable stock exchange or NASDAQ regulation. 
 13.3 Release from Restrictions. The obligation not to disclose or use Information shall not apply to any part of such Information that: 
 (a) is or becomes patented (but the existence of a patent shall only permit disclosure and not, unless otherwise provided hereunder, use),
published or otherwise part of the public domain, other than by unauthorized acts of the party obligated not to disclose such Information (for purposes of this Article 13 the “receiving party”) or its Affiliates or sublicensees in
contravention of this Agreement; or 
 (b) is disclosed to the receiving party or its Affiliates or sublicensees by a third
party provided that such Information was not obtained by such third party directly or indirectly from the other party to this Agreement; or 
 (c) prior to disclosure under the Confidentiality Agreement or this Agreement, as the case may be, was already in the possession of the receiving party, its Affiliates or sublicensees, provided that such Information
was not obtained directly or indirectly from the other party to this Agreement; or 
 (d) result from research and development
by the receiving party or its Affiliates or sublicensees, independent of disclosure from the other party to this Agreement, provided that the persons developing such information have not had exposure to the information received from the other party
to this Agreement; or 
 (e) is required by law to be disclosed by the receiving party, provided that in the case of
disclosure in connection with any litigation, the receiving party uses reasonable efforts to notify the other party immediately upon learning of such requirement in order to give the other party reasonable opportunity to oppose such requirement; or

 (f) Pharmasset and Bukwang agree in writing may be disclosed. 
  

 44 

 ARTICLE 14. CONDITIONS PRECEDENT 
 14.1 Conditions to Agreement Becoming Effective. This Agreement will not become effective until all of the following conditions shall have been
satisfied or, if applicable, waived by Pharmasset: 
 (a) the Primary Licensors and Bukwang shall have properly executed and
delivered all required consents and an Amendment to the Primary License Agreement to Pharmasset in the form and substance attached hereto as Exhibit I; 
 (b) promptly after the execution date of this Agreement, Bukwang shall provide access to and request that Gilead provide access to and
allow Pharmasset to review all files in Bukwang’s and Gilead’s possession or control, respectively, relating to the Compound and/or a Licensed Product, including without limitation, any and all studies undertaken by or on behalf of Gilead,
all data and information, regulatory correspondence and associated dossiers, in each case with respect to the Compound and/or a Licensed Product (and Bukwang shall make Commercially Reasonable Efforts to obtain same from Gilead). Such files, data
and information, regulatory correspondence and associated dossiers must be reasonably acceptable to Pharmasset in form and substance; 
 (c) promptly after the execution date of this Agreement, Bukwang shall provide access to and allow Pharmasset to review all files in Bukwang’s control regarding the protocol and data with respect to any
carcinogenicity studies with respect to the Compound and/or a Licensed Product, all data and information, regulatory correspondence and associated dossiers associated therewith. Such files, data and information, regulatory correspondence and
associated dossiers must be reasonably acceptable to Pharmasset in form and substance; 
 (d) Bukwang shall request Gilead to
provide directly a written statement that (i) all studies undertaken by or on behalf of Gilead with respect to the Compound and/or a Licensed Product were conducted in accordance with the current Good Clinical Practice standards for the design,
conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials, including the requirements in 21 C.F.R. Parts 11, 50, 54, 56, 312, and 314, (ii) provides assurance that the data and reported results are
credible and accurate, and (iii) 

  

 45 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
the rights, integrity, and confidentiality of trial subjects are protected. Such statement must be reasonably acceptable to Pharmasset in form and substance;
and 
 (e) Bukwang or Gilead, as applicable, shall have assigned to Pharmasset all INDs to the Compound and/or Licensed
Product in the Territory. 
 ARTICLE 15. TERM AND TERMINATION 
 15.1 Term. Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on the execution date of
this Agreement and shall expire on a country-by-country basis upon the expiration of the last to expire of the Bukwang Patents including any renewals or extensions thereof in such country or the invalidation of all Valid Claims covering the Bukwang
Patents in such country. In the event that there are no Valid Claims in a country, this Agreement shall expire in such country on the tenth (10th) anniversary of the Effective Date. 
 15.2 Termination by Default. If either party defaults in the performance of, or fails to be in compliance with, any material agreement, condition
or covenant of this Agreement, the non-defaulting party may terminate this Agreement with respect to the defaulting party if such default or noncompliance shall not have been remedied, or, in the event the default or non-compliance cannot be
remedied within such period, reasonable steps shall not have been initiated to remedy the same, within sixty (60) days after receipt by the defaulting party of a written notice thereof from the non-defaulting party. 
 15.3 Termination by Pharmasset. Pharmasset shall have the right to terminate this Agreement in the Territory or one or more countries of the
Territory (without affecting this Agreement in the remaining countries of the Territory), by giving Bukwang one hundred eighty (180) calendar days’ prior written notice thereof. 
  

 46 

 15.4 Effects of Termination. 
 (a) Termination for Pharmasset Breach or by Pharmasset at Will. If this Agreement is terminated by Bukwang as a result of
Pharmasset’s breach pursuant to Section 15.2, or is terminated by Pharmasset in accordance with Section 15.3, then: 
 (i) in the case of termination in the entire Territory, Pharmasset shall use, and shall cause its Affiliates and sublicensees to use, its and their Commercially Reasonable Efforts to return, or, in the sole discretion of Bukwang, destroy,
all Information supplied to Pharmasset by Bukwang properly organized and to provide Bukwang with reasonable transition assistance; provided that Pharmasset may keep one copy of such Information for record keeping purposes; 
 (ii) Bukwang shall have the option, exercisable within thirty (30) days following the effective date of such termination, to take
delivery and title to any inventory of Compound and Licensed Products affected by such termination, without charge. Bukwang may exercise such option by written notice to Pharmasset during such thirty (30)-day period. Upon such exercise, the parties
will establish mutually agreeable delivery terms for the return of such inventory. If Bukwang does not exercise such option during such thirty (30)-day period, or if Bukwang provides Pharmasset with written notice of its intention not to exercise
such option, then Pharmasset and its Affiliates and sublicensees will be entitled, during the period ending on the last day of the sixth (6th) full month following the effective date of such termination, to sell any inventory of Licensed
Products affected by such termination that remain on hand as of the effective date of the termination, so long as Pharmasset pays to Bukwang the royalties applicable to said subsequent sales, with respect to sales in the Territory, in accordance
with the terms and conditions set forth in this Agreement; 
 (iii) with respect to those countries with respect to which
termination occurs, Pharmasset shall provide Bukwang with full and complete copies of all toxicity, efficacy, and other data generated by Pharmasset or Pharmasset’s Affiliates and sublicensees, in the course of Pharmasset’s efforts to
develop Licensed Products or to obtain governmental approval for the sale of Licensed Products, including but not limited to any regulatory filings with any government agency in such countries. All such data regulatory approvals related to Compound

  

 47 

 
and/or Licensed Product, including all INDs and NDAs, in the particular terminated jurisdiction shall be assigned to Bukwang. Bukwang shall be authorized to
cross-reference any such regulatory filings made by Pharmasset, its Affiliates and sublicensees in the countries in which termination occurs where permitted by law. Bukwang shall be entitled to provide information pertaining to the Pharmasset
Patents, Pharmasset Know-How and Joint Know-How to any third party with a bona fide interest in licensing such technology in the countries in which termination occurs; provided that such third party is bound by obligations of confidentiality at
least as stringent as those contained in this Agreement. Such data shall be provided on a confidential basis; provided, however, that if such third party concludes a license with Bukwang, such third party shall be free to use such data for all
purposes, including to obtain government approvals to sell any product containing any Compound in such countries without obligation to Pharmasset; 
 (iv) Pharmasset agrees to grant and hereby grants to Bukwang, effective upon such termination of this Agreement, an exclusive, perpetual royalty-free right and license, with the right to sublicense and authorize the
grant of further sublicenses, under any Pharmasset Patents and Pharmasset’s rights and interest in the Joint Patents to make, have made, use, sell, offer for sale, and import Compound or Licensed Products affected by such termination in the
country for which such termination is effective; provided, however, that Bukwang will be responsible for any payments associated with the grant of any license pursuant to the preceding sentence (including, without limitation, any royalty or other
payment obligations to an upstream licensor of any such Patents). In addition, if any Pharmasset Know-How is then used in connection with the manufacture, development or commercialization of Compound or a Licensed Product in the applicable
territory, Pharmasset agrees to grant and hereby grants to Bukwang, effective upon such termination of this Agreement, a non-exclusive, royalty-free right and license, with the right to grant sublicenses, under such Pharmasset Know-How, to make,
have made, use, sell, offer for sale, and import Licensed Products in the country for which such termination is effective; and 
 (v) Each of Pharmasset’s sublicensees with respect to any affected Licensed Products in any affected country at such time will continue to have the rights and license set forth in their sublicense agreements, subject to the continued
performance of the obligations thereunder; provided, however, that such sublicensee agrees in writing that Bukwang 

  

 48 

 
is entitled to enforce all relevant terms and conditions of such sublicense agreement directly against such sublicensee; and provided, further, that such
sublicensee is not then in breach of its sublicense agreement. 
 (b) Termination for Bukwang Breach. In the event this
Agreement is terminated by Pharmasset for Bukwang’s breach pursuant to Section 15.2, then: 
 (i) Bukwang shall use,
and shall cause its Affiliates and sublicensees to use, its and their Commercially Reasonable Efforts to return, or, in the sole discretion of Pharmasset, destroy, all Information supplied to Bukwang by Pharmasset properly organized; provided that
Bukwang may keep one copy of such Information for record keeping purposes; 
 (ii) upon Pharmasset’s request, assign to
Pharmasset all of Bukwang’s right, title and interest in and to any agreements between Bukwang and third parties that are freely assignable by Bukwang without consent not to be unreasonably withheld or delayed and that relate solely to the
manufacture of any Compound or Licensed Products for the Territory; 
 (iii) provide copies of any books, records, documents
and instruments to the extent related to Compound or Licensed Product; 
 (iv) upon Pharmasset’s request, if Bukwang is
then manufacturing Compound or Licensed Product, supply Pharmasset with clinical and commercial quantities of such Compound or Licensed Product for the shorter of (x) the period until Pharmasset or its designee has established and validated a
manufacturing process for such Compound or Licensed Product and is approved to manufacture clinical trial and commercial supplies of such Compound or Licensed Product or (y) eighteen (18) months from the effective date of such termination;
provided, however, that Pharmasset will reimburse Bukwang for Bukwang’s Acquisition Cost or Manufacturing Cost for such Compound or Licensed Product; 
 (v) if Bukwang is then manufacturing Compound or Licensed Product, provide, at Pharmasset’s request, Pharmasset or its designee with copies of such information including plans and specifications relating to the
manufacturing process for such Compound or Licensed Product, and reasonably cooperate with Pharmasset or its designee, at Pharmasset’s cost and expense, to facilitate the transition of such manufacturing responsibilities; and 
  

 49 

 (vi) with respect to any Bukwang Patents or Bukwang Know-How that are sublicensed to
Pharmasset from the Primary Licensors, to the extent permitted by the Primary Licensors, Pharmasset shall assume Bukwang’s obligations under the Primary License Agreement and be a direct licensee of the Primary Licensors, and with respect to
all other Bukwang Patents and Bukwang Know-How, each license granted by Bukwang to Pharmasset shall, effective upon such termination of this Agreement, become an exclusive, perpetual, non-terminable, royalty-free right and license, with the right to
sublicense and authorize the grant of further sublicenses, and shall include the right to manufacture Compound and Licensed Products. 
 (c) Effects of Expiration. Upon expiration of this Agreement pursuant to Section 15.1, on a country-by-country basis, (i) each license granted by Bukwang to Pharmasset under the Bukwang Patents,
Bukwang Know-How, Bukwang Trademark, if any, and Bukwang’s rights in any Joint Know-How and Joint Inventions shall become an exclusive, perpetual, non-terminable, royalty-free right and license within the Field and in the Territory, with the
right to sublicense and authorize the grant of further sublicenses, and shall include the right to manufacture Compound, and (ii) each license granted by Pharmasset to Bukwang under the Pharmasset Patents, Pharmasset Know-How and
Pharmasset’s rights in any Joint Know-How and Joint Inventions shall become an exclusive, perpetual, non-terminable, royalty-free right and license within the Field and in the Retained Territory, with the right to sublicense and authorize the
grant of further sublicenses. 
 (d) General Effects of Expiration or Termination. 
 (i) Bukwang will have the right to receive all payments accrued prior to the effective date of termination; 
 (ii) termination or expiration of this Agreement for any reason shall have no effect on the parties’ obligations under Articles 9,
11, 12 and 13 or their respective rights in Joint Know-How or Joint Inventions; and 
 (iii) the parties’ shall retain
any other remedies for breach of this Agreement they may otherwise have. 
  

 50 

 15.5 Default by Pharmasset’s Affiliates and Sublicensees. For purposes of this Article 15 but
subject to the cure provisions of Section 15.2(a), any breach or default of the provisions of this Agreement by Pharmasset’s Affiliates or sublicensees shall be deemed to be breach of this Agreement by Pharmasset, and Pharmasset shall be
liable to Bukwang for such breach or default to the same extent as if such breach or default had been made directly by Pharmasset. 
 ARTICLE 16. ASSIGNMENT 
 Neither party shall assign this Agreement or any part thereof without the prior written
consent of the other party, which consent shall not be unreasonably withheld or delayed. Each party may, however, without such consent, assign or sell its rights under this Agreement (a) in connection with the sale or transfer of all or
substantially all of its pharmaceutical business to a third party; (b) in the event of a merger or consolidation with a third party; or (c) to an Affiliate. No assignment shall relieve any party of responsibility for the performance of any
accrued obligation which such party has under this Agreement. Any assignment shall be contingent upon the assignee assuming in writing all of the obligations of its assignor under this Agreement. 
 ARTICLE 17. REGISTRATION OF LICENSE 
 Pharmasset, at its expense, may register the license granted under this Agreement in any country of the Territory where the use or manufacture of Compounds or a Licensed Product or the sale of a Licensed Product in such country would be
covered by a Valid Claim. Upon request by Pharmasset, Bukwang agrees promptly to execute any “short form” licenses submitted to it by Pharmasset reasonably necessary in order to effect the foregoing registration in such country.

 ARTICLE 18. NOTIFICATION AND AUTHORIZATION UNDER DRUG PRICE 
 COMPETITION AND PATENT TERM RESTORATION ACT 
 18.1 Notices Relating to
the Act. Bukwang shall use its diligent efforts to cause the Primary Licensors to notify Pharmasset of (a) the issuance of each U.S. patent included among the Bukwang Patents, giving the date of issue and patent number for each such patent;
and (b) each notice pertaining to any patent included among the Bukwang Patents which the Primary Licensors receive as patent owners pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (hereinafter the
“Act”), including but not necessarily limited to notices 

  

 51 

 
pursuant to §§101 and 103 of the Act from persons who have filed an abbreviated NDA (“ANDA”) or a “paper” NDA. Bukwang
shall request that such notices be given promptly, and in any event within ten (10) days of notice of each such patent’s date of issue or receipt of each such notice pursuant to the Act, whichever is applicable. 
 18.2 Authorization Relating to Patent Term Extension. Bukwang hereby authorizes Pharmasset and will use its diligent efforts to obtain the Primary
Licensors’ authorization for Pharmasset (a) to include in any NDA for a Licensed Product, as Pharmasset may deem appropriate under the Act, a list of patents included among the Bukwang Patents that relate to such Licensed Product and such
other information as Pharmasset in its reasonable discretion believes is appropriate to be filed pursuant to the Act; (b) to commence suit for any infringement of the Bukwang Patents under § 271 (e) (2) of Title 35 of the United
States Code occasioned by the submission by a third party of an IND or a paper NDA for a Licensed Product pursuant to §§101 or 103 of the Act; and (c) in consultation with Bukwang and the Primary Licensors, to exercise any rights that
may be exercisable by Bukwang or the Primary Licensors, as applicable, as patent owners under the Act to apply for an extension of the term of any patent included among the Bukwang Patents. In the event that applicable law in any other country of
the Territory hereafter provides for the extension of the term of any patent included among the Bukwang Patents in such country, upon request by Pharmasset, Bukwang shall authorize Pharmasset and shall use its diligent efforts to obtain the Primary
licensors’ authorization for Pharmasset or, if requested by Pharmasset or its sublicensees, to apply for such extension, in consultation with Bukwang and the Primary Licensors. Bukwang agrees to cooperate and shall use its diligent efforts to
cause the Primary Licensors to cooperate with Pharmasset or its sublicensees, as applicable, in the exercise of the authorizations granted herein or which may be granted pursuant to this Section 18.2 and will execute such documents and take
such additional action and use its diligent efforts to cause the Primary Licensors to execute such documents and to take such additional actions as Pharmasset may reasonably request in connection therewith, including, if necessary, permitting itself
and using its diligent efforts to cause the Primary Licensors to permit themselves, if required by law or if required in order to permit Pharmasset or its sublicensees to bring suit or take legal action, to be joined as proper parties in any suit
for infringement brought by Pharmasset under subsection (b) above. Pharmasset shall bear the costs 

  

 52 

 
and expenses, including but not limited to attorneys’ fees, of any suit for infringement brought by Pharmasset under subsection (b) above.

 ARTICLE 19. DISPUTE RESOLUTION AND ARBITRATION 
 19.1 Initial Resolution. In the case of any disputes between the parties arising from this Agreement, and in case this Agreement does not provide a solution for how to resolve such disputes, the parties shall
discuss and negotiate in good faith a solution acceptable to both parties and in the spirit of this Agreement. If after negotiating in good faith pursuant to the foregoing sentence, the parties fail to reach agreement within thirty (30) days,
then the President, Chief Executive Officer or Chief Operating Officer of Bukwang and the President, Chief Executive Officer or Chief Operating Officer of Pharmasset shall discuss in good faith an appropriate resolution to the dispute. If these
executives fail, after good faith discussions not to exceed thirty (30) days, to reach an amicable agreement then the parties shall submit to binding arbitration pursuant to Section 19.2 (“Arbitration”). The date of
submission of the matter to arbitration shall be the “Dispute Date”. 
 19.2 Arbitration. The following provisions
shall govern any Arbitration pursuant to this Agreement. 
 (a) Arbitration shall be conducted in accordance with the Rules of
the American Arbitration Association. In the event of any conflict between the Rules and this Section, the provisions of this Section shall govern. The Arbitration shall be conducted in Atlanta, Georgia, USA. 
 (b) The Arbitration shall be heard by a panel of three arbitrators (each an “Arbitrator”). Pharmasset and Bukwang shall
each select one Arbitrator. Such Arbitrators shall be attorneys, licensed to practice law in the State of Georgia, actively engaged in the full-time practice of law for a period of no less than seven (7) years. Such Arbitrators shall not be
affiliated, directly or indirectly, with the parties or the attorneys representing the parties in the Arbitration and shall not have any prior involvement in the matter. In the event that either party fails within fifteen (15) days after the
Dispute Date (i) to select an Arbitrator who, to its knowledge, meets the requirements set forth in this subsection (b) and (ii) to notify the other party of the selection, the other party will then have the right to select such
Arbitrator. The third 

  

 53 

 
Arbitrator shall be selected by mutual agreement of the parties from a list of neutral arbitrators compiled by the American Arbitration Association for the
parties. Such Arbitrator shall be an attorney, licensed to practice law in the State of Georgia, actively engaged in the full time practice of law for a period of no less than ten (10) years. The third Arbitrator shall not have any prior or
current relationship, direct or indirect, with any party to this Agreement. If the parties to the Arbitration are unable to agree upon the third Arbitrator within fifteen (15) days from the Dispute Date, the appointment of the third Arbitrator
shall be made as expeditiously as possible and in compliance with this Section 19.2 by the two Arbitrators selected by the parties. If those Arbitrators cannot agree on the third Arbitrator within ten (10) days, then the third Arbitrator
shall be designated by the American Arbitration Association or the appropriate designated representative thereof upon the written request of any party with simultaneous notice of such request to the other party to the Arbitration. The third
Arbitrator shall preside over the panel of Arbitrators and the Arbitration. 
 (c) The Arbitrators shall apply the substantive
laws of the State of Georgia to the validity, construction and interpretation of this Agreement as is applicable to contracts made wholly performable within the state. 
 (d) The Arbitration shall be resolved no later than sixty (60) days from the date of acceptance by the third Arbitrator of his or her
appointment unless otherwise agreed to by the parties to the Arbitration. 
 (e) Each party shall bear the expenses and costs
of the Arbitrator selected by that party. The third Arbitrator shall be compensated for services rendered at the prevailing hourly rate of compensation and reimbursed for any expenses incurred in connection with rendering such services. The
non-prevailing party shall bear the costs and expenses of compensation and reimbursement for the third Arbitrator. 
 (f) The
decision of the Arbitrators shall be rendered in writing and shall be final and binding and may be enforced at the request of either party to the Arbitration in the United States District Court for the Northern District of Georgia or any court of
the State of Georgia having competent jurisdiction. Such decision may not be appealed except upon a claim of bad faith or fraud by the Arbitrators. 
  

 54 

 (g) This Article 19 shall not apply to issues relating to the validity, construction or
effect of the Bukwang Patents. In the event that in any Arbitration, any issue arises concerning the validity, construction or effect of any of the Bukwang Patents, the Arbitrators shall assume the validity of all claims as set forth in such Bukwang
Patents. Matters, controversies or disputes concerning the Bukwang Patents shall be resolved in any court having jurisdiction thereof or in any other manner mutually agreed to by the parties. 
 ARTICLE 20. GENERAL PROVISIONS 
 20.1 Export Controls. Bukwang
acknowledges that Pharmasset is subject to United States laws and regulations controlling the export of technical data, biological materials, chemical compositions and other commodities and that Pharmasset’s obligations under this Agreement are
contingent upon compliance with applicable United States export laws and regulations. The transfer of technical data, biological materials, chemical compositions and commodities may require a license from the cognizant agency of the United States
government or written assurances by Bukwang that Bukwang shall not export data or commodities to certain foreign countries without the prior approval of certain United States agencies, or as otherwise prescribed by applicable law or regulation.
Pharmasset neither represents that an export license shall not be required nor that, if required, such export license shall issue. 
 20.2
Independent Contractors. It is understood and agreed that the parties hereto are independent contractors and are engaged in the operation of their own respective businesses, and neither party hereto is to be considered the agent of the other
party for any purpose whatsoever, and neither party shall have any authority to enter into any contracts or assume any obligations for the other party nor make any warranties or representations on behalf of that other party. 
 20.3 Patent Marking. Pharmasset shall mark Licensed Products sold in the United States with United States patent numbers. Licensed Products
manufactured or sold in other countries shall be marked in compliance with the intellectual property laws in force in such countries. The foregoing obligations shall be subject to size and space limitations in accordance with any regulatory
requirements and any later agreement between the parties. If Bukwang believes that a Licensed Product should be marked with the number of a Bukwang Patent, Bukwang shall provide written notice to Pharmasset which identifies the patent number and the

  

 55 

 
Licensed Product on which it should appear. It shall also be Bukwang’s responsibility to inform Pharmasset in writing when marking with a Bukwang Patent
number should be discontinued. To the extent that Pharmasset complies with Bukwang’s instructions, Bukwang shall indemnify and hold Pharmasset harmless for any liability, claim or action for false patent marking or non-marking. 
 20.4 Publicity. The parties agree to issue mutual press releases concerning their entry into this Agreement, with the content of such releases to
be approved (which consent shall not be unreasonably withheld or delayed) in advance by the parties. In all other respects, except as required by law, neither party shall use the name of the other party or the Primary Licensors, the University of
Georgia, or the Inventors (as defined in the Primary License Agreement) in any publicity release without the prior written permission of such other party or Primary Licensors, the University of Georgia, or the Inventors (as defined in the Primary
License Agreement), as applicable, which shall not be unreasonably withheld or delayed. The other party shall have a reasonable opportunity to review and comment on any such proposed publicity release. Except as required by law, neither party shall
publicly disclose the terms of this Agreement or issue any publicity release with regard thereto unless expressly authorized to do so by the other party which authorization shall be agreed upon. 
 20.5 Governing Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the State of Georgia exclusive of its conflicts of laws principles. 
 20.6 Entire
Agreement. This Agreement, together with the Exhibits attached hereto, constitutes the entire agreement between Bukwang and Pharmasset with respect to the subject matter hereof and shall not be modified, amended or terminated, except as herein
provided or except by another agreement in writing executed by the parties hereto. 
 20.7 Waiver. No provision of this Agreement may
be waived except by a writing signed by the party entitled to the benefit thereof, and no such waiver of any provision hereof in one instance shall constitute a waiver of any other provision or of such provision in any other instance. No omission,
delay or failure on the part of any party hereto in exercising any rights hereunder will constitute a waiver of such rights or of any other rights hereunder. 
  

 56 

 20.8 Severability. All rights and restrictions contained herein may be exercised and shall be
applicable and binding only to the extent that they do not violate any applicable laws and are intended to be limited to the extent necessary so that they will not render this Agreement illegal, invalid or unenforceable. If any provision or portion
of any provision of this Agreement, not essential to the commercial purpose of this Agreement, shall be held to be illegal, invalid or unenforceable by a court of competent jurisdiction, it is the intention of the parties that the remaining
provisions or portions thereof shall constitute their agreement with respect to the subject matter hereof, and all such remaining provisions, or portions thereof, shall remain in full force and effect. To the extent legally permissible, any illegal,
invalid or unenforceable provision of this Agreement shall be replaced by a valid provision which shall implement the commercial purpose of the illegal, invalid or unenforceable provision. In the event that any provision essential to the commercial
purpose of this Agreement, this Agreement and the rights granted herein shall terminate. 
 20.9 Force Majeure. 
 (a) Any delays in, or failure of performance of, any party to this Agreement, shall not constitute a default hereunder, or give rise to
any claim for damages, if and to the extent caused by occurrences beyond the control of the party affected, including, but not limited to, acts of God, strikes or other concerted acts of workmen, civil disturbances, terrorism, fires, floods,
explosions, riots, war, rebellion, sabotage, acts of governmental authority or failure of governmental authority to issue licenses or approvals which may be required (“Force Majeure”). 
 (b) The party asserting the Force Majeure shall promptly notify the other party of the event constituting Force Majeure and of all
relevant details of occurrence and where appropriate an estimate of how long such Force Majeure event shall continue. 
 (c)
If such Force Majeure event continues thereafter and in any event, the parties shall consult with each other in order to find a fair solution and shall use all reasonable endeavors to minimize the consequences of such Force Majeure. 
  

 57 

 20.10 Counterparts. This Agreement may be executed in one or more counterparts (including by
facsimile), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 20.11
Notices. All notices, statements, and reports required to be given under this Agreement shall be in writing and shall be deemed to have been given upon delivery in person or, when deposited in the mail in the country of residence of party
giving the notice, registered or certified postage prepaid or with a professional courier service (e.g., FedEx or UPS), and addressed as follows: 
  

			
	 To Bukwang:
	  	Bukwang Pharm. Co., Ltd
		  	398-1 Daebang-Dong-Dongjak-Ku
		  	Seoul 156-811
		  	Korea
		  	Attn: Sang Hoon Kim, Director of Bukwang
		  	Fax: 02-816-2792
		
	 To Pharmasset
	  	Pharmasset, Inc.
		  	1860 Montreal Road
		  	Tucker, Georgia 30084 U.S.A.
		  	Attn: Legal Affairs
		  	Fax: +1 678-395-0030

 Any party hereto may change the address to which notices to such party are to be sent by giving
notice to the other party at the address and in the manner provided above. Any notice may be given, in addition to the manner set forth above, by telex, facsimile or cable, provided that the party giving such notice obtains acknowledgment by telex,
facsimile or cable that such notice has been received by the party to be notified. Notices made in this manner shall be deemed to have been given when such acknowledgment has been transmitted. Any provision of this Section 20.11 to the contrary
notwithstanding, any notice to Bukwang shall be effective if given as to Bukwang prescribed above by Pharmasset, despite any failure to deliver copies as prescribed above. 
 20.12 Interpretation. In the event of any conflict between the terms hereof and the terms of the Primary License Agreement, the terms of the
Primary License Agreement shall control. Any amendment to the Primary License Agreement effective subsequent to the date hereof, to the extent such amendment would adversely affect the rights and obligations of Pharmasset hereunder, shall not be
effective unless Pharmasset has given prior written consent thereto in writing. 
  

 58 

 20.13 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by a party
hereto are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(56) of the Bankruptcy Code. The parties agree that
a party, as a licensee of such rights and licenses, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The parties further agree that, in the event than any proceeding shall be instituted by or against a
party as seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of it or its debts under any law relating to bankruptcy, insolvency or
reorganization or relief of debtors, or seeking an entry of an order for relief or the appointment of a receiver, trustee or other similar official for it or any substantial part of its property or seeking to take any action to authorize any of the
foregoing actions (each a “Proceeding”), the other party, as licensee, shall have the right to retain and enforce its rights under this Agreement, including but not limited to the following rights: 
 (a) the right to continue to use the relevant licensed Patents and Know-How and all documentation and other supporting material related
thereto, in accordance with the terms and conditions of this Agreement; and 
 (b) the right to a complete duplicate of (or
complete access to, as appropriate) all relevant licensed Patents and Know-How and all embodiments of such, and the same if not already in such licensee’s possession, shall be promptly delivered to such licensee (i) upon any such
commencement of a Proceeding upon written request therefor by such licensee, unless the other party as licensor elects to continue to perform all of its obligations under this Agreement; or (ii) if not delivered under (i) above, upon the
rejection of this Agreement by or on behalf of the other party as licensor upon written request therefor by licensee; 
 (c)
the right to obtain from the other party as licensor all documentation and other supporting materials related to the relevant licensed Patent and Know-How. 
  

 59 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 ARTICLE 21. SUPPLY OF COMPOUND 
 21.1 General. Pharmasset may, at its option, act as, or appoint a third party to act as, primary supplier for Pharmasset’s requirements of
the Compound for the Territory. To the extent allowed by law and subject to Pharmasset’s right pursuant to this Article to act as primary supplier, Pharmasset, at its option, may purchase from Bukwang, its Affiliates or Bukwang’s
designated suppliers all of Pharmasset’s requirements of the Compound for the Territory; provided that such Compound has been manufactured in a timely manner and in accordance with applicable cGMPs, laws and the specifications. If Pharmasset
exercises its option to have Bukwang manufacture Compound, Bukwang agrees to supply Pharmasset with all of its requirements of the Compound, in accordance with this Agreement. The Compound will be supplied by Bukwang in form of Bulk Drug Substance.

 21.2 Clinical Supply. Pharmasset shall place orders for clinical supplies of Compound and clinical supplies of Licensed Product on
a purchase order basis on at least thirty (30) days written notice prior to the requested delivery date. 
 21.3 Commercial
Supply. If Pharmasset exercises its option to have Bukwang manufacture Compound, the parties will establish the terms and conditions applicable to the commercial supply of Compound by Bukwang to Pharmasset, and enter into an appropriate supply
agreement with respect thereto containing terms and conditions consistent with the terms of this Agreement, and at a minimum those terms and conditions as set forth on Exhibit J. 
 21.4 Back-Up Manufacturing Rights. If Pharmasset exercises its option to have Bukwang manufacture Compound, subject to Exhibit J,
Pharmasset will retain the right to act as, or to appoint a third party to act as, a second source to supply Compound for up to [***] percent ([***]%) of Pharmasset’s requirements for the Territory. In the event that Bukwang does not properly
administer any agreement with a third party manufacturer for the manufacture of Compound or otherwise is at fault in permitting circumstances to exist such that there is a reasonable likelihood of insufficient quantities of Compound to satisfy the
need thereof for the manufacture of Licensed Products, then Pharmasset shall be entitled, but not be required, to assume in whole or in part Bukwang’s rights and related obligations under such agreement (to the extent permissible thereunder) or
otherwise direct the exercise of rights and performance of obligations by Bukwang under such agreement, including the establishment of additional third party manufacturers or manufacture by Pharmasset. 
  

 60 

 IN WITNESS WHEREOF, Bukwang and Pharmasset have caused this Agreement to be signed by their duly
authorized representatives, under seal, as of the day and year indicated above. 
  

			
	 BUKWANG PHARM. CO., LTD.

		
	By:	 	 /s/ Sung-Koo Lee

	 Name:
	 	 Sung-Koo Lee

	 Title:
	 	 President and CEO

	
	 PHARMASSET, INC.

		
	By:	 	 /s/ P. Schaefer Price

	 Name:
	 	P. Schaefer Price
	 Title:
	 	 President and CEO

  

 61 

 EXHIBIT A 
 PRIMARY LICENSE AGREEMENT BETWEEN 
 BUKWANG, YALE UNIVERSITY AND UNIVERSITY OF GEORGIA RESEARCH

 FOUNDATION, INC. DATED DECEMBER 28, 1995 AND AS AMENDED 

 LICENSE AGREEMENT 
 between 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY, AND 
 BUKWANG PHARM. IND.
CO., LTD. 

 TABLE OF CONTENTS 
  

					
	 Article 1.
	  	Definitions	  	2
			
	 Article 2.
	  	Grant of License	  	4
			
	 Article 3.
	  	Diligence and Commercialization	  	6
			
	 Article 4.
	  	Consideration for License	  	7
			
	 Article 5.
	  	Reports and Payments	  	8
			
	 Article 6.
	  	Records	  	10
			
	 Article 7.
	  	Patent Prosecution	  	11
			
	 Article 8.
	  	Abatement of Infringement	  	13
			
	 Article 9.
	  	Disclosure of Information and Confidentiality	  	14
			
	 Article 10.
	  	Representations, Merchantability and Exclusion of Warranties	  	16
			
	 Article 11.
	  	Damages, Indemnification, and Insurance	  	17
			
	 Article 12.
	  	Term and Termination	  	18
			
	 Article 13.
	  	Assignment	  	20
			
	 Article 14.
	  	Miscellaneous	  	20
			
	 Article 15.
	  	Notices	  	23
			
	 Exhibit A.
	  	Licensed Patents	  	
			
	 Exhibit B.
	  	Licensee’s Development Plan	  	

 THIS LICENSE AGREEMENT is dated the 28th day of December, 1995, by and among the UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION, INC., a nonprofit Georgia corporation with offices located in Boyd Graduate Studies Research Center, The University of Georgia, Athens, Georgia 30602 (hereinafter “UGARF”), and YALE UNIVERSITY (hereinafter
“YALE”), located in New Haven, Connecticut, and BUKWANG PHARM. IND. CO. LTD., a Korean corporation with headquarters located at 398-1, Daebang-Dong, Dongjak-ku, Seoul 156-020, Republic of Korea (hereinafter “BUKWANG”).

 WITNESSETH 
 WHEREAS,
Dr. Chung K. Chu, during the course of his employment at The University of Georgia, and Dr. Yung-chi Cheng, during the course of his employment at YALE, developed certain inventions as more fully defined herein; and 
 WHEREAS, UGARF is the assignee of all right, title, and interest in inventions developed by employees of The University of Georgia and is responsible for
the protection and commercial development of such inventions; and 
 WHEREAS, UGARF and YALE want to have the inventions further developed
and made available for commercial use by the public; and 
 WHEREAS, BUKWANG represents that it has the necessary expertise and resources to
fully develop and commercialize the inventions; and 
 WHEREAS, UGARF and YALE wish to grant BUKWANG such a license in accordance with the
terms and conditions of this Agreement. 
  

 1 

 NOW, THEREFORE, for and in consideration of the mutual covenants and the premises herein contained, the
parties, intending to be legally bound, hereby agree as follows. 
 ARTICLE 1. DEFINITIONS 
 The following terms as used herein shall have the following meaning: 
 1.1 “Affiliates” shall mean any corporation, partnership or other business entity which is directly or indirectly controlled by BUKWANG or any entity which directly or indirectly controls BUKWANG.
“Controls” as used herein means owns directly or indirectly at least thirty percent (30%) of the voting shares. 
 1.2
“Agreement” or “License Agreement” shall mean this Agreement, including all Exhibits attached to this Agreement. 
 1.3
“BUKWANG’s Development Plan” shall mean the development plan reproduced as EXHIBIT B of this Agreement. 
 1.4 “Field of
Use” shall mean the treatment of viral infections. 
 1.5 “Indemnitees” shall mean UGARF, UGARF’s officers and directors,
UGA, UGA’s employees, YALE, YALE’s officers and directors, the Inventors, and their heirs, executors, administrators, and legal representatives. 
 1.6 “Inventors” shall mean Dr. Yung-chi Cheng and Dr. Chung K. Chu. 
 1.7
“License Agreement Year” shall mean and include each twelve-month period, beginning with the Operative Date, during the term of this Agreement. 
 1.8 “Licensed Patents” shall mean the patent applications and patents identified in EXHIBIT A hereof, together with all divisionals, continuations, reissues, reexaminations and foreign counterparts of such
applications or patents. 
  

 2 

 1.9 “Licensed Product(s)” shall mean any process, service, or product, the manufacture, use, or
sale of which is covered by a Valid Claim or incorporates or uses any Licensed Technology. 
 1.10 “Licensed Technology” shall mean
all designs, technical information, know-how, knowledge, data, specifications, test results and other information, whether or not patented, which are known to the Inventors, except such technology already existing in the public domain or such
technology already known to BUKWANG, on the date of this Agreement, and which are useful for the development, commercialization, manufacture, use or sale of any Licensed Product. 
 1.11 “Licensed Territory” shall mean the world. 
 1.12 “LICENSOR” shall mean UGARF and YALE, jointly. 
 1.13 “Net Selling Price” of
Licensed Products shall mean the total invoiced price paid to BUKWANG or its Affiliates by a purchaser of a Licensed Product less the following discounts: a) customary trade, quantity and cash discounts actually allowed and taken; b) credits
actually given for rejected or returned Licensed Products; c) freight and insurance costs, if separately itemized on the invoice paid by the customer; and d) excise taxes and customs duties included in the invoiced amount. Where a Sale is deemed
consummated by a gift, use, or other disposition of Licensed Products for other than a selling price stated in cash, the term “Net Selling Price” shall mean the average gross selling price billed by BUKWANG for the same quantity of Sales
of Licensed Products during the three (3) month period immediately preceding such Sale, without reduction of any kind. 
 1.14
“Operative Date” of this Agreement shall mean the date on which LICENSOR receives notification from the United States Government of its approval of the grant of rights made to BUKWANG hereunder. 
 1.15 “Sale” or “Sold” shall mean the sale, transfer, exchange, or other disposition of Licensed Products whether by gift or
otherwise, by BUKWANG, its Affiliates or any other 

  

 3 

 
person authorized by BUKWANG. For the purposes of this Agreement, the following activities shall not be deemed a Sale: (a) the provision of Licensed
Products, prior to the approval of Licensed Products in a country and pursuant to a requirement issued by the appropriate governmental agency in that country, for consumption by or administration to persons for humanitarian purposes or compassionate
use, (b) the provision of Licensed Products for use in clinical trials, or (c) the provision of samples of Licensed Products without charge by BUKWANG for promotional purposes. Sales of Licensed Products shall be deemed consummated upon
the first to occur of: (a) receipt of payment from the purchaser; (b) delivery of Licensed Products to the purchaser or a common carrier; (c) release of Licensed Products from consignment; (d) if deemed Sold by use, when first
put to such use; or (e) if otherwise transferred, exchanged, or disposed of whether by gift or otherwise when such transfer, exchange, gift, or other disposition occurs. 
 1.16 “UGA” shall mean The University of Georgia. 
 1.17 “Valid Claim” shall mean a claim included among the Licensed Patents so long as such claim shall not have been irrevocably abandoned or held invalid in an unappealable decision of a court or other
authority of competent jurisdiction. 
 ARTICLE 2. GRANT OF LICENSE 
 2.1 License. LICENSOR hereby grants BUKWANG an exclusive right and license under the Licensed Patents to make, have made, use, and Sell Licensed
Products and to practice Licensed Technology for the Field of Use in the Licensed Territory during the term of this Agreement. 
 2.2
Retained License. LICENSOR retains on behalf of UGARF, YALE, and UGA and any research collaborators, a royalty-free right and license to make and use Licensed Products and to practice Licensed Technology for research and educational purposes
only. 
  

 4 

 2.3 No Implied License. The license and right granted in this Agreement shall not be construed to
confer any rights upon BUKWANG by implication, estoppel, or otherwise as to any technology not specifically identified in this Agreement as Licensed Patents or Licensed Technology. 
 2.4 United States Government Rights. The Licensed Patents, Licensed Technology, or portions thereof were developed with financial or other
assistance through grants or contracts funded by the United States government. BUKWANG acknowledges that in accordance with Public Law 96-517 and other statutes, regulations, and Executive Orders as now exist or may be amended or enacted, the United
States government has certain rights in the Licensed Patents and Licensed Technology. BUKWANG shall take all reasonable actions necessary to enable LICENSOR to satisfy its obligations under any federal law relating to the Licensed Patents or
Licensed Technology. BUKWANG acknowledges that LICENSOR must obtain a waiver from the United States government, pursuant to United States Code of Federal Regulations, Section 37, 401.14(i), to enable LICENSOR to grant the rights and license
hereunder. LICENSOR has requested such a waiver, but if this Agreement is executed prior to the granting of said waiver, BUKWANG agrees that this Agreement will automatically terminate if the request for waiver is denied. LICENSOR shall notify
BUKWANG within ten (10) days of receipt of notice of denial of said waiver from the United States government. If at any time during the term of this Agreement, the United States government should take action which renders it impossible or
impractical for LICENSOR to grant the rights and license granted herein to BUKWANG under this Agreement or otherwise perform LICENSOR’s obligations, LICENSOR or BUKWANG may terminate this Agreement immediately by notice to the other party.
BUKWANG shall not have any right to the return of any payments of any kind made by it to LICENSOR prior to the date of termination. 
 2.5
Republic of Korea Government Approval. It will be necessary for The Fair Trade Committee in Economic Planning Ministry of the Republic of Korea to approve this Agreement. If this Agreement is executed prior to the granting of such approval,
LICENSOR agrees that this Agreement shall automatically terminate if approval is denied. BUKWANG shall not have any right to the return of any payments of any kind made by it to LICENSOR prior to the date of termination. 
  

 5 

 ARTICLE 3. DILIGENCE AND COMMERCIALIZATION 
 3.1 Diligence and Commercialization. BUKWANG shall use its best efforts throughout the term of this Agreement to diligently pursue BUKWANG’s
Development Plan and to bring Licensed Products to market through a thorough, rigorous, and diligent program for exploitation of the rights and license herein granted to BUKWANG and to create, supply, and service in the Licensed Territory as
extensive a market as possible. In no instance shall BUKWANG’s best efforts be less than efforts customary in the pharmaceutical industry. 
 3.2 Lack of Diligence. If LICENSOR concludes that BUKWANG is not diligent in developing and Selling Licensed Products pursuant to paragraph 3.1 for any reason other than a) the withholding by a regulatory agency of marketing approval
despite BUKWANG’s diligent effort to obtain such approval; or b) unanticipated technical or scientific problems which have been reported to LICENSOR in writing; or c) other causes beyond the reasonable control of BUKWANG; then LICENSOR may, at
its sole discretion, terminate this Agreement pursuant to paragraph 12.4 hereof. 
 3.3 No Competing Products. BUKWANG agrees that it
will not concurrently develop a compound or composition with the same mode or mechanism of action as compound(s) or compositions (s) covered by the Licensed Patents. BUKWANG shall provide, on a semi-annual basis, a certified statement from a
corporate officer of BUKWANG that BUKWANG is not concurrently developing a competing compound or composition with the same mode or mechanism of action as compound(s) or compositions (s) covered by the Licensed Patents. In the event that BUKWANG
undertakes the concurrent development of such a competing product or does not provide certification as stipulated in this paragraph, LICENSOR shall have the right, at its sole discretion, to terminate this Agreement upon thirty (30) days
written notice to BUKWANG. 
  

 6 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 ARTICLE 4. CONSIDERATION FOR LICENSE 
 4.1 Research Gift. As partial consideration for the license granted to BUKWANG under this Agreement, BUKWANG shall provide nonrefundable research
funding to UGARF and YALE according to the following schedule: 
  

	 	(a)	On the Operative Date of this Agreement: 

 US$[***] payable
to UGARF, and 
 US$[***] (including US$[***] for administrative fees) payable to Yale School of Medicine 
  

	 	(b)	On the First Day of the Second License Agreement Year: 

 US$[***] payable to UGARF, and 
 US$[***] (including US$[***] for administrative fees) payable to Yale School of Medicine

  

	 	(c)	On the First Day of the Third License Agreement Year: 

 US$[***] payable to UGARF, and 
 US$[***] (including US$[***] for administrative fees) payable to Yale School of Medicine

  

	 	(d)	On the First Day of the Fourth License Agreement Year: 

 US$[***] payable to UGARF, and 
 US$[***] (including US$[***] for administrative fees) payable to Yale School of Medicine

 Such payments shall be made on a quarterly basis on each of the first (1st), ninetieth (90th), one-hundred eightieth (180th), and
two-hundred seventieth (270th) days of the indicated License Agreement Year. In the event that this Agreement is terminated for any reason during one of the first four (4) License Agreement Years, BUKWANG agrees to make all four quarterly
payments due under this paragraph for the License Agreement Year in which this Agreement is terminated. 
  

 7 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 4.2 Milestone Payments. As partial consideration for the license granted to BUKWANG under this
Agreement, BUKWANG shall pay LICENSOR nonrefundable milestone payments according to the following schedule: 
  

						
	  	  	 Milestone:
	  	Payment:
	 (a)
	  	The completion of a Phase II clinical trial in the United States	  	US$	[***]
	 (b)
	  	The first filing of a New Drug Application (“NDA”) relating to the Licensed Product with the United States Food and Drug Administration (“FDA”)	  	US$	[***]
	 (c)
	  	The granting by the FDA of approval of the NDA for the Licensed Product	  	US$	[***]

 [***] percent ([***]%) of the milestone payments shall be credited against royalties actually due and payable
under Article 4.3; provided, however, that in any single License Agreement Year, such credit shall not exceed [***] percent ([***]%) of the royalties otherwise due. 
 4.3 Royalties. As partial consideration for the license granted to BUKWANG under this Agreement, BUKWANG shall pay LICENSOR a royalty equal to [***] percent ([***]%) of the Net Selling Price of all Licensed
Products Sold by BUKWANG or its Affiliates during the term of this Agreement. 
 4.4 Reimbursement for Patent Expenses. BUKWANG shall
reimburse LICENSOR for all external fees, costs, and expenses heretofore and hereafter during the term of this Agreement paid or incurred by LICENSOR in filing, prosecuting, and maintaining the Licensed Patents in the Licensed Territory. 

ARTICLE 5. REPORTS AND PAYMENTS 
 5.1 Payments. All royalty payments required under this Agreement pursuant to Article 4.3 shall be due sixty (60) days following the end of a quarter, for Sales occurring during the immediately preceding quarter of each License
Agreement Year. Such royalties shall be 

  

 8 

 
accompanied by a royalty report, as detailed in paragraph 5.3. All other payments required under this Agreement are payable on the due date, or, for payments
due under Article 4.4, such reimbursement shall be delivered within thirty (30) days after receipt by BUKWANG from time to time of an invoice from UGARF, including all supportive documentation of such fees and costs. 
  

	 	(a)	Payments due under Articles 4.2 and 4.3 shall be made in person, via the United States mail, or by private carrier to the following addresses: 

  

			
	Fifty Percent (50%) of the Total Due, made payable to:	  	 University of Georgia Research Foundation, Inc.
 Attention: Patsy Songer
 Boyd Graduate Studies Research Center
 Athens, Georgia, U.S.A. 30602-7411
 Facsimile: (706) 542-5638

		
	Fifty Percent (50%) of the Total Due, made payable to:	  	 Yale University
 Attention: Office of Cooperative
Research
 246 Church Street, Suite 401
 New Haven, Connecticut,
U.S.A. 06510
 Facsimile: (203)-432-7245

  

	 	(b)	Payments due under Article 4.4 shall be made payable to UGARF and sent to the address give in 5.1(a) for UGARF. 

 5.2 Progress Reports. BUKWANG will provide UGARF with semi-annual progress reports detailing the activities of BUKWANG described in BUKWANG’s
Development Plan. Such reports shall be due on July 1 and January 1 of each License Agreement Year, beginning with July 1, 1996, for the immediately preceding half-year. 
 5.3 Royalty Reports. Within sixty (60) days of the first (1st), ninetieth (90th), one-hundred eightieth (180th), and two-hundred seventieth
(270th) days of each License Agreement Year, beginning with the License Agreement Year in which the first approval for marketing 

  

 9 

 
Licensed Products in any country of the Licensed Territory is granted, and ending with the year following the termination or expiration of this Agreement,
BUKWANG shall provide a written report to LICENSOR setting forth for the preceding calendar quarter, the following as may be applicable: 
  

	 	(a)	all Sales (including Net Selling Price of each product sold) of Licensed Products by BUKWANG and its Affiliates on a country-by-country basis throughout the Licensed Territory;

  

	 	(b)	the amount of royalties payable pursuant to this Agreement; 

  

	 	(c)	any other information reasonably necessary to show the basis on which such royalties have been computed; 

  

	 	(d)	the amount of any credits taken pursuant to Article 4.2; 

  

	 	(e)	in case no payment is due, BUKWANG shall so report. 

 5.4
Currency Conversion. If any Licensed Products are Sold for monies other than United States dollars, the Net Selling Price of such Licensed Products shall first be determined in the foreign currency of the country in which such Licensed
Products are Sold and then converted to United States dollars at the spot rate published by the Wall Street Journal (U.S. edition) for conversion of that foreign currency into United States dollars on the last day of the quarter for which
such payment is due. 
 5.5 Interest. Payments required under this Agreement shall, if overdue, bear interest until payment at a per
annum rate two percent (2%) above the prime rate in effect at the Trust Company Bank in Atlanta, Georgia, on the due date. The payment of such interest shall not foreclose LICENSOR from exercising any other rights it may have because any
payment is late. 
 ARTICLE 6. RECORDS 
 6.1 Records of Sales. During the term of this Agreement and for a period of three (3) years thereafter, BUKWANG shall keep at its principal place of business true and accurate 

  

 10 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
records of all Sales in accordance with generally accepted accounting principles and in such form and manner so that all royalties owed to LICENSOR may be
readily and accurately determined. BUKWANG shall furnish LICENSOR copies of such records upon LICENSOR’s request, which shall not be made more often than once per License Agreement Year. 
 6.2 Audit of Records. LICENSOR shall have the right, from time to time at reasonable times during normal business hours through an independent
certified public accountant, to examine the records of BUKWANG maintained in accordance with the provisions of paragraph 6.1 in order to verify the calculation of any royalties payable under this Agreement. Such examination and verification shall
not occur more than once each License Agreement Year and the calendar year immediately following termination of this Agreement. Unless otherwise agreed in writing by BUKWANG, the fees and expenses of performing such examination and verification
shall be borne by LICENSOR. If such examination reveals an underpayment by BUKWANG of more than five percent (5%) for any quarter examined, BUKWANG shall pay LICENSOR the amount of such underpayment plus interest and shall reimburse LICENSOR
for all expenses of the accountant performing the examination. 
 ARTICLE 7. PATENT PROSECUTION 
 7.1 Prosecution and Maintenance of Licensed Patents. The prosecution and maintenance of the Licensed Patents shall be the primary responsibility
of LICENSOR. LICENSOR shall keep BUKWANG informed as to all developments with respect to Licensed Patents. BUKWANG shall be afforded reasonable opportunities to advise LICENSOR and cooperate with LICENSOR in such prosecution and maintenance. On or
before March 1, 1996, BUKWANG shall notify LICENSOR of the countries in which BUKWANG wishes the International Patent Cooperation Treaty Application No. [***], filed [***], to be filed. LICENSOR may, at its own expense, file patent applications
in those countries in which BUKWANG elects not to file national applications. Such non-elected countries in which LICENSOR has filed a patent application will no longer be included in the Licensed Territory, and BUKWANG shall not have the right to
Sell Licensed Products in non-elected countries. 

  

 11 

 
Prior to the execution of any third party licenses in such non-elected countries, LICENSOR shall offer BUKWANG a right of first refusal, which, if it is to
be exercised, shall be exercised within thirty (30) days of BUKWANG’s receipt in writing from LICENSOR of a written proposal outlining the terms of a third party license. If BUKWANG elects to exercise its right of first refusal, then
LICENSOR and BUKWANG shall execute a license on the same terms and conditions as those referred to in the third party license. If BUKWANG elects not to exercise its right of first refusal or fails to exercise its right of first refusal before the
expiration of the aforesaid thirty (30) day period, then LICENSOR shall be free to execute the third party license. 
 If BUKWANG should
fail to timely make reimbursement for patent expenses incurred in filing, prosecuting or maintaining applications or patents in a particular country(ies) as required by Article 4.4 of this Agreement, LICENSOR shall have no further obligation to
prosecute or maintain the Licensed Patents in said country(ies). 
 BUKWANG, upon ninety (90) days advance written notice to LICENSOR,
may advise LICENSOR that it no longer wishes to pay expenses for filing, prosecuting or maintaining one or more Licensed Patents. LICENSOR may, at its option, elect to pay such expenses or permit such Licensed Patents to become abandoned or lapsed.
If LICENSOR elects to pay such expenses, such patents shall not be subject to any license granted to BUKWANG hereunder. 
 7.2 Extension
of Licensed Patents. In the event that it is possible to have the normal term of any Licensed Patent extended or restored under a country’s procedure of extending patent terms for time lost in government regulatory approval processes,
BUKWANG agrees to cooperate fully with LICENSOR and provide all necessary documentation and information needed to enable LICENSOR to timely apply for such extension(s). All out-of-pocket expenses incurred by LICENSOR in applying for such
extension(s) shall be borne in accordance with the terms of Article 4.4. In the case of such extension(s), royalties due LICENSOR pursuant to Article 4.3 hereof shall be payable until the end of the extended term of the Licensed Patent. 

 

 12 

 ARTICLE 8. ABATEMENT OF INFRINGEMENT 
 8.1 BUKWANG shall promptly inform LICENSOR of any suspected infringement of any Licensed Patents. During the term of this Agreement, LICENSOR and BUKWANG
shall have the right to institute an action for infringement of the Licensed Patents against such third party in accordance with the following: 
  

	 	(a)	If LICENSOR and BUKWANG agree to institute suit jointly, the suit shall be brought in both their names and the out-of-pocket costs thereof shall be borne equally. Any recovery or
settlement received by LICENSOR and/or BUKWANG for punitive or exemplary damages shall be shared equally, and any other recovery or settlement received, including compensatory damages or damages based on a loss of revenues, shall be paid to BUKWANG,
and BUKWANG shall pay to LICENSOR an amount representing the royalty which would have been paid by BUKWANG on such amount in accordance with the provisions of Article 4 had such amount been accrued by BUKWANG as Sales. BUKWANG and LICENSOR shall
agree upon the manner in which they shall exercise control over such action. LICENSOR may, if it so desires, also be represented by separate counsel of its own selection, the fees for which counsel shall be paid by LICENSOR;

  

	 	(b)	In the absence of agreement to institute a suit jointly, LICENSOR may institute suit, and, at its option, name BUKWANG as a plaintiff. LICENSOR shall bear the entire cost of such
litigation, including defending any counterclaims brought against BUKWANG and paying any judgments rendered against BUKWANG, and shall be entitled to retain the entire amount of any recovery or settlement; and 

  

	 	(c)	 In the absence of agreement to institute a suit jointly and if LICENSOR notifies BUKWANG that it has decided not to join in or institute a suit, as provided in
(a) or (b) above, BUKWANG may institute suit and, at its option, name LICENSOR as a plaintiff. BUKWANG shall bear the entire cost of such litigation, including 

  

 13 

	 	 
defending any counterclaims brought against LICENSOR and paying any judgments rendered against LICENSOR, and shall be entitled to retain the entire amount of
any recovery or settlement. 

 8.2 Should either LICENSOR or BUKWANG commence a suit under the provisions of this Article
and thereafter elect to abandon such suit, the abandoning party shall give timely notice to the other party who may, if it so desires, continue prosecution of such suit, provided that the sharing of expenses and any recovery in such suit shall be as
agreed upon between LICENSOR and BUKWANG. 
 ARTICLE 9. DISCLOSURE OF INFORMATION AND CONFIDENTIALITY 
 9.1 It will be necessary for LICENSOR to disclose to BUKWANG and for BUKWANG to disclose to LICENSOR such information and technology as will assist the
parties to successfully carry out the objectives of this Agreement. BUKWANG will need to disclose to LICENSOR such information and technology relating to the filing of any patents related to Licensed Products and such other information as may be
requested by LICENSOR which is necessary for LICENSOR to ascertain that BUKWANG is performing its obligations pursuant to this Agreement. All such information and technology to be exchanged will be in writing and marked “CONFIDENTIAL”.
BUKWANG or LICENSOR, as the case may be, shall not, during the life of this Agreement and for a period of five (5) years after the termination or expiration of this Agreement, disclose to any third party the other’s technology, except to
an Affiliate under appropriate written confidentiality provisions who requires such information to carry out the objectives of this Agreement; shall use the same degree of care as is exercised with respect to its own confidential information to
prevent disclosure of the same to any third party; and shall not use the same for any purpose other than exercising any right or rights granted to it herein; provided, however, that nothing herein contained shall restrict either party with respect
to the disclosure or use of information which the recipient party can show: 
  

	 	(a)	was in its possession at the time of its receipt of same from the disclosing party; or 

  

 14 

	 	(b)	was part of the public knowledge or literature at the time of its receipt from the disclosing party, or thereafter becomes part of the public knowledge or literature through no
fault of either party, their Affiliates, employees, representatives or any third party to whom such information was disclosed in accordance with the provisions of this Agreement; or 

  

	 	(c)	was received from a third party having the right to disclose such information. 

 Specific technology disclosed by one party to the other hereunder shall not be deemed to be within any of the above three (3) exclusions merely because it is embraced by more general information included within one of the exclusions.

 9.2 Notwithstanding the provisions of paragraph 9.1 above, and to the extent necessary: 
  

	 	(a)	a party may disclose and use the other party’s information for purposes of securing the registration of, and or governmental approval to market, pursuant to this Agreement, any
Licensed Products; 

  

	 	(b)	a party may disclose and use the other party’s information where the disclosure and use of such will be necessary to the procurement of patent protection, pursuant to this
Agreement, for a Licensed Product; 

  

	 	(c)	a party may disclose and use the other party’s information to the extent that it is necessary to aid in the development and commercialization, pursuant to this Agreement, of
any Licensed Product provided that any such disclosure of the disclosing party’s information shall be in confidence and subject to provisions the same, or substantially the same, as those in paragraph 9.1 hereof. 

  

 15 

 If this Agreement is terminated for any reason whatsoever, LICENSOR shall have the unrestricted right to use and disclose
information generated by LICENSOR or BUKWANG pertaining to methods of synthesis, pharmacokinetics, toxicology, efficacy, clinical and other technical data related to Licensed Products. Such use and disclosure shall not be subject to the
confidentiality provisions of paragraph 9.1 that survive termination of this Agreement. 
 9.3 Prior Agreements. The provisions of
this Agreement supersede and shall be substituted for any terms of any prior confidentiality agreements between BUKWANG and LICENSOR which are not consistent with this Agreement. 
 ARTICLE 10. REPRESENTATIONS, MERCHANTABILITY AND EXCLUSION OF WARRANTIES 
 10.1 LICENSOR represents and warrants that it has the right and authority to enter into this Agreement and that neither the execution of this Agreement nor the performance of its obligations hereunder will constitute a breach of the terms
and provisions of any other agreement to which UGARF or YALE is a party. LICENSOR does not warrant the validity of the Licensed Patents licensed hereunder and makes no representation whatsoever with regard to the scope of the Licensed Patents or
that such Licensed Patents may be exploited by BUKWANG or its Affiliates without infringing other patents. 
 10.2 BUKWANG has the necessary
expertise and skill in the technical areas in which the Licensed Products and Licensed Technology are involved to make, and has made, its own evaluation of the capabilities, safety, utility, and commercial application of the Licensed Patents and
Licensed Technology. ACCORDINGLY, LICENSOR MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED PATENTS OR LICENSED TECHNOLOGY AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND
ANY OTHER IMPLIED WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL APPLICATION OF LICENSED PATENTS OR LICENSED TECHNOLOGY. 
  

 16 

 ARTICLE 11. DAMAGES, INDEMNIFICATION, AND INSURANCE 
 11.1 NO LIABILITY. LICENSOR shall not be liable to BUKWANG or BUKWANG’s customers for special, incidental, indirect, or consequential damages
resulting from defects in the testing, labeling, manufacture, or other application of Licensed Products manufactured, tested, or Sold pursuant to this Agreement. 
 11.2 Indemnification. BUKWANG shall defend, indemnify, and hold harmless the Indemnitees from and against any and all claims, demands, loss, liability, expense, or damage (including investigative costs, court
costs and attorneys’ fees) Indemnitees may suffer, pay, or incur as a result of claims, demands or actions against any of the Indemnitees arising or alleged to arise by reason of or in connection with any and all personal injury and property
damage caused or contributed to in whole or in part by BUKWANG’s manufacture, testing, use, sale, or labeling of any Licensed Products, or the practice by BUKWANG of any Licensed Patents. BUKWANG’s obligations under this Article shall
survive the expiration or termination of this Agreement for any reason. 
 11.3 Insurance. Without limiting LICENSEE’s indemnity
obligations under the preceding paragraph, LICENSEE shall maintain throughout the term of this Agreement and for ten (10) years thereafter a commercial, general liability insurance policy, written by a reputable insurance company authorized to
do business in the United States of America, which: 
  

	 	(a)	insures Indemnitees for all claims, damages, and actions mentioned in Article 11.1 of this Agreement; 

  

	 	(b)	includes a contractual endorsement providing coverage for all liability which may be incurred by Indemnitees in connection with this Agreement; 

  

	 	(c)	Requires the insurance carrier to provide UGARF with no less than thirty (30) days written notice of any change in the terms or coverage of the policy or its cancellation; and

  

 17 

	 	(d)	Provides Indemnitees product liability coverage in an amount no less than One Million Dollars ($1,000,000) per occurrence for bodily injury and One Million Dollars ($1,000,000) per
occurrence for property damage, subject to a reasonable aggregate amount. 

 BUKWANG shall provide LICENSOR with Certificates of Insurance
evidencing the above. 
 11.4 Notice of Claims. BUKWANG shall promptly notify LICENSOR of all claims involving the Indemnitees and
will advise LICENSOR of the policy amounts that might be needed to defend and pay any such claims. 
 ARTICLE 12. TERM AND TERMINATION

 12.1 Term. Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on
the Operative Date and shall continue until the date of expiration of the last-to-expire of the Licensed Patents, including any renewals or extensions thereof. In the event that there are no Valid Claims, this Agreement shall terminate on the tenth
anniversary of the date of this Agreement. 
 12.2 Termination by LICENSOR. LICENSOR shall have the right to terminate this Agreement
upon the occurrence of any one or more of the following events: 
  

	 	(a)	failure of BUKWANG to make any payment required pursuant to this Agreement when due; or 

  

	 	(b)	failure of BUKWANG to render reports to LICENSOR as required by this Agreement; or 

  

	 	(c)	failure of BUKWANG to comply with BUKWANG’s Development Plan, attached hereto as Exhibit B; or 

  

	 	(d)	the insolvency of BUKWANG; or 

  

	 	(e)	the institution of any proceeding by BUKWANG under any bankruptcy, insolvency, or moratorium law; or 

  

 18 

	 	(f)	any assignment by BUKWANG of substantially all of its assets for the benefit of creditors; or 

  

	 	(g)	placement of BUKWANG’s assets in the hands of a trustee or a receiver unless the receivership or trust is dissolved within thirty (30) days thereafter; or

  

	 	(h)	the breach of any other material term of this Agreement by BUKWANG. 

 12.3 Notice of Bankruptcy. BUKWANG must inform LICENSOR of its intention to file a voluntary petition in bankruptcy or of another’s intention to file an involuntary petition in bankruptcy to be received at
least thirty (30) days prior to filing such a petition. A party’s filing without conforming to this requirement shall be deemed a material, pre-petition incurable breach. 
 12.4 Exercise. LICENSOR may exercise its right of termination by giving BUKWANG, its trustees or receivers or assigns, thirty (30) days prior
written notice of the occurrence of an event giving cause for termination hereunder and of LICENSOR’s election to terminate. Upon the expiration of such period, this Agreement shall automatically terminate unless BUKWANG has cured the breach.
Such notice and termination shall not prejudice LICENSOR’s right to receive royalties or other sums due hereunder and shall not prejudice any cause of action or claim of LICENSOR accrued or to accrue on account of any breach or default by
BUKWANG. 
 12.5 Failure to Enforce. The failure of LICENSOR at any time, or for any period of time, to enforce any of the provisions
of this Agreement shall not be construed as a waiver of such provisions or as a waiver of the right of LICENSOR thereafter to enforce each and every such provision. 
 12.6 Termination by BUKWANG. LICENSEE may terminate this Agreement at its sole discretion upon six (6) months’ written notice to UGARF. 
 12.7 Effect. 
  

	 	(a)	 In the event this Agreement is terminated for any reason whatsoever, BUKWANG shall return, or at LICENSOR’s direction destroy, all plans, notes, 

  

 19 

	 	 
writings and other documents, samples, and other materials pertaining to the Licensed Patents and Licensed Technology, retaining only one copy in its
corporate counsel’s office for the sole purpose of compliance with surviving terms of this Agreement or defense against any legal actions related to this Agreement. Immediately upon termination of this Agreement, BUKWANG shall cease
manufacturing, processing, producing, using, Selling, or distributing Licensed Products; provided, however, that BUKWANG may continue to Sell in the ordinary course of business for a period of three (3) months reasonable quantities of Licensed
Products which are fully manufactured and in BUKWANG’s normal inventory at the date of termination if (a) all monetary obligations of BUKWANG to LICENSOR have been satisfied and (b) royalties on such sales are paid to LICENSOR in the
amounts and in the manner provided in this Agreement. 

  

	 	(b)	Upon termination of the Agreement for any reason whatsoever, BUKWANG shall provide LICENSOR with full and complete copies of all toxicology, pharmacokinetics, efficacy, clinical and
other technical data and all correspondence to and from regulatory agencies relating to approval of Licensed Products generated by BUKWANG and/or its Affiliates, contractors and agents in the course of BUKWANG’s efforts to develop Licensed
Products and/or obtain governmental approval for the Sale of Licensed Products. 

 12.8 Survival. The provisions of
Articles 9 (except as explicitly stated in paragraph 9.2), 10, and 11 of this Agreement shall remain in full force and effect notwithstanding the termination of this Agreement. 
 ARTICLE 13. ASSIGNMENT 
 This Agreement is dependent upon the special
relationship between the parties and the special knowledge and unique skills of BUKWANG. Therefore, BUKWANG shall not grant, transfer, convey, or otherwise assign any of its rights or delegate any of its obligations under this 

  

 20 

 
Agreement, without the prior written consent of LICENSOR. This Agreement shall be assignable by UGARF to UGA, the University of Georgia Foundation, or any
other nonprofit corporation which promotes the research purposes of UGA. 
 ARTICLE 14. MISCELLANEOUS 
 14.1 Export Controls. BUKWANG acknowledges that LICENSOR is subject to United States laws and regulations controlling the export of technical
data, computer software, laboratory prototypes, and other commodities and that LICENSOR’s obligations under this Agreement are contingent upon compliance with applicable United States export laws and regulations. The transfer of technical data
and commodities may require a license from the cognizant agency of the United States government or written assurances by BUKWANG that BUKWANG shall not export data or commodities to certain foreign countries without the prior approval of certain
United States agencies. LICENSOR neither represents that an export license shall not be required nor that, if required, such export license shall issue. 
 14.2 Legal Compliance. BUKWANG shall comply with all laws and regulations relating to its manufacture, processing, producing, use, Selling, or distributing of Licensed Products. BUKWANG shall not take any
action which would cause LICENSOR or BUKWANG to violate any laws and regulations. 
 14.3 Independent Contractor. BUKWANG’s
relationship to LICENSOR shall be that of a licensee only. BUKWANG shall not be the agent of LICENSOR and shall have no authority to act for or on behalf of LICENSOR in any matter. Persons retained by BUKWANG as employees or agents shall not by
reason thereof be deemed to be employees or agents of UGARF, UGA or YALE. 
 14.4 Patent Marking. BUKWANG shall mark Licensed Products
Sold in the United States with United States patent numbers. Licensed Products manufactured or Sold in other countries shall be marked in compliance with the intellectual property laws in force in such foreign countries. 
  

 21 

 14.5 Use of Names. BUKWANG shall obtain the prior written approval of YALE, UGARF, UGA, or the
Inventors prior to making use of their names for any commercial purpose, except as required by law. As an exception to the foregoing, both BUKWANG and LICENSOR shall have the right to publicize the existence of this Agreement; however, neither
BUKWANG nor LICENSOR shall disclose the terms and conditions of this Agreement without the other party’s consent, except as may be required by law. 
 14.6 Place of Execution. This Agreement and any subsequent modifications or amendments hereto shall be deemed to have been executed in the State of Georgia, U.S.A. 
 14.7 Governing Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the State of Georgia and the United States of America. 
 14.8 Entire Agreement.
This Agreement constitutes the entire agreement between LICENSOR and BUKWANG with respect to the subject matter hereof and shall not be modified, amended or terminated except as herein provided or except by another agreement in writing executed by
the parties hereto. 
 14.9 Severability. All rights and restrictions contained herein may be exercised and shall be applicable and
binding only to the extent that they do not violate any applicable laws and are intended to be limited to the extent necessary so that they will not render this Agreement illegal, invalid or unenforceable. If any provision or portion of any
provision of this Agreement not essential to the commercial purpose of this Agreement shall be held to be illegal, invalid or unenforceable by a court of competent jurisdiction, it is the intention of the parties that the remaining provisions or
portions thereof shall constitute their agreement with respect to the subject matter hereof, and all such remaining provisions or portions thereof shall remain in full force and effect. To the extent legally permissible, any illegal, invalid or
unenforceable provision of this Agreement shall be replaced by a valid provision which will implement the commercial purpose of the illegal, invalid or unenforceable provision. In the event that any provision essential to the commercial purpose of
this Agreement is held to be illegal, invalid or 

  

 22 

 
unenforceable and cannot be replaced by a valid provision which will implement the commercial purpose of this Agreement, this Agreement and the rights
granted herein shall terminate. 
 14.10 Force Majeure. Any delays in, or failure of, performance of any party to this Agreement shall
not constitute default hereunder, or give rise to any claim for damages, if and to the extent caused by occurrences beyond the control of the party affected, including, but not limited to, acts of God, strikes or other work stoppages; civil
disturbances, fires, floods, explosions, riots, war, rebellion, sabotage, acts of governmental authority or failure of governmental authority to issue licenses or approvals which may be required. 
 ARTICLE 15. NOTICES 
 All
notices and other communications shall be hand delivered, sent by private overnight mail service, or sent by registered or certified U.S. mail, postage prepaid, return receipt requested, and addressed to the party to receive such notice or other
communication at the address given below, or such other address as may hereafter be designated by notice in writing: 
  

			
	If to LICENSOR:	  	Executive Vice President
		  	University of Georgia Research Foundation, Inc.
		  	Boyd Graduate Studies Research Center, 6th Floor
		  	Athens, Georgia 30602             Facsimile: (404) 542-5638
		
	If to BUKWANG:	  	Attention: Dr. C. H. Koo
		  	Bukwang Pharm. Ind. Co., Ltd.
		  	398-1 Daebang-Dong
		  	Dongjak-ku
		  	Seoul 156-020
		  	Republic of Korea             Facsimile: 82-2-816-2792

 Such notices or other communications shall be effective upon receipt by an employee, agent or representative of
the receiving party authorized to receive notices or other communications sent or delivered in the manner set forth above. 
  

 23 

 IN WITNESS WHEREOF, LICENSOR and BUKWANG have caused this Agreement to be signed by their duly authorized
representatives, under seal, as of the day and year indicated above. 
  

									
	 LICENSOR:
	 		 	 BUKWANG:

			
	UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION, INC.	 		 	BUKWANG PHARM.IND.CO.LTD.
					
	 By:
	 	 /s/ Joe L. Key
	 		 	 By:
	 	 /s/ C. H. Koo

	 Name:
	 	 Joe L. Key
	 		 	 Name:
	 	 C. H. Koo

	 Title:
	 	 Executive Vice President
	 		 	 Title:
	 	 Managing Director

			
	 (corporate seal)
	 		 	 (corporate seal)

			
	YALE UNIVERSITY	 		 	
				
	 By:
	 	 /s/ Janet H. Ackerman
	 		 	
	 Name:
	 	 Janet Ackerman
	 		 		 	
	 Title:
	 	 Associate V.P. for Finance
	 		 		 	

  

 24 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 EXHIBIT A 
 Licensed Patents 
 U.S.S.N. [***] filed [***], entitled [***]. 
 U.S.S.N. [***] filed [***], entitled [***]. 
 U.S.S.N. [***]
filed [***], entitled [***]. 
 International Patent Cooperation Treaty (PCT) Application No. [***], filed [***]. 
  

 25 

 EXHIBIT B 
 BUKWANG’s L-FMAU Development Plan 
  

					
	 Procedure
	  	Starting Date	  	Completion Date
	 Chemical Synthesis(laboratory method)
	  	1/1/96	  	6/30/96
	 In Vivo Woodchuck Study
	  	3/1/96	  	6/30/96
	 Pilot Synthesis
	  	7/1/96	  	12/31/97
			
	 Preclinical studies
	  	4/1/97	  	8/31/98
			
	 Submission of IND in Korea
	  	3/1/98	  	
	 Phase I clinical studies in Korea
	  	5/1/98	  	12/31/98
	 Phase II           “         “
        “
	  	1/1/99	  	6/30/99
	 Phase III         “         “
        “
	  	7/1/99	  	12/31/2001
	 Marketing
	  	6/1/2001	  	
			
	 Synthesis in USA
	  	7/1/98	  	12/31/98
	 Preclinical studies
	  	1/1/99	  	6/30/99
			
	 Submission of Investigational New Drug Application (IND) in U.S. and other countries
	  	6/1/2000	  	
			
	 Phase I clinical studies in U.S.
	  	8/1/2000	  	7/31/2001
	 Phase II clinical studies in U.S.
	  	10/1/2001	  	9/30/2002
	 Phase III clinical studies in U.S.
	  	10/1/2002	  	9/30/2004
			
	 Filing of New Drug Application (NDA) in Korea and U.S.
	  	1/01/2005	  	

  

 26 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 <The Development Schedule for L-FMAU> 
  

					
	 	  	 <Test>
	  	 <Expected Period>

	Acute Toxicity	  	 Acute toxicity for [***]
 Acute Toxicity for
[***]
	  	 Jun. 1998 ~ Jul. 1998
 Jul. 1998 ~ Aug.
1998

			
	Subcute & Chronic Toxicity	  	 DRF test for [***]
 [***] 13wks toxicity
 DRF test for [***]
 [***] 13wks toxicity
	  	 Jul. 1998 ~ Oct. 1998
 Sep. 1998 ~ Mar.
1999
 Aug. 1998 ~ Dec. 1998
 Sep. 1998 ~ Mar.
1999

			
	Genetic Toxicity	  	 Ames test
 Chromosome aberration study
 Mouse micronucleus test
	  	 Jun. 1998 ~ Jul. 1999
 Jun. 1998 ~ Nov.
1998
 Jan. 1999 ~ Mar. 1999

			
	Pharmacokinetic	  		  	Jan. 1997 ~ Jul. 1998
			
	Pharmacology	  		  	May 1998 ~ Oct. 1998
			
	Submission of IND in Korea	  		  	April 1999
			
	Clinical trial in KOREA	  	 Phase I Clinical Study
 Phase II Clinical
Study
 Phase III Clinical Study
	  	 May 1999 ~ Oct. 1999
 Nov. 1999 ~ Apr. 2000

May 2000 ~ Apr. 2001

			
	Marketing in KOREA	  		  	June 2001
			
	Submission of IND in U.S. & other countries	  		  	June 1999
			
	Clinical trial in U.S.	  	 Phase I Clinical Study
 Phase II Clinical
Study
 Phase III Clinical Study
	  	 1/1/2000 ~ 8/31/2000
 9/1/2000 ~ 8/31/2001

9/1/2001 ~ 12/31/2002

			
	Filing of NDA in U.S.	  		  	June 2003

 BUKWANG PHARM. IND. CO., LTD.: Research & Development Dept. 
  

 27 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 AMENDMENT 
 to 
 LICENSE AGREEMENT 
 between 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY, and 
 BUKWANG PHARM. INC.
CO., LTD. 
 This AMENDMENT to LICENSE AGREEMENT (AMENDMENT) is effective on September 1, 1997, by and among the UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION, INC., a nonprofit Georgia corporation with offices located in Boyd Graduate Studies Research Center, The University of Georgia, Athens, Georgia 30602-7411 (UGARF), YALE UNIVERSITY, located in New Haven, Connecticut (YALE), and
BUKWANG PHARM. IND. CO., LTD., a Korean corporation with headquarters located at 398-1 Daebong-dong, Dongjak-ku, Seoul 156-020, Republic of Korea (BUKWANG). 
 WITNESSETH 
 WHEREAS, UGARF, YALE and BUKWANG entered into a License Agreement (LICENSE) as of
December 28, 1995; and 
 WHEREAS, UGARF, YALE and BUKWANG desire to amend the LICENSE to provide sublicensing rights to BUKWANG;

 NOW, THEREFORE, UGARF, YALE and BUKWANG agree as follows: 
  

	1.	In partial consideration of the grant by UGARF and YALE of sublicensing rights to BUKWANG, BUKWANG agrees to pay a one-time, nonrefundable, nonceditable fee of [***] Dollars
($[***]) to be split equally between UGARF and YALE. 

  

	2.	The following new paragraphs are added to the LICENSE: 

  

	 	2.5	BUKWANG shall have the right to enter into sublicensing agreements for the rights, privileges and licenses granted hereunder. Upon any termination of this Agreement,
sublicensees’ rights shall also terminate. 

  

	 	2.6	BUKWANG agrees that any sublicenses granted by it shall provide that the obligations to UGARF and YALE of Articles 2, 3.3, 5, 6, 8, 9, 10, 11, 12 and 14 of this Agreement shall be
binding upon the sublicensee as if it were a party to this Agreement. BUKWANG further agrees to attach copies of these Articles to sublicense agreements. 

  

 Page 1 of 3 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	2.7	BUKWANG shall not receive from sublicensees anything of value in lieu of cash payments in consideration for any sublicense under this Agreement without the prior written permission
of UGARF and YALE. 

  

	 	2.8	BUKWANG shall obtain in advance the written approval of UGARF and YALE before it enters into any sublicense agreements. However, in the event that the sublicense from BUKWANG is
with a company on the list of 100 largest pharmaceutical companies, then such written approval is not needed in advance. 

  

	 	2.9	BUKWANG agrees to forward to UGARF and YALE a copy of any and all sublicense agreements promptly upon execution by the parties. 

  

	 	2.10	BUKWANG agrees that any sublicense agreement shall contain a provision for the payment of a royalty of no less than [***] percent ([***]%) of the Net Selling Price of all Licensed
Products by the sublicensee. 

  

	 	2.11	BUKWANG, UGARF and YALE agree to share income from sublicensing in the following manner: 

  

							
	 	  	UGARF/YALE	 	 	BUKWANG	 
	Income from royalties from sublicensee(s)	  	[***]	%	 	[***]	%
			
	Income from sublicense issue fees, milestone payments, or fees other than royalties	  	[***]	%	 	[***]	%

 Except as otherwise modified herein, the LICENSE remains in full force and effect. 
  

 Page 2 of 3 

 IN WITNESS WHEREOF, the parties have caused this AMENDMENT to be executed by their duly authorized
representatives, under seal, as of the effective date. 
  

									
	UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION, INC.	 		 	BUKWANG PHARM. IND. CO., LTD.
					
	 By:
	 	 /s/ Joe L. Key
	 		 	 By:
	 	 /s/ C. H. Koo

	 Name:
	 	 Joe L. Key
	 		 	 Name:
	 	 C. H. Koo

	 Title:
	 	 Executive Vice President
	 		 	 Title:
	 	 Managing Director

			
	(corporate seal)	 		 	(corporate seal)
		 		 	BUKWANG PHARM. IND. CO., LTD.
		 		 	398-1, Daebang-Dong, Dongjak-Ku
		 		 	Seoul, 156-920, KOREA
			
	 YALE UNIVERSITY
	 		 	
				
	 By:
	 	 /s/ Gregory E. Gardiner
	 		 	
	 Name:
	 	 Gregory E. Gardiner, Ph.D.
	 		 		 	
	 Title:
	 	 Director, Cooperative Research
	 		 		 	
			
	(corporate seal)	 		 	

  

 Page 3 of 3 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 AMENDMENT NUMBER 2 
 to 
 LICENSE AGREEMENT and AMENDMENT 
 between 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY, and 
 BUKWANG PHARM. INC.
CO., LTD. 
 This AMENDMENT NUMBER 2 to LICENSE AGREEMENT and AMENDMENT (dated September 1, 1997) is effective on December 1, 1997,
by and among the UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., a nonprofit Georgia corporation with offices located in Boyd Graduate Studies Research Center, The University of Georgia, Athens, Georgia 30602-7411 (UGARF), YALE UNIVERSITY, located
in New Haven, Connecticut (YALE), and BUKWANG PHARM. IND. CO., LTD., a Korean corporation with headquarters located at 398-1 Daebong-dong, Dongjak-ku, Seoul 156-020, Republic of Korea (BUKWANG). 
 WITNESSETH 
 WHEREAS, UGARF, YALE and BUKWANG
entered into a License Agreement (LICENSE) as of December 28, 1995, and an AMENDMENT dated September 1, 1997; and 
 WHEREAS,
UGARF, YALE and BUKWANG desire to amend the LICENSE and AMENDMENT as follows: 
 NOW, THEREFORE, UGARF, YALE and BUKWANG agree as follows:

  

	1.	Article 1 of the AMENDMENT dated September 1, 1997, is replaced with the following: 

 In partial consideration of the grant by UGARF and YALE of sublicensing rights to BUKWANG, BUKWANG agrees to pay on completion of a sublicense agreement with a third party, a one-time, nonrefundable, noncreditable fee
of [***] Dollars ($[***]) to be split equally between UGARF and YALE. This fee is in addition to the [***]% sharing of sublicense fees, milestone payments or fees other than royalties received by BUKWANG from a sublicensee, as provided in Article
2.11 of this AMENDMENT. 
  

	2.	Paragraph 2.6 of the LICENSE is replaced by the following: 

  

	 	2.6	 BUKWANG agrees that any sublicenses granted by it shall provide that the obligations to UGARF and YALE of Articles 2, 3.3, 5, 6, 8, 9, 10, 11, 12 and 14 of this
Agreement shall be binding upon the sublicensee as if it were a party to this Agreement. BUKWANG further agrees to attach copies of these Articles to 

  

 Page 1 of 2 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
sublicense agreements. With regard to Article 3.3, BUKWANG agrees that sublicensee shall not concurrently develop a compound or composition with the same
mechanism of action as compound or composition covered by Licensed Patents, unless such development is directed towards compounds which will be used in complementary or synergistic efficacy combination with L-FMAU. 

  

	3.	Exhibit A of the LICENSE is amended to include Provisional U.S. Patent Application Serial No. [***] (formerly identified as [***]) filed [***], for “[***],” its conversion
to a regular U.S. patent application, and all divisionals, continuations, reissues, reexaminations, and foreign counterparts thereof. 

 Except
as otherwise modified herein, the LICENSE remains in full force and effect. 
 IN WITNESS WHEREOF, the parties have caused this AMENDMENT to
be executed by their duly authorized representatives, under seal, as of the effective date. 
  

									
	UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION, INC.	 		 	BUKWANG PHARM. IND. CO., LTD.
					
	 By:
	 	 /s/ Joe L. Key
	 		 	 By:
	 	 /s/ S. K. Lee

	 Name:
	 	 Joe L. Key
	 		 	 Name:
	 	 S. K. Lee

	 Title:
	 	 Executive Vice President
	 		 	 Title:
	 	 Managing Director

			
	(corporate seal)	 		 	(corporate seal)
			
	 YALE UNIVERSITY
	 		 	
				
	 By:
	 	 /s/ Gregory E. Gardiner
	 		 	
	 Name:
	 	 Gregory E. Gardiner
	 		 		 	
	 Title:
	 	 Director, Office of Cooperative Research
	 		 		 	
			
	(corporate seal)	 		 	

  

 Page 2 of 2 

 AMENDMENT NUMBER 3 
 to 
 LICENSE AGREEMENT 
 among 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY and 
 BUKWANG PHARM.
IND. CO., LTD. 
 This AMENDMENT NUMBER 3, dated as of this February 27, 1998, and effective in accordance with paragraph 15 hereof,
by and among the UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., a nonprofit Georgia corporation with offices located in Boyd Graduate Studies Research Center, The University of Georgia, Athens, Georgia 30602-7411 (“UGARF”), YALE
UNIVERSITY, located in New Haven, Connecticut (“YALE”), and BUKWANG PHARM. IND. CO., LTD., a Korean corporation with headquarters located at 398-1 Daebong-dong, Dongjak-ku, Seoul 156-020, Republic of Korea (“BUKWANG”).

 WITNESSETH: 
 WHEREAS, UGARF,
YALE, and BUKWANG entered into a License Agreement as of December 28, 1995, and Amendment Number 1 thereto, dated September 1, 1997 and Amendment Number 2 thereto dated December 1, 1997 (collectively, the “License
Agreement”); and 
 WHEREAS, BUKWANG and TRIANGLE PHARMACEUTICALS, INC., a Delaware corporation with offices located at 4 University
Place, 4611 University Drive, Durham, North Carolina 27707 (“TRIANGLE”) have entered into a license agreement, dated as of even date 

  

 1 

 
herewith (the “Triangle Sublicense Agreement”), pursuant to which BUKWANG has granted TRIANGLE an exclusive sublicense to the Bukwang Patents and
Bukwang Know-How (each as defined in the Triangle Sublicense Agreement), in the entire world, except Korea; and 
 WHEREAS, TRIANGLE has
requested that BUKWANG, UGARF and YALE execute this Amendment Number 3 in order, inter alia, to reconcile certain inconsistencies between this License Agreement and the Triangle Sublicense Agreement and BUKWANG, UGARF and YALE are
willing to do so; 
 NOW, THEREFORE, UGARF, YALE and BUKWANG agree as follows: 
  

	1.	All capitalized terms used in this Amendment Number 3 and not defined in this Amendment Number 3 shall have the meanings given them in the License Agreement, except as otherwise
explicitly set forth herein. 

  

	2.	UGARF and YALE hereby expressly consent to BUKWANG’s entering into the Triangle Sublicense Agreement. 

  

	3.	UGARF and YALE confirm that the License Agreement is in full force and effect and UGARF and YALE are not aware of any breach thereof by any party thereto. 

 

	4.	The following amendments are made to Article 2 of the License Agreement: 

 (a) Delete the last two sentences of paragraph 2.4 of the License Agreement and replace them with the following: 
 If at any time during the term of this License Agreement, the United States government should take action which terminates this License Agreement or requires that this License Agreement be terminated, BUKWANG acknowledges this License
Agreement will automatically terminate. In such event, BUKWANG shall not have any right to the return of any payments of any kind made by it to LICENSOR prior to the date of termination, other than any overpayment of 

  

 2 

 
earned royalties as determined by any audit conducted pursuant to paragraph 6.2 of this License Agreement. 
 (b) Delete paragraph 2.5 of the License Agreement entitled “Republic of Korea Government Approval” and add the following sentences to
paragraph 2.5 of Amendment Number 1 to the License Agreement: 
 Notwithstanding the foregoing, UGARF and YALE agree that, if this License
Agreement terminates pursuant to paragraph 12.4 or 12.6, the Triangle Sublicense Agreement shall, with respect to the Licensed Patents and Licensed Technology, automatically become a direct license with UGARF and YALE on the terms stated therein;
provided, however that UGARF and YALE shall be entitled to receive only those percentages of milestone payments, royalties and other fees payable to UGARF and YALE under the Triangle Sublicense Agreement as are specified in paragraph 2.11 hereof on
the date of such termination. In such event, UGARF and YALE agree promptly to provide Triangle with written confirmation of such a direct license. 
 (c) Delete the paragraph 2.6 of Amendment Number 2 and replace it with the following: 
 UGARF and YALE agree that: 
 (i) TRIANGLE’s performance of its obligations set forth in the Triangle Sublicense Agreement shall be deemed to be complete performance of any
obligations which Triangle, as BUKWANG’s sublicensee, and Bukwang have pursuant to the provisions of this License Agreement including, but not limited to, any and all obligations set forth herein relating to diligence, progress reports,
royalties (and the calculation thereof), milestone payments and any other amounts payable to UGARF and YALE pursuant to the terms of the License Agreement and the due dates in respect of any of the foregoing and including the provisions of Articles
2, 5, 6, 8, 10, 11, 12 and 14 of the License Agreement; provided 

  

 3 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
however, BUKWANG agrees that the Triangle Sublicense Agreement shall contain a provision for the payment of a royalty of no less than [***] percent ([***]%)
of the Net Sales of all Licensed Products by TRIANGLE (as defined therein); 
 (ii) Triangle’s sole financial obligations as
BUKWANG’s sublicensee shall be those which are set forth in the Triangle Sublicense Agreement and shall be deemed to be performance by BUKWANG of its financial obligations hereunder; and 
 (iii) Triangle’s performance of its diligence obligations as set forth in Article 6 of the Triangle Sublicense Agreement shall be deemed to be
performance by BUKWANG of its diligence obligations under the License Agreement including, but not limited to, those set forth in Article 3 hereof. 
 (d) Delete paragraph 2.10 of Amendment Number 1 and replace it as follows: 
 BUKWANG agrees that payments to LICENSOR in respect of
royalties received by BUKWANG under the Triangle Sublicense Agreement shall not be less than [***] percent ([***]%) of Net Sales of Licensed Products (as defined in the Triangle Sublicense Agreement) for any royalty period during the term thereof.

 (e) Add the following paragraph 2.12 to Article 2 of the License Agreement: 
 To the extent that the rights have not already been licensed exclusively to another party, UGARF and YALE agree not to sue BUKWANG or its Affiliates or
sublicensees for patent infringement for practicing a claim of a patent assigned to UGARF and YALE if practicing said claim is required to make, have made, use, import, offer for sale, sell or have sold Licensed Products. 
  

 4 

	5.	Delete paragraph 3.3 of the License Agreement and replace it with the following paragraph: 

 3.3 Chemical Utility Diligence Obligation. As used herein, the term “Compounds” shall mean the compound known as L-FMAU, with the
chemical name, 2’-fluoro-5-methyl-ß-L-arabinofuranosyluracil, including any salts and esters thereof. BUKWANG acknowledges that viral resistance may limit the clinical utility and commercial potential of the Compounds. In the conduct of
the BUKWANG Development Program, BUKWANG shall use its best efforts to conduct, or shall cause its sublicensee to use its best efforts to conduct, preclinical and clinical studies of the Compounds in combination with other anti-HBV drugs or drug
candidates in order to determine whether in vitro, synergy, pharmacologic compatibility, differing resistance patterns, chemical structures, mechanisms of action or other factors of the combination treatment regimens may limit or
reduce the development of resistance to the Compounds. BUKWANG shall conduct, or shall cause its sublicensee to conduct, preclinical combination studies with at least two other drugs or drug candidates and shall use, or shall cause its sublicensee
to use, its best efforts to conduct clinical combination studies with as many other drugs or drug candidates as it deems appropriate to determine the optimal combinations or sequence of combinations necessary to provide maximum efficacy against HBV
and enhance the clinical utility and commercial potential of the Compounds. Such combination studies may include two or more drugs or drug candidates and various sequences of treatment regimens and, because the outcome of such combination studies
cannot be predicted with certainty, these studies may include other drugs or drug candidates being developed by BUKWANG, its sublicensee or third parties which because of various factors are ultimately determined not to be additive to, or
synergistic with, the Compounds. 
  

	6.	Add the following paragraph to paragraph 4.4 of the License Agreement: 

 Invoices, including reasonable substantiation thereof, shall be submitted once in respect of each fiscal quarter as promptly as practicable after the end of such quarter. Payments 

  

 5 

 
shall be due net thirty (30) days from the date of invoice. BUKWANG hereby authorizes UGARF and YALE to submit, and UGARF and YALE hereby agree to
submit, all such invoices in respect of the Licensed Territory (other than Korea) directly to TRIANGLE for reimbursement. 
  

	7.	Make the following amendments to Article 5 of the License Agreement: 

 (a) Add the following sentence to paragraph 5.1 of the License Agreement: 
 Any provision of this License
Agreement to the contrary notwithstanding, payments and reports due hereunder in respect of payments and reports received by BUKWANG from TRIANGLE pursuant to the Triangle Sublicense Agreement will not be due to be submitted to LICENSOR until ten
(10) days after the date of receipt by BUKWANG from TRIANGLE. 
 (b) Delete the first sentence of paragraph 5.5 and replace it with the
following: 
 Payments required under the License Agreement shall, if overdue, bear
interest at the rate of one and one-half percent (1 1/2%) per month until paid. 
 (c) Add the following paragraph 5.6 to Article 5 of the License Agreement: 
 5.6 Performance of BUKWANG’s Sublicensee. UGARF and YALE agree that any and all reports required to be submitted by BUKWANG pursuant to this Article 5 may instead be submitted by TRIANGLE in respect of
that portion of the Licensed Territory in which the Triangle Sublicense Agreement is in effect and that submission of a report by TRIANGLE to UGARF and YALE in accordance with this Article 5 shall be deemed to satisfy BUKWANG’s obligation to do
so under this Article 5. 
  

 6 

	8.	Make the following amendments to Article 7 of the License Agreement: 

 (a) Delete the second paragraph of paragraph 7.1 and replace it as follows: 
 If BUKWANG or its sublicensee,
as applicable, fail to reimburse LICENSOR for any undisputed patent prosecution expenses respecting any patent application or issued patent included in the Licensed Patents within the time allowed therefor, upon at least thirty (30) days’
prior notice to BUKWANG or its sublicensee, as applicable, LICENSOR may remove such patent application or issued patent from the Licensed Patents and LICENSOR shall be free, at its election, to abandon or maintain the prosecution of such patent
application or issued patent or grant rights to such patent application or issued patent to third parties. 
 (b) Add the following paragraph
7.3 to Article 7: 
  

	 	7.3	Further Obligations. 

 (a) Except as otherwise
provided in Article 8, each party’s responsibilities for patent prosecution activities pursuant to this Article 7 shall also include all ex parte and inter partes activities relating to the relevant patent
applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents.
Each party agrees to give due consideration to the other party’s or its sublicensee’s position with respect to any such patent prosecution activities (which term, as used herein, shall include without limitation, any inter
partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent
prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensee, as applicable, may
initiate, pursue or assume such patent prosecution activities, at its sole expense. 
 (b) In conducting its patent prosecution activities
under this License Agreement, each party may use patent attorneys selected by it in its own 

  

 7 

 
discretion. In addition to the other obligations set forth in this Article 7, each party undertakes to keep the other party and, if applicable, such other
party’s sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this License Agreement including, but not limited to, supplying the other
party or its sublicensee, as applicable, upon reasonable request and at reasonable intervals, with all correspondence with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents
and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensee in connection with any of its activities or the
exercise of any of its rights pursuant to Articles 7, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent
applications and patents in the Licensed Patents, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application
or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 7, it shall give the other party or its sublicensee notice thereof in a sufficiently timely manner so
as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least sixty (60) days before any abandonment,
lapse or any other relevant deadline. 
 (c) BUKWANG and LICENSOR agree that, during the term of the Triangle Sublicense Agreement, the rights
of BUKWANG under this Article 7 shall be exercised, if at all, by TRIANGLE with respect to all patent prosecution activities in any portion of the Licensed Territory in which the Triangle Sublicense Agreement is then in effect. With respect to such
patent prosecution activities, LICENSOR shall communicate with TRIANGLE directly. 
  

 8 

	10.	Make the following amendments to Article 8 of the License Agreement: 

 (a) Delete subparagraph (c) to paragraph 8.1 and replace it as follows: 
 (c) If LICENSOR shall fail
with ninety (90) days after receiving notice from BUKWANG of a potential infringement, to either (i) terminate such infringement or (ii) to institute, either jointly as provided in subparagraph (a) above or solely as provided in
subparagraph (b) above and, thereafter, to prosecute such suit diligently, or (iii) if LICENSOR notifies BUKWANG that it does not plan to institute or join in such suit, BUKWANG may institute suit and, at its option, name LICENSOR as a
plaintiff. BUKWANG shall bear the entire cost of such litigation, including defending any counterclaims brought against LICENSOR and paying any judgments rendered against LICENSOR, and shall be entitled to retain the entire amount of any recovery or
settlement. 
 (b) Add the following subparagraph (d) to paragraph 8.1: 
 (d) In the event BUKWANG commences a suit pursuant to subparagraph (c), BUKWANG may deposit up to thirty percent (30%) of any royalties and milestone
payments which are otherwise payable to LICENSOR during the pendency of such suit in an interest-bearing escrow account. Upon final resolution of such suit, BUKWANG shall provide LICENSOR with an accounting of the amounts escrowed and BUKWANG’s
expenses incurred in such infringement suit. BUKWANG shall be entitled to offset any expenses which BUKWANG fails to recoup in such suit against the escrowed amounts. Any escrowed amounts (and interest thereon) in excess of BUKWANG’s unrecouped
expenses shall be promptly paid to LICENSOR. 
  

 9 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 (c) Add the following paragraph 8.3 to Article 8: 
 8.3 Sublicensee Rights. BUKWANG and LICENSOR agree that, during the term of the Triangle Sublicense Agreement, the rights of BUKWANG under this
Article 8 shall be exercised, if at all, by TRIANGLE with respect to any infringements in any portion of the Licensed Territory in which the Triangle Sublicense Agreement is then in effect. With respect to such infringements, LICENSOR shall contact
Triangle regarding decisions relating to whether it desires to commence any infringement suit and, if so, whether such suit should be commenced jointly. 
  

	11.	Add the following paragraph 9.4 to Article 9 of the License Agreement: 

 9.4 Rights to Disclose. Notwithstanding any provision of this Article 9 to the contrary, BUKWANG shall have the right to disclose any and all information and technology disclosed to it by LICENSOR to TRIANGLE.
LICENSOR agrees that TRIANGLE shall have the right to disclose such information and technology as provided in Article 13 of the Triangle Sublicense Agreement. 
  

	12.	Exhibit A of the License Agreement is deleted and replaced with Exhibit A attached hereto. LICENSOR warrants and represents that, with the exception of the two patent cases
identified by serial numbers [***] and [***], (a) Exhibit A is a complete list of all patents and patent applications which it owns as of the date hereof which relate to the Compounds per se, the use of the Compounds in the Field
of Use or the manufacture of the Compounds; and (b) no patents or patent applications which relate to the Compounds per se, the use of the Compounds in the Field of Use or the manufacture of the Compounds have been filed by
LICENSOR in any non-elected countries (as defined in paragraph 7.1 hereof). 

  

 10 

	13.	Attached hereto as Exhibit B is a true and correct copy of the waiver obtained by LICENSOR from the United States government pursuant to 35 USC § 204, pursuant to which
LICENSOR was authorized to grant the rights and license granted to BUKWANG under this License Agreement. 

  

	14.	BUKWANG, UGARF and YALE agree not to amend this Amendment Number 3 in any manner which would adversely affect TRIANGLE’s rights and obligations under the Triangle Sublicense
Agreement. Any such purported amendment, without TRIANGLE’s prior written consent (which Triangle may withhold at its sole discretion), shall be void. BUKWANG, UGARF and YALE agree to give TRIANGLE at least thirty (30) days’ notice of
any other proposed amendment to the License Agreement (including a true and correct copy thereof) and will not enter into such an amendment if prior to such thirty (30) days’ TRIANGLE identifies any provisions contained in such proposed
amendment which would adversely affect the rights and obligations of TRIANGLE under the Triangle Sublicense Agreement. If TRIANGLE gives such notice in a timely fashion, the parties will meet in an attempt to mutually agree on acceptable terms of
such amendment or, in lieu thereof, BUKWANG, UGARF, and YALE may enter into such amendment deleting the adverse provisions identified in TRIANGLE’s notice. 

  

	15.	This Amendment Number 3 shall become effective upon the Effective Date of the Triangle Sublicense Agreement (as defined therein) provided, however, that in the event the Triangle
Sublicense Agreement terminates in one or more countries, this Amendment Number 3 shall terminate automatically in respect of such countries. 

  

	16.	Except as otherwise expressly amended hereby, the License Agreement remains in full force and effect. 

  

	17.	This Amendment Number 3 may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 

  

 11 

 [REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK] 
  

 12 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized
representatives, under seal, as of the date set forth above. 
  

									
	LICENSOR:	 		 	BUKWANG:
			
	 UNIVERSITY OF GEORGIA
	 		 	 BUKWANG PHARM. IND. CO., LTD.

	 RESEARCH FOUNDATION, INC.
	 		 	
					
	 By:
	 	 /s/ Joe L. Key
	 		 	 By:
	 	 /s/ Sung Koo, Lee

	 Name:
	 	 Joe L. Key
	 		 	 Name:
	 	 Sung Koo, Lee

	 Title:
	 	 Executive Vice President
	 		 	 Title:
	 	 Managing Director

			
	 [Corporate Seal]
	 		 	 [Corporate Seal]

			
		 		 	 BUKWANG PHARM. IND. CO., LTD.

		 		 	 Yeoeuido P.O. Box 572

		 		 	 Seoul, Korea

			
	 YALE UNIVERSITY
	 		 	
					
	 By:
	 	 /s/ Gregory E. Gardiner
	 		 		 	
	 Name:
	 	 Gregory E. Gardiner
	 		 		 	
	 Title:
	 	 Director, OCR
	 		 		 	
			
	 [Corporate Seal]
	 		 	

  

 13 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 Exhibit A 
 [***] 
 Inventors [***] 
  

											
	Docket Name	 	Country	 	Serial No	 	Filing Date	 	Patent No	 	Grant Date
						
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	Div (1)	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	Div (2)	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	PCT	 		 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	

  

 14 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 [***] 
 Inventors [***] 
  

											
	Docket Name	 	Country	 	Serial No.	 	Filing Date	 	Patent No.	 	Grant Date
						
	[***]	 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	
						
		 	[***]	 	[***]	 	[***]	 		 	

  

 15 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 EXHIBIT B 
 [Department of Health & Human Services LOGO] 
 [STAMPED “CONFIDENTIAL”] 
  

			
	 DATE:
	  	March 28, 1996
		
	 TO:
	  	Barbara M. McGarey, J.D.
		  	Deputy Director, OTT
		
	 FROM:
	  	Technology Licensing Specialist, OTT
		
	 SUBJECT:
	  	Recommendation to Grant U.S. Manufacture Requirement Waiver on Extramural Inventions entitled “[***]” Invented by [***]/ (University of Georgia and Yale University [***],
[***])
		
		  	OTT Reference #: [***]

 The Office of Technology Transfer (OTT) has evaluated the U.S. Manufacturers Requirement waiver request by the
University of Georgia and Yale University and determined that granting the waiver would be consistent with the statutory criteria and will enable the licensee, Bukwang Pharm. Ind. Co., Ltd., to continue the manufacturing and the commercialization of
this federally supported technology. 
 The U.S. manufacturing requirements are set forth at 35 U.S.C. 204. Waivers of the U.S. manufacturing requirements
may be granted upon a showing that 1) reasonable but unsuccessful efforts have been made to license the invention to licensees likely to manufacture substantially in the U.S.; or that 2) domestic manufacture is not commercially feasible under the
circumstances. 
 Technology Profile 
 The
federally supported ([***], [***]) technologies resulted in the filing of a U.S. Patent Application in February of 1994, covering a method and compound for the treatment of Hepatitis B Virus (HBV). 
 The inhibitory effects of the L-analogs of nucleotides represent a new strategy in the development of potential drugs against viruses like HBV, EBV, and HIV. Lack of
toxicity of these compounds in the human systems in comparison to their D-counterparts and efficient inhibition of viral processes makes it a novel strategy to combat viral diseases. L-FMAU falls into this category and could prove to be a very
active anti viral agent against HBV and EBV. 
 Licensing Activities 
 The grantee institutions that developed the present technology have made a substantial effort to license this invention. The following U.S. companies that manufacture and market technologies in this field have had an
opportunity to review this invention for the purpose of licensing: 
  

 16 

 Abbott Laboratories, Avid Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Lipitek International, Microscobe
Corporation, and OncoRx. Unfortunately, no U.S. companies have sufficient interest to license this invention. There are several competing technologies to this invention. The grantee institutions are not certain but they believe one of the reasons
they have not been successful in securing a U.S. manufacturer is due to these competing technologies. Two of the other competing technologies are nucleoside analogs and the U.S. market for treatment of HBV is apparently too small for U.S. companies
to pursue another alternative therapy. Further, it follows that if the U.S. market is not large enough to attract a domestic manufacturer, it would not be commercially feasible to create an FDA compliant facility to manufacture the subject compounds
in the U.S. 
 Recommendation 
 OTT recommends
approval of the University of Georgia’s and Yale University’s request to waive the U.S. manufacturing requirement for Bukwang Pharm. Ind. Co., Ltd. based on provisions in 35 U.S.C. 204, for the following reasons: 
 1.) The University of Georgia and Yale University have been unsuccessful in their efforts to license the present invention to a U.S. company. 
 2.) There is an exclusive license agreement between the University of Georgia and Yale University and Bukwang Pharm. Ind. Co., Ltd of South Korea that will allow this
invention to be developed into a therapeutic for the treatment of HBV. 
 3.) The commercial market for the present invention in the U.S. is not large enough
to support the investment required to construct an FDA compliant facility in the U.S. 
 Please sign below to facilitate whether you concur with the
recommendation to grant the waiver under these conditions, or whether you elect to deny the waiver. 
 J.E. Fahner-Vihtelic 
  

			
	x Approve waiver
	
	      ̈ Disapprove
waiver

  

					
			
	 /s/ Barbara M.
McGarey                                       
                 
	 		 	 3/29/96                    

	 Barbara M. McGarey, J.D.
	 		 	 Date

  

 17 

 [LOGO of The University of Georgia Research Foundation, Inc.] 
 Technology Commercialization Office 
 March 12, 2002 
 Dr. S. K. Lee 
 Managing Director 
 Bukwang Pharmaceutical Ind. Co. LTD 
 398-1 Daebang-Dong 
 Dongjak-Ku, Seoul 156-020 
 KOREA 
 Sent via facsimile transmission to #9-011-82-2-816-2792 
  

	Re:	Amendment Number 4 to the L-FMAU License Agreement 

 Dear Dr. Lee:

 Amendment Number 4 to the License Agreement amongst the University of Georgia Research Foundation, Inc., (UGARF), Yale University and
Bukwang Pharm. Ind. Co., Ltd., was completed in August of 2001. Yale University was the last party to sign the Amendment and unfortunately, we have been unable to locate UGARF’s and Bukwang’s original copies. Yale has its own fully
executed original, but has no record of sending the other two originals to UGARF and UGARF has no record of their receipt. 
 UGARF counsel
advises us that it will be acceptable for UGARF to retain as its copy, a photocopy of the fully executed agreement in the possession of Yale. For your information, I have attached this copy. Would such a photocopy be acceptable to Bukwang or does
Bukwang need to have an original? If Bukwang needs an original, we will need to reprint new agreements and send them again to our three parties for signature. 
 I’ll appreciate your opinion in this matter and apologize for the delay in being able to provide with you a copy of the Amendment. 
  

	
	 Sincerely,

	
	 /s/ John P. DesRosier/KMB

	 John P. DesRosier, Ph.D.

	 Consultant to UGARF

	 E-mail: jpd@ovpr.uga.edu

  

			
	 Attachment
	  	
		
	 Cc w/attachment:
	  	Dr. Alfred Brown
		  	Dr. David Chu

  

 18 

 AMENDMENT NUMBER 4 
 to 
 LICENSE AGREEMENT 
 amongst 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY and 
 BUKWANG PHARM.
IND. CO., LTD. 
 This AMENDMENT NUMBER 4, Effective as of this fifteenth day of July, 2001, by and among the UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION, INC., a nonprofit Georgia corporation with offices located at Boyd Graduate Studies Research Center, The University of Georgia, Athens, Georgia 30602-7411 (“UGARF”), YALE UNIVERSITY, located in New Haven, Connecticut
(“YALE”), and BUKWANG PHARM. IND. CO., LTD., a Korean corporation with headquarters located at 398-1 Daebong-dong, Dongjak-ku, Seoul 156-020, Republic of Korea (“BUKWANG”). 
 WITNESSETH: 
 WHEREAS, UGARF, YALE, and BUKWANG have entered into a License Agreement
as of December 28, 1995, and Amendment Number 1 thereto dated September 1, 1997, Amendment Number 2 thereto dated December 1, 1997 and Amendment Number 3 thereto dated February 27, 1998 (collectively, the “License
Agreement”); and 
 WHEREAS, UGARF, YALE, and BUKWANG desire to clarify BUKWANG’s direct obligations to LICENSOR with regard to
BUKWANG’s development of Licensed Product(s) within its retained rights in the licensed territory of Korea, in view of Amendment Number 3. 
 NOW, THEREFORE, UGARF, YALE, and BUKWANG agree s follows: 
  

	1.	The following shall be added in Article 1. Definitions. 

  

	 	1.18	 “Phase II Completion Date” shall mean sixty (60) days after the completion of statistical analyses of the final results of those Phase II clinical
studies which BUKWANG or its sublicensee considers reasonably necessary for the purpose of inclusion in a New Drug Application, “NDA”, or other such application submitted to the regulatory authorities in a given country, requesting
marketing approval for Licensed Product(s). As used in the preceding sentence, “Phase II clinical trials shall mean those well-controlled clinical trials sponsored by BUKWANG or its sublicensee, the primary objective of which (as reasonably
determined by BUKWANG or its sublicensee) is to ascertain additional data regarding the safety 

  

 1 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
and tolerance of Licensed Product(s)and preliminary data regarding the efficacy of such Licensed Product(s). 

  

	 	1.19	“Phase III Completion Date” shall mean sixty (60) days after the completion of statistical analyses of the final results of those Phase III clinical studies which
BUKWANG or its sublicensee considers reasonably necessary for the purpose of inclusion in an NDA, or other such application submitted to the regulatory authorities in a given country, requesting marketing approval for Licensed Product(s). As used in
the preceding sentence, “Phase III clinical trials shall mean those well-controlled clinical trials sponsored by BUKWANG or its sublicensee, the primary objective of which (as reasonably determined by BUKWANG or its sublicensee) is to ascertain
definitive safety data and efficacy data regarding such Licensed Product(s) antiviral effects sufficient to support an NDA. 

  

	 	1.20	“Registration” shall mean, in relation to Licensed Product(s), such written approval[s] by FDA (or the regulatory authorities in a given country) as may be legally
required before such Licensed Product(s) may be commercialized or sold (in such country). 

  

	2.	Article 4.2 Milestone Payments shall be replaced as follows. 

  

	 	4.2	Milestone Payments. As partial consideration for the license granted to BUKWANG under this License Agreement, BUKWANG shall pay LICENSOR nonrefundable milestone payments for
each Licensed Product(s) developed by BUKWANG according to the following schedule: 

 (I) [***] U.S. dollars ($[***]): upon the
first to occur of Phase II Completion Date or sixty (60) days after initiation of a Phase III clinical trial. 
 (II) [***] U.S. dollars
($[***]): upon the first to occur of Phase III Completion Date or sixty (60) days after filing of an NDA. 
 (III) [***] U.S. dollars
($[***]): within sixty (60) days from the date of Registration. 
 For the purposes of this Article 4.2, Licensed
Product(s) developed for hepatitis B virus and Epstein-Barr virus indications shall be considered as a single Licensed Product(s), with respect to milestone payments (I) – (III). Such milestone payments shall be due as each milestone is
first completed for either the hepatitis B or Epstein Barr indication. 
 Such payments shall be paid to LICENSOR in addition
to those paid to LICENSOR under Paragraph 2.11 of this Agreement. 
 BUKWANG shall pay [***] percent ([***]%) of each
milestone payment to UGARF and [***] percent ([***]%) to YALE. 
  

 2 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 [***] percent ([***]%) of the milestone payments shall be credited against royalties
actually due and payable for sales of Licensed Product(s) in Korea, under Article 4.3; provided, however, that in any single License Agreement Year, such credit shall not exceed [***] percent ([***]%) of the royalties otherwise due. 
 Except as otherwise modified herein, the License Agreement remains in full force and effect. 
 IN WITNESS WHEREOF, the parties have caused this AMENDMENT to be executed by their duly authorized representatives, under seal, as of the effective date. 
  

									
	 UNIVERSITY OF GEORGIA
	 		 	 BUKWANG PHARM. IND. CO., LTD.

	 RESEARCH FOUNDATION, INC.
	 		 	
					
	By:	 	 /s/ Gordhan L. Patel
	 		 	 By:
	 	 /s/ S.K. Lee

	 Name:
	 	 Dr. Gordhan L. Patel
	 		 	 Name:
	 	 S.K. Lee

	 Title:
	 	 Executive Vice President
	 		 	 Title:
	 	 Managing Director

			
	 (Corporate Seal)
	 		 	 (Corporate Seal)

  

			
	 YALE UNIVERSITY

		
	 By:
	 	 /s/ E. Jonathan Soderstrom

	 Name:
	 	 E. Jonathan Soderstrom

	 Title:
	 	 Managing Director, Office of Cooperative Research

	
	 (Corporate Seal)

  

 3 

 EXHIBIT B 
 LICENSE AGREEMENT BETWEEN BUKWANG AND TRIANGLE 
 PHARMACEUTICALS DATED FEBRUARY 2, 1998 

 (LICENSE AGREEMENT TERMINATION PROCEDURE LETTER DATED JULY 5, 2003) 

 LICENSE AGREEMENT 
 BETWEEN 
 BUKWANG PHARM. IND. CO., LTD. 
 AND 
 TRIANGLE PHARMACEUTICALS, INC.

 TABLE OF CONTENTS 
  

					
	 ARTICLE 1.
	  	 DEFINITIONS
	  	2
			
	 ARTICLE 2.
	  	 LICENSES
	  	8
			
	 ARTICLE 3.
	  	 LICENSE FEE, ROYALTIES, AND MILESTONE PAYMENTS
	  	11
			
	 ARTICLE 4.
	  	 REPORTS AND ACCOUNTING
	  	16
			
	 ARTICLE 5.
	  	 PAYMENTS
	  	19
			
	 ARTICLE 6.
	  	 DEVELOPMENT PROGRAM
	  	20
			
	 ARTICLE 7.
	  	 JOINT PROJECT COMMITTEE
	  	23
			
	 ARTICLE 8.
	  	 PATENT PROSECUTION
	  	25
			
	 ARTICLE 9.
	  	 INFRINGEMENT
	  	29
			
	 ARTICLE 10.
	  	 TRANSFER OF KNOW-HOW; TECHNICAL ASSISTANCE
	  	30
			
	 ARTICLE 11.
	  	 WARRANTIES AND REPRESENTATIONS; LIMITATION OF LIABILITY; AND DISCLAIMERS
	  	32
			
	 ARTICLE 12.
	  	 INDEMNIFICATION
	  	36
			
	 ARTICLE 13.
	  	 CONFIDENTIALITY
	  	37
			
	 ARTICLE 14.
	  	 CONDITIONS PRECEDENT
	  	39
			
	 ARTICLE 15.
	  	 TERM AND TERMINATION
	  	39
			
	 ARTICLE 16.
	  	 ASSIGNMENT
	  	42
			
	 ARTICLE 17.
	  	 REGISTRATION OF LICENSE
	  	43
			
	 ARTICLE 18.
	  	NOTIFICATION AND AUTHORIZATION UNDER DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT	  	43
			
	 ARTICLE 19.
	  	 DISPUTE RESOLUTION AND ARBITRATION
	  	44
			
	 ARTICLE 20.
	  	 GENERAL PROVISIONS
	  	46

  

 i 

 THIS LICENSE AGREEMENT is made and entered into as of this 27th day of February 1998, by and between
BUKWANG PHARM. IND. CO., LTD., with its principal offices at 398-1, Daebang-Dong, Dongjak-Ku, Seoul l56-020, Korea (hereinafter referred to as “Bukwang”), and TRIANGLE PHARMACEUTICALS, INC., with principal offices located at
4 University Place, 4611 University Drive, Durham, NC 27707 (hereinafter referred to as “Triangle”). 
 WITNESSETH: 

WHEREAS, Bukwang has evidenced the in vitro and in vivo activity of an L-nucleoside compound known generically as
“L-FMAU”; 
 WHEREAS, L-FMAU is covered by patents and patent applications filed in various countries throughout the world;

 WHEREAS, Bukwang, has entered into a License Agreement, dated December 28, 1995, as amended effective September l , 1 997 and
December 1, 1997 (the “Primary License Agreement”) with Yale University (“Yale”) and University of Georgia Research Foundation, Inc. (“UGARF”; Yale and UGARF are hereinafter referred to as the “Primary
Licensors”), a copy of which Primary License Agreement is attached hereto as Exhibit A, pursuant to which Bukwang has obtained an exclusive worldwide license under the Primary Licensors’ patents and patent applications and has
acquired the right to grant licenses under such patents and patent applications; 
 WHEREAS, Bukwang possesses certain technology and
know-how relating to L-FMAU and has the right to grant licenses in respect of such technology and know-how; and 
 WHEREAS, Triangle desires
to obtain an exclusive license under such patents, patent applications, technology and know-how; 
  

 1 

 NOW, THEREFORE, in consideration of the premises and the covenants herein contained, the parties agree as
follows: 
 ARTICLE 1. DEFINITIONS 
 The following terms as used herein, when written with an initial capital letter, shall have the meanings ascribed to them below: 
 1.1 “Acquisition Cost” shall mean the actual invoiced price paid by a party to any non-Affiliate third party for acquiring any item (e.g., a Compound or other active ingredient), including but not limited
to, shipping and handling costs and customs duties incurred and paid by such party in connection with the acquisition of such item. 
 1.2
“Affiliate” shall mean any corporation or non-corporate business entity which controls, is controlled by, or is under common control with a party to this Agreement. A corporation or non-corporate business entity shall be regarded as in
control of another corporation if it owns, or directly or indirectly controls, at least fifty (50%) percent of the voting stock of the other corporation, or (a) in the absence of the ownership of at least fifty (50%) percent of the
voting stock of a corporation or (b) in the case of a non-corporate business entity, or non-profit corporation, if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such
corporation or non-corporate business entity, as applicable. 
 1.3 “Agreement” or “License Agreement” shall mean this
Agreement, including all Exhibits attached to this Agreement. 
 1.4 “Bukwang Know-How” shall mean all inventions, discoveries,
trade secrets, information, experience, data, formulas, procedures and results which are useful for the development and registration of the Compounds or the Licensed Products and the development, registration, manufacturing, using or selling of the
Licensed Products which are rightfully held by Bukwang as of the Effective Date (including, but not limited to, any of the foregoing items licensed to Bukwang under the Primary License Agreement), or which are not Joint Know-How or Joint Inventions
and are developed or acquired by Bukwang during the period beginning on the Effective Date and ending upon termination or expiration of this Agreement pursuant to Article 15 including, but not limited to, all manufacturing and synthesis know-how.

  

 2 

 1.5 “Bukwang Patents” shall mean all patents and patent applications in the Territory owned or
controlled by Bukwang or under which Bukwang has a right to practice with the right to extend such right to practice to Triangle (including, but not limited to, all patents and patent applications licensed to Bukwang under the Primary License
Agreement) which contain claims the rights to which are useful for the development, registration, manufacturing, using or selling of the Compounds or Licensed Products which are filed prior to or during the term of this Agreement in the United
States or any foreign jurisdiction in the Territory, including any addition, continuation, continuation-in-part or division thereof or any substitute application thereof; any patent issued with respect to such patent application, any reissue,
extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other United States and foreign patent or inventor’s certificate with regard
thereto. Bukwang Patents shall include but not be limited to those listed in Exhibit B attached hereto. 
 1.6 “Bulk Drug
Substance” shall mean the Compound in bulk form which, if appropriately formulated and finished, would be suitable for preclinical or clinical use. 
 1.7 “Compounds” shall mean the compound known as L-FMAU, with the chemical name 2’-fluoro-5-methyl-ß-L-arabinofuranosyluracil, including any salts and esters thereof 
 1.8 “Development Program” shall mean the research and development program described in Article 6 of this Agreement. 
 1.9 “Dollars” shall mean United States dollars. 
 1.10 “EBV” shall mean Epstein-Barr virus. 
 1.11 “Effective Date” shall mean the later
of (a) the date first written above and (b) the date, if any, that the condition set forth in Article 14 shall have been satisfied or, if applicable, waived. 
 1.12 “FDA” shall mean the United States Food and Drug Administration or any successor entity. 
 1.13 “Field” shall mean all human antiviral applications and uses. 
  

 3 

 1.14 “HBV” shall mean hepatitis B virus. 
 1.15 “IND” shall mean an Investigational New Drug Application or its domestic equivalent. 
 1.16 “Indemnitees” shall mean (a) in the case of the indemnity set forth in Section 12.1, Bukwang, its Affiliates, the Primary
Licensors and the directors, officers and employees of any of the foregoing; (b) in the case of the indemnity set forth in Section 12.2, Triangle, its Affiliates and sublicensees, and their directors, officers and employees; and
(c) in the case of the Indemnitees referenced in Section 12.3, the parties identified in Subsections 1.16(a) and 1.16(b) above, as applicable. 
 1.17 “Joint Inventions” shall mean any inventions related to the Compounds or the Licensed Products, whether patented or not, which are jointly made during the period beginning on the Effective Date and
ending two (2) years after termination or expiration of this Agreement pursuant to Article 15 by at least one (1) Bukwang employee or person contractually required to assign or license patent rights covering such inventions to Bukwang and
at least one (1) Triangle employee or person contractually required to assign or license patent rights covering such inventions to Triangle. 
 1.18 “Joint Know-How” shall mean all inventions, discoveries, trade secrets, information, data, formulas, procedures and results which are useful for the development, registration, manufacturing, using or selling of the Compounds
or the Licensed Products which are developed jointly by at least one (1) Bukwang employee or person contractually required to assign or license such data and know-how to Bukwang and at least one (1) Triangle employee or person
contractually required to assign or license such data or know-how to Triangle, during the period beginning on the Effective Date and ending two (2) years after termination or expiration of this Agreement pursuant to Article 15. All Joint
Know-How shall be owned jointly by the parties hereto. Triangle shall have the exclusive right to use such Joint Know-How in the Territory, unless the license granted pursuant to Section 2.1 is terminated in a given country or countries of the
Territory by Bukwang pursuant to Section 6.3 or 15.2 or by Triangle pursuant to Section 15.3, in which case, Bukwang shall have a non-exclusive right to use the Joint Know-How 

  

 4 

 
in such country or countries. Bukwang shall have the exclusive right to use such Joint Know-How outside the Territory. 
 1.19 “Joint Project Committee” shall mean the committee described in Article 7 hereof. 
 1.20 “Licensed Product(s)” shall mean any Compound or any pharmaceutical product containing one or more Compounds as an active ingredient,
alone or in combination with other active ingredients. 
 1.21 “Manufacturing Cost,” in respect of a particular item (e.g., a
Compound or other active ingredient), shall mean the costs of direct labor (including allocable employee benefits and employment taxes), direct material, direct energy, direct utilities and other charges incurred directly by a party in the
manufacture by it of such item and, without duplication, normal production overhead (i.e., indirect labor, utilities, maintenance, depreciation of the manufacturing equipment and facilities and other allocable overhead of the manufacturing
facility), all determined in accordance with U.S. GAAP. 
 1.22 “NDA” shall mean a New Drug Application or its domestic equivalent.

 1.23 “Net Sales” of Licensed Products which contain as their active ingredients only one or more Compounds shall mean the gross
sales price of such Licensed Products billed by Triangle, its Affiliates or sublicensees to independent customers including any consideration received, directly or indirectly, from such customers in respect of the sale, distribution or transfer of
Licensed Products, less (a) normal and customary trade, quantity and cash discounts, all rebates (including those paid to third party payors), sales, use, or other similar taxes, and all transportation, insurance and handling charges; and
(b) all credits and allowances granted to such independent customers on account of returns or retroactive price reductions in lieu of returns, whether during the specific royalty period or not, all determined in accordance with U.S. GAAP. In
the event that Triangle or its Affiliates or sublicensees distribute any Licensed Products to a third party for non-monetary consideration (e.g., barter or exchange), such distribution shall be considered a sale for accounting and royalty purposes.
Net Sales for any such distributions shall be determined on a country-by-country basis and shall be the average price of “arm’s length” 

  

 5 

 
sales by Triangle or its Affiliates or sublicensees in such country in the Territory during the royalty period in which such sale occurs or, if no such
“arm’s length” sales occurred in such country in the Territory during such royalty period, during the last royalty period in which such “arm’s length” sales occurred. If no “arm’s length” sales have
occurred in a particular country in the Territory, Net Sales for any such distributions in such country in the Territory, shall be the average price of “arm’s length” sales in all countries in the Territory during such royalty period.

 1.24 “Net Sales” of Licensed Products which contain as their active ingredients both or one or more Compounds and other
compounds (a “Combination Product”) shall mean the gross sales price of such Combination Product billed by Triangle, its Affiliates or sublicensees to independent customers, including any consideration received, directly or indirectly,
from such customers in respect of the sale, distribution or transfer of Licensed Products, less all the allowances, adjustments, reductions, discounts, taxes, duties, rebates and other items referred to in Section 1.23 multiplied by a fraction,
the numerator of which shall be the billing party’s Acquisition Cost or Manufacturing Cost, as applicable, for all Compounds included in such Licensed Product and the denominator of which shall be the billing party’s Acquisition Cost or
Manufacturing Cost, as applicable, for all active ingredients contained in such Licensed Product, all determined in accordance with U.S. GAAP. In the event that Triangle or its Affiliates or sublicensees distribute any Licensed Products to a third
party for non-monetary consideration (e.g., barter or exchange), such distribution shall be considered a sale for accounting and royalty purposes. Net Sales for any such distributions shall be determined on a country-by-country basis and shall be
the average price of “arm’s length” sales by Triangle or its Affiliates or sublicensees in such country in the Territory during the royalty period in which such sale occurs or, if no such “arm’s length” sales occurred
in such country in the Territory during such royalty period, during the last royalty period in which such “arm’s length” sales occurred. If no “arm’s length” sales have occurred in a particular country in the Territory,
Net Sales for any such distributions in such country in the Territory, shall be the average price of “arm’s length” sales in all countries in the Territory during such royalty period. 
 1.25 “Phase II Completion Date” shall mean sixty (60) days after the completion of statistical analyses of the final results of those
Phase II clinical studies which Triangle considers reasonably necessary for purposes of inclusion in an NDA for a Licensed Product for HBV. As 

  

 6 

 
used in the preceding sentence, “Phase II clinical trials” shall mean those well-controlled clinical trials sponsored by Triangle, the primary
objective of which (as reasonably determined by Triangle) is to ascertain additional data regarding the safety and tolerance of a Licensed Product and preliminary data regarding such Licensed Product’s antiviral effects against HBV. 

1.26 “Phase III Completion Date” shall mean sixty (60) days after the completion of statistical analyses of the final results of those
Phase III clinical studies which Triangle considers reasonably necessary for inclusion in an NDA for a Licensed Product for HBV. As used in the preceding sentence, “Phase III clinical trials” shall mean those well-controlled clinical
trials sponsored by Triangle the primary objective of which (as reasonably determined by Triangle) is to ascertain definitive safety data and efficacy data regarding such Licensed Product’s antiviral effects against HBV sufficient to support an
NDA. 
 1.27 “Registration” shall mean, in relation to any Licensed Product, such approvals by the regulatory authorities in a
given country (including pricing approvals, if any) as may be legally required before such Licensed Product may be commercialized or sold in such country. 
 1.28 “Territory” shall mean the entire world, excluding Korea. 
 1.29 “Toxicity Study
Completion Date” shall mean thirty (30) days after completion of statistical analyses of the results of the second toxicity study referred to in Section 6.1. 
 1.30 “Triangle Know-How” shall mean all inventions, discoveries, trade secrets, information, experience, data, formulas, procedures and results
arising solely out of the Development Program or the manufacture, use or sale of the Licensed Products which are useful for development, registration, manufacturing, using or selling of the Compounds or the Licensed Products which are rightfully
held by Triangle as of the Effective Date, or which are not Joint Know-How or Joint Inventions and are developed or acquired by Triangle during the period beginning on the Effective Date and ending upon termination or expiration of this Agreement
pursuant to Article 15. 
 1.31 “Triangle Patents” shall mean all patents and patent applications owned or controlled by Triangle
or under which Triangle has a right to practice with the right to extend such right to practice to Bukwang which contain claims the rights to which are useful for the 

  

 7 

 
development, registration, manufacturing, using or selling of the Compounds or the Licensed Products, including any addition, continuation,
continuation-in-part or division thereof or any substitute application thereof; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or
registration patent or patent of addition based on any such patent, and any other United States and foreign patent or inventor’s certificate with regard thereto. 
 1.32 “U.S. GAAP” shall mean generally accepted accounting principles in the United States, consistently applied. 
 1.33 “Valid Claim” shall mean an issued or granted claim of any issued and unexpired patent included among the Bukwang Patents, which has not been held unenforceable, unpatentable or invalid by a decision of
a court or governmental body of competent jurisdiction, which is unappealable or unappealed within the time allowed for appeal, which has not been rendered unenforceable through disclaimer or otherwise or which has not been lost through an
interference or opposition proceeding. 
 ARTICLE 2. LICENSES 
 2.1 License Under Bukwang Patents and Bukwang Know-How. Bukwang hereby grants Triangle the exclusive right and license to practice the Bukwang
Patents and the Bukwang Know-How to make, have made, use, import, offer for sale, sell and have sold Licensed Products (including, but not limited to, Bulk Drug Substance) in the Territory during the term of this Agreement. 
 2.2 Extension to Affiliates. Triangle shall have the right to extend its rights under the license granted in Section 2.1 to one or more of
its Affiliates, provided, that Triangle (a) gives Bukwang at least thirty (30) days’ prior written notice of such extension and (b) shall remain responsible for such Affiliate’s compliance with all obligations under this
Agreement which apply to such Affiliate. 
 2.3 Sublicenses. Triangle may grant sublicenses to non-Affiliate third parties without any
consent; provided, however, that in the event that Triangle proposes to grant a sublicense to a prospective non-Affiliate sublicensee [BUKWANG REDACTED], then Triangle must first 

  

 8 

 
obtain the prior consent of Bukwang and the Primary Licensors, which consent shall not be unreasonably withheld or delayed. No sublicense granted by Triangle
shall relieve it of any obligation hereunder. With respect to any sublicense for which Bukwang’s consent is not required pursuant to the immediately preceding sentence, Triangle shall provide Bukwang with notice of its intention to grant a
sublicense at least fifteen (15) days prior to entering into the applicable sublicense agreement. Triangle shall promptly provide Bukwang with a copy of any executed sublicense agreement. 
 2.4 License Under Triangle Patents and Triangle Know-How. Triangle hereby grants Bukwang a non-exclusive right and license to practice the
Triangle Patents and Triangle Know-How to make, have made, use, import, offer for sale, sell and have sold Licensed Products, with a right to sublicense, outside the Territory and, in the event Triangle’s license granted under Section 2.1
is terminated in a given country of the Territory (other than by expiration or by Triangle pursuant to Section 15.2 of this Agreement), in such country from and after the date of termination. The license granted pursuant to this
Section 2.4 shall be royalty free. 
 2.5 Covenant Not to Sue. Each party granting a license agrees that during the term of this
Agreement, neither it nor any of its Affiliates, will assert against the other party (a “licensed party”) or its Affiliates or sublicensees any patent not included in the Bukwang Patents or Triangle Patents, as applicable, that is or might
be infringed by reason of such licensed party’s or its Affiliates’ or sublicensees’ exercise of the license granted to it hereunder. 
 2.6 Right of First Discussion. If, at any time during the term hereof, Bukwang (a) acquires rights in respect of human uses or applications of L-FMAU outside the Field (a “Non-Field Use”) and (b) decides to
license any rights relating to such Non-Field Use, it shall give prompt notice thereof to Triangle. Such notice shall include a description of the rights which Bukwang wishes to license, together with all data and information in Bukwang’s
possession relating to the applicable Non-Field Use. Thereafter, Triangle shall have thirty (30) days to notify Bukwang whether Triangle is interested in commencing negotiations to obtain a license to such rights (the “Non-Field
License”). If Triangle does not give such notice within such thirty (30) day period, Bukwang shall be entitled to commence negotiations with a third party in respect of the Non-Field License. If Triangle gives such notice within such
thirty (30)

  

 9 

 
days, the parties shall commence good faith negotiations in an effort to reach agreement on the terms of the Non-Field License. If such negotiations do not
result in the execution of the Non-Field License, Bukwang agrees that, for a period of twelve (12) months after cessation of such negotiations, it will not offer the Non-Field License to a third party containing financial terms more favorable
than those last offered to Triangle during such negotiations without first offering the Non-Field License to Triangle on the same terms. In such event, Triangle shall have thirty (30) days to accept the Non-Field License containing such more
favorable financial terms and if it fails to do so, it shall have no further rights to such Non-Field Use. 
 2.7 Retained License.
Triangle acknowledges that, pursuant to paragraph 2.2 of the Primary License Agreement, the Primary Licensors have retained on their behalf and on the behalf of any of their research collaborators a royalty-free right and license to make and use
Licensed Products and to practice the Licensed Technology (as defined therein) for research and educational purposes only. 
 2.8 United
States Government Rights. Triangle acknowledges that the Bukwang Patents, Bukwang Know-How, or portions thereof were developed with financial or other assistance through grants or contracts funded by the United States government. Triangle
acknowledges that in accordance with Public Law 96-517, other applicable statutes, regulations and Executive Orders now in existence or as may be amended or subsequently enacted, the United States government has certain rights in the Bukwang Patents
and Bukwang Know-How. Triangle shall take all reasonable actions necessary to enable the Primary Licensors to satisfy their obligations of which Triangle is aware under any federal law relating to the Bukwang Patents or Bukwang Know-How. If at any
time during the term of this Agreement, the United States government should take action which terminates the Primary License Agreement or requires that the Primary License Agreement be terminated, Triangle acknowledges that upon such termination,
this Agreement will automatically terminate. In such event, Triangle shall not have any right to the return of any payments of any kind made by it to Bukwang prior to the date of termination, other than any overpayment of earned royalties as
determined by any audit conducted pursuant to Section 4.2. 
  

 10 

 2.9 No Implied License. The license and rights granted in this Agreement to Triangle shall not be
construed to confer any rights upon Triangle by implication, estoppel or otherwise as to any technology, know-how or any other intellectual property not specifically identified as Bukwang Patents or Bukwang Know-how. 
 ARTICLE 3. LICENSE FEE, ROYALTIES, AND MILESTONE PAYMENTS 
 3.1 License Fee. As partial consideration for entering into this Agreement, Triangle agrees to pay Bukwang a license fee of [BUKWANG REDACTED] payable within [BUKWANG REDACTED] after the Effective Date.

 3.2 Milestone Payments. 
 (a) Triangle shall pay Bukwang a milestone payment (“Milestone Payment”) in the amount specified below no later than [BUKWANG REDACTED] after the occurrence of the corresponding event designated below
(except as otherwise specified in Subsection 3.2(e)), unless Triangle has given Bukwang notice of termination of this Agreement in the entire Territory prior to such due date. 
  

							
	 Milestone
	  	Milestone Payment	 
	 (i)     
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (ii)    
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (iii)  
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (iv)   
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (v)    
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (vi)   
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (vii) 
	 	[BUKWANG REDACTED]	  	$	[BUKWANG REDACTED	]
	 (viii)
	 	[BUKWANG REDACTED]	  			
		 	(in accordance with Subsection 3.2(c))	  	$	[BUKWANG REDACTED	]
		 		  	 	 	 
		 	 Total Milestone Payments
	  	$	[BUKWANG REDACTED	]
		 		  			

 (b) On each [BUKWANG REDACTED] Net Sales (up to a cumulative total of [BUKWANG
REDACTED] in Net Sales within the Territory) a Marketing Milestone Payment of [BUKWANG REDACTED] will be due (up to an aggregate of [BUKWANG REDACTED]), as reflected in clause (vii) of the Subsection 3.2(a). Upon payment of the final [BUKWANG
REDACTED] in respect of the first [BUKWANG REDACTED] in cumulative Net Sales within the Territory, the Marketing Milestone Payment obligations will terminate. 

  

 11 

 
Each Marketing Milestone Payment will be due at the same time the royalty report covering the royalty period in which such incremental [BUKWANG REDACTED] in
Net Sales is due. 
 (c) The [BUKWANG REDACTED] total reflects the additional Milestone Payments which will be due upon
[BUKWANG REDACTED]. The Milestone Payment due upon [BUKWANG REDACTED]. 
 (d) All Milestone Payments described in clauses (i),
(ii), and (iii) of Subsection 3.2(a) will be [BUKWANG REDACTED] against earned royalties payable to Bukwang. Such credit may be applied during each royalty period (up to a maximum of [BUKWANG REDACTED] of royalties payable for such royalty
period) until [BUKWANG REDACTED] of such Milestone Payments have been credited. 
 (e) In the event Bukwang terminates this
Agreement pursuant to Section 6.3 or 15.2 or Triangle terminates this Agreement with respect to the entire Territory pursuant to Section 15. 3, any [BUKWANG REDACTED] Milestone Payment due pursuant to clause (vii) of
Subsection 3.2(a) shall be [BUKWANG REDACTED]. By way of example only, if Triangle terminates the Agreement in the entire Territory and, at the time of termination [BUKWANG REDACTED] Triangle would owe Bukwang a final [BUKWANG REDACTED]
Milestone Payment of [BUKWANG REDACTED]. 
 3.3 Earned Royalties; Duration and Reduction. 
 (a) Triangle shall pay Bukwang a royalty equal to [BUKWANG REDACTED] of the Net Sales of Licensed Products sold in the Territory by
Triangle and its Affiliates and sublicensees for the periods and subject to the reductions set forth in this Agreement. 
 (b)
Royalties shall be paid in respect of Licensed Products in a given country for a period of ten (10) years after the initial commercial introduction of a Licensed Product in such country. After such ten (10) year period in a given country,
royalties shall be paid in respect of a given Licensed Product in such country only so long as the manufacture, use, offer for sale, sale or importation of such Licensed Product in such country would, in the absence of this license, infringe a Valid
Claim. 
  

 12 

 (c) If at any time during such ten (10) year period, (i) a third party or third
parties commence selling a therapeutic product in a country of the Territory in which no Valid Claims exist and (ii) such product contains any Compound (“unlicensed unit sales”) and (iii) such unlicensed unit sales for any
royalty period amount to [BUKWANG REDACTED] or more of Triangle’s unit sales of such Licensed Product in such country in such royalty period, determined in accordance with Subsection 3.3(d) below, then Triangle’s royalty obligation in such
country with respect to such Licensed Product shall be reduced by [BUKWANG REDACTED] of the royalty otherwise payable commencing with the royalty period next succeeding the royalty period in which such [BUKWANG REDACTED] threshold was initially
exceeded and shall resume with the royalty period next succeeding the first royalty period in which such [BUKWANG REDACTED] threshold is no longer exceeded. 
 (d) For purposes of this Section 3.3, (i) “unlicensed unit sales” and “Triangle unit sales” shall be deemed
to mean the grams of Compounds contained in the third party product (irrespective of dosage form) or the Licensed Product (irrespective of dosage form), respectively, as reflected on the label of each such unit; and (ii) unlicensed unit sales
shall be determined by the sales reports of IMS America Ltd. of Plymouth Meeting, Pennsylvania (“IMS”) or any successor to IMS or any other independent marketing auditing firm selected by Triangle or its Affiliates or sublicensees and
reasonably acceptable to Bukwang. If Triangle is entitled to a royalty reduction based on unlicensed unit sales pursuant to Subsection 3.3(b) for any royalty period, it or its Affiliates or sublicensees shall submit the sales report of IMS or such
other independent firm, as applicable, for the relevant royalty period to Bukwang, together with Triangle’s or its Affiliates’ or sublicensees’ sales report for the relevant royalty period. Such sales reports for each royalty period
in which Triangle is entitled to such royalty reduction shall be submitted with the royalty report for such royalty period submitted pursuant to Section 4.1. 
 3.4 Annual Minimum Royalties. In the event that, during the third full calendar year following the year during which the FDA Registration for an HBV indication is granted for a Licensed Product or any calendar
year thereafter for as long as royalty obligations exist [BUKWANG REDACTED], Triangle’s total annual royalty payments (without giving effect to any credits taken pursuant to Subsection 3.2(d)) to Bukwang pursuant to Section 3.3 above are
less than the annual minimum amount set forth opposite such year below (the “Annual 

  

 13 

 
Minimum”), Triangle shall make a payment to Bukwang together with the royalty report for the fourth quarter of such year required in Section 4.1 of
this Agreement equal to the difference between such Annual Minimum and the royalties paid to Bukwang for the preceding year pursuant to Section 3.3 above. 
  

					
	 Calendar Year
	  	Annual Minimum	 
	 [BUKWANG REDACTED]
	  	$	[BUKWANG REDACTED	]
	 [BUKWANG REDACTED]
	  	$	[BUKWANG REDACTED	]
	 [BUKWANG REDACTED]
	  	$	[BUKWANG REDACTED	]
	 [BUKWANG REDACTED]
	  	$	[BUKWANG REDACTED	]

 As used in this Section 3.4, [BUKWANG REDACTED]. 
 3.5 Accrual of Royalties. No royalty shall be payable on a Licensed Product made, sold, or used for tests or development purposes, or distributed
as samples. No royalties shall be payable on sales among Triangle, its Affiliates and sublicensees, but royalties shall be payable on subsequent sales by Triangle, its Affiliates or sublicensees to a third party. No multiple royalty shall be payable
because the manufacture, use, offer for sale, sale or import of a Licensed Product is covered by more than one Valid Claim or by at least one Valid Claim and the Bukwang Know-How. 
 3.6 Third Party Royalties. If Triangle, its Affiliates or sublicensees determine, after consultation with Bukwang, but at Triangle’s sole
discretion, that it or they may be required to pay royalties and other amounts to any third party because the manufacture, use, offer for sale, sale or importation of a Licensed Product infringes or may infringe any patent or other intellectual
property rights of such third party in one or more countries (collectively, the “Third Party Royalties”), Triangle, its Affiliates or sublicensees may deduct the Third Party Royalties it or they pay to such third party from earned
royalties and Milestone Payments thereafter due to Bukwang. Triangle may credit [BUKWANG REDACTED] of any Third Party Royalties up to [BUKWANG REDACTED] of Net Sales of Licensed Products and [BUKWANG REDACTED] of the amount of any Third Party
Royalties in excess of [BUKWANG REDACTED] of Net Sales of Licensed Products. In no event shall the royalties due on Net Sales of Licensed Products in any royalty period or any Milestone Payment be thereby reduced on account of any 

  

 14 

 
reduction pursuant to this Section 3.6 by more than [BUKWANG REDACTED] of the amount which would have been otherwise payable. 
 3.7 Compulsory Licenses. Should a compulsory license be granted to any third party in any country of the Territory to make, have made, use,
import, offer for sale or sell Licensed Products, the royalty rate payable hereunder for sales of the Licensed Products by Triangle in such country shall be adjusted to match any lower royalty rate granted to the third party for such country.

 3.8 Reduction in Royalty Due to Invalid Claims. In the event that applicable claims of all patents or patent applications included
within the Bukwang Patents under which Triangle is selling or actively developing a Licensed Product shall be held invalid or not infringed by the Licensed Products Triangle is selling or actively developing by a court of competent jurisdiction in a
given country of the Territory, whether or not there is a conflicting decision by another court of competent jurisdiction in such country, Triangle may reduce all royalty payments on its, its Affiliates’ or its sublicensees’ sales of such
Licensed Product covered by such claims by [BUKWANG REDACTED] and, if it does so, shall deposit the reduced portion of such royalty payments in an interest-bearing escrow account until such judgment is finally reversed by an unappealed or
unappealable decision of a court of competent jurisdiction of higher dignity in such country or is otherwise unappealable or is unappealed within the time allowed therefor, except that, in those instances, if any, in which Triangle has patent
prosecution responsibility in respect of such patents and patent applications, if such judgment becomes unappealable due to the inaction of Triangle or its Affiliates or sublicensees such judgment will be deemed to have been reversed. If such
judgment is finally reversed by an unappealable decree of a court of competent jurisdiction of higher dignity in such country, or is deemed reversed as provided herein, the former royalty payments shall be resumed and the royalty payments not
theretofore made and interest earned thereon shall become due and payable to Bukwang. If such judgment is not reversed, deemed reversed, is unappealed or becomes unappealable, as aforesaid, Triangle shall be entitled to all sums in such escrow
account. Triangle will include an accounting of any escrow account established pursuant to this Section 3.8 in each royalty report submitted to Bukwang pursuant to Article 4. 
  

 15 

 3.9 Limitation on Royalty Reduction. Any provision of this Agreement to the contrary
notwithstanding, in no event will earned royalties paid to Bukwang be less than [BUKWANG REDACTED] of Net Sales of Licensed Products for any royalty period during the term hereof. 
 ARTICLE 4. REPORTS AND ACCOUNTING 
 4.1 Royalty Reports and
Records. 
 (a) During the term of this Agreement commencing with the commercial introduction of the first Licensed
Product, Triangle shall furnish, or cause to be furnished to Bukwang, written reports governing each of Triangle’s fiscal quarters showing: 
 (i) the gross sales of all Licensed Products sold by Triangle, its Affiliates and sublicensees during the reporting period, together with the calculations of Net Sales in accordance with Sections 1.23 and 1.24; and

 (ii) the royalties payable in Dollars, which shall have accrued hereunder in respect of such Net Sales; and 
 (iii) the exchange rates used, if any, in determining the amount of Dollars; and 
 (iv) any withholding taxes required to be made from such royalties. 
 (b) With respect to sales of the Licensed Product invoiced in Dollars, the gross sales, Net Sales, and royalties payable shall be
expressed in Dollars. With respect to sales of the Licensed Product invoiced in a currency other than Dollars, the gross sales, Net Sales, and royalties payable shall be expressed in the domestic currency of the party making the sale together with
the Dollar equivalent of the royalty payable, calculated using the simple average of the exchange rates published in the Wall Street Journal on the last day of each month during the reporting period. If any Triangle Affiliate or sublicensee
makes any sales invoiced in a currency other than its domestic currency, the gross sales and Net Sales shall be converted to its domestic currency in accordance with the Affiliate’s or sublicensee’s normal accounting practices. 

  

 16 

 
Triangle or its Affiliate or sublicensee making any royalty payment shall furnish to Bukwang appropriate evidence of payment of any tax or other amount
deducted from any royalty payment. 
 (c) Reports shall be made on a quarterly basis. Quarterly reports shall be due within
[BUKWANG REDACTED] of the close of every Triangle fiscal quarter and shall be prepared in accordance with U.S. GAAP. Triangle shall keep accurate records in sufficient detail to enable royalties and other payments payable hereunder to be determined.
Triangle shall be responsible for all royalties and late payments that are due to Bukwang that have not been paid by Triangle’s Affiliates and sublicensees. Triangle’s Affiliates and sublicensees shall have, and shall be notified by
Triangle that they have, the option of making any royalty payment directly to Bukwang. 
 4.2 Right to Audit. Bukwang (or the Primary
Licensors on Bukwang’s behalf if authorized in writing to Triangle by Bukwang and provided they agree to be bound by the provisions of Sections 4.2 and 4.3) shall have the right, upon prior notice to Triangle, not more than once in each
Triangle fiscal year nor more than once in respect of any fiscal year, through an independent certified public accountant selected by Bukwang or the Primary Licensors, as applicable, and acceptable to Triangle, which acceptance shall not be
unreasonably refused, to have access during normal business hours to those records of Triangle as may be reasonably necessary to verify the accuracy of the royalty reports required to be furnished by Triangle pursuant to Section 4.1 of the
Agreement. Such accountant may report only the accuracy or inaccuracy of the royalty reports furnished by Triangle and, in the event they are determined to be inaccurate, the corrections in the amounts which need to be made to such reports. Triangle
shall include in any sublicenses granted pursuant to this Agreement a provision requiring the sublicensee to keep and maintain records of sales made pursuant to such sublicense in accordance with U.S. GAAP and to grant access to such records by
Bukwang’s or the Primary Licensors’ independent certified public accountant, as applicable, under the same terms that Bukwang has access to Triangle’s records. If such independent certified public accountant’s report shows any
underpayment of royalties by Triangle its Affiliates or sublicensees, within thirty (30) days after Triangle’s receipt of such report, Triangle shall remit or shall cause its sublicensees to remit to Bukwang: 
 (a) the amount of such underpayment; and 
  

 17 

 (b) if such underpayment exceeds [BUKWANG REDACTED] of the total royalties owed for the
fiscal year then being reviewed, the reasonably necessary fees and expenses of such independent certified public accountant performing the audit. Otherwise, Bukwang’s accountant’s fees and expenses shall be borne by Bukwang. Any
overpayment of royalties shall be fully creditable against future royalties payable in any subsequent royalty periods or if this Agreement terminates or expires before such overpayment in fully credited, Bukwang agrees to refund the uncredited
portion of such overpayment within [BUKWANG REDACTED] after receipt of the final royalty payment hereunder. Upon the expiration of [BUKWANG REDACTED] following the end of any fiscal year, the calculation of royalties payable with respect to such
fiscal year shall be binding and conclusive on Bukwang and Triangle, unless an audit for such fiscal year is initiated before expiration of such [BUKWANG REDACTED]. Triangle shall retain, and shall cause its Affiliates and sublicensees to retain,
those records required to be maintained pursuant to this Section 4.2 in respect of each fiscal year for a period of [BUKWANG REDACTED] after the end of such fiscal year. 
 4.3 Confidentiality of Records. All information subject to review under this Article 4 shall be confidential. Except where otherwise required by
law, Bukwang and its accountant shall retain all such information in confidence. 
  

 18 

 ARTICLE 5. PAYMENTS 
 5.1 Payments and Due Dates. (a) Except as otherwise provided herein, royalties and other amounts payable to Bukwang as a result of activities
occurring during the period covered by each royalty report provided for under Article 4 of this Agreement shall be due and payable on the date such royalty report is due. Payments of royalties and other amounts in whole or in part may be made in
advance of such due date. Bukwang and Triangle agree that unless otherwise directed by Bukwang in writing, subject, however, to the last sentence of this Subsection 5.1(a), Triangle will remit all royalties and other amounts due pursuant to Article
3 of this Agreement in the following percentages (or, if different, in the percentages then in effect under the Primary License Agreement) to Bukwang and each of the Primary Licensors: 
  

							
	 	  	Percentage Allocation
	 Type of Payment (Section)
	  	UGARF	 	Yale	 	Bukwang
				
	 License Fee (Section 3.1)
	  	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]
				
	 Milestone Payments (Section 3.2)
	  	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]
				
	 Earned Royalties (Section 3.3)
	  	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]
				
	 Annual Minimum Royalties (Section 3.4)
	  	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]	 	[BUKWANG REDACTED]

 Bukwang agrees that payment by Triangle of any amounts due pursuant to Article 3 to Bukwang, UGARF and Yale in the
percentages set forth above shall be deemed to a payment to Bukwang. Bukwang further agrees that in the event royalties payable hereunder for a given royalty period are less than [BUKWANG REDACTED] of the Net Sales of Licensed Products during such
royalty period, Triangle may make such adjustments in the applicable percentages set forth above as are necessary to ensure that the sum of the royalties paid to UGARF and YALE is not less than [BUKWANG REDACTED] of the Net Sales of Licensed
Products for such royalty period. Bukwang shall have the option to have Triangle make all payments described in this Subsection 5.1(a) directly to Bukwang upon thirty (30) days’ prior written notice and, if it exercises such option, may,
thereafter, elect to have Triangle make payments as aforesaid to Bukwang, UGARF and Yale upon thirty (30) days’ prior written notice. Bukwang may not change its election more than once during each fiscal year unless such change is required
in order for Bukwang to comply with applicable laws and regulations. In the event this License Agreement becomes a direct license among Triangle and the Primary Licensors pursuant to paragraph 2.5 of the Primary License Agreement, all payments made
pursuant to this Subsection 5.1(a) will be made by Triangle to the Primary Licensors in the percentages then in effect under the Primary License Agreement and to Bukwang as provided in Subsection 5.1(b) below. 
 (b) Any provision of this Agreement to the contrary notwithstanding, any royalties on Net Sales of Licensed Products due pursuant to this
Agreement which would not 

  

 19 

 
constitute Licensed Products as defined in the Primary License Agreement shall be payable solely to Bukwang. Bukwang shall notify Triangle of any instances
to which this Subsection 5.1(b) applies and, thereafter, Triangle shall remit royalties on such sales as provided in this Subsection 5.1(b). 
 (c) All payments to Bukwang shall be made by wire transfer to an account of Bukwang designated by Bukwang from time to time; provided, however, that in the event that Bukwang fails to designate such account, Triangle
or its Affiliates and sublicensees may remit payment to Bukwang to the address applicable for the receipt of notices hereunder; provided, further, that any notice by Bukwang of such account or change in such account, shall not be effective until
fifteen (15) days after receipt thereof by Triangle. Unless otherwise agreed, all payments to Yale and UGARF shall be made as specified in paragraph 5.1 of the Primary License Agreement. 
 5.2 Currency Restrictions. Except as hereinafter specified in this Section 5.2, all royalties and other amounts shall be paid in Dollars. If,
at any time, legal restrictions prevent the prompt remittance of part of or all royalties with respect to any country in the Territory where Licensed Products are sold, Triangle or its sublicensee shall have the right and option to make such
payments by depositing the amount thereof in local currency to Bukwang’s accounts in a bank or depository in such country. 
 5.3
Overdue Pavrrients. In the event any payment due hereunder is not made when due, the payment shall accrue interest (beginning on the date such payment is due) calculated at the rate of [BUKWANG REDACTED] and such payment when made shall be
accompanied by all interest so accrued. The remittance of such interest shall not foreclose Bukwang from exercising any other rights it may have pursuant to this Agreement because such payment is late. 
 ARTICLE 6. DEVELOPMENT PROGRAM 
 6.1 Development Program. Subject to Bukwang’s timely performance of its obligations hereunder, and in complete fulfillment of Triangle’s diligence obligations hereunder and any such obligations implied by law, Triangle will
undertake, or, if applicable, will cause its Affiliates and sublicensees to undertake, the development activities described in this Article 6. Triangle shall, at its expense, use its [BUKWANG REDACTED] (a) to conduct a development 

  

 20 

 
program (the “Development Program”) relating to the use of the Licensed Product for HBV and (b) if the results of the Development Program so
justify, to seek Registration for such Licensed Product in the United States. As part of the Development Program, Triangle shall be responsible for conducting 3-month toxicity studies in two species of animals pursuant to protocols which it develops
or approves, as applicable. Triangle shall commence both toxicity studies as promptly as practicable [BUKWANG REDACTED] after it obtains Bulk Drug Substance of a quality and in such quantities reasonably necessary to perform such toxicity studies.
Bulkwang shall promptly reimburse Triangle for [BUKWANG REDACTED] of the out-of-pocket costs (excluding all drug costs, which shall be the responsibility of Triangle) incurred by Triangle in conducting such toxicity studies, subject to reasonable
substantiation by Triangle of such out-of-pocket costs. The Development Program shall be mutually discussed by the parties hereto at the meetings of the Joint Project Committee held pursuant to Article 7 and shall take into consideration studies and
experiments carried out, or to be carried out by, Bukwang and its licensees, if any, outside the Territory, but the activities within the Territory comprising the Development Program shall be determined at Triangle’s sole discretion. Anything
in this Agreement to the contrary notwithstanding, Triangle shall be entitled to exercise prudent and justifiable business judgment in meeting its [BUKWANG REDACTED] obligations hereunder. For purposes of this Article 6, [BUKWANG REDACTED].

 6.2 Fulfillment. 
 (a) Subject to the foregoing provisions of this Article 6, Triangle’s [BUKWANG REDACTED] obligations set forth in this Article 6 shall be deemed to have been satisfied if Triangle: 
 (i) files what it reasonably believes to be a complete NDA for a Licensed Product for HBV with the FDA within [BUKWANG REDACTED] after the
Effective Date; provided, however, said [BUKWANG REDACTED] period shall be subject to up to [BUKWANG REDACTED] extensions of [BUKWANG REDACTED], at Triangle’s election, by payment to Bukwang of a sum of [BUKWANG REDACTED] for each [BUKWANG
REDACTED] extensions and [BUKWANG REDACTED] for each [BUKWANG REDACTED] extensions; and 
  

 21 

 (ii) commercially introduces, or causes its Affiliates or sublicensees to commercially
introduce, such Licensed Product in the United States within [BUKWANG REDACTED] after FDA Registration of such Licensed Product, if otherwise commercially feasible. 
 (b) Triangle agrees to use its [BUKWANG REDACTED] to give Bukwang at least ten (10) days’ notice prior to the exercise of any
extension pursuant to Subsection 6.2(a). Extension payments under Subsection 6.2(a) shall be made within the first ten (10) days of each such extension period. Notwithstanding any provision of Subsection 6.2(a) to the contrary: (i) in the
event that Triangle is unable to obtain Bulk Drug Substance of a quality and in such quantities reasonably necessary to perform the toxicity studies referred in Section 6.1 within [BUKWANG REDACTED] after the Effective Date, the [BUKWANG
REDACTED] period referred to in Subsection 6.2(a) shall be adjusted by that period in excess of such [BUKWANG REDACTED] period that expires before Triangle obtains such Bulk Drug Substance; provided, however, that the period of the extension
prescribed in this clause (i) of this Subsection 6.2(b) shall, in no event, exceed [BUKWANG REDACTED]; and (ii) such [BUKWANG REDACTED] period shall also be adjusted appropriately (x) to account for any delay by Bukwang in the
transfer of Bukwang Know-How beyond the period specified in Section 10.1 and (y) in the event the FDA requires that toxicity studies other than those described in Section 6.1 be performed prior to the commencement of clinical trials
in the U.S. 
 6.3 Bukwang Remedies. 
 (a) In the event Triangle fails to meet any diligence requirements set forth in Subsection 6.2(a), and does not demonstrate to Bukwang’s reasonable satisfaction that, despite Triangle’s [BUKWANG REDACTED],
the failure to meet the diligence requirement was delayed due to reasons beyond Triangle’s reasonable control, Bukwang shall have the option, as its sole and exclusive remedy, to terminate the Agreement in the entire Territory. The remedy set
forth in this Section 6.3 shall be Bukwang’s sole and exclusive remedy. 
 (b) Prior to exercising any rights under
this Section 6.3, Bukwang shall give Triangle thirty (30) days’ notice and shall meet with Triangle, at Triangle’s request and expense, during such thirty (30) day period, to discuss any disagreements about whether Triangle
has 

  

 22 

 
complied with the applicable diligence requirement of this Article 6. Upon expiration of such thirty (30) day period, Bukwang shall have the right in
its sole discretion to proceed with the exercise of all rights and remedies provided for herein unless the applicable diligence requirement is fulfilled during such thirty (30) day period. 
 6.4 Clinical Utility Diligence Obligation. Triangle acknowledges that viral resistance may limit the clinical utility and commercial potential of
the Compounds. In the conduct of the Development Program, Triangle shall use its [BUKWANG REDACTED] to conduct preclinical and clinical studies of the Compounds in combination with other anti-HBV drugs or drug candidates in order to determine
[BUKWANG REDACTED]. Triangle shall conduct preclinical combination studies with at least [BUKWANG REDACTED] and shall use its [BUKWANG REDACTED] to conduct clinical combination studies with as many other drugs or drug candidates as it deems
appropriate to determine the optimal combinations or sequence of combinations necessary to provide maximum efficacy against HBV and enhance the clinical utility and commercial potential of the Compounds. Such combination studies may include [BUKWANG
REDACTED] and various sequences of treatment regimens and, because the outcome of such combination studies cannot be predicted with certainty, these studies may include other drugs or drug candidates being developed by Triangle or third parties
which because of various factors are ultimately determined not to be additive to, or synergistic with, the Compounds. 
 ARTICLE 7.
JOINT PROJECT COMMITTEE 
 7.1 Appointment of Coordinators. As soon as practicable after the Effective Date, Bukwang and
Triangle shall each appoint an authorized representative (a “Coordinator”). Each such party shall provide notice to the other as to the identity of the individual so appointed. Each Coordinator shall be responsible for communications,
other than legal notices, between the parties with respect to the subject matter of this Agreement. Each party may replace its Coordinator at any time for any or no reason by providing written notice to the other party. 
 7.2 Joint Project Committee. The Coordinators shall establish the Joint Project Committee consisting of representatives of Triangle and Bukwang.
The Joint Project Committee will consist of at least three (3) persons from each of Triangle and Bukwang, such persons 

  

 23 

 
having significant responsibility for the development and/or marketing of the Licensed Product. The Joint Project Committee will meet from time to time at
mutually agreeable times via teleconference or in-person, but no less than semi-annually during the term of the Agreement. The Coordinators shall set the agenda for each meeting, and each Coordinator shall determine which regular members of Joint
Project Committee and other representatives of such Coordinator’s party shall attend in light of the agenda. Each party shall bear its own costs incurred in connection with participation in the Joint Project Committee. 
 7.3 Objective of the Joint Project Committee. The primary objective of the Joint Project Committee will be to facilitate the expeditious
Registration of a Licensed Product in the U.S. by Triangle and in Korea by Bukwang by, inter alia: 
 (a)
facilitating the exchange of data and study results between the parties; 
 (b) providing a forum for protocol and development
plan review; and 
 (c) coordinating the developmental efforts of the parties so as to avoid duplication and inconsistency of
such efforts. 
 Each party agrees to give due consideration to any input received from the other party at such Joint Project Committee
meetings; provided, however, that all final decisions relating to the development of Licensed Products in the Territory will be made by Triangle and all final decisions relating to the development of Licensed Products in Korea will be made by
Bukwang; provided, further, that Bukwang will give due consideration to input from Triangle as to the design of clinical trial protocols from Phase I to Phase III in Korea and will give Triangle’s scientists access to the results of such
clinical trials. 
 7.4 Exchange of Study Results. Each party shall submit a report detailing the results of each non-clinical and
clinical study which it performs to the other party within thirty (30) days after completion of the final statistical analyses of the results of such study. In addition, each party will provide the other party with [BUKWANG REDACTED] progress
reports summarizing its activities in respect of the development of Licensed Products during the relevant semi-annual period. Such reports shall cover the [BUKWANG REDACTED] and shall be due on or before [BUKWANG REDACTED]. 
  

 24 

 7.5 Publications. Each party reserves the right to publish or publicly present the results of its
own development activities in respect of the Licensed Products (the “Results”). The party proposing to publish or publicly present the Results (the “publishing party”) will, however, submit a draft of any proposed manuscript,
abstract, speech, transparencies, presentation materials and press releases to the other party (the “non-publishing party”) for comments at least fifteen (15) days prior to submission for publication or oral presentation, except, in
the case of press releases, where applicable law, in the reasonable opinion of the publishing party, requires such press release to be issued within time constraints which would make such review impractical. The non-publishing party shall notify the
publishing party in writing within fifteen (15) days of receipt of such draft whether such draft contains Information (as hereinafter defined) of the non-publishing party which it considers to be confidential under the provisions of Article 13
hereof, or information that if published would have an adverse effect on a patent application for which the non-publishing party has initial patent prosecution responsibility pursuant to Article 8 of this Agreement. In the latter case, the
non-publishing party shall have the right to request a delay and the publishing party shall delay such publication for a period not exceeding sixty (60) days. In any such notification, the non-publishing party shall indicate with specificity
its suggestions regarding the manner and degree to which the publishing party may disclose such information. The publishing party shall have the final authority to determine the scope and content of any publication, provided that such authority
shall be exercised with reasonable regard for the interests of the non-publishing party, except that no publication will contain any information disclosed by the non-publishing party to the publishing party without the non-publishing party’s
prior written permission. Each party shall cause its Affiliates, licensees or sublicensees, as the case may be, to comply with the requirements of this Section 7.5 with respect to any of their proposed publications. 
 ARTICLE 8. PATENT PROSECUTION 
 8.1 Title to Inventions. Each party shall have and retain sole title in inventions, whether or not patentable, made by it or on its behalf (as by its employees or agents) in the course of work performed under this Agreement.

 8.2 Bukwang Patents. (a) During the period ending [BUKWANG REDACTED] after the Effective Date, Bukwang shall, in consultation
with Triangle, file, prosecute and 

  

 25 

 
maintain all patent applications and patents included in the Bukwang Patents which Bukwang owns, if any, at its sole expense. At the end of such [BUKWANG
REDACTED] period, Triangle shall assume responsibility for filing, prosecution and maintenance of the Bukwang Patents owned by Bukwang, if any, at Triangle’s expense. Bukwang and its patent counsel will cooperate fully with Triangle and its
patent counsel to effect an orderly transfer of such prosecution and maintenance responsibilities. 
 (b) With respect to any
Bukwang Patents licensed to it pursuant to the Primary License Agreement in the Territory, Triangle shall have those rights relating to the prosecution and maintenance of such Bukwang Patents as are set forth in Article 7 of the Primary License
Agreement. 
 (c) Except as otherwise expressly set forth in the first sentence of Subsection 82(a), Triangle agrees to
reimburse the Primary Licensors or Bukwang, as applicable, for all external fees, costs and expenses incurred by them in filing, prosecuting and maintaining the Bukwang Patents in the Territory. Invoices, including reasonable substantiation thereof,
shall be submitted once in respect of each fiscal quarter as promptly as practicable after the end of such quarter. Payments shall be due net thirty (30) days from the date of invoice. If Triangle fails to reimburse Bukwang or the Primary
Licensors, as applicable, for any undisputed patent prosecution expenses respecting any patent application or issued patent included in the Bukwang Patents within the time allowed therefor, upon at least thirty (30) days’ prior notice to
Triangle, Bukwang or the Primary Licensors, as applicable, may remove such patent application or issued patent from the Bukwang Patents and Bukwang or the Primary Licensors shall be free, at its or their election, to abandon or maintain the
prosecution of such patent application or issued patent or grant rights to such patent application or issued patent to third parties. 
 (d) Triangle reserves the right to terminate its obligations pursuant to this Section 8.2 with respect to any patent application or patent included in the Bukwang Patents in any country or countries upon at least
[BUKWANG REDACTED] prior written notice to Bukwang and the Primary Licensors. After the date specified in such notice on which Triangle’s obligation to pay further expenses terminates, such patent application or patent, as the case may 

  

 26 

 
be, shall no longer be included in the Bukwang Patents in those countries in which Triangle has exercised its rights to terminate such obligations.

 8.3 Triangle Inventions. Triangle shall, in consultation with Bukwang, file such patent applications regarding any of the Triangle
Patents owned or controlled by Triangle, and thereafter shall diligently and in the exercise or its discretion in a manner reasonably consistent with the goals and expectations of the parties hereunder, giving due and reasonable consideration to
Bukwang’s position, prosecute and maintain in force the resulting Triangle Patents, all at Triangle’s expense. Triangle shall enable Bukwang to directly contact and confer with Triangle’s patent counsel, at Bukwang’s expense,
with respect to the prosecution of any patent applications constituting part of the Triangle Patents and shall use its reasonable efforts to amend, correct or refile any patent or patent application included in the Triangle Patents to include claims
reasonably requested by Bukwang. The territorial scope of such filings shall be the subject of specific discussion between the parties. If for any reason Triangle declines to file a patent application or, having filed, declines to prosecute or
maintain any of the Triangle Patents in any country, Bukwang may so file, prosecute or maintain in Triangle’s name and at Bukwang’s expense in such country, in which event, Triangle shall, at Bukwang’s request and expense, provide all
reasonable assistance. 
 8.4 Joint Inventions. With respect to Joint Inventions: (a) all patent applications and patents with
respect thereto shall be jointly owned by Bukwang and Triangle; (b) Triangle and its sublicensees and assignees shall be free to use such patent applications and patents in the Territory and Bukwang and its licensees and assignees shall be free
to use such patent applications and patents outside the Territory, in each event, without payment of royalty or accounting therefor; (c) each party agrees to consult with the other party and to give due and reasonable consideration to the other
party’s position in determining the territorial scope of patent filings within the Territory (in the case of Triangle) and outside the Territory (in the case of Bukwang), and the prosecution and maintenance of resulting patent rights based on
Joint Inventions; and (d) Triangle shall have the sole right and discretion to file any patent application and prosecute and maintain any resulting patent rights on Joint Inventions. In which event, Bukwang shall, at Triangle’s request,
provide all reasonable assistance and shall promptly reimburse Triangle with [BUKWANG REDACTED] of the out-of-pocket expenses so incurred by Triangle. 
  

 27 

 8.5 Further Obligations. 
 (a) Except as otherwise provided in Articles 9 and 18, each party’s responsibilities for patent prosecution activities pursuant to
this Article 8 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any
patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party’s position with respect to any such
patent prosecution activities (which term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this Subsection8.5 (a)). In the event a party fails to initiate or
pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, the other party may initiate, pursue or assume such patent
prosecution activities, at its sole expense. 
 (b) In conducting its patent prosecution activities under this Agreement, each
party may use patent attorneys selected by it in its own discretion. In addition to the other obligations set forth in this Article 8, each party undertakes to keep the other party throughout the term of this Agreement regularly informed of the
status and progress of the patent prosecution activities it undertakes under this Agreement including, but not limited to, supplying the other, upon reasonable request and at reasonable intervals, with all correspondence with the United States,
Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party in order to
assist such other party in connection with any of its activities or the exercise of any of its rights pursuant to Articles 8 and 9, such party shall provide the other party with such additional relevant documentation which such other party may
reasonably request relating to such patent applications and patents in the Bukwang Patents, Triangle Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other
supporting data and 

  

 28 

 
relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution
activity for which it has patent prosecution responsibility pursuant to this Article 8, it shall give the other party notice thereof in a sufficiently timely manner so as to enable such other party to determine whether to assume patent prosecution
activity in connection therewith. Each party shall use its [BUKWANG REDACTED] to give such notice at least sixty (60) days before any abandonment, lapse or any other relevant deadline. 
 ARTICLE 9. INFRINGEMENT 
 9.1 Third Party Infringement. If
Triangle or Bukwang becomes aware of any activity that it believes represents a substantial infringement of a Valid Claim or patents relating to Joint Inventions, the party obtaining such knowledge shall promptly advise the other of all relevant
facts and circumstances pertaining to the potential infringement. 
 9.2 Triangle’s Rights Against Third Party Infringers.

 (a) Except to the extent otherwise provided in paragraph 8.1 of the Primary License Agreement in respect of those Bukwang
Patents licensed to Bukwang thereunder, Triangle shall have the first right to enforce or have enforced, at no expense to Bukwang, any Bukwang Patents or patent rights relating to Joint Inventions against infringement by third parties and shall be
entitled to retain recovery from such enforcement as prescribed by this Subsection 9.2(a). Upon Triangle’s undertaking to pay all expenditures reasonably incurred by Bukwang, Bukwang shall reasonably cooperate in any such enforcement and, as
necessary, join as a party therein. After first deducting its costs and expenses incurred in respect of enforcement (to the extent not otherwise awarded by settlement or a court), Triangle shall pay royalties (calculated per Section 3.3) on the
balance of any monetary recovery. In the event that Triangle does not file suit against or commence settlement negotiations with a substantial infringer of the Bukwang Patents or patent rights relating to Joint Inventions within six (6) months
after receipt of a written demand from Bukwang that Triangle bring suit, then the parties will consult with one another in an effort to determine whether a reasonably prudent licensee would institute litigation to enforce the patent in question in
light of all relevant business and economic factors (including, but not limited to, the projected cost of such litigation, the likelihood of success on 

  

 29 

 
the merits, the probable amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of
counterclaims against Triangle and Bukwang, the diversion of Triangle’s human and economic resources, the impact of any possible adverse outcome on Triangle and the effect any publicity might have on Triangle’s and Bukwang’s
respective reputations and goodwill). If the parties cannot agree, the determination will be made by a mutually and reasonably acceptable third party consultant. If after such process, it is determined that a suit should be filed and Triangle does
not file suit or commence settlement negotiations forthwith against the substantial infringer, then Bukwang shall have the right to enforce any patent licensed hereunder on behalf of itself and Triangle (with Bukwang retaining all recoveries from
such enforcement). 
 (b) In the event Triangle commences a suit pursuant to Subsection 9.2(a), Triangle may deposit up to
[BUKWANG REDACTED] of any royalties and Milestone Payments which are otherwise payable to Bukwang during the pendency of such suit in an interest-bearing escrow account. Upon final resolution of such suit, Triangle shall provide Bukwang with an
accounting of the amounts escrowed and Triangle’s expenses incurred in such infringement suit. Triangle shall be entitled to offset any expenses which Triangle fails to recoup in such suit against the escrowed amounts. Any escrowed amounts (and
interest thereon) in excess of Triangle’s unrecouped expenses shall be promptly paid to Bukwang and the Primary Licensors pursuant to Section 5.1. 
 ARTICLE 10. TRANSFER OF KNOW-HOW: TECHNICAL ASSISTANCE 
 10.1 Transfer by Bukwang.
Within [BUKWANG REDACTED] following the Effective Date and as far as it has not previously done so, Bukwang shall supply Triangle with all Bukwang Know-How. With respect to any Bukwang Know-How developed by Bukwang during the term of this Agreement,
such disclosure will he made at least on a quarterly basis or sooner, if practicable. 
 10.2 Technical Assistance. 
 (a) Bukwang shall, upon request by Triangle, provide Triangle with reasonable cooperation and assistance, consistent with the other
provisions hereof, in connection with the transfer of Bukwang Know-How. Such assistance may include, but is not limited to, 

  

 30 

 
development of the formulations of the Licensed Products; procurement of supplies and raw materials; initial developmental and production batch manufacturing
runs; process, specification and analytical methodology design and improvement; and, in general, such other assistance as may contribute to the efficient application by Triangle of the Bukwang Know-How. In this regard, Bukwang agrees to make
appropriate employees of Bukwang reasonably available to assist Triangle, and Bukwang agrees to provide reasonable numbers of appropriate Triangle personnel with access during normal business hours to the appropriate personnel and operations of
Bukwang for such periods of time as may be reasonable in order to familiarize Triangle personnel with the Bukwang Know-How as applied by Bukwang. At Triangle’s reasonable request, such assistance shall be furnished at Triangle’s or its
subcontractors’ or sublicensees’ facilities in the Territory, subject to a mutually agreed upon schedule. Such technical assistance shall include but not be limited to the following: 
 (i) Bukwang shall: (A) provide Triangle with access to any and all Drug Master File(s) or counterparts thereof in any countries of
the Territory (“DMF”) of Bukwang relating to the manufacture of Bulk Drug Substance existing as of the Effective Date; (B) provide Triangle with letters of authorization to the FDA and other applicable government authorities in other
countries of the Territory to refer to Bukwang’s DMF’s; and (C) reasonably cooperate with Triangle in obtaining access to and letters of authorization to refer to the DMF’s of Bukwang’s subcontractors which are, or will be,
supplying any Bulk Drug Substance; and 
 (ii) Within [BUKWANG REDACTED] after the Effective Date, Bukwang shall provide
Triangle with copies of all documentation in Bukwang’s possession, including all correspondence between Bukwang and its subcontractors, regarding the manufacture of the Bulk Drug Substance which would be necessary or useful to assist Triangle
in the commercial production of Bulk Drug Substance or to support Registration of the Licensed Products. 
 (b) During the
period prior to the [BUKWANG REDACTED] anniversary of the Effective Date, (i) Bukwang shall provide up to [BUKWANG REDACTED] man-days of such technical assistance during each year of such period at Bukwang’s sole expense and
(ii) subsequent to such [BUKWANG REDACTED] man-days of technical assistance, Bukwang 

  

 31 

 
shall provide such additional technical assistance as may be reasonably requested by Triangle, provided, that all reasonable out-of-pocket travel costs and
expenses incurred by Bukwang in rendering technical assistance pursuant to this Section 10.2 in excess of such [BUKWANG REDACTED] man-days per year shall be reimbursed to Bukwang by Triangle and, in addition, Triangle will pay Bukwang a
consultancy fee in an amount to be negotiated by the parties hereto in good faith (but not to exceed the consultancy fee, if any, then being charged by Bukwang to third parties) for each consultancy day in excess of [BUKWANG REDACTED] man-days spent
by personnel of Bukwang in rendering technical assistance to Triangle. Technical assistance furnished pursuant to this Section 10.2 shall continue only until the [BUKWANG REDACTED] anniversary of the Effective Date of this Agreement.

 (c) In the event Bukwang supplies any Bulk Drug Substance to Triangle, Triangle will reimburse Bukwang for its
Manufacturing Cost or Acquisition Cost therefor, subject, however, to reasonable substantiation thereof. 
 (d) Triangle shall
be responsible for arranging for the synthesis of adequate quantities of Licensed Products for all clinical, non-clinical and commercial purposes in the Territory to fulfill its obligations hereunder. 
 10.3 Transfer by Triangle. With respect to any Triangle Know-How developed by Triangle during the term of this Agreement, Triangle shall supply
Bukwang with such Triangle Know-How on at least a quarterly basis or sooner, if practicable. 
 10.4 Language of Disclosures. All
disclosures pursuant to this Agreement will be in English. 
 ARTICLE 11. WARRANTIES AND REPRESENTATIONS; LIMITATION OF LIABILITY; AND
DISCLAIMERS 
 11.1 Warranties and Representations of Bukwang. Bukwang warrants and represents the following as of the date
hereof: 
 (a) It possesses the necessary rights to enter into this License Agreement; 
  

 32 

 (b) Exhibit A is a true, complete and accurate copy of the Primary License Agreement;

 (c) Exhibit B is a complete list of all patents and patent applications included in the Bukwang Patents as of the Effective
Date; 
 (d) it is not aware of any material facts which it has not disclosed to Triangle regarding the manufacture, use or
sale of any Licensed Product or the practice of any inventions included in the Bukwang Patents or the use of the Bukwang Know-How by Triangle (except, potentially, details regarding the Bukwang Know-How to be provided under Article 10), including
without limitation any material facts regarding the possibility that such manufacture use, sale or practice might infringe any third party’s know-how , patent rights or other intellectual property in the Territory; 
 (e) it is aware of no third party using or infringing all or any of the Bukwang Patents in derogation of the rights granted pursuant to
this Agreement; 
 (f) it is aware of no third party claim to any rights in the Bukwang Patents or the Bukwang Know-How;

 (g) it is aware of no pending interference or opposition proceeding or litigation or any communication which threatens an
interference or opposition proceeding or litigation before any patent and trademark office, court, or any other governmental entity or court in any jurisdiction in regard to the Bukwang Patents; and 
 (h) the Primary License Agreement is in full force and effect and Bukwang will: (i) use its best efforts to fulfill all of its
obligations under the Primary License Agreement, including, but not limited to any due diligence obligations outside the Territory set forth therein; (ii) take no action or fail to take any action which will cause it to be in breach of any
provision of the Primary License Agreement; (iii) immediately notify Triangle in the event that Bukwang receives written notice from the Primary Licensors (or their successors) that Bukwang is in default under the Primary License Agreement or
that the Primary Licensors (or their successors) have terminated or intend to terminate the Primary License Agreement; and (iv) not amend the Primary License Agreement in a manner which adversely affects Triangle’s rights and obligations
hereunder. 
  

 33 

 11.2 Warranties and Representations by Triangle. Triangle represents and warrants that it has or
will obtain, the skill and expertise in the technical areas relating to the Bukwang Patents and Bukwang Know-How to make or have made an evaluation of the capabilities, safety, utility and commercial application of the Bukwang Patents and the
Bukwang Know-How. 
 11.3 Warranties and Representations of Each Party. Each party hereto warrants and represents to: (a) the
other that it is free to enter into this Agreement (including the receipt of all corporate authorizations) and to carry out all of the provisions hereof, including, its grant to the other of the licenses described in Article 2; (b) to its
knowledge, there is no failure to comply with, no violation of or any default under, any law, permit or court order applicable to it which might have a material adverse effect on its ability to execute, deliver and perform this Agreement or on its
ability to consummate the transactions contemplated hereby; and (c) it shall comply with laws and regulations relating to the performance of its obligations or the exercise of its rights hereunder including, in the case of Triangle, those
relating to the manufacture, processing, producing, use, sale, or distribution of Licensed Products; and that it shall not take any action which would cause it or the other party to violate such laws and regulations. 
 11.4 Disclaimer and Limitation of Warranties. Bukwang makes no warranty as to validity of the Bukwang Patents licensed hereunder and, except as
expressly stated in Section 11.1, makes no representation whatsoever with regard to the scope of the Bukwang Patents or Bukwang Know-How, or that the Bukwang Patents or Bukwang Know-How may be exploited by Triangle or its Affiliates or
sublicensees without infringing intellectual property rights of third parties. EXCEPT AS OTHERWISE SET FORTH IN SECTION 11.1 ABOVE, BUKWANG MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE BUKWANG PATENTS OR BUKWANG KNOW-HOW AND
EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL APPLICATION OF BUKWANG PATENTS OR BUKWANG KNOW-HOW.

  

 34 

 11.5 Limitation of Liability. 
 (a) Neither Bukwang nor the Primary Licensors shall he liable to Triangle or Triangle’s Affiliates, sublicensees or any of its or
their customers for any special, incidental or consequential damages resulting from defects in the testing, labeling, manufacture or other application of the Licensed Products manufactured, tested or sold pursuant to this Agreement. 
 (b) Any provision of this Agreement to the contrary notwithstanding, Bukwang shall not be liable to Triangle, its Affiliates or
sublicensees for any damage that any party may suffer as a result of any third party actions for patent infringement or for any other claims against Triangle, its Affiliates or sublicensees in connection with their use of Bukwang Patents or Bukwang
Know-How; provided, however, that the foregoing limitation shall in no way affect or otherwise limit any remedies which Triangle or its Affiliates or sublicensees may have against Bukwang as a result of Bukwang’s breach of any of its warranties
and representations set forth in Article 11 hereof. 
 11.6 Insurance. Without limiting Triangle’s indemnity obligations under
Article 12, Triangle shall maintain throughout the term of this Agreement, and shall use its [BUKWANG REDACTED] to maintain for a reasonable period of time thereafter, a commercial, general liability insurance policy, written by a reputable
insurance company authorized to do business in the United States, which: 
 (a) insures Indemnitees for all claims, damages,
and actions mentioned in Section 12.1 of this Agreement; 
 (b) includes a contractual endorsement providing coverage for
all liability arising out of bodily injury and property damage; 
 (c) requires the insurance carrier to provide Bukwang with
no less than thirty (30) days’ written notice of any change in the terms or coverage of the policy or its cancellation; and 
  

 35 

 (d) provides the Indemnitee with product liability coverage in an amount no less than
[BUKWANG REDACTED] per occurrence for bodily injury and [BUKWANG REDACTED] per occurrence for property damage, subject to a reasonable aggregate amount. 
 Triangle shall provide Bukwang with certificates of insurance evidencing the above insurance coverage. 
 ARTICLE 12.
INDEMNIFICATION 
 12.1 Triangle’s Indemnification. Subject to compliance by the Indemnitees with the provisions set
forth in Section 12.3, Triangle shall defend, indemnify, and hold harmless the Indemnitees, from and against any and all claims, demands, losses, liabilities, expenses, and damages including investigative costs, court costs and reasonable
attorneys’ fees (collectively, the “Liabilities”) which Indemnitees may suffer, pay, or incur as a result of or in connection with: (a) any and all personal injury (including death) and property damage caused or contributed to,
in whole or in part, by manufacture, testing, design, use, sale, or labeling of any Licensed Products or the practice of the Bukwang Patents or Bukwang Know-How by Triangle or Triangle’s Affiliates or sublicensees, excluding any Liabilities
arising as a result of Bukwang’s or, if applicable, its subcontractor’s negligence, intentional misconduct or breach of contract in supplying Bulk Drug Substance (it being acknowledged by Triangle that neither Bukwang nor any Bukwang
subcontractor currently intends to supply any Bulk Drug Substance to Triangle and in the event Triangle acquires any Bulk Drug Substance from [BUKWANG REDACTED], such acquisition will be pursuant to a direct contract); and (b) any breach by
Triangle of its representations, warranties and covenants contained in this Agreement. Triangle’s obligations under this Article shall survive the expiration or termination of this Agreement for any reason. 
 12.2 Bukwang’s Indemnification. Subject to compliance by the Indemnitees with the provisions set forth in Section 12.3, Bukwang shall
indemnify and hold the Indemnitees harmless from and against any and all Liabilities which Indemnitees may suffer, pay or incur as a result of or in connection with: (a) any breach by Bukwang of any of its representations, warranties and
covenants set forth in this Agreement; and (b) any claims or suits asserted or commenced by the Primary Licensors regarding any royalty payments made by Triangle to Bukwang pursuant to 

  

 36 

 
Subsection 5.1(b) of this Agreement. Bukwang’s obligations under this Article shall survive expiration or termination of this Agreement for any reason.

 12.3 Indemnification Procedures. Any Indemnitee which intends to claim indemnification under this Article shall, promptly after
becoming aware thereof, notify the party from whom it is seeking indemnification (the “Indemnitor”) in writing of any matter in respect of which the Indemnitee or any of its employees intend to claim such indemnification. The Indemnitee
shall permit, and shall cause its employees to permit, the Indemnitor, at its discretion, to settle any such matter and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that such settlement does not
adversely affect the Indemnitee’s rights hereunder or impose any obligations on the Indemnitee in addition to those set forth herein in order for it to exercise such rights. No such matter shall be settled by such Indemnitee without the prior
written consent of the Indemnitor and neither the Indemnitor nor the Indemnitee shall be responsible for any legal fees or other costs incurred other than as provided herein. The Indemnitee and its employees shall cooperate fully with the Indemnitor
and its legal representatives in the investigation and defense of any matter covered by the applicable indemnification. The Indemnitee shall have the right, but not the obligation, to be represented by counsel of its own selection and expense.

 ARTICLE 13. CONFIDENTIALITY 
 13.1 Treatment of Confidential Information. Except as otherwise provided hereunder, during the term of this Agreement and for a period of [BUKWANG REDACTED] thereafter: 
 (a) Triangle and its Affiliates and sublicensees shall retain in confidence and use only for purposes of this Agreement, any written
information and data supplied by or on behalf of Bukwang under this Agreement and the Restricted Disclosure and Testing Agreement, dated October 27, 1997, between Bukwang and Triangle (the “Confidentiality Agreement”); and 

(b) Bukwang shall retain in confidence and use only for purposes of this Agreement any written information and data supplied by or on
behalf of Triangle to Bukwang under this Agreement. 
  

 37 

 For purposes of this Agreement, all such information and data which a party is obligated to retain in
confidence shall be called “Information.” 
 13.2 Right to Disclose. To the extent that it is reasonably necessary to
fulfill its obligations or exercise its rights under this Agreement, or any rights which survive termination or expiration hereof, each party may disclose Information to its Affiliates, sublicensees (actual or prospective), consultants, outside
contractors, actual or prospective investors, and clinical investigators on condition that such entities or persons agree in writing: 
 (a) to keep the Information confidential for a period of at least [BUKWANG REDACTED] from the date of disclosure by such party to the same extent as such party is required to keep the Information confidential; and

 (b) to use the Information only for those purposes for which the disclosing party is authorized to use the Information.

 Each party or its Affiliates or sublicensees, as applicable, may disclose Information to the government or other regulatory authorities to
the extent that such disclosure (i) is necessary for the prosecution and enforcement of patents, or authorizations to conduct preclinical or clinical trials to commercially market Licensed Products, provided such party is then otherwise
entitled to engage in such activities in accordance with the provisions of this Agreement, or (ii) is legally required. 
 13.3
Release from Restrictions. The obligation not to disclose or use Information shall not apply to any part of such Information that: 
 (a) is or becomes patented (but the existence of a patent shall only permit disclosure and not, unless otherwise provided hereunder, use), published or otherwise part of the public domain, other than by unauthorized
acts of the party obligated not to disclose such Information (for purposes of this Article 13 the “receiving party”) or its Affiliates or sublicensees in contravention of this Agreement; or 
  

 38 

 (b) is disclosed to the receiving party or its Affiliates or sublicensees by a third
party provided that such Information was not obtained by such third party directly or indirectly from the other party to this Agreement; or 
 (c) prior to disclosure under the Confidentiality Agreement or this Agreement, as the case may be, was already in the possession of the receiving party, its Affiliates or sublicensees, provided that such Information
was not obtained directly or indirectly from the other party to this Agreement; or 
 (d) results from research and
development by the receiving party or its Affiliates or sublicensees, independent of disclosures from the other party to this Agreement, provided that the persons developing such information have not had exposure to the information received from the
other party to this Agreement; or 
 (e) is required by law to be disclosed by the receiving party, provided that in the case
of disclosure in connection with any litigation, the receiving party uses reasonable efforts to notify the other party immediately upon learning of such requirement in order to give the other party reasonable opportunity to oppose such requirement;
or 
 (f) Triangle and Bukwang agree in writing may be disclosed. 
 ARTICLE 14. CONDITIONS PRECEDENT 
 This Agreement will not become
effective until the Primary Licensors and Bukwang shall have properly executed and delivered an Amendment to the Primary License Agreement to Triangle in the form and substance attached hereto as Exhibit C. In the event the condition set forth in
this Article 14 has not been satisfied within thirty (30) days from the date set forth at the beginning of this Agreement, Triangle may terminate this Agreement by giving Bukwang ten (10) days’ prior notice. 
 ARTICLE 15. TERM AND TERMINATION 
 15.1 Term. Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until the expiration of Triangle’s
obligations to pay royalties hereunder. 
  

 39 

 15.2 Termination by Default. 
 (a) If either party defaults in the performance of, or fails to be in compliance with, any material agreement, condition or covenant of
this Agreement, including, as to Triangle, the provisions of Section 16.2 hereof, the non-defaulting party may terminate this Agreement with respect to the defaulting party if such default or noncompliance shall not have been remedied, or, in the
event the default or non-compliance cannot be remedied within such period, reasonable steps shall not, have been initiated to remedy the same, within [BUKWANG REDACTED] after receipt by the defaulting party of a written notice thereof from the
non-defaulting party. 
 (b) In the event that: (i) any proceeding is commenced by or against a party seeking relief under any
bankruptcy, insolvency or similar law and if such proceeding is involuntary, it remains undismissed for [BUKWANG REDACTED]; or a party, by action or answer, approves of, consents to or acquiesces in such proceeding or admits the material allegations
of or defaults in answering a petition filed in such proceeding; or (ii) a receiver, liquidator, assignee, custodian or trustee (or similar official) is appointed for a party in respect of any substantial part of its assets or for purposes of the
winding-up or liquidating of its business and such appointment remains unstayed and in effect for a period of [BUKWANG REDACTED]; or (iii) a party makes an assignment for the benefit of creditors; then, in any such event, such party shall be deemed
in default for purposes of this Section 15.2. 
 15.3 Termination by Triangle. Triangle shall have the right to terminate this
Agreement in the entire Territory or one or more countries of the Territory (without affecting this Agreement in the remaining countries of the Territory), by giving Bukwang sixty (60) days’ prior written notice thereof. 
 15.4 Obligations Upon Termination. If this Agreement is terminated as a result of Triangle’s breach pursuant to Section 15.2, or is
terminated in whole or in part by Bukwang in accordance with Section 6.3 or by Triangle in accordance with Section 15.3, then: (a) in the case of termination in the entire Territory, Triangle shall use, and shall cause its Affiliates and
sublicensees to use, its and their [BUKWANG REDACTED] to return, or at Bukwang’s direction, destroy all data, writings and other documents and tangible materials supplied to 

  

 40 

 
Triangle by Bukwang properly organized and to provide Bukwang with reasonable transition assistance, and upon Bukwang’s request, Triangle shall sell any
Licensed Product in its possession to Bukwang at Triangle’s Acquisition Cost or Manufacturing Cost therefor, as applicable; and (b) with respect to those countries with respect to which termination occurs, Triangle shall provide Bukwang
with full and complete copies of all toxicity, efficacy, and other data generated by Triangle or Triangle’s Affiliates, and sublicensees, in the course of Triangle’s efforts to develop Licensed Products or to obtain governmental approval
for the sale of Licensed Products, including but not limited to any regulatory filings with any government agency in such countries. Bukwang shall be authorized to cross-reference any such regulatory filings made by Triangle, its Affiliates and
sublicensees in the countries in which termination occurs where permitted by law. Bukwang shall be entitled to provide information pertaining to the Triangle Patents, Triangle Know-How and Joint Know-How to any third party with a bona fide interest
in licensing such technology in the countries in which termination occurs. Such data shall be provided on a confidential basis; provided, however, that if such third party concludes a license with Bukwang, such third party shall be free to use such
data for all purposes, including to obtain government approvals to sell any product containing any Compound in such countries. 
 15.5
Effect of Termination. In the event of any expiration or termination pursuant to this Article 15, neither party shall have any remaining rights or obligations under this Agreement other than as provided below: 
 (a) Bukwang will have the right to receive all payments accrued prior to the effective date of termination; 
 (b) termination or expiration of this Agreement for any reason shall have no effect on the parties’ obligations under Articles 9, 12
and 13 or their respective rights in Joint Know-How set forth in Section 1.18; 
 (c) upon expiration of Triangle’s
royalty obligations under this Agreement in a given country, Triangle shall have a perpetual, fully paid-up, non-exclusive license to use the Bukwang Know-How in such country; 
  

 41 

 (d) termination of this Agreement by Bukwang pursuant to Section 6.3 or 15.2 or by
Triangle pursuant to Section 15.3, shall have no effect on the rights and obligations of the parties under Section 15.4; and 
 (e) the parties’ shall retain any other remedies for breach of this Agreement they may otherwise have. 
 15.6 Default by Triangles’ Affiliates and Sublicensees. For purposes of this Article 15, any breach or default of the provisions of this Agreement by Triangle’s Affiliates or sublicensees shall be deemed to be breach of
this Agreement by Triangle, and Triangle shall be liable to Bukwang for such breach or default to the same extent as if such breach or default had been made directly by Triangle. 
 ARTICLE 16. ASSIGNMENT 
 16.1 Assignment by Either Party. Neither
party shall assign this Agreement or any part thereof without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed. Each party may, however, without such consent, assign or sell its rights under
this Agreement (a) in connection with the sale or transfer of all or substantially all of its pharmaceutical business to a third party; (b) in the event of a merger or consolidation with a third party; or (c) to an Affiliate. No
assignment shall relieve any party of responsibility for the performance of any accrued obligation which such party has under this Agreement. Any assignment shall be contingent upon the assignee assuming in writing all of the obligations of its
assignor under this Agreement. 
 (a) [BUKWANG REDACTED] Subsequent to any assignment by Triangle pursuant Subsection 16.1(a)
or (b) above, [BUKWANG REDACTED], Bukwang shall so inform Triangle in writing specifying with reasonable particularity the basis for such determination. If Triangle disagrees with Bukwang regarding Bukwang’s determination, Triangle shall
so inform Bukwang in writing within thirty (30) days after receipt of such written notice and this issue shall be determined pursuant to the provisions set forth in Section 19.2. If the arbitrator(s) determine that [BUKWANG REDACTED],
Triangle shall have [BUKWANG REDACTED] from the date it receives written notice of the arbitration result [BUKWANG REDACTED] that is not reasonably curable within such [BUKWANG REDACTED] period, Triangle shall have an 

  

 42 

 
additional reasonable period of time to effect such cure (which additional period shall in no event exceed [BUCKWANG REDACTED]). If Triangle does not send
written notice of Bukwang within such thirty (30) day period disagreeing with Bukwang’s position on the matter, Triangle shall have [BUKWANG REDACTED] from the date of its receipt of Bukwang’s written notice [BUKWANG REDACTED] that is
not reasonably curable within such period, Triangle shall have an additional reasonable period of time to effect such cure (which additional period shall in no event exceed [BUKWANG REDACTED]). 
 ARTICLE 17. REGISTRATION OF LICENSE 
 Triangle, at its expense, may register the license granted under this Agreement in any country of the Territory where the use, sale or manufacture of a Licensed Product in such country would be covered by a Valid Claim. Upon request by
Triangle, Bukwang agrees promptly to execute any “short form” licenses submitted to it by Triangle reasonably necessary in order to effect the foregoing registration in such country. 
 ARTICLE 18. NOTIFICATION AND AUTHORIZATION UNDER DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT 
 18.1 Notices Relating to the Act. Bukwang shall use its best efforts to cause the Primary Licensors to notify Triangle of (a) the issuance of each U.S. patent included among the Bukwang Patents, giving the
date of issue and patent number for each such patent; and (b) each notice pertaining to any patent included among the Bukwang Patents which the Primary Licensors receive as patent owners pursuant to the Drug Price Competition and Patent Term
Restoration Act of 1984 (hereinafter the “Act”), including but not necessarily limited to notices pursuant to §§101 and 103 of the Act from persons who have filed an abbreviated NDA (“ANDA”) or a “paper” NDA.
Such notices shall be given promptly, but in any event within ten (10) days of notice of each such patent’s date of issue or receipt of each such notice pursuant to the Act, whichever is applicable. 
 18.2 Authorization Relating to Patent Term Extension. Bukwang hereby authorizes Triangle and will use its best efforts to obtain the Primary
Licensors’ authorization for Triangle (a) to include in any NDA for a Licensed Product, as Triangle may deem appropriate under the Act, a list of patents included among the Bukwang Patents that relate to such Licensed Product 

  

 43 

 
and such other information as Triangle in its reasonable discretion believes is appropriate to be filed pursuant to the Act; (b) to commence suit for
any infringement of the Bukwang Patents under § 271(e) (2) of Title 35 of the United States Code occasioned by the submission by a third party of an IND or a paper NDA for a Licensed Product pursuant to §§101 or 103 of the Act;
and (c) in consultation with Bukwang and the Primary Licensors, to exercise any rights that may be exercisable by Bukwang or the Primary Licensors, as applicable, as patent owners under the Act to apply for an extension of the term of any
patent included among the Bukwang Patents. In the event that applicable law in any other country of the Territory hereafter provides for the extension of the term of any patent included among the Bukwang Patents in such country, upon request by
Triangle, Bukwang shall authorize Triangle and shall use its best efforts to obtain the Primary Licensors’ authorization for Triangle or, if requested by Triangle, its sublicensees, to apply for such extension, in consultation with Bukwang and
the Primary Licensors. Bukwang agrees to cooperate and shall use its best efforts to cause the Primary Licensors to cooperate with Triangle or its sublicensees, as applicable, in the exercise of the authorizations granted herein or which may be
granted pursuant to this Section 18.2 and will execute such documents and take such additional action and use its best efforts to cause the Primary Licensors to execute such documents and to take such additional actions as Triangle may
reasonably request in connection therewith, including, if necessary, permitting itself and using its best efforts to permit the Primary Licensors to permit themselves to be joined as proper parties in any suit for infringement brought by Triangle
under subsection (b) above. Triangle shall bear the costs and expenses, including but not limited to attorneys’ fees, of any suit for infringement brought by Triangle under subsection (b) above. 
 ARTICLE 19. DISPUTE RESOLUTION AND ARBITRATION 
 19.1 Initial Resolution. In the case of any disputes between the parties arising from this Agreement, and in case this Agreement does not provide a solution for how to resolve such disputes, the parties shall
discuss and negotiate in good faith a solution acceptable to both parties and in the spirit of this Agreement. If after negotiating in.good faith pursuant to the foregoing sentence, the parties fail to reach agreement within thirty (30) days,
then the President of Bukwang and the Chief Executive Officer or Chief Operating Officer of Triangle shall discuss in good faith an appropriate resolution to the dispute. If these executives fail, after good faith 

  

 44 

 
discussions not to exceed thirty (30) days, to reach an amicable agreement then the parties shall submit to binding arbitration pursuant to Section 19.2
(“Arbitration”). The date of submission of the matter to substrate shall be the “Dispute Date”. 
 19.2
Arbitration. The following provisions shall govern any arbitration pursuant to this Agreement. 
 (a) Arbitration shall
be conducted in accordance with the Rules of the American Arbitration Association. In the event of any conflict between the Rules and this Section, the provisions of this Section shall govern. The Arbitration shall be conducted in [BUKWANG
REDACTED]. 
 (b) The Arbitration shall be heard by a panel of three arbitrators (each an “Arbitrator”). Triangle
and Bukwang shall each select one Arbitrator. Such Arbitrators shall be attorneys, licensed to practice law in the State of Georgia, actively engaged in the full-time practice of law for a period of no less than seven (7) years. Such
Arbitrators shall not be affiliated, directly or indirectly, with the parties or the attorneys representing the parties in the Arbitration and shall not have any prior involvement in the matter. In the event that either party fails within fifteen
(15) days after the Dispute Date (i) to select an Arbitrator who, to its knowledge, meets the requirements set forth in this subsection (b) and (ii) to notify the other party of the selection, the other party will then have the
right to select such Arbitrator. The third Arbitrator shall be selected by mutual agreement of the parties from a list of neutral arbitrators compiled by the American Arbitration Association for the parties. Such Arbitrator shall be an attorney,
licensed to practice law in the State of Georgia, actively engaged in the full time practice of law for a period of no less than ten (10) years. The third Arbitrator shall not have any prior or current relationship, direct or indirect, with any
party to this Agreement. If the parties to the Arbitration are unable to agree upon the third Arbitrator within fifteen (15) days from the Dispute Date, the appointment of the third Arbitrator shall be made as expeditiously as possible and in
compliance with this Section 19.2 by the two Arbitrators selected by the parties. If those Arbitrators cannot agree on the third Arbitrator within ten (10) days, then the third Arbitrator shall be designated by the American Arbitration
Association or the appropriate designated representative thereof upon the written request of any party with simultaneous notice of such request to the other party to the Arbitration. The third Arbitrator shall preside over the panel of Arbitrators
and the Arbitration. 
  

 45 

 (c) The Arbitrators shall apply the substantive laws of the [BUKWANG REDACTED] to the
validity, construction and interpretation of this Agreement as is applicable to contracts made wholly performable within the state. 
 (d) The Arbitration shall be resolved no later than sixty (60) days from the date of acceptance by the third Arbitrator of his or her appointment unless otherwise agreed to by the parties to the Arbitration. 
 (e) Each party shall bear the expenses and costs of the Arbitrator selected by the party. The third Arbitrator shall be compensated for
services rendered at the prevailing hourly rate of compensation and reimbursed for any expenses incurred in connection with rendering such services. The non-prevailing party shall bear the costs and expenses of compensation and reimbursement for the
third Arbitrator. 
 (f) The decision of the Arbitrators shall be rendered in writing and shall be final and binding and may
be enforced at the request of either party to the Arbitration in the United States District Court for the Northern District of Georgia or any court of the State Georgia having competent jurisdiction. Such decision may not be appealed except upon a
claim of bad faith or fraud by the Arbitrators. 
 (g) This Article 19 shall not apply to issues relating to the validity,
construction or effect of the Bukwang Patents. In the event that, in any Arbitration, any issue arises concerning the validity, construction or effect of any of the Bukwang Patents, the Arbitrators shall assume the validity of all claims as set
forth in such Bukwang Patents. Matters, controversies or disputes concerning the Licensed Patents shall be resolved in any court having jurisdiction thereof or in any other manner mutually agreed to by the parties. 
 ARTICLE 20. GENERAL PROVISIONS 
 20.1 Export Controls. Bukwang acknowledges that Triangle is subject to United States laws and regulations controlling the export of technical data, biological materials, chemical 

  

 46 

 
compositions and other commodities and that Triangle’s obligations under this Agreement are contingent upon compliance with applicable United States
export laws and regulations. The transfer of technical data, biological materials, chemical compositions and commodities may require a license from the cognizant agency of the United States government or written assurances by Bukwang that Bukwang
shall not export data or commodities to certain foreign countries without the prior approval of certain United States agencies, or as otherwise prescribed by applicable law or regulation. Triangle neither represents that an export license shall not
be required nor that, if required, such export license shall issue. 
 20.2 Independent Contractors. It is understood and agreed that
the parties hereto are independent contractors and are engaged in the operation of their own respective businesses, and neither party hereto is to be considered the agent of the other party for any purpose whatsoever, and neither party shall have
any authority to enter into any contracts or assume any obligations for the other party nor make any warranties or representations on behalf of that other party. 
 20.3 Patent Marking. Triangle shall mark Licensed Products sold in the United States with United States patent numbers. Licensed Products manufactured or sold in other countries shall be marked in compliance
with the intellectual property laws in force in such countries. The foregoing obligations shall be subject to size and space limitations. If Bukwang believes that a Licensed Product should be marked with the number of a Bukwang Patent, Bukwang shall
provide written notice to Triangle which identifies the patent number and the Licensed Product on which it should appear. It shall also be Bukwang’s responsibility to inform Triangle in writing when marking with a Bukwang Patent number should
be discontinued. To the extent that Triangle complies with Bukwang’s instructions, Bukwang shall indemnify and hold Triangle harmless for any liability, claim or action for false patent marking or non-marking. 
 20.4 Publicity. The parties agree to issue mutual press releases concerning their entry into this Agreement, with the content of such releases to
be approved (which consent shall not be unreasonably withheld or delayed) in advance by the parties. In all other respects, except as required by law, neither party shall use the name of the other party in any publicity release without the prior
written permission of such other party, which shall not be unreasonably withheld. The other party shall have a reasonable opportunity to review and comment on any 

  

 47 

 
such proposed publicity release. Except as required by law, neither party shall publicly disclose the terms of this Agreement or issue any publicity release
with regard thereto unless expressly authorized to do so by the other party which authorization shall be agreed upon. 
 20.5 Governing
Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder, shall be construed under and governed by the laws of the [BUKWANG REDACTED] exclusive of its conflicts of laws
principles. 
 20.6 Entire Agreement. This Agreement, together with the Exhibits attached hereto, constitutes the entire agreement
between Bukwang and Triangle with respect to the subject matter hereof and shall not be modified, amended or terminated, except as herein provided or except by another agreement in writing executed by the parties hereto. Upon the Effective Date, the
Confidentiality Agreement shall terminate. 
 20.7 Interpretation. Except (a) as otherwise provided in the Primary License
Agreement and (b) for any amendment to the Primary License Agreement to the extent such amendment would adversely affect the rights and obligations of Triangle hereunder (unless Triangle has given prior written consent thereto in writing), in
the event of any conflict between the terms hereof and the terms of the Primary License Agreement, the terms of the Primary License Agreement shall control. 
 20.8 Waiver. No provision of this Agreement may be waived except by a writing signed by the party entitled to the benefit thereof and no such waiver of any provision hereof in one instance shall constitute a
waiver of any other provision or of such provision in any other instance. No omission, delay or failure on the part of any party hereto in exercising any rights hereunder will constitute a waiver of such rights or of any other rights hereunder.

 20.9 Severability. All rights and restrictions contained herein may be exercised and shall be applicable and binding only to the
extent that they do not violate any applicable laws and are intended to be limited to the extent necessary so that they will not render this Agreement illegal, invalid or unenforceable. If any provision or portion of any provision of this Agreement,
not essential to the commercial purpose of this Agreement, shall be held to be illegal, invalid or 

  

 48 

 
unenforceable by a court of competent jurisdiction, it is the intention of the parties that the remaining provisions or portions thereof shall constitute
their agreement with respect to the subject matter hereof, and all such remaining provisions, or portions thereof, shall remain in full force and effect. To the extent legally permissible, any illegal, invalid or unenforceable provision of this
Agreement shall be replaced by a valid provision which shall implement the commercial purpose of the illegal, invalid, or unenforceable provision. In the event that any provision essential to the commercial purpose of this Agreement is held to be
illegal, invalid or unenforceable and cannot be replaced by a valid provision which will implement the commercial purpose of this Agreement, this Agreement and the rights granted herein shall terminate, 
 20.10 Force Maieure. 
 (a) Any delays in, or failure of performance of, any party to this Agreement, shall not constitute a default hereunder, or give rise to any claim for damages, if and to the extent caused by occurrences beyond the control of the party
affected, including, but not limited to, acts of God, strikes or other concerted acts of workmen, civil disturbances, fires, floods, explosions, riots, war, rebellion, sabotage, acts of governmental authority or failure of governmental authority to
issue licenses or approvals which may be required (“Force Majeure”). 
 (b) The party asserting the Force Majeure
shall promptly notify the other party of the event constituting Force Majeure and of all relevant details of the occurrence and where appropriate an estimate of how long such Force Majeure event shall continue. 
 (c) If such Force Majeure event continues thereafter and in any event, the parties shall consult with each other in order to find a fair
solution and shall use all reasonable endeavors to minimize the consequences of such Force Majeure. 
 20.11 Counterparts. This
Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 20.12 Notices. All notices, statements, and reports required to be given under this Agreement shall be in writing and shall be deemed to have been given upon delivery in person or, when deposited (a) in
the mail in the country of residence of the party giving the notice, 

  

 49 

 
registered or certified postage prepaid or (b) with a professional courier service (e.g., FedEx or UPS), and addressed as follows: 
  

					
	To Bukwang	 	Bukwang Pharm. IND. Co., Ltd
		 	398-1 Daebang-Dong-Dongjak-Ku
		 	Seoul 156-020
		 	Korea
		 	Attn:	 	Sung-Koo Lee, Managing Director
		 	Fax:	 	02-816-2792
		
	With a copy to:	 	Robert Finch, Esq.
		 	Arnall, Golden & Gregory, LLP
		 	2800 One Atlantic Center
		 	1201 W. Peachtree St.
		 	Atlanta, Georgia 30309 USA
		 	Fax:	 	(404) 873-8617
		
	To Triangle:	 	Triangle Pharmaceuticals, Inc.
		 	4 University Place, 4611 University Drive
		 	Durham, NC 27707, U.S.A.
		 	Attn:	 	Chris A. Rallis, Vice President Business Development,
		 		 	General Counsel
		 	Fax:	 	(919) 493-5925

 Any party hereto may change the address to which notices to such party are to be sent by giving notice to the
other party at the address and in the manner provided above. Any notice may be given, in addition to the manner set forth above, by telex, facsimile or cable, provided that the party giving such notice obtains acknowledgment by telex, facsimile or
cable that such notice has been received by the party to be notified. Notices made in this manner shall be deemed to have been given when such acknowledgment has been transmitted. Any provision of this Section 20.12 to the contrary
notwithstanding, any notice to Bukwang shall be effective if given as to Bukwang prescribed above by Triangle, despite any failure to deliver copies as prescribed above. 
  

 50 

 IN WITNESS WHEREOF, Bukwang and Triangle have caused this Agreement to be signed by their duly authorized
representatives, under seal, as of the day and year indicated above. 
  

			
	BUKWANG PHARM. IND. CO., LTD.
		
	By:	 	/s/ Dong Yeon Kim
		
	Title:	 	  
	
	TRIANGLE PHARMACEUTICALS, INC.
		
	By:	 	/s/ David Barry
		
	Title:	 	Chairman and CEO

 [SIGNATURE PAGE FOR BUKWANG LICENSE AGREEMENT] 
  

 51 

 Exhibit A 
 Bukwang Chu&500.ELA 
 12/4/95 
 LICENSE AGREEMENT 
 between 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY, AND 
 BUKWANG PHARM IND. CO., LTD. 
  

 52 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 Exhibit B 
 [***] 
 Inventors [***] 
  

													
	 Docket Name
	  	 Country
	  	 Serial No.
	  	 Filing Date
	  	 Patent No.
	  	 Grant Date
	  	 
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	Div (1)	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	Div (2)	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	PCT	  		  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  	[***]	  	[***]	  	[***]	  		  		  	
		  		  	[***]	  	[***]	  		  		  	

  

 53 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 [***] 
 Inventors [***] 
  

											
	 Docket Name
	  	 Country
	  	 Serial No.
	  	 Filing Date
	  	 Patent No.
	  	 Grant Date

	[***]	  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	
		  	[***]	  	[***]	  	[***]	  		  	

  

 54 

 AMENDMENT NUMBER 3 
 to 
 LICENSE AGREEMENT 
 among 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY and 
 BUKWANG PHARM.
IND. CO., LTD. 
 [Please see Exhibit A, Amendment Number 3 page.] 
  

 55 

 Triangle 
 Pharmaceuticals

 July 5, 2003 
 Sung-Koo Lee 
 Executive Vice President 
 Bukwang Pharm
Co., Ltd. 
 398-1, Daebong-dong, Dongjak-gu 
 Yeoeuido

 PO Box 572 
 Seoul, Korea 
 Re: Termination Procedure 
 Dear Mr. Lee,

 I am writing to you in response to your letter dated June 12, 2003 to Dr. John Milligan. Gilead is fully prepared to comply with its obligations
under the License Agreement, particularly Article 13 and Section 15.4. Accordingly, we are preparing to deliver to you the items described in Appendix 1 to this letter. 
 We expect to be able to deliver these items to you by August 2, 2003 unless otherwise noted. To the extent that any items that we are obligated to deliver to you are inadvertently omitted, Gilead will use
reasonable efforts to transfer to Bukwang any such items within 30 days of learning of such omission. 
 Responses to some of your specific requests are set
out below: 
  

	1.	Details for the acquisition of clevudine synthetic intermediate, drug substance and drug product, coordination of shipment of materials and information regarding the manufacturing
process and cost to Bukwang will be coordinated by Bernhard Lampert of Gilead. 

  

	2.	Appendix 2 sets forth ongoing and planned activities for clevudine development and Gilead’s plans for fulfilling its obligations to Bukwang with respect to these activities.
Appendix 2 also indicates costs that Bukwang would need to assume to take over indicated activities or materials. Gilead will not assign agreements to Bukwang; Bukwang will be free to contact third parties to establish agreements with them.

  

	3.	Gilead will continue clinical studies L-FMAU-102B and FTCB-204 until the last randomized patient completes each study under Gilead’s regulatory filings.

  

	4.	Gilead will pay all invoices related to development activities under the Agreement that were addressed to Gilead or Triangle prior to June 12, 2003, provided that Bukwang will
be responsible for the reimbursement to Gilead for all invoices received after June 12, 2003 and paid by Gilead. 

  

 56 

	5.	Gilead will make the following individuals available for a period not to exceed 9 months to assist Bukwang in the transfer of knowledge regarding the clevudine development program
as conducted by Gilead under the Agreement for up to the amount of time indicated. There will be no cost for assistance provided before August 2, 2003. After such date, the costs and availability of Gilead personnel will be as follows:

 Cary Moxham – Overall Development, Clinical, and Regulatory – 40 hours at $92 per hour 
 Lars Trost – Toxicology – 10 hours at $92 per hour 
 Bob Blum – Clinical Pharmacology – 20 hours at $92 per hour 
 Bernhard Lampert – Manufacturing
– 20 hours at $92 per hour 
 Gilead expects that Bukwang recognizes that Gilead employees will be reasonably available, but will not be
expected to devote an unreasonable proportion of any individual’s time to such activities and that no individual’s ongoing responsibilities at Gilead will be unduly interfered with by such activities. Gilead also expects that Gilead’s
support role shall diminish over time. 
  

	6.	The majority of patents and the case files for those patents belong to UGARF and Yale. Please discuss obtaining copies of the case files with UGARF and Yale and their respective
Patents Counsels. Appendix 3 lists the patents that belong to Triangle/Gilead. The inclusion of this list does not imply a license of any kind. 

  

	7.	All communication regarding the termination procedure should be directed to Cary Moxham in writing. 

 Please feel free to contact me should you have any questions. 
  

	
	 Sincerely,

	
	 /s/ [illegible]

  

	cc.	John Milligan 

	 	Jung Choi 

	 	Rachel Mandell 

  

 57 

 Appendix 1 
  

	1.	Toxicology 

  

	 	•	 	 An inventory of archived tissues and samples for each of the completed toxicology studies is included in the final study report for each study. Transfer of the
storage of these samples to Bukwang needs to be discussed. 

  

	 	•	 	 Additional samples located at Triangle include: 

  

	 	•	 	 Thirty-two wet tissues to Trump’s fixative for electron microscopy from study TOX045 from Week 119 (one female sacrificed moribund) and from Week 148 (3
females and 4 males, control and high dose). There are 4 tissues from each animal - heart, kidney, liver, and skeletal muscle. 

  

	 	•	 	 Photomicrographs of liver, heart, and skeletal muscle and negatives of same; lepon blocks; glass slides; and 44 vials of heart, muscle, kidney, and liver (in
formalin) from the woodchuck study 98-11-A conducted by Cornell. The 44 vials contain huge chunks of issue that would not have fixed well and were removed from dead animals, and therefore may have been subject to significant autolysis.

  

	 	•	 	 Another set of positives (slides) and photographs taken during examination by light microscopy of skeletal muscle (myopathy) from selected monkeys from study
TOX045. 

  

	2.	Pharmaceutical Development 

  

	 	•	 	 All results for clevudine drug substance and drug product will be provided. 

  

	 	•	 	 Excess CTM held by Triangle includes the following. 

  

	 	•	 	 13,580 5 mg clevudine capsules 

  

	 	•	 	 269 bottles of 50 mg clevudine capsules (30 per bottle) 

  

	 	•	 	 40 bottles of 50 mg clevudine capsules labeled for study CLV-202. 

  

	 	•	 	 293 bottles of placebo capsules (30 per bottle) 

 The acquisition cost of this material is [BUCKWANG REDACTED] 
  

	 	•	 	 A total of 41 kg of clevudine drug substance is available. The acquisition cost of this material is [BUCKWANG REDACTED]. 

  

	 	•	 	 TSIBR intermediate to synthesize clevudine drug substance is available. The acquisition cost of this material needs to be determined. 

 

	 	•	 	 A complete inventory of all analytical methods is being prepared. 

  

 58 

	3.	Bioanalytical 

  

	 	•	 	 The current inventory of bioanalytical documents includes: 

 Bioanalytical Methods 
 Doc #3982 Determination of TP-0239/97 in Mouse Rat and Monkey Plasma by
HPLC/UV 
 Doc #7488 Determination of TP-0239 (L-FMAU) in Human Plasma Using LC/MS/MS 
 Doc #8778 (Report #M-00-TP0239-01) Determination of Clevudine in Human Urine by LC/MS/MS with the Packard MultiPROBE II 
 Doc #13811 (Report #M-02-BIO-TP0239-01) Determination of Clevudine in Rabbit and Rat Plasma Using LC/MS/MS 
 Sample Analysis Reports 
 Doc
#3584-3596: Preclinical Analytical Report - L-FMAU Dosing Solution Assay Results for TOX-068 to TOX-071 
 Doc #5548: TOX-043: Determination
of TP-0239 Concentrations in Rat Plasma 
 Doc. #6263: TOX-100: TP-0239 Dosing Solution Assay Results 
 Doc #6266: WHV 98-11: Determination of TP-0239 Concentrations in Woodchuck Serum 
 Doc #6307: TOX-042: Preclinical Analytical Report: Determination of TP-0239 in Cynomolgus Monkey Plasma 
 Doc #6239: TOX-045: Determination of TP-0239 Concentrations in Cynomolgus Monkey Plasma 
 Doc #6250 TOX-046: Determination of TP-0239 Concentrations in Rat Plasma 
 Doc #6252 TOX-065: Determination of TP-0239 Concentrations in Cynomolgus Monkey Plasma 
 Doc #6261 TOX-066:
Determination of TP-0239 Concentrations in Rat Plasma 
 Doc #9062: L-FMAU-101: Determination of Clevudine Concentrations in Human Plasma and
Urine by LC/MS/MS 
 Doc #11058: (Report #CRO-S-01-BIO-TP0239-01) TOX-111 Determination of the Metabolic Profile of Clevudine in Rat Plasma,
Urine, and Feces (including Metabolite Identification) 
  

 59 

 Doc #11086: (Report #CRO-S-01-BIO-TP0239-02) TOX-112 Determination of the Metabolic Profile of Clevudine
in Monkey Plasma, Urine, and Feces (including Metabolite Identification) 
 Doc #13643: (Report #S-02-BIO-TP0239-01) CLV-104: Determination of
Emtricitabine and Clevudine Concentrations in Human Plasma by LC/MS/MS 
 Doc #13972: (Report #S-02-BIO-TP0239-02) CLV-104: Determination of
Emtricitabine and Clevudine Concentrations in Human Urine by LC/MS/MS 
 Doc #14565: (Report #S-02-BIO-TP0239-03) L-FMAU-102: Interim Report -
Determination of Clevudine Concentrations in Human Plasma by LC/MS/MS 
 Doc #14921: (Report #S-02-BIO-TP0239-04) TOX-130: Determination of
Clevudine Concentrations in Rat Plasma by LC/MS/MS 
 Doc #15095: (Report #S-03-BIO-IP0239-01) TOX-143: Determination of Clevudine
Concentrations in Mouse Plasma by LC/MS/MS 
 Doc #15452: (Report #S-03-BIO-TP0239-02) TOX-131: Determination of 15599 Clevudine
Concentrations in Rabbit Plasma by LC/MS/MS 
 Doc #15600: (Report #S-03-BIO-TP0239-03) L-FMAU-102B: Determination of Clevudine Concentrations
in Human Plasma by LC/MS/MS – DRAFT 
 Analytical Standard Specifications 
 S.008.08 - Clevudine Drug Substance 
 S.015.00
- LFMAU Capsules, 25 mg and 100 mg 
 S.026.02 - LFMAU Capsules, 50 mg and 150 mg 
 S.038.00 - Clevudine Capsules, 50 mg 
 S.039.00 - Clevudine Capsules, 10 mg 
 S.040.00 - Clevudine Capsules, 5 mg 
 S.042.00 - Placebo to Match Clevudine Capsules 
 Analytical Standard Testing Instructions 
 T.008.08 Clevudine Drug Substance 
 T.015.00 - LFMAU Capsules, 25 mg and 100 mg 
 T.026.02 - LFMAU Capsules, 50 mg and 150 mg 
 T.038.00 - Clevudine Capsules, 50 mg 
 T.039.01 - Clevudine Capsules, 10 mg 
 T.040.01 - Clevudine Capsules, 5 mg 
 T.042.00 - Placebo to Match Clevudine Capsules 
  

 60 

 Bioanalytical Method Validation Reports 
 Doc #6229 - Determination of TP-0239 in Mouse, Rat, and Monkey Plasma 
 Doc #9160 - Determination of TP-0239 in Human Plasma (Report No. V-00-TP0239-01) 
 Doc #9101 - Determination
of Clevudine in Human Urine (Report No. V-00-TP0239-02) 
 Doc #14893 - Determination of Clevudine in Rabbit, Rat, and Mouse Plasma (Report
No. V-02-BIO-TP0239-01) 
 Bioanalytical Research Reports 
 Doc #9962 - Determination of D-FMAU Plasma Concentrations in Support of Protocol FMAU-101 (Report No. R-00-BIO-TP0268-01) 
 Doc #11457 - Determination of D-FMAU Human Urine Concentrations in Support of Protocol FMAU 101 (Report No. R-01-BIO-TO0268-01) 
 Doc #11747 - Determination of D-FMAU Feces Concentrations in Support of Protocol TTAQ-107 (Report No. R-01-BIO-TP0268-02) 
 Certificates of Analysis, Drug Substance 
 Doc #6404, Clevudine Drug Substance,TP-0239-99041 
 Doc #7481, Internal Standard for L-FMAU,TP-0321-99117

 Doc #8810, Clevudine Primary Reference Standard,TP-0239-99041 
 Doc #9273, 14C- Radiolabeled Drug Substance,TP-0239-00118 
 Doc #1039, Synthetic Intermediate of Clevudine,
Route 1,TP-0345-00199 
 Doc #13685, Clevudine Drug Substance,TP-0239-01100 
 Certificates of Analysis, Drug Product: 
 Doc #13013, Clevudine Capsules, 10 mg,TP-0239-01116 
 Doc #13014, Clevudine Capsules, 50 mg,TP-0239-01117

 Doc #13015, Clevudine Capsules, 5 mg, GMP,TP-0239-01115 
 Doc #13019, Placebo to Match Clevudine Capsules, 5,10, and 50 mg,TP-0286-01114 
  

	 	•	 	 The current inventory of pharmacokinetic samples includes. 

 Clinical * 
  

			
	L-FMAU-101	  	1296 samples
	L-FMAU-102	  	1176 samples
	L-FMAU-102B	  	2004 samples
	L-FMAU-104	  	1584 samples

  

	*	Please be advised that due to the language within each study-specific Informed Consent Form addressing sample storage and/or confidentiality, these samples must remain under the
control of Gilead and can not be transferred to Bukwang. 

  

 61 

 Toxicology/Preclinical 
  

			
	NIH study	  	151 samples
	Duck study	  	38 samples
	TOX 042	  	144 samples
	TOX 043	  	200 samples
	TOX 045	  	1311 samples
	TOX 046	  	790 samples
	TOX 065	  	124 samples
	TOX 066	  	90 samples
	TOX 111	  	191 samples
	TOX 112	  	183 samples
	TOX 130	  	88 samples
	TOX 131	  	91 samples
	TOX 143	  	215 samples

  

	4.	Clinical Pharmacology 

  

	 	•	 	 PharmacoKinetic analysis of samples from L-FMAU-102B will be completed by July 31, 2003. 

 Pharmacokinetic analysis of samples from the pharmacokinetic substudy in FTCB-204 will be completed in August 2003. 
  

 62 

 Appendix 2 
 Ongoing or Planned Activities for Clevudine Development in HBV 
  

	1.	Preclinical Virology 

  

	 	 •
	 	 Synthesis of radiolabeled clevudine triphosphate (CLV-TP). A total of 1 mCi of 14[C]-CLV-TP is being synthesized. The material can be used for studies regarding mechanism of action, incorporation into HBV DNA, and metabolism of
clevudine. The material was synthesized at a cost of $15,000. 

  

	 	•	 	 Gilead had been approached by the NIH to have all of its compounds, at the time including clevudine, tested against the SARS virus. Gilead would agree to provide
Bukwang the results of the testing as soon as they are available. Alternatively, Gilead can supply Bukwang with the contact details of the people doing the testing to negotiate its own arrangements. Allowing Gilead to proceed on behalf of Bukwang
would expedite the testing of clevudine. 

  

	 	•	 	 A study to examine the activity of clevudine in a chimeric mouse model of HBV is ongoing. There is no cost associated with this study. This study also includes FTC
and therefore the responsibility for this study will reside with Triangle and will not be transferred to Bukwang. 

  

	 	•	 	 A study to examine the pharmacokinetics of clevudine in woodchucks was scheduled to begin shortly at North Carolina State University. The details of this study were
discussed at the April 25 Joint Project Committee Meeting. This study will be cancelled. 

  

	2.	Toxicology 

  

	 	•	 	 The draft report for TOX142 “A Study of the Effects of Orally Administered TP-0239 on Pre- and Postnatal Development, Including Maternal Function, in the
Rat” is due Sept. 23, 2003. The date for delivery of the final report is targeted for November 1, 2003. 

  

	3.	Pharmaceutical Development 

  

	 	•	 	 Stability studies for drug product, 10 mg capsules and placebo, are ongoing at Triangle. This study will continue at Triangle in support of study FTCB-204 and will
not be transferred to Bukwang. Results will be provided to Bukwang as they become available. 

  

	 	•	 	 A campaign to produce additional CTM at Patheon in August has been cancelled. 

  

	4.	Clinical Virology and Diagnostics 

  

	 	•	 	 Genotype analysis of samples from L-FMAU-102 are complete and will be included with the final clinical data from this study. 

  

 63 

	 	•	 	 Genotype analyses of samples from L-FMAU-102B and FTCB-204 are ongoing and will continue through completion of the studies. Results will be provided with the final
data from these studies. 

  

	 	•	 	 The current inventory of serum samples includes: 

  

			
	L-FMAU-102	  	1561 samples
	L-FMAU-102B	  	2021 samples

  

	*	Please be advised that due to the language within each study-specific Informed Consent Form addressing sample storage and/or confidentiality, these samples must remain under the
control of Gilead and can not be transferred to Bukwang. 

  

	5.	Clinical Research 

  

	 	•	 	 Preparation of the final clinical study report for L-FMAU-102 is ongoing and is expected to be complete in March 2004. 

  

	 	•	 	 Study L-FMAU-102B will continue until the last patient completes the study (currently targeted for Nov. 23, 2003). The final database lock is scheduled for
December 31, 2003. The final data from this study will be provided. 

  

	 	•	 	 Study FTCB-204 will continue until the last patient completes the study (currently targeted for June 2004). The final database lock is scheduled for July 22,
2004. The final data from this study will be provided. 

  

	 	•	 	 All activities for study CLV-202 are being terminated. 

  

	 	•	 	 The regulatory process for study CLV-205 in Turkey is ongoing. The possibility to transfer this filing to Bukwang to be discussed. 

  

	6.	Drug Safety Surveillance 

  

	 	•	 	 The process for exchange of safety information for clevudine between Triangle and Bukwang will continue as per the Safety Agreement. Bukwang will ensure that future
collaborators also report to Gilead per the Safety Agreement until the end of Study FTCB 204. 

  

	7.	Regulatory Affairs 

  

	 	•	 	 Regulatory filings for clevudine will remain open to support ongoing studies L-FMAU-102B and FTCB-204. As sites within a given country for either study are closed,
regulatory filings will be inactivated as soon as possible after the last patient completes the study. Dates when the last patient will complete a study each country are indicated below. 

  

 64 

 France – last patient complete L-FMAU-102B on 20-Oct-2003 Hong Kong – last patient completes
L-FMAU-102B on 13-Nov-2003 Czech Republic – last patient completes FTCB-204 on 17-Mar-2004 Bulgaria – last patient completes FTCB-204 on 24-Mar-2004 US – last patient completes FTCB-204 on 14-May-2004 Canada – last patient
completes FTCB-204 on 31-May-2004 Singapore – last patient completes FTCB-204 on 31-May-2004 
  

	8.	Publications 

  

	 	•	 	 An oral presentation of the results from study L-FMAU-102 is scheduled for July 5, 2003 at the EASL meeting in Geneva, Switzerland. Dr. George Lau is
scheduled to present. 

  

	 	•	 	 A manuscript describing the results of study L-FMAU-102 was submitted to Hepatology. 

  

	 	•	 	 A manuscript is being prepared for submission to AAC by Dr. Zoulim regarding his work on combination therapy with clevudine and FTC in WHV-infected woodchucks.

  

	 	•	 	 The results of study L-FMAU-102B will be published by Gilead and the Investigators shortly after completion of the study. 

  

 65 

 Appendix 3 
  

 66 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 [***] 
 [***] 

 

													
	Docket No.	  	Country	 	MATTER
NUMBER	 	SERIAL
NUMBER	 	PATENT
NUMBER	  	FILE DATE	 	STATUS
	[***]	  	[***]	 	[***]	 	[***]	 		  	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 		  	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 		  	[***]	 	[***]

 [***] 
 [***]

  

													
	Docket No.	  	Country	 	MATTER
NUMBER	 	SERIAL
NUMBER	 	PATENT
NUMBER	  	FILE DATE	 	STATUS
	[***]	  	[***]	 	[***]	 	[***]	 		  	[***]	 	[***]

  

 67 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 EXHIBIT C 
 LIST OF BUKWANG PATENTS 
 C-1. [***] 
 Inventors: [***] 
 Applicant: [***] 
  

													
	CASE	  	COUNTRY	 	SERIAL
NUMBER	 	REGISTRATION
NUMBER	 	MATTER
NUMBER	 	File Date	 	Status
	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 		 		 	[***]	 		 	
		  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

 C-1 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

													
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

 C-1 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 C-2. [***] 
 Inventors: [***] 
 Applicant: [***] 
  

													
	CASE	  	COUNTRY	 	SERIAL
NUMBER	 	REGISTRATION
NUMBER	 	MATTER
NUMBER	 	File Date	 	Status
	[***]	  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]

  

 C-2 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 C-3. [***] 
 ([***]) 
 Inventor: [***] 
 Applicant: [***] 
  

									
	Docket Name	  	Country	 	Serial No.	 	File Date	 	Patent No.
	[***]	  	[***]	 	[***]	 	[***]	 	
	[***]	  	[***]	 	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]	 	
	[***]	  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	

  

 C-3 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 C-4. [***] ([***]) 
 Inventor: [***] 
 Applicant: [***] 
  

									
	Docket Name	  	Country	 	Serial No.	 	File Date	 	Patent No.
	[***]	  	[***]	 	[***]	 	[***]	 	
		  	[***]	 	[***]	 	[***]	 	
		  	[***]	 		 		 	
		  	[***]	 	[***]	 	[***]	 	

  

 C-4 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 EXHIBIT D 
 LIST OF PHARMASSET PATENTS 
 [***] 
  

 D-1 

 EXHIBIT E 
 TERRITORY 
  

	
	 Albania

	 Andorra

	 Anguilla

	 Antigua & Barbuda

	 Argentina

	 Aruba

	 Austria

	 Bahamas

	 Barbados

	 Belarus

	 Belgium

	 Belize

	 Bermuda

	 Bolivia

	 Bosnia and Herzegovina

	 Brazil

	 British Virgin Islands

	 Bulgaria

	 Canada

	 Cayman Islands

	 Chile

	 Colombia

	 Costa Rica

	 Croatia

	 Cuba

	 Cyprus

	 Czech Republic

	 Denmark

	 Dominica

	 Dominican Republic

	 Ecuador

	 El Salvador

	 Estonia

	 Falkland Islands

	 Faroe Islands

	 Finland

	 France

	 French Guiana

	 Germany

	 Gibraltar

	 Greece

	 Greenland

	 Grenada

	 Guadeloupe

	 Guatemala

	 Guyana

	 Haiti

	 Honduras

	 Hungary

	 Iceland

	 Ireland

	 Israel

	 Italy

	 Jamaica

	 Latvia

	 Liechtenstein

	 Lithuania

	 Luxembourg

	 Macedonia

	 Malta

	 Martinique

	 Mexico

	 Moldova

	 Monaco

	 Montserrat

	 Navassa Island

	 Netherlands

	 Netherlands Antilles

	 Nicaragua

	 Norway

	 Panama

	 Paraguay

	 Peru

	 Poland

	 Portugal

	 Puerto Rico

	 Romania

	 Russia

	 San Marino

	 Serbia and Montenegro

	 Slovakia

	 Slovenia

	 Spain

	 St. Thomas

	 St. Helena

	 St. John’s

	 St. Kitts and Nevis

	 St. Lucia

	 St. Vincent and the Grenadines

	 Suriname

	 Sweden

	 Switzerland

	 Trinidad & Tobago

	 Turkey

	 Turks & Caicos

	 Ukraine

	 United Kingdom

	 United States of America

	 Uruguay

	 Vatican City

	 Venezuela

	 Virgin Islands

  

 E-1 

 EXHIBIT F 
 FORM OF LETTER TO FDA 
 Bukwang Pharm. Co., Ltd. IND Transfer Information and Forms 

                    ,
200     
 [Name, Title] 
 [Division] 
 Food and Drug Administration 
 [Address] 
  

					
	Subject:	  	IND [number]	  	General Correspondence:
		  	[product]®	  	Transfer of IND
		  		  	Serial No. XXX

 Dear
                    : 
 The
purpose of this correspondence is to inform you that effective                     , 200    , Bukwang Pharm. Co.,
Ltd. hereby transfers the sponsorship and all responsibilities of IND [number] ([name]®) to Pharmasset, Inc. [                     will no longer be the agent for the IND.] 
 Bukwang Pharm. Co., Ltd. and [agent] will provide Pharmasset, Inc. with the original IND and all records pertaining to it. Pharmasset, Inc. will assume
all administrative and reporting responsibilities of the [product]® IND from the date of transfer. 
 Future communications regarding this IND should be directed to: 

[Employee] 
 [Title] 
 Pharmasset, Inc. 
 [Address] 
 Phone:                      
 Fax:
                         
 If
you have any questions, please contact the undersigned at [telephone number]. 
 Sincerely, 
 [Name] 
 [Title] 
 [Company]

 [Address] 
 [cc:
                    , FDA Project Manager] 
  

 F-1 

 EXHIBIT G 
 BUKWANG LICENSEES 

 EXHIBIT G 
 BUKWANG LICENSEES 
 LICENSE AGREEMENT BETWEEN 
 BUKWANG PHARM. CO., LTD. AND EISAI CO., LTD. 

 LICENSE AGREEMENT 
 BETWEEN 
 BUKWANG PHARM. CO., LTD. 
 AND 
 EISAI CO., LTD. 
  

 1 

 TABLE OF CONTENTS 
  

					
	ARTICLE 1.	 	DEFINITIONS	  	3
			
	ARTICLE 2.	 	LICENSES	  	8
			
	ARTICLE 3.	 	LICENSE FEE, ROYALTIES, AND MILESTONE PAYMENT	  	10
			
	ARTICLE 4.	 	REPORT AND ACCOUNTING	  	16
			
	ARTICLE 5.	 	PAYMENTS	  	19
			
	ARTICLE 6.	 	DEVELOPMENT PROGRAM	  	20
			
	ARTICLE 7.	 	JOINT PROJECT COMMITTEE	  	22
			
	ARTICLE 8.	 	TRANSFER OF KNOW-HOW; TECHNICAL ASSISTANCE	  	25
			
	ARTICLE 9.	 	SUPPLY OF BULK DRUG SUBSTANCE, BULK FORMULATION AND FINISHED GOODS	  	26
			
	ARTICLE 10.	 	SAFETY INFORMATION EXCHANGE	  	27
			
	ARTICLE 11.	 	PATENT PROSECUTION	  	28
			
	ARTICLE 12.	 	INFRINGEMENT	  	31
			
	ARTICLE 13.	 	WARRANTIES AND REPRESENTATIONS; LIMITATION OF LIABILITY; AND DISCLAIMERS	  	34
			
	ARTICLE 14.	 	INDEMNIFICATION	  	37
			
	ARTICLE 15.	 	CONFIDENTIALITY	  	39
			
	ARTICLE 16.	 	TERM AND TERMINATION	  	41
			
	ARTICLE 17.	 	ASSIGNMENT	  	44
			
	ARTICLE 18.	 	REGISTRATION OF LICENSE	  	45
			
	ARTICLE 19.	 	DISPUTE RESOLUTION AND ARBITRATION	  	45
			
	ARTICLE 20.	 	GENERAL PROVISIONS	  	47

  

 2 

 THIS LICENSE AGREEMENT is made and entered into as
of this Oct 29th, 2004, by and between BUKWANG PHARM. CO., LTD., with its principal offices at 398-1,
Daebang-Dong, Dongjak-Ku, Seoul 156-020, Korea (hereinafter referred to as “Bukwang”), and EISAI CO., LTD., with principal offices located at 6-10, Koishikawa 4 chome, Bunkyo-ku, Tokyo JAPAN 112-8088 (hereinafter referred to as
“Eisai”). 
 WITNESSETH: 
 WHEREAS, Bukwang has evidenced the in vitro, and in vivo activity of an L-nucleoside compound known generically as “L-FMAU”; 
 WHEREAS, L-FAMU is covered by patents and patent applications filed in various countries; 
 WHEREAS, Bukwang, has entered into a license agreement, dated December 28, 1995, as amended effective September 1, 1997, December 1,
1997, February 27, 1998 and July 15, 2001 (collectively the “Primary License Agreement”) with Yale University (“Yale”) and University of Georgia Research Foundation, Inc. (“UGARF”; Yale and UGARF are
hereinafter referred to as the “Primary Licensors”), a copy of which Primary License Agreement and Amendments are attached hereto as Exhibit A, pursuant to which Bukwang has obtained an exclusive worldwide license under the
Primary Licensors’ patents and patent applications and has acquired the right to grant licenses under such patents and patent applications; 
 WHEREAS, Bukwang possesses certain technology and know-how relating to L-FMAU and has the right to grant licenses in respect of such technology and know-how; and 
 WHEREAS, Eisai desires to obtain an exclusive license under such patents, patent applications, technology and know-how; 
 NOW, THEREFORE, in consideration of the premises and the covenants herein contained, the parties agree as follows: 
 ARTICLE 1. DEFINITIONS 
 The following terms as used herein, when written with an initial capital letter, shall have
the meanings ascribed to them below: 
  

 3 

 1.1 “Acquisition Cost” shall mean the actual invoiced price paid by a party to any
non-Affiliate third party for acquiring any item (e.g., a Compound or other active ingredient), including but not limited to, shipping and handling costs and customs duties incurred and paid by such party in connection with the acquisition of such
item. 
 1.2 “Affiliate” shall mean any corporation or non-corporate business entity which controls, is controlled by, or is under
common control with a party to this Agreement. A corporation or non-corporate business entity shall be regarded as in control of another corporation if it owns, or directly or indirectly controls, at least fifty (50%) percent of the voting
stock of the other corporation, or (a) in the absence of the ownership of at least fifty (50%) percent of the voting stock of a corporation or (b) in the case of a non-corporate business entity, or non-profit corporation, if it
possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such corporation or non-corporate business entity, as applicable. 
 1.3 “Agreement” shall mean this Agreement, including all Exhibits attached to this Agreement. 
 1.4 “Bukwang Know-How” shall mean all inventions, discoveries, trade secrets, information, experience, data, formulas, procedures and results
which are useful for the development, manufacturing and registration of the Compounds or the Licensed Products which are rightfully held by Bukwang as of the Effective Date (including, but not limited to, any of the foregoing items licensed to
Bukwang under the Primary License Agreement), or which are developed or acquired by Bukwang during the Term of this Agreement pursuant to Article 14 including, but not limited to, all manufacturing and synthesis know-how. 
 1.5 “Bukwang Patents” shall mean all patents and patent applications in the Territory having patent claims to which are useful for the
development, registration, manufacturing, using or selling of the Compounds or Licensed Products, which are owned or controlled by Bukwang as of the Effective Date, or which are developed or acquired by Bukwang during the Term of this Agreement,
including any addition, continuation, continuation-in-part or division thereof or any substitute application thereof; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and

  

 4 

 
any confirmation patent or registration patent or patent of addition based on any such patent; and foreign patent or inventor’s certificate with regard
thereto. Bukwang Patents shall include those listed in Exhibit B attached hereto. 
 1.6 “Bulk Drug Substance”
shall mean the Compounds in bulk form which, if appropriately formulated and finished, would be suitable for preclinical or clinical use or commercial use. 
 1.7 “Bulk Formulation” shall mean the Licensed Product in capsule form or tablet form. 
 1.8
“Closing Date” shall mean the completion date for study of drug-drug interaction for the Compound by Eisai, and shall be no later than November 15, 2004. 
 1.9 “Compounds” shall mean the compound known as L-FMAU, with the chemical name 2’-fluoro-5-methyl-ß-L-arabinofuranosyluracil, including any salts and esters thereof. 
 1.10 “Development Program” shall mean the research and development program described in Article 6 of this Agreement. 
 1.11 “Dollars” shall mean United States dollars. 
 1.12 “Effective Date” shall mean the date written above. 
 1.13 “FDA” shall mean the
United States Food and Drug Administration or any successor entity. 
 1.14 “Field” shall mean all human antiviral applications and
uses. 
 1.15 “Filing of Chinese Regulatory Application” shall mean a filing of regulatory approval application with Chinese
regulatory authority, which includes clinical data in China. 
 1.16 “Finished Product” shall mean Licensed Product in packaged
product form suitable for distribution to customers. 
  

 5 

 1.17 “HBV” shall mean hepatitis B virus. 
 1.18 “IND” shall mean an Investigational New Drug Application or its domestic equivalent. 
 1.19 “Indemnitees” shall mean (a) in the case of the indemnity set forth in Section 14.1, Bukwang, its Affiliates, the Primary
Licensors and the directors, officers and employees of any of the foregoing; (b) in the case of the indemnity set forth in Section 12.2, Eisai, its Affiliates and sublicensees, and their directors, officers and employees; and (c) in
the case of the Indemnitees referenced in Section 12.3, the parties identified in Subsections 1.16(a) and 1.16(b) above, as applicable. 
 1.20 “Joint Inventions” shall mean any inventions related to the Compounds or the Licensed Products, whether patented or not, which are jointly made during the Term of this Agreement by at least one (1) Bukwang employee or
person contractually required to assign or license patent rights covering such inventions to Bukwang and at least one (1) Eisai employee or person contractually required to assign or license patent rights covering such inventions to Eisai. All
joint inventions shall be owned jointly by the parties hereto. Joint Inventions owned by Bukwang shall be deemed as Bukwang Know-How. 
 1.21
“Joint Know-How” shall mean all inventions, discoveries, trade secrets, information, data, formulas, procedures and results which are useful for the development, registration, manufacturing, using or selling of the Compounds or the
Licensed Products which are developed jointly by at least one (1) Bukwang employee or person contractually required to assign or license such data and know-how to Bukwang and at least one (1) Eisai employee or person contractually required
to assign or license such data or know-how to Eisai during the Term of this Agreement. All Joint Know-How shall be owned jointly by the parties hereto. Joint Know-How owned by Bukwang shall be deemed as Bukwang Know-How. 
 1.22 “Joint Project Committee” shall mean the committee described in Article 7 hereof. 
  

 6 

 1.23 “Licensed Product(s)” shall mean any Compound or any pharmaceutical product containing one
or more Compounds as an active ingredient, alone or in combination with other active ingredients. 
 1.24 “Manufacturing Cost,” in
respect of a particular item (e.g., a Compound or other active ingredient), shall mean the costs of direct labor (including allocable employee benefits and employment taxes), direct material, direct energy, direct utilities and other charges
incurred directly by a party in the manufacture by it of such item and, normal production overhead (i.e., indirect labor, utilities, maintenance, depreciation of the manufacturing equipment and facilities and other allocable overhead of the
manufacturing facility), all determined in accordance with GAAP. 
 1.25 “NDA” shall mean a New Drug Application or its domestic
equivalent. 
 1.26 “Net Sales” of Licensed Products which contain as their active ingredient Compounds shall mean the gross sales
of such Licensed Products billed by Eisai, its Affiliates or sublicensees to independent customers including any consideration received, directly or indirectly, from such customers in respect of the sale, distribution or transfer of Licensed
Products, less normal and customary trade, quantity and cash discounts, all allowances and rebates (including those paid to third party payors), sales, use, V.A.T. or other similar taxes, and all transportation, insurance and handling charges.

 1.27 “Registration” shall mean, in relation to any Licensed Product, such approvals by the regulatory authorities in a given
country. 
 1.29 “Term” shall mean the Patent and Know-How Royalty Period set forth in Section 3.3(b). 
 1.30 “Territory” shall mean Japan, China, Taiwan, Indonesia, Singapore, Thailand, Vietnam, Malaysia, Philippines and India. 
 1.31 “Eisai Know-How” shall mean all inventions, discoveries, trade secrets, information, experience, data, formulas, procedures and results
arising solely out of the Development Program or the manufacture, use or sale of the Licensed Products which are useful 

  

 7 

 
for development, registration manufacturing, using or selling of the Compounds or the Licensed Products which are rightfully held by Eisai as of the
Effective Date, or Which are not Joint Know-How or Joint Inventions and are developed or acquired by Eisai during the period beginning on the Effective Date and ending upon termination or expiration of this Agreement pursuant to Article 14.

 1.32 “Eisai Patents” shall mean all patents and patent applications owned or controlled by Eisai or under which Eisai has a
right to practice with the right to extend such right to practice to Bukwang which contain claims the rights to which are useful for the development, registration, manufacturing, using or selling of the Compounds or the Licensed Products, including
any addition, continuation, continuation-in-part or division thereof or any substitute application thereof; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any
confirmation patent or registration patent or patent of addition based on any such patent; and any other foreign patent in the Territory or inventor’s certificate with regard thereto. 
 1.33 “GAAP” shall mean generally accepted accounting principles in the applicable countries in the Territory, consistently applied.

 1.34 “Valid Claim” shall mean issued or granted claims of any issued and unexpired patent included among the Bukwang Patents,
which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, which is unappealable or unappealed within the time allowed for appeal, which has not been rendered unenforceable
through disclaimer or otherwise or which has not been lost through an interference of opposition proceeding. 
 ARTICLE 2. LICENSES

 2.1 License Under Bukwang Patents and Bukwang Know-How. Subject to the terms and conditions set forth herein Bukwang hereby
grants Eisai the exclusive right and license to practice the Bukwang Patents and the Bukwang Know-How in the Field to develop, make, have made, use, import, export, offer for sale, sell and have sold Licensed Products (including, but not limited to,
Bulk Drug Substance) in the Territory during the term of this Agreement. 
  

 8 

 2.2 Extension to Affiliates. Eisai shall have the right to extend its rights under the license
granted in Section 2.1 and 2.2 to one or more of its Affiliates, as attached hereto as Exhibit C, within the Territory provided, that Eisai shall remain responsible for such Affiliate’s compliance with all obligations under
this Agreement which apply to such Affiliate. If Eisai intent to extend its rights under the license granted in Section 2.1 and 2.2 to Affiliates not described in Exhibit C Eisai shall: (a) give Bukwang at least thirty
(30) days’ prior written notice of such extension and (b) remain responsible for such Affiliate’s compliance with all obligations under this Agreement which apply to such Affiliate. 
 2.3 Sublicenses. Eisai may grant sublicenses to non-Affiliate third parties in the Territory without any consent; provided, however, that in the
event that Eisai proposes to grant a sublicense to a prospective non-Affiliate sublicensee [BUKWANG REDACTED], then Eisai must first obtain the prior consent of Bukwang, which consent shall not be unreasonably withheld or delayed. No sublicense
granted by Eisai shall relieve it of any obligation hereunder. With respect to any sublicense for which Bukwang’s consent is not required pursuant to the immediately preceding sentence, Eisai shall provide Bukwang with notice of its intention
to grant a sublicense at least fifteen (15) days prior to entering into the applicable sublicense agreement. Eisai shall promptly provide Bukwang with a copy of any executed sublicense agreement. 
 2.4 License Under Eisai Patents and Eisai Know-How. Eisai hereby grants Bukwang a non-exclusive right and license to practice the Eisai Patents
and Eisai Know-How to make, have made, use, import, offer for sale, sell and have sold Licensed Products, with a right to sublicense, with prior approval by Eisai which shall not be unreasonably withheld or delayed, outside the Territory during the
term of this Agreement. The license granted pursuant to this Section 2.4 shall be royalty free. 
 2.5 Covenant Not to Sue. Each
party granting a license agrees that during the term of this Agreement, neither it nor any of its Affiliates, will assert against the other party (a “licensed party”) or its Affiliates or sublicensees any patent not included in the Bukwang
Patents 

  

 9 

 
or Eisai Patents, as applicable, that is or might be infringed by reason of such licensed party’s or its Affiliates’ or sublicensees’ exercise
of the license granted to it hereunder. 
 2.6 Right of First Discussion. If, at any time during the term hereof, Bukwang
(a) acquires rights in respect of human uses or applications of L-FMAU outside the Field (a “Non-Field Use”) and (b) decides to license any rights relating to such Non-Field Use in the Territory, it shall give prompt notice
thereof to Eisai. Such notice shall include a description of the rights which Bukwang wishes to license, together with all data and information in Bukwang’s possession relating to the applicable Non-Field Use. Thereafter, Eisai shall have
ninety (90) days to notify Bukwang whether Eisai is interested in commencing negotiations to obtain a license to such rights (the “Non-Field License”). If Eisai does not give such notice within such ninety (90) day period,
Bukwang shall be entitled to commence negotiations with a third party in respect of the Non-Field-License and shall be free to license such rights of “the Non-Field License” to the third parties. 
 2.7 Retained License. Eisai acknowledges that, pursuant to paragraph 2.2 of the Primary License Agreement, the Primary Licensors have
retained on their behalf and on the behalf of any of their research collaborators a royalty-free right and license to make and use Licensed Products and to practice the Licensed Technology (as defined therein) for research and educational purposes
only. 
 2.8 No Implied License. The license and rights granted in this Agreement to Eisai shall not be construed to confer any rights
upon Eisai by implication, estoppel or otherwise as to any technology, know-how or any other intellectual property not specifically identified as Bukwang Patents or Bukwang Know-How. 
 ARTICLE 3. LICENSE FEE, ROYALTIES, AND MILESTONE PAYMENTS 
 3.1
Closing Fee. As partial consideration for entering into this Agreement, Eisai agrees to pay Bukwang a nonrefundable license fee of US [BUKWANG REDACTED] payable within [BUKWANG REDACTED] after the Closing Date. 
  

 10 

 3.2 Milestone Payments. 
 (a) Bukwang shall submit to Eisai a written report regarding the 303 study of the Product set forth in Exhibit D for Eisai’s
evaluation. Eisai shall complete the evaluation and inform Bukwang in writing of whether to keep this Agreement or not, within thirty (30) days of receipt of Bukwang’s report. In the event that Eisai inform Bukwang of its intent to keep
this Agreement, this Agreement will continue and Eisai shall pay Bukwang a milestone payment of [BUKWANG REDACTED] its written notice. In the event that Eisai informs Bukwang of its intent not to keep this Agreement, this Agreement will terminate
thereby without any consideration. 
 (b) Eisai shall pay Bukwang a milestone payment (“Milestone Payment”) in the amount specified
below no later than [BUKWANG REDACTED] after the occurrence of the corresponding event designated below (except as otherwise specified in Subsection 3.2(d)), unless Eisai has given Bukwang notice of termination of this Agreement in the entire
Territory prior to such due date. 
  

					
	   Milestone
	  	Milestone Payment	 
	 (i)     [BUKWANG REDACTED]
	  	US$	[BUKWANG REDACTED	]
	 (ii)    [BUKWANG REDACTED]
	  	US$	[BUKWANG REDACTED	]
	 (iii)  [BUKWANG REDACTED]
	  	US$	[BUKWANG REDACTED	]
	 (iv)   [BUKWANG REDACTED]
	  			
	          [BUKWANG REDACTED]
	  	US$	[BUKWANG REDACTED	]
	          [BUKWANG REDACTED]
	  	US$	[BUKWANG REDACTED	]

 (c) On [BUKWANG REDACTED] in cumulative Net Sales in China, a Marketing Milestone Payment of
[BUKWANG REDACTED] will be due. On [BUKWANG REDACTED] in cumulative Net Sales in China, a Marketing Milestone Payment of [BUKWANG REDACTED] will be due again, and on [BUKWANG REDACTED] in cumulative Net Sales in China, a Marketing Milestone Payment
of [BUKWANG REDACTED] will be due again , as reflected in clause (iv) of the Subsection 3.2(b). Upon payment of the final [BUKWANG REDACTED] in respect of the first [BUKWANG REDACTED] in cumulative Net Sales within China, the Marketing
Milestone Payment obligations will terminate. 
  

 11 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 Each Marketing Milestone Payment will be due at the same time the royalty report covering the royalty period in which
such incremental [BUKWANG REDACTED] in Net Sales is due. The above Sales Milestone payable up to the expiration date of Chinese product patent (Patent No. [***]), which is expected [BUKWANG REDACTED]. 
 (d) In the event Bukwang terminates this Agreement pursuant to Section 6.3 or 16.2 or Eisai terminates this Agreement with respect to the entire
Territory pursuant to Section 16.3, any Marketing Milestone Payment due pursuant to clause (iv) of Subsection 3.2(b) shall be prorated based on the amount of incremental Net Sales in China since the last Marketing Milestone Payment over
[BUKWANG REDACTED]. By way of example only, if Eisai terminates the Agreement in the entire Territory and, at the time of termination [BUKWANG REDACTED] in Net Sales in China had accrued since the last Marketing Milestone Payment became payable,
Eisai would owe Bukwang a final Marketing Milestone Payment of [BUKWANG REDACTED] (i.e., [BUKWANG REDACTED]). 
 3.3 Earned Royalties;
Duration and Payment Scheme. 
 (a) For the Bukwang Patents and Bukwang Know-How, Eisai shall pay Bukwang a royalty equal to [BUKWANG
REDACTED] of the Net Sales of Licensed Products sold in the Territory by Eisai and its Affiliates and sublicensees during the term of this Agreement. 
 (b) Royalties set forth in Section 3.3(a) shall be paid in respect of Licensed Products in a given country until the occurrence of the later of i) a period of [BUKWANG REDACTED] after the initial commercial
introduction of a Licensed Product in such country; or ii) the expiration, lapse or invalidation of the last remaining Valid Claims in a given country (“Patent and Know-How Royalty Period”). 
 (c) If at any time during the term of this Agreement, (i) a third party or third parties commence selling a therapeutic product in a country of the
Territory and (ii) such product contains any Compound (“unlicensed unit sales”) and (iii) such unlicensed unit sales for any 

  

 12 

 
royalty period amount to [BUKWANG REDACTED] and [BUKWANG REDACTED] of Eisai’s unit sales of such Licensed Product in such country in such royalty
period, determined in accordance with Subsection 3.3(d) below, then Eisai’s royalty obligation in such country with respect to such Licensed Product shall be reduced to [BUKWANG REDACTED] of the Net Sales of Licensed Products. iv) Such
unlicensed unit sales for any royalty period amount to more than [BUKWANG REDACTED] of Eisai’s unit sales of such licensed Product in such country in such royalty period, determined in accordance with subsection 3.3(d) below, then Eisai royalty
obligation in such country with such Licensed Product shall be reduced to [BUKWANG REDACTED] of the Net Sales of Licensed Product. 
 (d) For
purposes of this Section 3.3, (i) “unlicensed unit sales” and “Eisai’s unit sales” shall be deemed to mean the grams of Compounds contained in the third party product (irrespective of dosage form) or the Licensed
Product (irrespective of dosage form), respectively, as reflected on the label of each such unit; and (ii) unlicensed unit sales shall be determined by the sales reports of IMS or any successor to IMS or any other independent marketing auditing
firm selected by Eisai or its Affiliates or sublicensees and reasonably acceptable to Bukwang. If Eisai is entitled to a royalty reduction based on unlicensed unit sales pursuant to Subsection 3.3(c) for any royalty period, Eisai, its Affiliates or
sublicensees shall submit the sales report of IMS or such other independent firm, as applicable, for the relevant royalty period to Bukwang, together with Eisai’s, its Affiliates’ or sublicensees’ sales report for the relevant royalty
period. Such sales reports for each royalty period in which Eisai is entitled to such royalty reduction shall be submitted with the royalty report for such royalty period submitted pursuant to Section 4.1. 
 (e) With respect to determination of trademark to be used for the Licensed Product, the following procedures will apply: 
 (i) Bukwang shall disclose to Eisai a list of candidates of trademark to be used by Eisai for the Licensed Product in the Territory. 
 (ii) Eisai may determine whether to use trademark selected by Bukwang in accordance with the preceding sentence or Eisai’s own trademark.

  

 13 

 (iii) In the event that Eisai decides to use Eisai’s own trademark for the Licensed Product in the
Territory, Eisai shall assign Bukwang the trademark, which constitutes “Assigned Bukwang Trademark” thereafter. 
 (f) In the event
Eisai determines to use Assigned Bukwang Trademark, Bukwang shall grant Eisai an exclusive license to use Assigned Bukwang Trademark in the Territory during the term of this Agreement. In consideration of the exclusive license to. Assigned Bukwang
Trademark, Eisai shall pay Bukwang a royalty equal to [BUKWANG REDACTED] of the Net Sales of Licensed Products sold in the Territory by Eisai, its Affiliates and sublicensees during the term of this Agreement. It is agreed and acknowledged that
Bukwang shall, at its own cost and expense, transfer back Assigned Bukwang Trademark to Eisai immediately after the termination of the Agreement without any compensation. 
 (g) In the event that Eisai determines to use Bukwang Trademark, Bukwang shall grant Eisai an exclusive license to use Bukwang Trademark in the Territory during the term of this Agreement. In consideration of the
exclusive license to Bukwang Trademark, Eisai shall pay Bukwang a royalty equal to [BUKWANG REDACTED] of the Net Sales of Licensed Products sold in the Territory by Eisai, its Affiliates and sublicensees during the term of this Agreement. In this
case, Eisai shall continue to use Bukwang Trademark for the Licensed Product after the termination of this Agreement. In consideration of Eisai’s right to use Bukwang Trademark after the termination of this Agreement, Eisai shall pay Bukwang a
royalty equal to [BUKWANG REDACTED] of the Net Sales of Licensed Products sold in the Territory by Eisai, its Affiliates and sublicensees during the term beginning with the termination date of the Agreement and ending with the [BUKWANG REDACTED]
date thereof. After the [BUKWANG REDACTED] date, the exclusive license to Bukwang Trademark for the Licensed Product in the Territory shall become a fully paid-up, perpetual exclusive license to Eisai in the Territory. 
 3.4 Annual Minimum Royalties. In the event that, from the third full Eisai’s fiscal year ending March 31 (“Fiscal Year”)
following the year during which the Licensed Product for an HBV indication is launched in China or any Fiscal Year thereafter for the eighth full Fiscal Year, Eisai’s total annual royalty payments to Bukwang pursuant to Section 3.3 above

  

 14 

 
are less than the annual minimum amount set forth opposite such Fiscal Year below (the “Annual Minimum”), Eisai shall make a payment to Bukwang
together with the royalty report for the latter half of such Fiscal Year required in Section 4.1 of this Agreement and the difference between such Annual Minimum and the royalties paid to Bukwang for the preceding year pursuant to
Section 3.3 above. 
  

			
	 Fiscal Year
	  	 Annual Minimum

	 [BUKWANG REDACTED]
	  	$ [BUKWANG REDACTED]
	 [BUKWANG REDACTED]
	  	$ [BUKWANG REDACTED]
	 [BUKWANG REDACTED]
	  	$ [BUKWANG REDACTED]

 However, Eisai shall have no obligation to pay such annual minimum royalties after the expiration, lapse or
invalidation of Chinese product patent (Patent No. 1143966). 
 3.5 Accrual of Royalties. No royalty shall be payable on a Licensed
Product made, sold, or used for tests or development purposes, or distributed as samples. No royalties shall be payable on sales among Eisai, its Affiliates and sublicensees, but royalties shall be payable on subsequent sales by Eisai, its
Affiliates or sublicensees to a third party. No multiple royalty shall be payable because the manufacture, use, offer for sale, sale or import of a Licensed Product is covered by more than one Valid Claim or by at least one Valid Claim, the Bukwang
Know-How. 
 3.6 Withholding Tax. Any income or other tax, duties, and other levies (if any) applied by a government of any country in
the Territory, which Eisai, its Affiliates and sublicensees is required to pay or withhold on behalf of Bukwang with respect to payments as described in Article 3 of this Agreement payable to Bukwang shall be deducted from the amount of such
payments otherwise due, provided, however, that in regard to any such deduction Eisai, its Affiliates and sublicensees shall give Bukwang such assistance as may reasonably be necessary to enable or assist Bukwang to claim exemption therefrom and
shall upon request give Bukwang proper evidence from time to time as to the payment of the tax. 
 3.7 Third Party Royalties. If
Eisai, its Affiliates or sublicensees determine, after consultation with Bukwang, but at Eisai’s sole discretion, that it or they may be required to pay royalties and other amounts to any third party because the manufacture, use, offer for
sale, 

 15 

 
sale or importation of a Licensed Product infringes or may infringe any patent or other intellectual property rights of such third party in one or more
countries (collectively, the “Third Party Royalties”), Eisai, its Affiliates or sublicensees may deduct the Third Party Royalties it or they pay to such third party from earned royalties and Milestone Payments thereafter due to Bukwang.
Eisai may credit [BUKWANG REDACTED] of any Third Party Royalties up to [BUKWANG REDACTED] of Net Sales of Licensed Products and [BUKWANG REDACTED] of the amount of any Third Party Royalties in excess of [BUKWANG REDACTED] of Net Sales of Licensed
Products. In no event shall the royalties due on Net Sales of Licensed Products in any royalty period or any Milestone Payment be thereby reduced on account of any reduction pursuant to this Section 3.6 by more than [BUKWANG REDACTED] of the
amount which would have been otherwise payable. 
 3.8 Compulsory Licenses. Should a compulsory license be granted to any third party
in any country of the Territory to make, have made, use, import, offer for sale or sell Licensed Products, the royalty rate payable hereunder for sales of the Licensed Products by Eisai in such country shall be adjusted to match any lower royalty
rate granted to the third party for such country. 
 3.9 Limitation on Royalty Reduction. Any provision of this Agreement to the
contrary notwithstanding, in no event will earned royalties paid to Bukwang be less than the [BUKWANG REDACTED] of Net Sales of Licensed Products for any royalty period during the term hereof. 
 ARTICLE 4. REPORTS AND ACCOUNTING 
 4.1 Royalty Reports and
Records. 
 (a) During the term of this Agreement commencing with the commercial introduction of the first Licensed Product, Eisai shall
furnish, or cause to be furnished to Bukwang, written reports governing each of Eisai’s half Fiscal Year showing: 
 (i) The gross sales
of all Licensed Products sold by Eisai, its Affiliates and sublicensees during the reporting period, together with the calculations of Net Sales in accordance with Sections 1.23 and 1.24; and 
  

 16 

 (ii) the royalties payable in Dollars, which shall have accrued hereunder in respect of such Net Sales;
and 
 (iii) the exchange rates used, if any, in determining the amount of Dollars; and 
 (iv) any withholding taxes required to be made from such royalties. 
 (b) With respect to sales of the Licensed Product invoiced in Dollars, the gross sales, Net Sales, and royalties payable shall be expressed in Dollars. With respect to sales of the Licensed Product invoiced in a
currency other than Dollars, the gross sales, Net Sales, and royalties payable shall be expressed in the domestic currency of the party making the sale together with the Dollar equivalent of the royalty payable, calculated using the simple average
of the exchange rates published in the Wall Street Journal on the last day of each month during the reporting period. If any Eisai Affiliate or sublicensee makes any sales invoiced in a currency other than its domestic currency, the gross
sales and Net Sales shall be converted to its domestic currency in accordance with the Affiliate’s or sublicensee’s normal accounting practices. Eisai, its Affiliate or sublicensee making any royalty payment shall furnish to Bukwang
appropriate evidence of payment of any tax or other amount deducted from any royalty payment. 
 (c) Reports shall be made on semiannual
basis. Semiannual reports shall be due [BUKWANG REDACTED] of the close of every half Fiscal Year and shall be prepared in accordance with GAAP. Eisai shall keep accurate records in sufficient detail to enable royalties and other payments payable
hereunder to be determined. Eisai shall be responsible for all royalties and late payments that are due to Bukwang that have not been paid by Eisai’s Affiliates and sublicensees. Eisai’s Affiliates and sublicensees shall have, and shall be
notified by Eisai that they have, the option of making any royalty payment directly to Bukwang. 
 4.2 Right to Audit. Bukwang (or the
Primary Licensors on Bukwang’s behalf if authorized in wiring to Eisai by Bukwang and provided they agree to be bound by the provisions of Sections 4.2 and 4.3) shall have the right, upon prior notice to Eisai, not more than once in each Fiscal
Year nor more than once in respect of any Fiscal Year, through an independent certified public accountant selected by Bukwang or the Primary Licensors, as applicable, and acceptable to Eisai, which acceptance shall not be unreasonably refused, to
have 

  

 17 

 
access during normal business hours to those records of Eisai as may be reasonably necessary to verify the accuracy of the royalty reports required to be
furnished by Eisai pursuant to Section 4.1 of the Agreement. Such accountant may report only the accuracy or inaccuracy of the royalty reports furnished by Eisai and, in the event they are determined to be inaccurate, the corrections in the
amounts which need to be made to such reports. Eisai shall include in any sublicenses granted pursuant to this Agreement a provision requiring the sublicensee to keep and maintain records of sales made pursuant to such sublicense in accordance with
GAAP and to grant access to such records by Bukwang’s or the Primary Licensors’ independent certified public accountant, as applicable, under the same terms that Bukwang has access to Eisai’s records. If such independent certified
public accountant’s report shows any underpayment of royalties by Eisai its Affiliates or sublicensees, within thirty (30) days after Eisai’s receipt of such report, Eisai shall remit or shall cause its sublicensees to remit to
Bukwang: 
 (a) the amount of such underpayment; and 
 (b) if such underpayment exceeds [BUKWANG REDACTED] percent of the total royalties owed for the Fiscal Year then being reviewed, the reasonably necessary fees and expensed of such independent certified public
accountant performing the audit. 
 Otherwise, Bukwang’s accountant’s fees and expenses shall be borne by Bukwang. Any overpayment of royalties
shall be fully creditable against future royalties payable in any subsequent royalty periods or if this Agreement terminates or expires before such overpayment in fully credited, Bukwang agrees to refund the uncredited portion of such overpayment
within [BUKWANG REDACTED] after receipt of the final royalty payment hereunder. Upon the expiration of [BUKWANG REDACTED] following the end of any Fiscal Year, the calculation of royalties payable with respect to such Fiscal Year shall be binding
and conclusive on Bukwang and Eisai, unless an audit for such Fiscal Year is initiated before expiration of such [BUKWANG REDACTED] Eisai shall retain, and shall cause its Affiliates and sublicensees to 

  

 18 

 
retain, those records required to be maintained pursuant to this Section 4.2 in respect of each Fiscal Year for a period of [BUKWANG REDACTED] after the
end of such Fiscal Year. 
 4.3 Confidentiality of Records. All information subject to review under this Article 4 shall be
confidential. Except where otherwise required by law, Bukwang and its accountant shall retain all such information in confidence. 
 ARTICLE 5. PAYMENTS 
 5.1 Payments and Due Dates. 
 (a) Except as otherwise provided herein, royalties and other amounts payable to Bukwang as a result of activities occurring during the period covered by
each royalty report provided for under Article 4 of this Agreement shall be due and payable on the date such royalty report is due. Payments of royalties and other amounts in whole or in part may be made in advance of such due date. 
 (b) Any provision of this Agreement to the contrary notwithstanding, any royalties on Net Sales of Licensed Products due pursuant to this Agreement which
would not constitute Licensed Products as defined in the Primary License Agreement shall be payable solely to Bukwang. 
 (c) All payments to
Bukwang shall be made by wire transfer to an account of Bukwang designated by Bukwang from time to time; provided, however, that in the event that Bukwang fails to designate such account, Eisai or its Affiliates and sublicensees may remit payment to
Bukwang to the address applicable for the receipt of notices hereunder; provided, further, that any notice by Bukwang of such account or change in such account, shall not be effective until fifteen (15) days after receipt thereof by Eisai.

 5.2 Currency Restrictions. Except as hereinafter provided in this Section 5.2, all royalties and other amounts shall be paid
in Dollars. If, at any time, legal restrictions prevent the prompt remittance of part of or all royalties with respect to any country in the Territory 

  

 19 

 
where Licensed Products are sold, Eisai or its sublicensee shall have the right and option to make such payments by depositing the amount thereof in local
currency to Bukwang’s accounts in a bank or depository in such country. 
 5.3 Overdue Payments. In the event any payment due
hereunder is not made when due, the payment shall accrue interest (beginning on the date such payment is due) calculated at the rate of [BUKWANG REDACTED] and such payment when made shall be accompanied all interest so accrued. The remittance of
such interest shall not foreclose Bukwang from exercising any other rights it may have pursuant to this Agreement because such payment is late. 
 ARTICLE 6. DEVELOPMENT PROGRAM 
 6.1 Development Program. Subject to Bukwang’s timely performance of its
obligations hereunder, and in complete fulfillment of Eisai’s diligence obligations hereunder and any such obligations implied by law, Eisai will undertake, or, if applicable, will cause its Affiliates and sublicensees to undertake, the
development activities described in this Article 6. Eisai shall, at its expense except for the cost of samples for clinical studies and HBV DNA quantification assay and mutation test, use its Commercially Reasonable Efforts (as defined below)
(a) to conduct a development program relating to the use of the Licensed Product for HBV (the “Development Program”) and (b) if the results of the Development Program so justify, to seek Registration for such Licensed Product in
the Territory. The Development Program shall be mutually discussed by the parties hereto at the meetings of the Joint Project Committee held pursuant to Article 7 and shall take into consideration studies and experiments carried out, or to be
carried out by, Bukwang and its licensees, if any, outside the Territory, but the activities within the Territory comprising the Development Program shall be determined at Eisai’s sole discretion. Anything in this Agreement to the contrary
notwithstanding, Eisai shall be entitled to exercise prudent and justifiable business judgment in meeting its Commercially Reasonable Efforts obligations. 
  

 20 

 “Commercially Reasonable Efforts” shall mean the efforts and resources customarily used by
Eisai for Eisai’s in-house products with equivalent sales and profit potential to the Licensed Product. 
 6.2 Fulfillment.

 (a) Subject to the foregoing provisions of this Article 6, Eisai’s Commercially Reasonable Efforts obligations set forth in this
Article 6 shall be deemed to have been satisfied if Eisai: 
 (i) files what it reasonably believes to be a complete NDA or foreign
equivalent for a Licensed Product for HBV with FDA equivalent in given countries in the Territory. 
 (ii) commercially introduces, or causes
its Affiliates or sublicensees to commercially introduce, any Licensed Product (including any Licensed product containing the Compound as its sole active ingredient) approved in any country in which an NDA has been filed within [BUKWANG REDACTED] of
Registration of such Licensed Product in such country. 
 6.3 Bukwang Remedies. 
 (a) In the event Eisai fails to meet any diligence requirements set forth in Subsection 6.2(a), and does not demonstrate to Bukwang’s reasonable
satisfaction that, despite Eisai’s Commercially Reasonable Efforts, the failure to meet the diligence requirement was delayed due to reasons beyond Eisai’s reasonable control, Bukwang shall have the option, as its sole and exclusive
remedy, to terminate the Agreement in the entire Territory. The remedy set forth in this Section 6.3 shall be Bukwang’s sole and exclusive remedy. 
 (b) Prior to exercising any rights under this Section 6.3, Bukwang shall give Eisai thirty (30) days’ notice and shall meet with Eisai, at Eisai’s request and expense, during 

  

 21 

 
such thirty (30) day period, to discuss any disagreements about whether Eisai has complied with the applicable diligence requirements of this Article 6.
Upon expiration of such thirty (30) day period, Bukwang shall have the right in its sole discretion to proceed with the exercise of all rights and remedies provided for herein unless the applicable diligence requirement is fulfilled during such
thirty (30) day period. 
 ARTICLE 7. JOINT PROJECT COMMITTEE 
 7.1 Appointment of Coordinators. As soon as practicable after the Effective Date, Bukwang and Eisai shall each appoint an authorized
representative (a “Coordinator”). Each such party shall provide notice to the other as to the identity of the individual so appointed. Each Coordinator shall be responsible for communications, other than legal notices, between the parties
with respect to the subject matter of this Agreement. Each party may replace its Coordinator at any time for any or no reason by providing written notice to the other party. 
 7.2 Joint Project Committee. The Coordinators shall establish the Joint Project Committee consisting of the same number of representatives from
Eisai and Bukwang. The Joint Project Committee will consist of at least three (3) persons from each of Eisai and Bukwang, such persons having significant responsibility for the development and/or marketing of the Licensed Product. In the event
that Bukwang establish Bukwang’s affiliate company in the USA for outside of Territory and Korea, a joint development committee for Korea, business Territory of Eisai and the rest of the world among Eisai, Bukwang and the future Bukwang’s
affiliate company in the USA shall be organized. In this case, the Joint Project Committee will consist of at least two (2) persons from each party. 
 The Joint Project Committee will meet from time to time at mutually agreeable times via teleconference or in person, but no less than semi-annually during the term of the Agreement. The Coordinators shall set the
agenda for each meeting, and each Coordinator shall determine which regular members of Joint Project Committee and other representatives of such Coordinator’s party shall attend in light of the agenda. Each party shall bear its own costs
incurred in connection with participation in the Joint Project Committee. 
  

 22 

 7.3 Objective of the Joint Project Committee. The Primary objective of the Joint Project Committee
will be to facilitate the expeditious Registration of a Licensed Product in the each territory by each party by, inter alia: 
 (a) facilitating the exchange of data and study results between the parties; 
 (b) providing a forum for protocol and development
plan review; and 
 (c) coordinating the developmental efforts of the parties so as to avoid duplication and inconsistency of such efforts;

 (d) coordinating the production of the Finished Product, Bulk Formulation and Bulk Drug Substance. 
 Each party agrees to give due consideration to any input received from the other party at such Joint Project Committee meetings; provided, however, that
all final decisions relating to the development of Licensed Products in the Territory will be made by Eisai and all final decisions relating to the development of Licensed Products outside the Territory will be made by Bukwang. 
 7.4 Exchange of Study Results. Each party shall submit a report detailing the results of each non-clinical and clinical study which it performs to
the other party within thirty (30) days after completion of the final statistical analyses of the results of such study. In addition, each party will provide the other party with [BUKWANG REDACTED] progress reports summarizing its activities in
respect of the development of Licensed Products during the relevant semi-annual period. Such reports shall cover [BUKWANG REDACTED] and shall be due on or before [BUKWANG REDACTED]. Bukwang allows Eisai to cross-file in the business territory of the
data filed in Korea with the KFDA (or FDA equivalent in other countries 

  

 23 

 
by Bukwang’s affiliate company) at no cost. Similarly, any data generated by Eisai will be given free to Bukwang for regulatory purposes. 
 7.5 Publications. Each party reserves the right to publish or publicly present the results of its own development activities in respect of the
Licensed Products (the “Results”). The party proposing to publish or publicly present the Results (the “publishing party”) will, however, submit a draft of any proposed manuscript, abstract, speech, transparencies, presentation
materials and press releases to the other party (the “non-publishing party”) form comments at least thirty (30) days prior to submission for publication or oral presentation, except, in the case of press releases, where applicable
law, in the reasonable opinion of the publishing party, requires such press release to be issued within time constraints which would make such review impractical. The non-publishing party shall notify the publishing party in writing within fifteen
(15) days of receipt of such draft whether such draft contains Information (as hereinafter defined) of the non-publishing party which it considers to be confidential under the provisions of Article 13 hereof, or information that if published
would have an adverse effect on a patent application for which non-publishing party has initial patent prosecution responsibility pursuant to Article 8 of this Agreement. In the latter case, the non-publishing party shall have the right to request a
delay and the publishing party shall delay such publication for a period not exceeding sixty (60) days. In any such notification the non-publishing party shall indicate with specificity its suggestions regarding the manner and degree to which
the publishing party may disclose such information. The publishing party shall have the final authority to determine the scope and content of any publication, provided that such authority shall be exercised with reasonable regard for the interests
of the non-publishing party, except that no publication will contain any Information disclosed by the non-publishing party to the 

  

 24 

 
publishing party without the non-publishing party’s prior written permission. Each party shall cause its Affiliates, licensees or sublicensees, as the
case may be, to comply with the requirements of this Section 7.5 with respect to any of their proposed publications. 
 ARTICLE 8.
TRANSFER OF KNOW-HOW; TECHNICAL ASSISTANCE 
 8.1 Transfer by Bukwang. Within [BUKWANG REDACTED] following the Effective Date
and as far as it has not previously done so, Bukwang shall supply Eisai with all Bukwang Know-How listed in Exhibit E attached hereto and by regulatory approval in Korea, but no later than the end of calendar year 2005, Bukwang shall
supply Eisai with all Bukwang Know-How listed in Exhibit F attached hereto. With respect to any Bukwang Know-How developed by Bukwang during the term of this Agreement, such disclosure will be made at least on a quarterly basis or
sooner, if practicable. 
 8.2 Technical Assistance. In order to obtain regulatory approval in China and other applicable countries in
the Territory, and in general, Bukwang shall, upon request by Eisai, provide Eisai with reasonable cooperation and assistance, consistent with the other provisions hereof, in connection with the transfer of Bukwang Know-How. Such assistance may
include, but is not limited to, development of the formulations of the Licensed Products; procurement of supplies and raw materials; initial developmental and production batch manufacturing runs; process, specification and analytical methodology
design and improvement; and, in general, such other assistance as may contribute to the efficient application by Eisai of the Bukwang Know-How. In this regard, Bukwang agrees to make appropriate employees of Bukwang reasonably available to assist
Eisai, and Bukwang agrees to provide reasonable numbers of appropriate Eisai personnel with access during normal business hours to the appropriate personnel and operations of Bukwang for such periods of time as may be reasonable in order to
familiarize Eisai personnel with the Bukwang Know-How as applied by Bukwang. At Eisai’s reasonable request, such 

  

 25 

 
assistance shall be furnished at Eisai’s or its subcontractors’ or sublicensees’ facilities in the Territory, subject to a mutually agreed
upon schedule. Such technical assistance shall include but not be limited to the following: 
 (i) Bukwang shall provide Eisai with access to
any and all Drug Master File(s) or counterparts thereof in any countries of the Territory (“DMF”) of Bukwang relating to the manufacture of Bulk Drug Substance existing as of the Effective Date. (ii) Within [BUKWANG REDACTED] after
the Effective Date, Bukwang shall provide Eisai with copies of all documentation in Bukwang’s possession, including all correspondence between Bukwang and its subcontractors, regarding the manufacture of the Bulk Drug Substance which would be
necessary or useful to assist Eisai in the commercial production of Bulk Drug Substance or to support Registration of the Licensed Products. (iii) Bukwang shall provide Eisai with access to any and all communication with relative regulatory
authorities in any countries of the Territory as of the Effective Date. (iv) Bukwang shall provide Eisai with testing data for other applicable regulatory authorities in the Territory. Testing shall include, but not limited to, long term
stability test based on ASEAN ICH condition (30 Celcius±2Celsius/75%±5%RH for 3 years). However, the procedural details of such testing shall be discussed by Joint Project Committee. 
 8.3 Transfer by Eisai. With respect to any Eisai Know-How developed by Eisai during the term of this Agreement, Eisai shall supply Bukwang with
such Eisai Know-How on at least a quarterly basis or sooner, if practicable. 
 8.4 Language of Disclosures. All disclosures pursuant
to this Agreement will be in English. 
 ARTICLE 9. SUPPLY OF BULK DRUG SUBSTANCE, BULK FORMULATION AND FINISHED PRODUCTS

 9.1 Supply for Pre-clinical and Clinical Use. Bukwang shall supply with Eisai all Eisai’s requirements of the Bulk Drug
Substance, Bulk Formulation, and/or Finished Product free of charge for pre-clinical and clinical studies in the Territory. 
  

 26 

 9.2 Supply for Commercial Use. 
 (a) Upon the request of Eisai, Bukwang shall supply with Eisai all Eisai’s requirements of the Bulk Drug Substance at Acquisition Cost or
Manufacturing Cost. 
 (b) Upon the request of Eisai, Bukwang shall supply with Eisai all Eisai’s requirements of the Bulk Formulation
and/or the Finished Product at Acquisition Cost or Manufacturing Cost in a given country or countries of the Territory until Eisai, its Affiliate and/or sublicensee commences formulation of Licensed Product in a such country. 
 9.3 Supply Agreement. Bukwang and Eisai shall execute a supply agreement for the Bulk Formulation, the Bulk Drug Substance and Finished Product in
the Territory, which shall have articles concerning specifications, order and delivery including lead time, invoice and payment, inspection, claim and other necessary terms and conditions for the supply of the Bulk Formulation, the Bulk Drug
Substance and/or Finished Product. 
 9.4 Specification. Bukwang shall manufacture the Bulk Formulation, the Bulk Drug Substance and
the Finished Product in accordance with the Specifications attached here to as Exhibit G which may be amended from time to time during the term of this Agreement by the parties (“Specification”). 
 ARTICLE 10. SAFETY INFORMATION EXCHANGE 
 10.1 Adverse Effect. The parties shall establish and implement a procedure for the mutual exchange of adverse effects reports and safety information concerning the Licensed Product to compliance with applicable
law and regulatory guidelines. The detail of the operating procedure shall be separately agreed by the parties. 
  

 27 

 ARTICLE 11. PATENT PROSECUTION 
 11.1 Title to inventions. Each party shall have and retain sole title in inventions, whether or not patentable, made by it or on its behalf (as by
its employees or agents) in the course of work performed under this Agreement. 
 11.2 Bukwang Patents. 
 (a) During the term of this Agreement ending [BUKWANG REDACTED] after the Effective Date, Bukwang shall file, prosecute and maintain all patent
applications and patents included in the Bukwang Patents which Bukwang owns, if any, at its sole expense. At the end of such [BUKWANG REDACTED] period, Eisai shall assume responsibility for filing, prosecution and maintenance of the Bukwang Patents
owned by Bukwang, if any, at Eisai’s expense in the Territory. Bukwang and its patent counsel will cooperate fully with Eisai and its patent counsel to effect an orderly transfer of such prosecution and maintenance responsibilities. 

(b) With respect to any Bukwang Patents licensed to it pursuant to the Primary License Agreement in the Territory, Eisai shall have those rights
relating to the prosecution and maintenance of such Bukwang Patents as are set forth in Article 7 of the Primary License Agreement. 
 (c)
Except as otherwise expressly set forth in the first sentence of Subsection 11.2(a), Eisai agrees to reimburse the Primary Licensors or Bukwang, as applicable, for all external fees, costs and expenses incurred by them in filing, prosecuting and
maintaining the Bukwang Patents in the Territory. Invoices, including reasonable substantiation thereof, shall be submitted once in respect of each fiscal quarter as promptly as practicable after the end of such quarter. Payments shall be due net
thirty (30) days from the date of invoice. If Eisai fails to reimburse Bukwang or the Primary Licensors, as applicable, for any undisputed patent prosecution expenses respecting any patent application or issued patent included in the Bukwang

  

 28 

 
Patents within the time allowed therefor, upon at least thirty (30) days’ prior notice to Eisai, Bukwang or the Primary Licensors, as applicable,
may remove such patent application or issued patent from the Bukwang Patents and Bukwang or the Primary Licensors shall be free, at its or their election, to abandon or maintain the prosecution of such patent application or issued patent or grant
rights to such patent application or issued patent to third parties. 
 (d) Eisai reserves the right to terminate its obligations pursuant to
this Section 11.2 with respect to any patent application or patent included in the Bukwang Patents in any country or countries upon in the Territory at least [BUKWANG REDACTED] prior written notice to Bukwang and the Primary Licensors. After
the date specified in such notice on which Eisai’s obligation to pay further expenses terminates, such patent application or patent, as the case may be, shall no longer be included in the Bukwang Patents in those countries in which Eisai has
exercised its rights its rights to terminate such obligations. 
 11.3 Eisai Inventions. Eisai shall, in consultation with Bukwang,
file such patent applications regarding any of the Eisai Patents owned or controlled by Eisai, and thereafter shall diligently and in the exercise of its discretion in a manner reasonably consistent with the goals and expectations of the parties
hereunder, giving due and reasonable consideration to Bukwang’s position, prosecute and maintain in force the resulting Eisai Patents, all at Eisai’s expense. Eisai shall enable Bukwang to directly contact and confer with Eisai’s
patent counsel, at Bukwang’s expense, with respect to the prosecution of any patent applications constituting part of the Eisai Patents and shall use its reasonable efforts to amend, correct or refile any patent or patent application included
in the Eisai Patents to include claims reasonably requested by Bukwang. The territorial scope of such filings shall be the subject of specific discussion between the parties. If for any reason Eisai declines to file a patent application or, having
filed, declines 

  

 29 

 
to prosecute or maintain any of the Eisai Patents in any country, Bukwang may so file, prosecute or maintain in Eisai’s name and at Bukwang’s
expense in such country, in which event, Eisai shall, at Bukwang’s request and expense, provide all reasonable assistance. 
 11.4
Joint Inventions. With respect to Joint Inventions: (a) all patent applications and patents with respect thereto shall be jointly owned by Bukwang and Eisai; (b) Eisai and its sublicensees and assignees shall be free to use such
patent application and patents in the Territory and Bukwang and its licensees and assignees shall be free to use such patent applications and patents outside the Territory, in each event, without payment of royalty or accounting therefor;
(c) each party agrees to consult with the other party and to give due and reasonable consideration to the other party’s position in determining the territorial scope of patent filings within the Territory (in the case of Eisai) and outside
the Territory, and the prosecution and maintenance of resulting patent rights based on Joint Inventions; and (d) Eisai shall have the sole right and discretion to file any patent application and prosecute and maintain any resulting patent
rights on Joint Inventions, in which event, Bukwang shall, at Eisai’s request, provide all reasonable assistance and shall promptly reimburse Eisai with [BUKWANG REDACTED] of the out-of-pocket expenses so incurred by Eisai. 
 11.5 Further Obligations. 
 (a)
Except as otherwise provided in Article 12, each party’s responsibilities for patent prosecution activities pursuant to this Article 11 shall also include all ex parte and inter partes activities relating to the
relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications
and patents. Each party agrees to give due consideration to the other party’s position with respect to any such patent prosecution activities (which term, as used herein, shall include without limitation, any inter partes activities of
the type described in the first sentence of this Subsection 11.5(a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is 

  

 30 

 
responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, the other party may initiate,
pursue or assume such patent prosecution activities, at its sole expense. 
 (b) In conducting its patent prosecution activities under this
Agreement, each party may use patent attorneys selected by it in its own discretion. In addition to the other obligations set forth in this Article 11, each party undertakes to keep the other party throughout the term of this Agreement regularly
informed of the status and progress of the patent prosecution activities it undertakes under this Agreement including, but not limited to, supplying the other, upon reasonable request and at reasonable intervals with all correspondence with the
United States, Japan, China and European patent office counterparts with respect to the United States, Japan, China and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the
other party in order to assist such other party in connection with any of its activities or the exercise of any of its rights pursuant to Articles 8 and 9, such party shall provide the other party with such additional relevant documentation which
such other party may reasonably request relating to such patent applications and patent in the Bukwang Patents, Eisai Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory
notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility
pursuant to this Article 11, it shall give the other party notice thereof in a sufficiently timely manner so as to enable such other party to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its
[BUKWANG REDACTED] to give such notice at least sixty (60) days before any abandonment, lapse or any other relevant deadline. 
 ARTICLE 12. INFRINGEMENT 
 12.1 Third Party Infringement. If Eisai or Bukwang becomes aware of any activity
that it believes represents a substantial or threatened infringement of a Valid Claim or patents relating to Joint inventions, the party obtaining such knowledge shall promptly advise the other of all relevant facts and circumstances pertaining to
the potential infringement. 
  

 31 

 12.2 Eisai’s Rights Against Third Party Infringers. Except to the extent otherwise provided
in paragraph 11.1 of the Primary License Agreement in respect of those Bukwang Patents licensed to Bukwang thereunder, Eisai shall have the first right to enforce or have enforced, at no expense to Bukwang, any Bukwang Patents or patent rights
relating to Joint Inventions against infringement by third parties and shall be entitled to retain recovery from such enforcement as prescribed by this Section 12.2 in the Territory. Upon Eisai’s undertaking to pay all expenditures
reasonably incurred by Bukwang, Bukwang shall reasonably cooperate in any such enforcement and, as necessary, join as a party therein. After first deducting its costs and expenses incurred in respect of enforcement (to the extent not otherwise
awarded by settlement or a court), Eisai shall pay royalties (calculated per Section 3.3) on the balance of any monetary recovery. In the event that Eisai does not file suit against or commence settlement negotiations with a substantial
infringer of the Bukwang Patents or patent rights relating to Joint Inventions within six (6) months after receipt of a written demand from Bukwang that Eisai bring suit, then the parties will consult with one another in an effort to determine
whether a reasonably prudent licensee would institute litigation to enforce the patent in question in light of all relevant business and economic factors (including, but not limited to, the projected cost of such litigation, the likelihood of
success on the merits, the probable amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims against Eisai and Bukwang, the diversion of Eisai’s human and
economic resources, the impact of any possible adverse outcome on Eisai and the effect any publicity might have on Eisai’s and Bukwang’s respective reputations and goodwill). If the parties cannot agree, the determination will be made by a
mutually and reasonably acceptable third party consultant. If after such process, it is determined that a suit should be filed and Eisai does not file suit or commence 

  

 32 

 
settlement negotiations forthwith against the substantial infringer, then Bukwang shall have the right to enforce any patent licensed hereunder on behalf of
itself and Eisai (with Bukwang retaining all recoveries from such enforcement). 
 12.3 Bukwang’s Rights Against Third Party
Infringers. Bukwang shall have the first right to enforce or have enforced, at no expense to the Eisai, the Bukwang Trademark and Bukwang Patents, except the patents that Eisai have the first rights set forth in Section 12.2, against
infringement by third parties and shall be entitled to retain recovery from such enforcement as prescribed by this Subsection 12.3 in the Territory. Upon Bukwang’s undertaking to pay all expenditures reasonably incurred by Eisai, Eisai shall
reasonably cooperate in any such enforcement and, as necessary, join as a party therein. In the event that Bukwang does not file suit against or commence settlement negotiations with a substantial infringer of the Bukwang Patents or Bukwang
Trademark within six (6) months after receipt of a written demand from Eisai that Bukwang bring suit, then the parties will consult with one another in an effort to determine whether a reasonably prudent licensee would institute litigation to
enforce the patent in question in light of all relevant business and economic factors (including, but not limited to, the projected cost of such litigation, the likelihood of success on the merits, the probable amount of any damage award, the
prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims against Bukwang and Eisai, the diversion of Bukwang’s human and economic resources, the impact of any possible adverse outcome on Bukwang
and the effect any publicity might have on Bukwang’s and Eisai’s respective reputations and goodwill). If the parties cannot agree, the determination will be made by a mutually and reasonably acceptable third party consultant. If after
such process, it is determined that a suit should be filed and Bukwang does not file suit or commence settlement negotiations 

  

 33 

 
forthwith against the substantial infringer, then Eisai shall have the right to enforce any patent licensed hereunder on behalf of itself and Bukwang (with
Eisai retaining all recoveries from such enforcement). 
 ARTICLE 13. WARRANTIES AND REPRESENTATIONS; LIMITATION OF LIABILITY; AND
DISCLAIMERS 
 13.1 Warranties and Representations of Bukwang. Bukwang warrants and represents the following as of the date
hereof: 
 (a) it possesses the necessary rights to enter into this Agreement; 
 (b) Exhibit A is a true, complete and accurate copy of the Primary License Agreement; 
 (c) Exhibit B is a complete list of all patents and patent applications included in the Bukwang Patents as of the Effective Date; 
 (d) it is not aware of any material facts which it has not disclosed to Eisai regarding the manufacture, use or sale of any Licensed Product or the
practice of any inventions included in the Bukwang Patents or the use of the Bukwang Know-How by Eisai (except, potentially, details regarding the Bukwang Know-How to be provided under Article 8, including without limitation any material facts
regarding the possibility that such manufacture, use, sale or practice might infringe any third party’s know-how, patent rights or other intellectual property in the Territory; 
 (e) it is aware of no third party using or infringing all or any of the Bukwang Patents in derogation of the rights granted pursuant to this Agreement;

 (f) it is aware of no third party claim to any rights in the Bukwang Patents or the Bukwang Know-How; 
  

 34 

 (g) it is aware of no pending interference or opposition proceeding or litigation or any communication
which threatens an interference or opposition proceeding or litigation before any patent and trademark office, court, or any other governmental entity or court in any jurisdiction in regard to the Bukwang Patent; and 
 (h) the Primary License Agreement is in full force and effect and Bukwang will: (i) use its best efforts to fulfill all of its obligations under the
Primary License Agreement, including, but not limited to any due diligence obligations outside the Territory set forth therein; (ii) take no action or fail to take any action which will cause it to be in breach of any provision of the Primary
License Agreement. 
 13.2 Warranties and representations by Eisai. Eisai represents and warrants that it has or will obtain, at its
Commercially Reasonable Effort, the skill and expertise in the technical areas relating to the Bukwang Patents and Bukwang Know-How to make or have made an evaluation of the capabilities, safety, utility and commercial application of the Bukwang
Patent and the Bukwang Know-How. 
 13.3 Warranties and Representations of Each Party. Each party hereto warrants and represents to:
(a) the other that it is free to enter into this Agreement (including the receipt of all corporate authorizations) and to carry out all of the provisions hereof, including, its grant to the other of the licensed described in Article 2;
(b) to its knowledge, there is no failure to comply with, no violation of or any default under, any law, permit or court order applicable to it which might have a material adverse effect on its ability to execute, deliver and perform this
Agreement or on its ability to consummate the transactions contemplated hereby; and (c) it shall comply with laws and regulations relating to the performance of its obligations or the exercise of its rights hereunder including, in the case of
Eisai, those relating to the manufacture, processing, 

  

 35 

 
producing, use, sale, or distribution of Licensed Products; and that it shall not take any action which would cause it or the other party to violate such
laws and regulations. 
 13.4 Disclaimer and Limitation of Warranties. Bukwang makes no warranty as to validity of the Bukwang Patents
licensed hereunder and, except as expressly stated in Section 13.1, makes no representation whatsoever with regard to the scope of the Bukwang Patents or Bukwang Know-How, or that the Bukwang Patents or Bukwang Know-How may be exploited by
Eisai or its Affiliates or sublicensees without infringing intellectual property rights of third parties. EXCEPT AS OTHERWISE SET FORTH IN SECTION 13.1 ABOVE, BUKWANG MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE BUKWANG
PATENTS OR BUKWANG KNOW-HOW AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL APPLICATION OF BUKWANG
PATENTS OR BUKWANG KNOW-HOW. 
 13.5 Limitation of Liability. 
 (a) Neither Bukwang nor the Primary Licensors shall be liable to Eisai or Eisai’s Affiliates, sublicensees or any of its or their customers for any
special, incidental or consequential damages resulting from defects in the testing, labeling, manufacture or other application of the Licensed Products manufactured, tested or sold pursuant to this Agreement. 
 (b) Any Provision of this Agreement to the contrary notwithstanding, Bukwang shall not be liable to Eisai, its Affiliates or sublicensees for any damage
that any party may suffer as a result of any third party actions for patent infringement or for any other claims against Eisai, its Affiliates or sublicensees in connection with their use of Bukwang Patents or Bukwang Know-How; provided, however,
that the foregoing limitation shall in no way affect or 

  

 36 

 
otherwise limit any remedies which Eisai or its Affiliates or sublicensees may have against Bukwang as a result of Bukwang’s breach of any of its
warranties and representations set forth in Article 11 hereof. 
 13.6 Insurance. Without limiting Eisai’s indemnity obligations
under Article 14, Eisai shall maintain throughout the term of this Agreement, and shall use its [BUKWANG REDACTED] to maintain for a reasonable period of time thereafter, a commercial, general liability insurance policy, written by a reputable
insurance company which: 
 (a) insures Indemnitees for all claims, damages, and actions mentioned in Section 14.1 of this Agreement;

 (b) includes a contractual endorsement providing coverage for all liability arising out of bodily injury and property damage. 

ARTICLE 14. INDEMNIFICATION 
 14.1 Eisai’s Indemnification. Subject to compliance by the Indemnitees with the provisions set forth in Section 14.3, Eisai shall defend, indemnify, and hold harmless the Indemnitees, from and against any and all claims,
demands, losses, liabilities, expenses, and damages including investigative costs, court costs and reasonable attorneys’ fees (collectively, the “Liabilities”) which Indemnitees may suffer, pay, or incur as a result of or in
connection with: (a) any and all personal injury (including death) and property damage caused or contributed to, in whole or in part, by manufacture, testing, design, use, sale, or labeling of any Licensed Products or the practice of the
Bukwang Patents or Bukwang Know-How by Eisai or Eisai’s Affiliates or sublicensees, excluding any Liabilities arising as a result of Bukwang’s or, if applicable, its subcontractor’s negligence, intentional misconduct or breach of
contract in supplying Bulk drug Substance, Bulk Formulation and Finished Product; and (b) any breach by Eisai of its representations, warranties and covenants contained in this Agreement. Eisai’s obligations under this Article shall
survive the expiration or termination of this Agreement for any reason. 
  

 37 

 14.2 Bukwang’s Indemnification. Subject to compliance by the Indemnitees with the provisions
set forth in Section 14.3, Bukwang shall defend, indemnify and hold the Indemnitees harmless from and against any and all Liabilities which Indemnitees may suffer, pay or incur as a result of or in connection with: (a) any breach by
Bukwang of any of its representations, warranties and covenants set forth in this Agreement; and (b) any claims or suits asserted or commenced by the Primary Licensors regarding any royalty payments made by Eisai to Bukwang pursuant to
Subsection 5.1(b) of this Agreement. Bukwang’s obligations under this Article shall survive expiration or termination of this Agreement for any reason. 
 14.3 Indemnification Procedures. Any Indemnitee which intends to claims indemnification under this Article shall, promptly after becoming aware thereof, notify the party from whom it is seeking indemnification
(the “Indemnitor”) in writing of any matter in respect of which the Indemnitee or any of its employees intend to claim such indemnification. The Indemnitee shall permit, and shall cause its employees to permit, the Indemnitor, at its
discretion, to settle any such matter and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that such settlement does not adversely affect the lndemnitee’s rights hereunder or impose any
obligations on the Indemnitee in addition to those set forth herein in order for it to exercise such rights. No such matter shall be settled by such Indemnitee without the prior written consent of the Indemnitor and neither the Indemnitor nor the
Indemnitee shall be responsible for any legal fees or other costs incurred other than as provided herein. The Indemnitee and its employees shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of
any matter covered by the applicable 

  

 38 

 
indemnification. The Indemnitee shall have the right, but not the obligation, to be represented by counsel of its own selection and expense. 
 ARTICLE 15. CONFIDENTIALITY 
 15.1 Treatment of Confidential Information. Except as otherwise provided hereunder, during the term of this Agreement and for a period of [BUKWANG REDACTED] thereafter: 
 (a) Eisai and its Affiliates and sublicensees shall retain in confidence and use only for purposes of this Agreement, any written or oral confidential
information and data supplied by or on behalf of Bukwang under this Agreement and the Restricted Disclosure and Testing Agreement, dated September 19th, 2003 and September 24th, 2004, between Bukwang and Eisai (the “Confidentiality
Agreement” and “Material Transfer Agreement”); and 
 (b) Bukwang shall retain in confidence and use only for purposes of this
Agreement any written and oral confidential information and data supplied by or on behalf of Eisai to Bukwang under this Agreement. 
 For
Purposes of this Agreement, all such confidential information and data which a party is obligated to retain in confidence shall be called “Information.” 
 15.2 Right to Disclose. To the extent that it is reasonably necessary to fulfill its obligations or exercise its rights under this Agreement, or any rights which survive termination or expiration hereof, each
party may disclose Information to its Affiliates, sublicensees (actual or prospective), consultants, outside contractors, actual or prospective investors, and clinical investigators on condition that such entities or persons agree in writing:

 (a) to keep the Information confidential for a period of at least [BUKWANG REDACTED] from the date of disclosure by such party to the same
extent as such party is required to keep the Information confidential; and 
  

 39 

 (b) to use the Information only for those purposes for which the disclosing party is authorized to use
the Information. 
 Each party or its Affiliates or sublicensees, as applicable, may disclose Information to the government or other
regulatory authorities to the extent that such disclosure (i) is necessary for the prosecution and enforcement of patents, of authorizations to conduct preclinical or clinical trials to commercially market Licensed Products, provided such party
is then otherwise entitled to engage in such activities in accordance with the provisions of this Agreement, or (ii) is legally required. 
 15.3 Release from Restrictions. The obligation not to disclose or use Information shall not apply to any part of such Information that 
 (a) is or becomes patented (but the existence of a patent shall only permit disclosure and not, unless otherwise provided hereunder, use), published or otherwise part of the public domain, other than by unauthorized
acts of the party obligated not to disclose such Information (for purposes of this Article 15 the “receiving party”) or its Affiliates or sublicensees in contravention of this Agreement; or 
 (b) is disclosed to the receiving party or its Affiliates or sublicensees by a third party provided that such Information was not obtained by such third
party directly or indirectly from the other party to this Agreement; or 
 (c) prior to disclosure under the Confidentiality Agreement or
this Agreement, as the case may be, was already in the possession of the receiving party, its Affiliates or sublicensees, provided that such Information was not obtained directly or indirectly from the other party to this Agreement; or 

 

 40 

 (d) result form research and development by the receiving party or its Affiliates or sublicensees,
independent of disclosure from the other party to this Agreement; or 
 (e) is required by law to be disclosed by the receiving party,
provided that in the case of disclosure in connection with any litigation, the receiving party uses reasonable efforts to notify the other party immediately upon learning of such requirement in order to give the other party reasonable opportunity to
oppose such requirement; or 
 (f) Eisai and Bukwang agree in writing may be disclosed. 
 ARTICLE 16. TERM AND TERMINATION 
 16.1 Term. Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on the Effective Date and shall continue in full force and effect on a country-by-country basis until the
expiration of the Term of this Agreement. 
 16.2 Termination by Default. 
 (a) If either party defaults in the performance of, or fails to be in compliance with, any material agreement, condition or covenant of this Agreement,
including the non-defaulting party may terminate this Agreement with respect to the defaulting party if such default or noncompliance shall not have been remedied, or, in the event the default or non-compliance cannot be remedied within such period,
reasonable steps shall not have been initiated to remedy the same, within [BUKWANG REDACTED] after receipt by the defaulting party of a written notice thereof from the non-defaulting party. 
 (b) In the event that: (i) any proceeding is commenced by or against a party seeking relief under any bankruptcy, insolvency or similar law and if
such proceeding is 

  

 41 

 
involuntary, it remains undismissed for [BUKWANG REDACTED] or a party, by action or answer, approves of, consents to or acquiesces in such proceeding or
admits the material allegations of or defaults in answering a petition filed in such proceeding; or (ii) a receiver, liquidator, assignee, custodian or trustee (or similar official) is appointed for a party in respect of any substantial part of
its assets of for purposes of the winding-up or liquidation of its business and such appointment remains unstayed and in effect for a period of [BUKWANG REDACTED]; or (iii) a party makes an assignment for the benefit of creditors; then, in any
such event, such party shall be deemed in default for purposes of this Section 16.2. 
 16.3 Termination by Eisai without any
cause. Eisai shall have the right to terminate this Agreement in the Territory or one or more countries of the Territory without any cause (without affecting this Agreement in the remaining countries of the Territory), by giving Bukwang sixty
(60) days’ prior written notice thereof. 
 16.4 Termination by Eisai for reason of the drug-drug interaction study. In the
event that Eisai finds any negative results from the drug-drug interaction study of the Compound, Eisai shall have the right to terminate this Agreement forthwith with its notice to Bukwang, to ether with the study report. 
 16.5 Obligation Upon Termination. If this Agreement is terminated as a result of Eisai’s breach pursuant to Section 16.2, or is
terminated in whole or in party by Bukwang in accordance with Section 6.3 or by Eisai in accordance with Section 16.3, then: (a) in the case of termination in the entire Territory; Eisai shall use, and shall cause its Affiliates and
sublicensees to use, its and their [BUKWANG REDACTED] to return, or at Bukwang’s direction, destroy all data, writing and other documents and tangible materials supplied to Eisai by Bukwang properly 

  

 42 

 
organized and to provide Bukwang with reasonable transition assistance, and upon Bukwang’s request, Eisai shall sell any Licensed Product in its
possession to Bukwang at Eisai’s Acquisition Cost or Manufacturing Cost therefor, as applicable; and (b) with respect to those countries with respect to which termination occurs, Eisai shall provide Bukwang with full and complete copies of
all toxicity, efficacy, and other data generated by Eisai or Eisai’s Affiliates, and sublicensees, in the course of Eisai’s efforts to develop Licensed Products or to obtain governmental approval for the sale of Licensed Products,
including but not limited to any regulatory filings with any government agency in such counties. Bukwang shall be authorized to cross-reference any such regulatory filings made by Eisai, its Affiliates and sublicensees in the countries in which
termination occurs where permitted by law. Bukwang shall be entitled to provide information pertaining to the Eisai Patents, Eisai Know-How and Joint Know-How to any third party with a bona fide interest in licensing such technology in the
countries in which termination occurs. Such data shall be provided on a confidential basis; provided, however, that if such third party concludes a license with Bukwang, such third party shall be free to use such data for all purposes, including to
obtain government approvals to sell any product containing any Compound in such countries. 
 16.6 Effect of Termination. In the event
of any expiration or termination pursuant to this Article 16, neither party shall have any remaining rights or obligations under this Agreement other than as provided below: 
 (a) Bukwang will have the right to receive all payments accrued prior to the effective date of termination; 
  

 43 

 (b) termination or expiration of this Agreement for any reason shall have no effect on the parties’
obligations under Articles 12, 114 and 15 or their respective rights in Joint Know-How set forth in Section 1.18; 
 (c) upon expiration
of Eisai’s royalty obligations under this Agreement in a given country, Eisai shall have a perpetual, fully paid-up, non-exclusive license to use the Bukwang Know-How in such country; 
 (d) termination of this Agreement by Bukwang pursuant to Section 6.3 or 16.2 or by Eisai pursuant to Section 16.3, shall have no effect on the
rights and obligations of the parties under Section 16.5; and 
 (e) the parties shall retain any other remedies for breach of this
Agreement they may otherwise have. 
 16.7 Default by Eisai’s Affiliates and Sublicensees. For purposes of this Article 16, any
breach or default of the provisions of this Agreement by Eisai’s Affiliates or sublicensees shall be deemed to be breach of this Agreement by Eisai, and Eisai shall be liable to Bukwang for such breach or default to the same extent as if such
breach or default had been made directly by Eisai. 
 ARTICLE 17. ASSIGNMENT 
 17.1 Assignment by Either Party. Neither party shall assign this Agreement or any part thereof without the prior written consent of the other
party, which consent shall not be unreasonably withheld or delayed. Each party may, however, without such consent, assign or sell its rights under this Agreement (a) in connection with the sale or transfer of all or 

  

 44 

 
substantially all of its pharmaceutical business to a third party; (b) in the event of a merger or consolidation with a third party; or (c) to an
Affiliate. No assignment shall relieve any party of responsibility for the performance of any accrued obligation which such party has under this Agreement. Any assignment shall be contingent upon the assignee assuming in writing all of the
obligations of its assignor under this Agreement. 
 ARTICLE 18. REGISTRATION OF LICENSE 
 18.1 Registration by Eisai. Eisai, at its expense, may register the license granted under this Agreement in any country of the Territory where the
use, sale or manufacture of a Licensed Product in such country would be covered by a Valid Claim. Upon request by Eisai, Bukwang agrees promptly to execute any “short form” licenses submitted to it by Eisai reasonably necessary in order to
effect the foregoing registration in such country. 
 ARTICLE 19. DISPUTE RESOLUTION AND ARBITRATION 
 19.1 Initial Resolution. In the case of any disputes between the parties arising from this Agreement, and in case this Agreement does not provide
a solution for how to resolve such disputes, the parties shall discuss and negotiate in good faith a solution acceptable to both parties and in the spirit of this Agreement. If after negotiating in good faith pursuant to the foregoing sentence, the
parties fail to each agreement within thirty (30) days, then the President of Bukwang and the Chief Executive Officer or Chief Operating Officer of Eisai shall discuss in good faith an appropriate resolution to the dispute. If these executives
fail, after good faith discussions not to exceed thirty (30) days, to reach an amicable agreement then the parties shall submit to binding arbitration pursuant to Section 19.2 (“Arbitration”). The date of submission of the matter
to substrate shall be the “Dispute Date”. 
  

 45 

 19.2 Arbitration. The following provisions shall govern any arbitration pursuant to this
Agreement. 
 (a) Arbitration shall be conducted in accordance with the Rules of the American Arbitration Association. In the event of any
conflict between the Rules and this Section, the provisions of this Section shall govern. The Arbitration shall be conducted in [BUKWANG REDACTED]. 
 (b) The Arbitration shall be heard by a panel of three arbitrators (each an “Arbitrator”). Eisai and Bukwang shall each select one Arbitrator. Such Arbitrators shall be attorneys, licensed to practice law in
the State of Georgia, actively engaged in the full-time practice of law for a period of no less than seven (7) years. Such Arbitrators shall not be affiliated, directly or indirectly, with the parties or the attorneys representing the parties
in the Arbitration and shall not have any prior involvement in the matter. In the event that either party fails within fifteen (15) days after the Dispute Date (i) to select an Arbitrator who, to its knowledge, meets the requirements set
forth in this subsection (b) and (ii) to notify the other party of the selection, the other party will then have the right to select such Arbitrator. The third Arbitrator shall be selected by mutual agreement of the parties from a list of
neutral arbitrators compiled by the American Arbitration Association for the parties. Such Arbitrator shall be an attorney, licensed to practice law in the State of Georgia, actively engaged in the full time practice of law for a period of no less
than ten (10) years. The third Arbitrator shall not have any prior or current relationship, direct or indirect, with any party to this Agreement. If the parties to the Arbitration are unable to agree upon the third Arbitrator within fifteen
(15) days from the Dispute Date, the appointment of the third Arbitrator shall be made as expeditiously as possible and in compliance with this Section 19.2 by the two Arbitrators selected by the parties. If those Arbitrators cannot agree
on the third Arbitrator within ten (10) days, then the third Arbitrator shall be designated by the American Arbitration Association or the appropriate designated representative thereof upon the written request of any party with simultaneous
notice of such request to the other party to the Arbitration. The third Arbitrator shall preside over the panel of Arbitrators and the Arbitration. 
  

 46 

 (c) The Arbitrators shall apply the substantive laws of the [BUKWANG REDACTED] to the validity,
construction and interpretation of this Agreement as is applicable to contracts made wholly performable within the state. 
 (d) The
Arbitration shall be resolved no later than sixty (60) days from the date of acceptance by the third Arbitrator of his or her appointment unless otherwise agreed to by the parties to the Arbitration. 
 (e) Each party shall bear the expenses and costs of the Arbitrator selected by party. The third Arbitrator shall be compensated for services rendered at
the prevailing hourly rate of compensation and reimbursed for any expenses incurred in connection with rendering such services. The non-prevailing party shall bear the costs and expenses of compensation and reimbursement for the third Arbitrator.

 (f) The decision of the Arbitrators shall be rendered in writing and shall be final and binding and may be enforced at the request of
either party to the Arbitration in the United States District Court for the Northern District of Georgia or any court of the State Georgia having competent jurisdiction. Such decision may not be appealed except upon a claim of bad faith or fraud by
the Arbitrators. 
 (g) This Article 19 shall not apply to issues relating to the validity, construction or effect of the Bukwang Patents and
Eisai Patents. Matters, controversies or disputes concerning the Bukwang Patents and Eisai Patents shall be resolved in any court having jurisdiction thereof or in any other manner mutually agreed to by the parties. 
 ARTICLE 20. GENERAL PROVISIONS 
 20.1 Independent Contractors. It is understood and agreed that the parties hereto are independent contractors and are engaged in the operation of their own respective businesses, and neither party hereto is to be considered the agent
of the other party for any 

  

 47 

 
purpose whatsoever, and neither party shall have any authority to enter into any contracts or assume any obligations for the other party nor make any
warranties or representations on behalf of that other party. 
 20.2 Patent Marking. Licensed Products manufactured or sold in the
Territory shall be marked in compliance with the intellectual property laws in force in such countries. The foregoing obligations shall be subject to size and space limitations. If Bukwang believes that a Licensed Product should be marked with the
number of a Bukwang Patent, Bukwang shall provide written notice to Eisai which identifies the patent number and the Licensed Product on which it should appear. It shall also be Bukwang’s responsibility to inform Eisai in writing when marking
with a Bukwang Patentnumber should be discontinued. To the extent that Eisai complies with Bukwang’s instructions, Bukwang shall indemnify and hold Eisai harmless for any liability, claim or action for false patent marking or non-marking.

 20.3 Publicity. The parties agree to issue mutual press releases concerning their entry into this Agreement, with the content of
such releases to be approved (which consent shall not be unreasonably withheld or delayed) in advance by the parties. In all other respects, except as required by law, neither party shall use the name of the other party in any publicity release
without the prior written permission of such other party, which shall not be unreasonably withheld. The other party shall have a reasonable opportunity to review and comment on any such proposed publicity release. Except as required by law, neither
party shall publicly disclose the terms of this Agreement or issue any publicity release with regard thereto unless expressly authorized to do so by the other party which authorization shall be agreed upon. 
  

 48 

 20.4 Governing Law. This Agreement and all amendments, modifications, alterations, or supplements
hereto, and the rights of the parties hereunder, shall be construed under and governed by the laws of the [BUKWANG REDACTED], me exclusive of its conflicts of laws principles. 
 20.5 Entire Agreement. This Agreement, together with the Exhibits attached hereto, constitutes the entire agreement between Bukwang and Eisai with
respect to the subject matter hereof and shall not be modified, amended or terminated, except as herein provided or except by another agreement in writing executed by the parties hereto. Upon the Effective Date, the Confidentiality Agreement shall
terminate. 
 20.6 Interpretation. Except (a) as otherwise provided in the Primary License Agreement and (b) for any
amendment to the Primary License Agreement to the extent such amendment would adversely affect the rights and obligations of Eisai hereunder (unless Eisai has given prior written consent thereto in writing), in the event of any conflict between the
terms hereof and the terms of the Primary License Agreement, the terms of the Primary License Agreement shall control. 
 20.7 Waiver.
No provision of this Agreement may be waived except by a writing signed by the party entitled to the benefit thereof, and no such waiver of any provision hereof in one instance shall constitute a waiver of any other provision or of such provision in
any other instance. No omission, delay or failure on the part of any party hereto in exercising any rights hereunder will constitute a waiver of such rights or of any other rights hereunder. 
 20.8 Severability. All rights and restrictions contained herein may be exercised and shall be applicable and binding only to the extent that they
do not violate any applicable laws 

  

 49 

 
and are intended to be limited to the extent necessary so that they will not render this Agreement illegal, invalid or unenforceable. If any provision or
portion of any provision of this Agreement, not essential to the commercial purpose of this Agreement, shall be held to be illegal, invalid or unenforceable by a court of competent jurisdiction, it is the intention of the parties that the remaining
provisions or portions thereof shall constitute their agreement with respect to the subject matter hereof, and all such remaining provisions, or portions thereof, shall remain in full force and effect. To the extent legally permissible, any illegal,
invalid or unenforceable provision of this Agreement shall be replaced by a valid provision which shall implement the commercial purpose of the illegal, invalid or unenforceable provision. In the event that any provision essential to the commercial
purpose of this Agreement, this Agreement and the rights granted herein shall terminate. 
 20.9 Force Majeure. 
 (a) Any delays in, or failure of performance of, any party to this Agreement, shall not constitute a default hereunder, or give rise to any claim for
damages, if and to the extent caused by occurrences beyond the control of the party affected, including, but not limited to, acts of God, strikes or other concerted acts of workmen, civil disturbances, fires, floods, explosions, riots, war,
rebellion, sabotage, acts of governmental authority or failure of governmental authority to issue licenses or approvals which may be required (“Force Majeure”). 
 (b) The party asserting the Force Majeure shall promptly notify the other party of the event constituting Force Majeure and of all relevant details of occurrence and where appropriate an estimate of how long such
Force Majeure event shall continue. 
 (c) If such Force Majeure event continues thereafter and in any event, the parties shall consult with
each other in order to find a fair solution and shall use all reasonable endeavors to minimize the consequences of such Force Majeure. 
  

 50 

 20.10 Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 20.11 Notices. All notices,
statements, and reports required to be given under this Agreement shall be in writing and shall be deemed to have been given upon delivery in person or, when deposited (a) in the mail in the country of residence of party giving the notice,
registered or certified postage prepaid or with a professional courier service (e.g., FedEx or UPS), and addressed as follows: 
  

			
	 To Bukwang:
	  	Bukwang Pharm. Co., Ltd
		  	398-1 Daebang-Dong-Dongjak-Ku
		  	Seoul 156-811
		  	Korea
		  	Attn: K. H. Kim
		  	Director of Product Development
		  	& Regulatory Affairs
		  	Tel: 82 2 828 8061
		  	Fax: 82 8 816 2792
		  	E-mail: khkim@bukwang.co.kr
		
	 With a copy to:
	  	Boh-Young Hwang, Esq.
		  	Bae, Kim & Lee
		  	Hankook Tire Bldg.,
		  	647-15 Yoksam-dong, Gangnam-gu,
		  	Seoul 135-723, Korea
		  	 Tel.: 82-2-3404-0135

		  	 Fax.: 82-2-3404-0004

		  	 E-mail: byh@BKL.co.kr

  

 51 

			
	 To Eisai:
	  	Eisai Co., Ltd.
		  	6-10, Koishikawa 4 chome
		  	Bunkyo-ku, Tokyo JAPAN 112-8088.
		  	 Attn: Hideki Hayashi

		  	Senior Director
		  	Corporate Business Development
		  	Eisai Co., Ltd.
		  	Tel.: 81-3-3817-5150
		  	Fax.: 81-3-3811-1459
		  	E-mail:h2-hayashi@hhc.eisai.co.jp

 Any party hereto may change the address to which notices to such party are to be sent by giving notice to the
other party at the address and in the manner provided above. Any notice may be given, in addition to the manner set forth above, by facsimile or e-mail, provided that the party giving such notice obtains facsimile or e-mail that such notice has been
received acknowledgment by the party to be notified. Notices made in this manner shall be deemed to have been given when such acknowledgment has been transmitted. Any provision of this Section 20.11 to the contrary notwithstanding, any notice
to Bukwang shall be effective if given as to Bukwang prescribed above by Eisai, Despite any failure to deliver copies as prescribed above. 
  

 52 

 IN WITNESS WHEREOF, Bukwang and Eisai have caused this Agreement to be signed by their duly authorized representatives,
under seal, as of the day and year indicated above. 
  

			
	 BUKWANG PHARM. CO., LTD.

		
	By:	 	 /s/ Sung-Koo Lee

	 Name: Sung-Koo Lee

	 Title: President & CEO

	
	 EISAI CO., LTD.

		
	By:	 	 /s/ Makoto Shiina

	 Name: Makoto Shiina

	 Title: Senior Vice President

	 Corporate Business Development

  

 53 

 Exhibit A: Primary License Agreement and Amendments 
  

			
	 AGREEMENT & AMENDMENTS
	  	 DATE

	 Primary License Agreement with Primary Licensors
	  	 December 28, 1995

	 Amendment
	  	 September 1, 1997

	 Amendment
	  	 December 1, 1997

	 Amendment
	  	 February 27, 1998

	 Amendment
	  	 July 15, 2001

  

 54 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 Exhibit B: Bukwang Patents 
 B-1. [***] 
 Inventors: [***] 
 Applicant: [***] 
  

									
	 Docket Name
	  	 Country
	  	 Serial No.
	  	 Filing Date
	  	 Patent No.

					
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
		  	 [***]
	  	 [***]
	  	 [***]
	  	
					
		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  

 55 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 B-2. [***] 
 Inventor: [***] 
 Applicant: [***] 
  

									
	 Docket Name
	  	 Country
	  	 Serial No.
	  	 File Date
	  	 Patent No.

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]
	  	 [***]
	  	
		  	 [***]
	  	 [***]
	  	 [***]
	  	
		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  	 [***]
	  	 [***]
	  	

  

 56 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 B-3. [***] 
 Inventor: [***] 
 Applicant: [***] 
  

											
	 Docket Name
	  	 Country
	  	 Matter No.
	  	 Serial No.
	  	 File Date
	  	 Patent No.

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

		  	 [***]
	  		  	 [***]
	  	 [***]
	  	
		  	 [***]
	  		  	 [***]
	  	 [***]
	  	
		  	 [***]
	  		  	 [***]
	  	 [***]
	  	
		  	 [***]
	  		  	 [***]
	  	 [***]
	  	
		  	 [***]
	  		  	 [***]
	  	 [***]
	  	

  

 57 

 Exhibit C: Eisai Affiliates 
 As defined in Section 1.2 of this Agreement: 
  

					
	 Country
	  	 Affiliates
	  	 Principal Place of Business

			
	China	  	Eisai China Inc.	  	 20th Floor, Plaza 66, 1266, Nanjing Xi Road, Shanghai City, 200040 China
 Tel.: 86-21-6288-3118
 Fax.: 86-21-6288-3198

			
	India	  	 Eisai Pharmaceuticals India
 Private
Limited
	  	 Krishanlal Marwah Marg, Andheri (E),
 Mumbai 400072,
India

			
	Indonesia	  	P.T. Eisai Indonesia	  	 Ratu Plaza Office Tower, 11th Floor J1.
 Jend. Sudirman 9, Jakarta 10270, Indonesia
 Tel.: 62-21-571-3304
 Fax.: 62-21-571-3305

			
	Malaysia	  	Eisai (Malaysia) Sdn. Bhd.	  	 74, Jalan University, 46200 Petaling Jaya, Selangor, Malaysia
 Tel.: 60-3-79576964
 Fax.: 60-3-79579211

			
	Philippines	  	Hi-Eisai Pharmaceutical, Inc.	  	 20th Floor,
Multinational Bancorporation
 Centre 6805 Ayala Avenue, 1200 Makati
 City, Philippines
 Tel: 63-2-887-1047
 Fax.:
63-2-887-5172

			
	Singapore	  	Eisai Asia regional Services Pte. Ltd.	  	 152 Beach Road, No.11-04 Gateway East, Singapore 189721
 Tel.: 65-6296-6977
 Fax.: 62-6292-2185

			
	Taiwan	  	Eisai Taiwan Inc.	  	 9th Floor,
No.18, Chang An E. Road,
 Sec. 1, Taipei, Taiwan
 Tel.:
886-2-2-563-2802
 Fax.: 886-2-2-531-0063

			
	Taiwan	  	Wei-zai Co., Ltd.	  	 9th Floor,
No.18, Chang An E. Road,
 Sec. 1, Taipei, Taiwan
 Tel.:
886-2-2-523-3668
 Fax.: 886-2-2-567-3418

			
	Thailand	  	Eisai (Thailand) Marketing Co., Ltd.	  	 6th fl.,
Diethelm Tower A, 93/1 Wireless
 Road, Bangkok 10330, Thailand
 Tel: 66-2-256-6296
 Fax.: 66-2-256-6299

			
	Vietnam	  	Eisai Vietnam Representative Office	  	 35 Nguyuen Hue Street, 6th Floor, Unit 601, District 1, Ho Chi Minh City, Vietnam
 Tel.: 84-8-917-1753
 Fax.: 84-8-914-1752

  

 58 

 Exhibit D: The 303 study of the Product 
 Results of the 303 Study which include intermittent result (24 weeks) and final (48 weeks) results. 
 Such results shall be
disclosed (i) as soon as it becomes available; or (ii) immediately upon completion of each Study at 24 weeks and 48 weeks. 
 Bukwang shall make
all data and information regarding the 303 Study available to Eisai at Bukwang’s facilities during the thirty(30)- day period set forth in Section 3.2. 
  

 59 

 Exhibit E: Bukwang Know-How List of Requirements to achieve registration in China 
  

	1.	General data 

 1. Drug substance name and its related documents

 2. Origin and history of discovery and its evidence 
 3.
Summary of research data 
 4. Draft of Package Insert and its reference. 
 5. Packaging 
  

	2.	Pharmaceutical research data 

 6. Summary of pharmaceutical research
data 
 7. Composition, manufacturing method of active ingredients and finished product. 
 8. Chemical structures and the evidence reference 
 9. Quality development (research) related data and its evidence
reference 
 10. Specification and analytical method, submission of reference standard 
 11. Certificate of analysis (3 lots) 
 12. Specification and test methods of Excipients, Manufacturers name list,
Supply & Sales agreement between with the manufacturers of excipients. 
 13. Specification and analytical methods of packaging materials, which
directly contact with the medicine, including reasons for selecting those materials and safety information thereof. 
 3. Pharmacological and toxicology
data 
 14. Summary of pharmacological and toxicology data 
 15. Pharmacokinetics data and reference 
 16. General pharmacological data and reference 
 17. Acute toxicity data and reference 
 18. Chronic toxicity data and
reference 
 19. In case of combination product, the drug interaction data about efficacy, toxicity and Pharmacokinetics and reference. 
  

 60 

 20. Mutagenicity and reference 
 21. Reproductive and Developmental Toxicity and reference 
 22. ADME (Animal data) and reference 
 4. Clinical study data 
 23. Summary of Clinical study (including
foreign country data) and reference 
 24. Protocol of clinical study 
 25. Description about investigational drug 
 26. Draft of consent form and certificate of ethic committee 
 27. Full report of clinical data 
  

	*	If there is any data which is not be completed, such data should be provided to Eisai upon completion thereof. 

  

 61 

 Exhibit F: Requirements for Application of Clinical Study in China 
  

			
	 Required Information, Documents, and Material
	  	 Deadline By:

	 1. Additional Documents for Excipients:
 1.1
Specification and analytical procedures of Excipients.
 1.2 Source of Excipients (Manufacturers name list of Excipients)
 1.3 Supply & Sales agreement between Bukwang and manufacturers.
	  	Regulatory approval in Korea, but no later than the end of calendar year 2005 (in accordance with Section 8.1.)
		
	 2. Specification and analytical methods of primary packaging materials:
 Its selected rationale and safety information on this materials
	  	
		
	 3. Analytical Procedures Validation, Impurity related raw data:
 Documents of Analytical procedure validation may be required by regulatory authority in China.
	  	
		
	 4. Stability data under Chinese regulation:
 Accelerated test under 40Celsius±2Celcius/75%±5%. 6M is needed for China.
	  	
		
	 5. Pharmaceutical research data
 Stability data
(Long term and accelerated test data)
	  	June, 2008
		
	 6. Others
 Carcinogenic Toxicity and
reference
 Free Sale Certificate
	  	June, 2006

 After entering into this Agreement, in consideration of appropriate regulatory authority in China
and other country or countries in the Territory, Eisai and Bukwang shall, in good faith, strive to examine the necessity of following studies: 
  

	 	•	 	 Local and general irritation study data and reference 

  

	 	•	 	 Drug Dependence data and reference 

  

	 	•	 	 Residual organic solvent data on Finished products 

  

	 	•	 	 BSE related certificates 

  

	 	•	 	 Impurity test on D-enantiomer(long term stability) 

  

	 	•	 	 Other impurities data on Finished products/Drug Substance/Bulk capsules for packing the finished products 

  

 62 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 Exhibit G: Specification 
 CLEVUDINE Capsules 30mg 
 (Finished products) 
 ANALYTICAL STANDARD SPECIFICATION 
  

			
	 APPEARANCE
	  	A white opaque size [***]1).
		
	 IDENTIFICATION
	  	
		
	 A- HPLC
	  	The retention time of the major peak in the sample chromatogram corresponds to that in the reference chromatogram.
		
	 B- UV
	  	The ultraviolet absorption spectrum of the sample preparation corresponds to that of the reference preparation.
		
	 CONTENT UNIFORMITY
	  	 Meets requirements (KP).
 Acceptance Value: Not more than
[***].

		
	 DISSOLUTION
	  	Not less than [***] of the labeled amount of [***] is dissolved in [***].
		
	CHROMATOGRAPHIC PURITY2)	  	
		
	 Impurity A
	  	Not more than [***]
		
	 Impurity C
	  	Not more than [***]
		
	 Other Impurities
	  	Not more than [***] each
		
	 Total Impurities
	  	Not more than [***] (Based on Clevudine assayed amount).
		
	 ASSAY(HPLC)
	  	Not less than [***] and not more than [***], based on Clevudine labeled amount of [***].

  

			
	 Note
	  	 1)      [***] inscription is not determined

		
		  	 2)      Impurity A: [***]

		
		  	     Impurity C: [***]

  

 63 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 CLEVUDINE Capsules 10mg 
 (Finished products) 
 ANALYTICAL STANDARD SPECIFICATION 
  

			
	 APPEARANCE
	  	A white opaque size [***]1).
		
	 IDENTIFICATION
	  	
		
	 A- HPLC
	  	The retention time of the major peak in the sample chromatogram corresponds to that in the reference chromatogram.
		
	 B- UV
	  	The ultraviolet absorption spectrum of the sample preparation corresponds to that of the reference preparation.
		
	 CONTENT UNIFORMITY
	  	 Meets requirements (KP).
 Acceptance Value: Not more than
[***]

		
	 DISSOLUTION
	  	Not less than [***] of the labeled amount of [***] is dissolved in [***].
		
	 CHROMATOGRAPHIC PURITY2)
	  	
		
	 Impurity A
	  	Not more than [***]
		
	 Impurity C
	  	Not more than [***]
		
	 Other Impurities
	  	Not more than [***] each
		
	 Total Impurities
	  	Not more than [***] (Based on Clevudine assayed amount).
		
	 ASSAY(HPLC)
	  	Not less than [***] and not more than [***], based on Clevudine labeled amount of [***].

  

			
	 Note
	  	 1)      [***] inscription is not determined

		
		  	 2)      Impurity A: [***]

		
		  	     Impurity C: [***]

  

 64 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 CLEVUDINE (Drug Substance) 
 ANALYTICAL STANDARD SPECIFICATION 
  

			
	 Appearance
	  	White [***]
		
	 IDENTIFICATION
	  	
		
	 A-IR
	  	The infrared absorption spectrum of the sample exhibits maxima at the wave numbers as, and with similar relative intensities to, that of a reference standard, similarly
obtained.
		
	 B-HPLC
	  	The retention time of the major peak in the sample chromatogram corresponds to that in the reference chromatogram.
		
	 MELTING POINTS
	  	[***] Celsius
		
	 SPECIFIC ROTATION
	  	[***]
		
	 [a]20 D (c=0.23 ,MeOH)
	  	
		
	 WATER (Karl Fisher)
	  	Not more than [***]
		
	 RESIDUE ON IGNITION
	  	Not more than [***]
		
	 HEAVY METAL
	  	Not more than [***]
		
	 RESIDUAL ORGANIC SOLVENT
	  	[***]
		
	 ENANTIOMERIC PURITY (D-FMAU)
	  	[***]
		
	 ASSAY(HPLC)
	  	[***]
		
	 CHROMATOGRAPHIC PURITY 1)
	  	Impurity A: [***]
		
		  	Impurity C: [***] The others: [***]

  

			
	 Note
	  	 1)      Impurity A: [***]

		
		  	     Impurity C: [***]

  

 65 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 CLEVUDINE Capsules 30mg 
 (Bulk capsules for packaging the finished products) 
 ANALYTICAL STANDARD
SPECIFICATION 
  

			
	 APPEARANCE
	  	A white opaque size [***]1).
		
	 IDENTIFICATION
	  	
		
	 A- HPLC
	  	The retention time of the major peak in the sample chromatogram corresponds to that in the reference chromatogram.
		
	 B- UV
	  	The ultraviolet absorption spectrum of the sample preparation corresponds to that of the reference preparation.
		
	 CONTENT UNIFORMITY
	  	Meets requirements (KP).
		
		  	Acceptance Value: Not more than [***]
		
	 DISSOLUTION
	  	Not less than [***] of the labeled amount of [***] is dissolved in [***].
		
	 CHROMATOGRAPHIC PURITY2)
	  	
		
	 Impurity A
	  	Not more than [***]
		
	 Impurity C
	  	Not more than [***]
		
	 Other Impurities
	  	Not more than [***] each
		
	 Total Impurities
	  	Not more than [***] (Based on Clevudine assayed amount).
		
	 ASSAY(HPLC)
	  	Not less than [***] and not more than [***], based on Clevudine labeled amount of [***].

  

			
	 Note
	  	 1)      [***] inscription is not determined

		
		  	 2)      Impurity A: [***]

		
		  	     Impurity C: [***]

  

 66 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 CLEVUDINE Capsules 10mg 
 (Bulk capsules for packaging the finished products) 
 ANALYTICAL STANDARD
SPECIFICATION 
  

			
	 APPEARANCE
	  	A white opaque size [***]1).
	 IDENTIFICATION
	  	
		
	 A- HPLC
	  	The retention time of the major peak in the sample chromatogram corresponds to that in the reference chromatogram.
		
	 B- UV
	  	The ultraviolet absorption spectrum of the sample preparation corresponds to that of the reference preparation.
		
	 CONTENT UNIFORMITY
	  	Meets requirements (KP).
		
		  	Acceptance Value: Not more than [***]
		
	 DISSOLUTION
	  	Not less than [***] of the labeled amount of [***] is dissolved in [***].
		
	 CHROMATOGRAPHIC PURITY2)
	  	
		
	 Impurity A
	  	Not more than [***]
		
	 Impurity C
	  	Not more than [***]
		
	 Other Impurities
	  	Not more than [***] each
		
	 Total Impurities
	  	Not more than [***] (Based on Clevudine assayed amount).
		
	 ASSAY(HPLC)
	  	Not less than [***] and not more than [***], based on Clevudine labeled amount of [***].

  

			
	 Note
	  	 1)      [***] inscription is not determined

		
		  	 2)      Impurity A: [***]

		
		  	     Impurity C: [***]

  

 67 

 FIRST AMENDMENT TO THE 
 LICENSE AGREEMENT 
 THIS FIRST AMENDMENT (this “Amendment”), is made and entered
into as of this June 16, 2005, by and between BUKWANG PHARM. CO., LTD., with its principal offices at 398-1, Daebang-Dong, Dongjak-Ku, Seoul 156-020, Korea (hereinafter referred to as “Bukwang”), and EISAI CO., LTD., with
principal offices located at 6-10, Koishikawa 4 chome, Bunkyo-ku, Tokyo, Japan 112-8088 (hereinafter referred to as “Eisai”). 
 WHEREAS, Bukwang and Eisai entered into the License Agreement dated October 28, 2004 (the “License Agreement”); 
 WHEREAS, Eisai and Bukwang desire to amend the License Agreement. 
 NOW, THEREFORE, in consideration of the promises and the
covenants herein contained, the parties agree as follows: 
  

	1.	Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the License Agreement. 

  

	2.	Section 7.4 of the License Agreement shall be amended in its entirety as follows: 

 Exchange of Study Results. Each party shall submit a report detailing the results of each non-clinical and clinical study which it performs to the other party within thirty (30) days after completion of
the final statistical analyses of the results of such study. In addition, each party will provide the other party with semi-annual progress reports summarizing its activities in respect of the development of Licensed Products during the relevant
semi-annual period. Such reports shall cover the semi-annual periods ending each June 30 and December 31 and shall be due on or before July 20 and January 20 of each year, respectively. 
 Each party shall permit the other party and any sublicensee of the other party to the License Agreement, access to and grant such other
party and sublicensee of the other party the right to reference and use solely for purposes of the License Agreement, all data, regulatory filings and regulatory communications associated with any submissions for regulatory approval or other issues
associated with any Licensed Product possessed by the party including respective sublicensees. To the extent that any such data, regulatory filings or regulatory communications are held by a third party, one party shall arrange direct access to the
portions of such data, regulatory filings or regulatory communications for the other party. 
  

	3.	Except as amended by this Amendment, the License Agreement shall remain unchanged and continue in full force and effect. 

  

	4.	This Amendment and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder, shall be construed under and governed by the laws of
the state of Georgia, exclusive of its conflicts of laws principles. 

  

 68 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	5.	This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

  

	6.	The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties under
the Agreements, nor constitute a waiver of an provision of the Agreements. 

 [Signature Page Follows] 

 

 69 

 IN WITNESS WHEREOF, Bukwang and Eisai have caused this Amendment to be signed by their duly authorized
representatives, under seal, as of the day and year indicated above. 
  

			
	BUKWANG PHARM. CO., LTD.
		
	 By:
	 	 /s/ Sung-Koo Lee

	 Name:
	 	 Sung-Koo Lee

	 Title:
	 	 President & CEO

	
	EISAI CO., LTD.
		
	 By:
	 	 /s/ Makoto Shiina

	 Name:
	 	 Makoto Shiina

	 Title:
	 	 Senior Vice President

		 	 Corporate Business Development

  

 70 

 EXHIBIT H 
 LIST OF ALL REGULATORY FILINGS AND APPROVALS IN THE TERRITORY 

 [Logo] GILEAD 
 Advancing Therapeutics 
 Improving Lives. 
 June 17, 2005 
 Food and Drug
Administration 
 Center for Drug Evaluation and Research 
 Division of Antiviral Drug Products (HFD-530)  
 Attention: Ms. Marsha Holloman  
 9201 Corporate Boulevard 
 1st Floor Document Room 
 Rockville, MD 20850 
  

	 	Subject:	IND 63,775 (Serial No. 063) Clevudine (L-FMAU) Capsules 

	 	    	General Correspondence: Transfer of Ownership of IND 

 Dear Ms. Holloman: 
 The purpose of this communication is to inform you of the transfer of ownership of IND 63,775 for
clevudine from Gilead Sciences (Gilead) to Bukwang Pharma. Co., Ltd (Bukwang). Bukwang is represented in the US by Quintiles, Inc. (Quintiles). The transfer of the IND will be effective as of June 20, 2005. 
 There are currently no studies being conducted under IND 63,775 and all outstanding clinical and nonclinical study reports have been previously submitted to the Agency.
An IND annual report for IND 63,775 (reporting period: January 13, 2004 through January 20, 2005) was submitted to the Agency on March 17, 2005 (Serial No. 061). 
 Contact information for IND 63, 775 for both Bukwang and Quintiles is noted below: 
  

			
	 Mr. Sung-Koo Lee, President
 Bukwang Pharm. Co.
Ltd.
 398-1, Daebang-dong
 Dongjak-gu, Yeoeuido
 PO Box 572, Seoul, Korea
 Phone Number: +82 2 828 8114
 Fax : +82 2 828 8222
 Email: sklee@bukwang.co.kr
	  	 Faraneh Attarchi, Ph.D., RAC
 Director, Regulatory and
Technical Services
 Quintiles, Inc.
 PO Box 9708
 Kansas City, MO 64134-0708
 Phone Number: 816-767-6483
 Fax Number: 816-767-7375
 E-mail:
faraneh.attarchi@quintiles.com

 Please contact me at 919/294 7534 or via facsimile at 919/294-7236 if you have any questions or need additional
information. You may also contact Martine Kraus, Ph.D., Director, Regulatory Affairs, at 650/522-5722 or via facsimile at 650/522-5489. 
  

	
	 Sincerely,

	
	   
	 Nikki McMillan

	 Manager, Regulatory Affairs

  

	Enclosures:	1 Original, 2 IND copies, 1 desk copy for M. Holloman 

  

			
	Gilead Sciences. Inc 333 Lakeside Drive Foster City, CA 94404 USA	  	
	phone 650 574 3000 facsimile 650 578 9264	  	www.gilead.com

  

 1 

			
	 DEPARTMENT OF HEALTH AND HUMAN SERVICES
  
 PUBLIC HEALTH SERVICE
  
 FOOD AND DRUG ADMINISTRATION
  
 INVESTIGATIONAL NEW DRUG APPLICATION (IND)
  
 (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)
	  	 Form Approved: OMB No. 0910-0014.
  
 Expiration Date: January 31, 2006
  
 See OMB Statement on Reverse.
  
 NOTE: No drug may
be shipped or clinical investigation begun until an IND for that investigation is in effect (21 CFR 312.40).

	  
		
	 1.      NAME OF SPONSER
          Gilead Sciences, Inc.
	  	 2.      DATE OF SUBMISSION
          June 17, 2005

		
	 3.      ADDRESS (Number, Street, City, State and Zip Code)
          333 Lakeside Drive Foster City, CA 94404
	  	 4.      TELEPHONE NUMBER (Include Area Code)
          650-574-3000

		
	 5.      NAME(S) OF DRUG (Include all available names: Trade, Generic,
Chemical, Code)
          Clevudine, L-FMAU
	  	 6.      IND NUMBER (If previously assigned)
          63,775

		
	 7.      INDICATION(S) (Covered by this submission) Treatment of HBV Infection
	  	
		
	 8.      PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED:
  
	  	
	
	  ̈
PHASE 1 x PHASE 2  ̈ PHASE 3  ̈ OTHER _________________
 (Specify)       

	
	 9.      LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR
ANTIBIOTIC APPLICATIONS (21 CFR Part 314), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION.

			
		
	 10.    IND submission should be consecutively numbered. The initial IND should be numbered: “Serial number:
000.” The next submission (e.g., amendment, report, or correspondence) should be numbered “Serial Number: 001.” Subsequent submissions should be numbered consecutively in the order in which they are submitted. 
	  	 SERIAL NUMBER
 0   6   3

		
	 11.    THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply)

q INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND)
	  	 q  RESPONSE TO CLINICAL HOLD

					
			
	 PROTOCOL AMENDMENT(S):
	  	INFORMATION AMENDMENT(S):	  	IND SAFETY REPORT(S):
			
	  ̈   NEW PROTOCOL
  ̈   CHANGE IN PROTOCOL
  ̈   NEW INVESTIGATOR
	  	  ̈
CHEMISTRY/MICROBIOLOGY
  ̈ PHARMACOLOGY/TOXIOCOLOGY
 x
CLINICAL
	  	  ̈
INITIAL WRITTEN REPORT
  ̈ FOLLOW-UP TO A WRITTEN REPORT

		
	  ̈   RESPONSE TO FDA REQUEST FOR INFORMATION      ̈ ANNUAL REPORT
	  	  ̈ GENERAL
CORRESPONDENCE

	
	  ̈   REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN,     x OTHER
            Transfer of IND
     INACTIVATED, TERMINATED OR DISCONTINUED
                                        
                                (Specify)

	
	CHECK ONLY IF APPLICABLE

					
	JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO CITED CFR SECTION FOR FURTHER INFORMATION.

  

					
	  ̈   TREATMENT IND 21
CFR 312.35(b)
	 	  ̈   TREATMENT PROTOCOL
21 CFR 312.35(a)
	 	  ̈   CHARGE REQUEST/
NOTIFICATION 21 CFR 312.7(d)

		 		 	
	FOR FDA USE ONLY
	CDR/DBIND/DGD RECEIPT STAMP	 	DDR RECEIPT STAMP	 	DIVISION ASSIGNMENT:
	 	 
		 		 	
		 		 	IND NUMBER ASSIGNED:
			
	FORM FDA 1571 (1/03)	 	PREVIOUS EDITION IS OBSOLETE.	 	PAGE 1 OF 2

  

 2 

									
	 12.
	  	 CONTENTS OF APPLICATION
 This application contains the following items: (Check all that apply)

		
	x	  	 1.      Form FDA 1571 [21 CFR 312.23(a)(1)]

		
	 ̈	  	 2.      Table of Contents [21 CFR 312.23(a)(2)]

		
	 ̈	  	 3.      Introductory statement [21 CFR 312.23(a)(3)]

		
	 ̈	  	 4.      General Investigational plan [21 CFR 312.23(a)(3)]

		
	 ̈	  	 5.      Investigator’s brochure [21 CFR 312.23(a)(5)]

		
	 ̈	  	 6.      Protocol(s) [21 CFR 312.23(a)(6)]

				
		  		  	 ̈	  	 a.      Study protocol(s) [21 CFR 312.23(a)(6)]

				
		  		  	 ̈	  	 b.      Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s)
FDA 1572

				
		  		  	 ̈	  	 c.      Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA
1572

				
		  		  	 ̈	  	 d.      Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or
completed Form(s) FDA 1572

		
	 ̈	  	 7.      Chemistry, manufacturing, and control data [21 CFR
312.23(a)(7)]

				
		  		  	 ̈	  	Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)]
		
	 ̈	  	 8.      Pharmacology and toxicology data [21 CFR
312.23(a)(8)]

		
	 ̈	  	 9.      Previous human experience [21 CFR 312.23(a)(9)]

		
	 ̈	  	 10.    Additional information [21 CFR 312.23(a)(10)]

									
		
	 13.
	  	 IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION     ̈  YES     ̈  NO
 IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION?     ̈  YES     ̈  NO
 IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL
STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED. This statement will be provided in the next submission.

		
	 14.
	  	 NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS
  
 Herve Mornmeja-Marin, M.D.
 Associate Director, Clinical Research

		
	 15.
	  	 NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG

 
 Franck Rousseau, M.D.
 Vice President, Clinical Research

	
	I agree not to begin clinical investigations until 30 days after FDA’s receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also
agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set fourth In 21 CFR Part 56 will be
responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.
			
	16.	  	 NAME OF SPONSOR OR SPONSOR’S AUTHORIZED REPRESENTATIVE
 Nikki McMillan Manager, Regulatory Affairs
	  	 17.      SIGNATURE OF SPONSOR OR SPONOR’S AUTHORIZED REPRESENTATIVE

				
	18.	  	 ADDRESS (Number, Street, City, State and Zip Code) 
 4611 University Dr., 4 University Place Durham, NC 27707
	  	 19.      TELEPHONE NUMBER (include Area Code)
            919/294-7534
	  	 20.      DATE
            June 17, 2005

					
	
	 (WARNING: A willfully false statement is a criminal offense. U.S.C. Title 1B, Sec. 1001.)

	
	 Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden to:

			
	 Food and Drug Administration
 CBER (HEM-99)
 1401 Rockville Pike
 Rockville, MD 20852-1448
	 	 Food and Drug Administration
 CDER (HFD-94)
 12229 Wilkins Avenue
 Rockville, MD 20852
	 	“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.”
	Please DO NOT RETURN this application to this address.
	FORM FDA 1571 (1/03)	 	PREVIOUS EDITION IS OBSOLETE	 	PAGE 2 OF 2

  

 3 

 June 20, 2005 
 Debra
Birnkrant, M.D. 
 Division of Antiviral Drug Products (HFD-530) 
 Center for Drug Evaluation and Research 
 Food and Drug Administration 
 1st Floor Document Room 
 9201 Corporate Boulevard 
 Rockville, MD 20850 
  

			
	Subject: IND 63,775	  	GENERAL CORRESPONDENCE:
	     Clevudine (L-FMAU) Capsules
	  	Transfer of Regulatory Responsibilities

 Serial No. 0064 
 Dear Dr. Birnkrant: 
 The purpose of this letter is to inform you that effective June 20, 2005, Quintiles, Inc.,
Kansas City, MO, assumes the responsibility from Bukwang Pharma. Co., Ltd (Bukwang), as the U.S. Agent and Authorized Representative for Clevudine (L-FMAU) capsule IND (ND # 63, 775). Previous to this transfer Gilead Sciences (Gilead) had the
regulatory responsibilities for the above mentioned IND. 
 The duties to be performed by Quintiles are: 
  

	 	•	 	 Verbal and written interaction with the FDA 

  

	 	•	 	 Conduct of meeting with the FDA 

  

	 	•	 	 Maintenance of the IND 

 The contact person at
Quintiles is: 
  

			
	 Faraneh Attarachi, Ph.D., RAC

	 Director, Regulatory Affairs and Technical Services

	 Quintiles, Inc.

	 Mail station F3-M3026

	 P.O. Box 9708

	 Kansas City, MO

	 64134-0708

	 Telephone:
	  	 (816) 767-6483

	 Fax:
	  	 (816) 767-7375

  

 4 

			
	Bukwang Pharma Co. Ltd. IND 63,775	  	Pg. 2
	Serial No. ####	  	
	June 15, 2005	  	

 If you have any questions regarding the above information, please do not hesitate to contact me at 301-272-3130.

  

	
	 Sincerely,

	
	 
	 Louise Shibley

	 Vice President, Regulatory Affairs and Technical Services

	 Quintiles, Inc.

	 Rockville, MD

  

	cc:	Ms. Marsha Holloman 

  

 5 

 EXHIBIT I 
 AMENDMENT TO THE PRIMARY LICENSE AGREEMENT 

 AMENDMENT NUMBER 5 
 to 
 LICENSE AGREEMENT 
 amongst 
 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 
 YALE UNIVERSITY and 
 BUKWANG PHARM.
CO., LTD 
 THIS AMENDMENT NUMBER 5 (this “Amendment Number 5”), effective as of this 17th day of June, 2005 (the
“Effective Date”), by and among the UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., a nonprofit Georgia corporation with offices located at Boyd Graduate Studies Research Center, The University of Georgia, Athens, Georgia
30602-7411 (“UGARF”), YALE UNIVERSITY, located in New Haven, Connecticut (“YALE”), and BUKWANG PHARM, CO., LTD., a Korean corporation, with headquarters located at 398-1, Daebang-Dong, Dongjak-Ku, Seoul 156-020,
Korea (hereinafter referred to as “BUKWANG”). 
 WITNESSETH: 
 WHEREAS, UGARF, YALE and BUKWANG have entered into a License Agreement as of December 28, 1995, and Amendment Number 1 thereto dated
September 1, 1997, Amendment Number 2 thereto dated December 1, 1997, Amendment Number 3 thereto dated February 27, 1998, and Amendment Number 4 thereto dated July 15, 2001 (collectively, the “License
Agreement”); 
 WHEREAS, BUKWANG and EISAI CO. LTD., with principal offices located at 6-10, Koishikawa 4 chome, Bunkyo-ku, Tokyo,
Japan 112-8088, (“EISAI”) have entered into a license agreement dated October 29, 2004 (the “Eisai Sublicense Agreement”), pursuant to which BUKWANG has granted EISAI an exclusive sublicense to the Bukwang
Patents and Bukwang Know-How (each as defined in the Eisai Sublicense Agreement), in certain countries; and 
 WHEREAS, BUKWANG and
PHARMASSET, INC., with principal offices located at 1860 Montreal Road, Tucker, Georgia 30084 (“PHARMASSET”) have entered into a license agreement dated as of even date herewith (the “Pharmasset Sublicense
Agreement”), pursuant to which BUKWANG has granted PHARMASSET an exclusive sublicense to the Bukwang Patents and Bukwang Know-How (each as defined in the Pharmasset Sublicense Agreement), in certain countries; and 
 WHEREAS, PHARMASSET has requested that UGARF, YALE and BUKWANG execute this Amendment Number 5 in order to reconcile certain inconsistencies between the
License Agreement and the Pharmasset Sublicense Agreement and to clarify certain terms of the Eisai Sublicense Agreement, and UGARF, YALE and BUKWANG are willing to do so. 
  

 1 

 NOW, THEREFORE, in consideration of the premises and the covenants herein contained, the parties agree as
follows: 
  

	1.	Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the License Agreement, except as otherwise explicitly set forth herein.

  

	2.	LICENSOR hereby expressly approves BUKWANG’s entering into the Pharmasset Sublicense Agreement. Accordingly, Section 2.8 of Amendment Number 1 is hereby satisfied.

  

	3.	LICENSOR confirms that the License Agreement is in full force and effect and LICENSOR is not aware of any breach thereof by any party thereto. 

  

	4.	Section 1.1 of the License Agreement shall be amended in its entirety as follows: 

 “Affiliate” shall mean any corporation or non-corporate business entity which controls, is controlled by, or is under common control with a party to this Agreement. A corporation or non-corporate business
entity shall be regarded as in control of another corporation if it owns, or directly or indirectly controls, at least fifty (50%) percent of the voting stock of the other corporation, or (a) in the absence of the ownership of at least
fifty (50%) percent of the voting stock of a corporation or (b) in the case of a non-corporate business entity, or non-profit corporation, if it possesses, directly or indirectly, the power to direct or cause the direction of the
management and policies of such corporation or non-corporate business entity, as applicable. 
  

	5.	Section 1.13 of the License Agreement shall be amended in its entirety as follows: 

 “Net Selling Price” of Licensed Products shall mean the gross sales price billed by BUKWANG, its Affiliates or sublicensees to independent customers less (to the extent actually paid, given or allowed, as
appropriate, without duplication and in direct connection to the sales of Licensed Product): (a) normal and customary trade, quantity and cash discounts, all rebates (including those paid to third party payors), price reductions,
reimbursements, credits or chargebacks, including any credits, volume rebates, charge-back and prime vendor rebates, or reimbursements granted or given to wholesalers and other distributors, buying groups, health care insurance carriers, pharmacy
benefit management companies, health maintenance organizations or other institutions or health care organizations; (b) sales, value added, use, or other similar taxes, and tariffs, custom duty, excise or other duty and any other official
governmental charges; (c) transportation, freight, insurance and handling charges; (d) adjustments, allowances or credits (calculated on a per unit basis) to customers, including on account of price adjustments, official governmental
requirements, billing errors, rejection, damage, recalls, or returns (including allowances actually given for spoiled damaged, out-dated, rejected, returned Licensed Product sold, withdrawals and recalls) of such Licensed Product; and
(e) rebates or like payments paid in connection with sales of Licensed Products to any governmental or regulatory authority in respect of any state or federal Medicare, Medicaid, P.P.R.S., or similar programs or to social or welfare systems,
all determined in accordance with U.S. GAAP. For purposes hereof, a sale shall be deemed to occur when a Licensed Product is billed. 
  

 2 

 In the event that BUKWANG or its Affiliates or sublicensees transfer, exchange or
otherwise dispose of any Licensed Products to a third party whether by gift, other than gifts for humanitarian purposes, or for non-monetary consideration (e.g., barter or exchange), such transfer, exchange or other disposition shall be considered a
Sale for accounting and royalty purposes in the royalty period in which such Sale occurs. The Net Selling Price for any such transfer, exchange or other disposition shall be determined on a country-by-country basis and shall be the average price of
“arm’s length” sales by BUKWANG or its Affiliates or sublicensees in such country during the royalty period in which such sale occurs or, if no such “arm’s length” sales occurred in such country during such royalty
period, during the last royalty period in which such “arm’s length” sales occurred. If no “arm’s length” sales have occurred in a particular country, the Net Selling Price for any such transfer, exchange or other
disposition in such country, shall be the average price of “arm’s length” sales in all countries in the particular territory of BUKWANG or its Affiliates or sublicensees during such royalty period. 
 For purposes of determining the Net Selling Price of a Licensed Product that is sold as a Combination Product, the Net Selling Price of any such
Combination Product shall be determined in any accounting period by multiplying the Net Selling Price of the Combination Product by the fraction A/(A+B), where A is the average invoiced price per unit of the Licensed Product when sold as a
stand-alone Licensed Product in finished form in the applicable country and B is the average invoice price of the other product(s) sold as stand-alone product(s) in finished form in the applicable country. In the event that such average invoiced
price cannot be determined for the Licensed Product or the other product(s), the fraction applied to the Net Selling Price in the applicable country for purposes of determining royalties shall be the percentage determined by dividing one by the
number of active ingredients in that Combination Product. 
  

	6.	Section 1.15 of the License Agreement shall be amended in its entirety as follows: 

 “Sale” or “Sold” shall mean the sale, transfer, exchange, or other disposition to a third party of Licensed Products whether by gift, other than gifts for humanitarian purposes, or for non-monetary
consideration (e.g., barter or exchange), by BUKWANG, its Affiliates or sublicensees. For purposes of this Agreement, the disposition of a Licensed Product or the use of the Licensed Product in clinical studies, compassionate use, named patient
programs, under a treatment IND, introduction, without sales, into a formulary or equivalent thereof, any nonregistrational non-commercial studies, patient assistance program or any similar instance shall not be deemed a Sale. 
  

	7.	The following definition shall be added to Article 1 of the License Agreement: 

 “Combination Product” shall mean any Licensed Product that contains one or more additional pharmaceutically active ingredients that are not Licensed Products. 
  

 3 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	8.	Delete the last two sentences of Section 2.4 of the License Agreement and replace them with the following: 

 If at any time during the term of this Agreement, the United States government should take action which terminates this Agreement or requires that this
Agreement be terminated, BUKWANG acknowledges this Agreement will automatically terminate. In such event, BUKWANG shall not have any right to the return of any payments of any kind made by it to LICENSOR prior to the date of termination, other than
any overpayment of earned royalties as determined by any audit conducted pursuant to Section 6.2 of this Agreement. 
  

	9.	Section 2.5 of the License Agreement shall be amended in its entirety as follows: 

 BUKWANG shall have the right to enter into sublicensing arrangements for the rights, privileges and licenses granted hereunder, provided that BUKWANG shall remain responsible for the operations of its sublicensees
relevant to this Agreement as if such operations were carried out by BUKWANG, including but not limited to the payment of all fees and royalties due under this Agreement. Upon any termination of this Agreement, the sublicensees’ rights shall
also terminate, however, Pharmasset and LICENSOR have entered into a Memorandum of Understanding that will permit Pharmasset to become a direct licensee of LICENSOR within the territory specified under the Pharmasset Sublicense Agreement.

 BUKWANG shall require its Affiliates and sublicensees to share with BUKWANG the results of non-clinical and clinical studies and progress
reports related to the development of Licensed Products. BUKWANG shall further ensure that such study results and progress reports may be shared among all of BUKWANG’s Affiliates and sublicensees involved in the development of Licensed
Products. 
  

	10.	Section 2.6 of the License Agreement shall be amended in its entirety as follows: 

  

	 	(i)	LICENSOR agrees that PHARMASSET’s performance of its obligations set forth in the Pharmasset Sublicense Agreement, as BUKWANG’s sublicensee, shall be deemed to be complete
performance of any diligence obligations which BUKWANG has in the countries licensed to PHARMASSET, including, but not limited to, any and all obligations set forth in Article 3. 

  

	 	(ii)	BUKWANG agrees that the Pharmasset Sublicense Agreement shall contain a provision for the payment of a royalty of no less than [***] percent ([***]%) of the Net Sales (as defined in
the Pharmasset Sublicense Agreement) of all Licensed Products (as defined in the Pharmasset Sublicense Agreement) by PHARMASSET with the following exceptions: 

  

	 	(a)	 if at any time during the term of the Pharmasset License Agreement, (i) a third party or third parties commence selling a product in a country of the territory
licensed to Pharmasset and (ii) such product contains any Licensed Product (as defined in the Pharmasset Sublicense Agreement) (“Unlicensed Unit Sales”), and (A) if such Unlicensed Unit Sales for any royalty period amount
to more than [***] percent ([***]%) and less than [***] percent ([***]%) of Pharmasset’s Unit Sales of Licensed Product (as 

  

 4 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	 
defined in the Pharmasset Sublicense Agreement) in such country in such royalty period, determined in accordance with the Pharmasset License Agreement, then
Pharmasset’s royalty obligation in such country with respect to such Licensed Product (as defined in the Pharmasset Sublicense Agreement) may be reduced by [***] percent ([***]%) of the Net Sales (as defined in the Pharmasset License
Agreement), or (B) if such Unlicensed Unit Sales for any royalty period amount to more than [***] percent ([***]%) of Pharmasset’s Unit Sales of Licensed Product (as defined in the Pharmasset Sublicense Agreement) in such country in such
royalty period, determined in accordance with the Pharmasset License Agreement, then Pharmasset’s royalty obligation in such country with respect to such Licensed Product (as defined in the Pharmasset Sublicense Agreement) may be reduced by
[***] percent ([***]%) of the Net Sales (as defined in the Pharmasset License Agreement). Notwithstanding the foregoing, in no event may the royalty due to Bukwang be reduced to less than [***] percent ([***]%); and 

  

	 	(b)	if Pharmasset, due to a claim of infringement by a third party, is required, after consultation with Bukwang, to obtain a license from any third party under any patent in order to
use, make, have made, offer for sale or sell a Licensed Product (as defined in the Pharmasset License Agreement), or if Pharmasset is required, after consultation with Bukwang, to pay a royalty under such license calculated on sales of a Licensed
Product (as defined in the Pharmasset License Agreement) in any country, and the infringement of such third party patent cannot reasonably be avoided by Pharmasset, or if Pharmasset is required by a court of competent jurisdiction to pay such a
royalty, then Pharmasset’s obligation to pay royalties to Bukwang based on sales of the same Licensed Product (as defined in the Pharmasset License Agreement) in such country may be reduced by [***] percent ([***]%) of the amount of the royalty
paid to such third party. In addition, if Pharmasset is required to pay upfront payments, license fees, milestone payments or other similar payments to such third party in consideration for such license, then Pharmasset may amortize the amount of
such other payment equally over a [***] ([***]) year period and apply such amounts as a credit against its royalty payment obligations. Notwithstanding the foregoing, in no event shall the royalty due to Bukwang pursuant to the Pharmasset License
Agreement be reduced to less than [***] percent ([***]%). 

  

	 	(c)	Should a compulsory license be granted to any third party in any country of the Territory (as defined in the Pharmasset License Agreement) to make, have made, use, import, offer for
sale or sell Licensed Products (as defined in the Pharmasset License Agreement), the royalty rate payable for sales of the Licensed Products (as defined in the Pharmasset License Agreement) by Pharmasset in such country shall be adjusted to match
any lower royalty rate granted to the third party for such country. 

  

 5 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	 	(iii)	Notwithstanding anything to the contrary, BUKWANG and LICENSOR acknowledge and agree that any amounts owed to LICENSOR as a result of the Pharmasset Sublicense Agreement shall be
the sole responsibility of BUKWANG. Any amounts owed or reports required by PHARMASSET under the Pharmasset Sublicense Agreement shall be paid and reported directly to BUKWANG who shall be solely responsible for remitting the proper amounts to
LICENSOR under this Agreement. 

  

	11.	Section 2.10 of the License Agreement shall be amended in its entirety as follows: 

 Except for those instances under Article 2.6 of this Agreement in which the royalty rate may drop to [***] percent ([***]%), BUKWANG agrees that payments to LICENSOR in respect of royalties received by BUKWANG under
the Pharmasset Sublicense Agreement shall not be less than [***] percent ([***]%) of Net Sales of Licensed Products (as defined in the Pharmasset Sublicense Agreement) for any royalty period during the term hereof. Should the royalty rate under
Article 2.6 drop from [***] percent ([***]%) to [***] percent ([***]%), BUKWANG agrees that payments to LICENSOR in respect of royalties received by BUKWANG under the Pharmasset Sublicense Agreement shall not be less than [***] percent ([***]%) of
Net Sales of Licensed Products (as defined in the Pharmasset Sublicense Agreement) for any royalty period during the term hereof. 
  

	12.	Section 2.11 of the License Agreement shall be amended in its entirety as follows: 

 BUKWANG agrees to share with LICENSOR all license issue fees, milestone payments or fees other than royalties and all royalties on Licensed Products (as that term is defined in the applicable sublicense agreement) it
receives under any sublicense agreement in the following manner: 
  

							
	 	  	LICENSOR	 	 	BUKWANG	 
	 Income from royalties from sublicensee(s)
	  	[***]	%	 	[***]	%
	 Income from sublicense issue fees, milestone payments, or fees other than royalties
	  	[***]	%	 	[***]	%

 For the purposes of this Section 2.11, the term “royalty” shall mean payments
received by Bukwang that are based upon actual or anticipated sales, including but not limited to running royalties, minimum royalty payments and any other fees that are based upon annual or cumulative sales volumes. 
 For the avoidance of doubt under this Article 2.11, with the exception of the first [***] dollars ($[***]) in payments under sublicenses granted within
the Asian territory and the first [***] dollars ($[***]) in payments under sublicenses granted in the territories outside of Asia, any payments received by BUKWANG that are based upon annual or cumulative sales of Licensed Products (as that term is
defined in the applicable sublicense agreement) shall be considered royalty payments and [***] percent ([***]%) 

  

 6 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 
of such payments paid to LICENSOR. [***] percent ([***]%) of such first [***] dollars ($[***]) in payments under sublicenses granted within the Asian
territory and such first [***] dollars ($[***]) in payments under sublicenses granted in the territories outside of Asia shall be paid to LICENSOR. 
 BUKWANG shall not be required to share with LICENSOR any license fees or royalties received as consideration from sublicensees under licenses to trademarks owned by BUKWANG. 
  

	13.	A new Section 2.12 shall be added to the License Agreement as follows: 

 LICENSOR agrees not to sue BUKWANG or its Affiliates or sublicensees for patent infringement for practicing a claim of Licensed Patents if practicing said claim is required to make, have made, use, import, offer for
sale, sell or have sold Licensed Products in the Territory in the Field of Use. 
 To the extent that the rights have not already been
obligated exclusively to another party, and subject to the exclusions found in Exhibit C of the Pharmasset Sublicense Agreement, LICENSOR hereby grants BUKWANG a first right of negotiation for a license, within the Field of Use, under
LICENSOR’s ownership rights in new inventions made by LICENSOR where such new inventions may not be practiced without infringing the Licensed Patents. Such first right of negotiation shall extend for a period of sixty (60) days from the
time that LICENSOR discloses such new inventions to BUKWANG in writing. In the event that BUKWANG exercises its first right to negotiate for a license, such license shall be restricted to the Territory and the Field of Use and shall be completed
within one hundred eighty (180) days of BUKWANG’s exercise of its first right to negotiate. Should BUKWANG not exercise its first right to negotiate within such sixty (60) day period, or should a license not be consummated within said
one hundred eighty (180) day period, LICENSOR shall be free to offer a license to third parties without obligation to BUKWANG, and BUKWANG shall not have the benefit of any agreement not to sue described above in this Section 2.12.

  

	14.	A new Section 2.12 shall be added to the License Agreement as follows: 

 In the event this Agreement is terminated and one or more of BUKWANG’s sublicensees becomes a direct licensee with LICENSOR and such sublicensees’ licenses with BUKWANG continue with respect to any BUKWANG
patents and/or know-how that are not licensed pursuant to the sublicense under this Agreement, BUKWANG agrees that the royalties to be paid by such sublicensees to BUKWANG in a given country shall not be more than [***] percent
([***]%) of the royalty due to Bukwang for such country before such termination of this Agreement. As an example, in the event that this Agreement is terminated and a sublicensee becomes a direct licensee with LICENSOR and the royalty payable
by such sublicensee to BUKWANG in a given country under the sublicense agreement prior to such termination was [***] percent ([***]%), then the royalty due to BUKWANG under such sublicensee’s continuing licenses with BUKWANG under any
BUKWANG patents and/or know-how for such country shall not be more than [***] percent ([***]%). 
  

 7 

	15.	Section 3.2 of the License Agreement shall be amended in its entirety as follows: 

 Lack of Diligence. If, on a country-by-country basis, LICENSOR concludes that BUKWANG is not diligent in developing and Selling Licensed Products pursuant to Section 3.1 for any reason other than
(a) the withholding by a regulatory agency of marketing approval despite BUKWANG’s diligent efforts to obtain such approval; or (b) unanticipated technical or scientific problems which have been reported to LICENSOR in writing; or
(c) other causes beyond the reasonable control of BUKWANG; then LICENSOR, may, at its sole discretion, on a country-by-country basis, terminate this Agreement pursuant to Section 12.4 hereof. 
  

	16.	Section 3.3 of the License Agreement shall be amended in its entirety as follows: 

 BUKWANG agrees, that BUKWANG, its Affiliates and sublicensees shall use commercially reasonable efforts, to clinically develop and obtain Registration of L-FMAU, either as a monotherapy or a combination therapy, on a
country by country basis, in their respective territories. 
  

	17.	Add the following paragraph to Section 4.4 of the License Agreement as follows: 

 Invoices, including reasonable substantiation thereof, shall be submitted once in respect of each fiscal quarter as promptly as practicable after the end of such quarter. Payments shall be due net thirty
(30) days from the date of invoice. BUKWANG hereby authorizes LICENSOR to submit, and LICENSOR hereby agrees to submit, all invoices in respect of the territory licensed to PHARMASSET under the Pharmasset Sublicense Agreement directly to
PHARMASSET for reimbursement. 
  

	18.	Add the following sentence to Section 5.1 of the License Agreement as follows: 

 Any provision of this Agreement to the contrary notwithstanding, payments and reports due hereunder in respect of payment and reports received by BUKWANG from PHARMASSET pursuant to the Pharmasset Sublicense Agreement
will not be due to be submitted to LICENSOR until sixty (60) days after the date of receipt by BUKWANG from PHARMASSET. 
  

	19.	Section 5.4 of the License Agreement shall be amended in its entirety as follows: 

 Currency Conversion. With respect to sales of the Licensed Product invoiced in United States dollars, the Net Selling Price shall be expressed in United States dollars. With respect to sales of the Licensed
Product invoiced in a currency other than United States dollars, the Net Selling Price shall be expressed in the domestic currency of the party making the sale together with the United States dollar equivalent of the royalty payable, calculated
using the simple average of the exchange rates published in the Wall Street Journal on the last day of each month during the reporting period. If any of BUKWANG, its Affiliates or sublicensees makes any sales invoiced in a currency other than its
domestic currency, the Net Selling Price shall be converted to its domestic currency in accordance with BUKWANG’s or its Affiliate’s or sublicensee’s normal accounting practices. 
  

 8 

	20.	Section 5.5 of the License Agreement shall be amended in its entirety as follows: 

 Interest. In the event any payment due hereunder is not made when due, the payment shall accrue simple interest (beginning on the date such payment is due) at the lower of (a) the US Prime Rate, as
reported in the Wall Street Journal, Eastern Edition, on the due date (or, if the due date is not a business day, on the last business day prior to such due date), or (b) the maximum rate permitted by applicable law, and such payment when made
shall be accompanied by all interest so accrued. The payment of such interest shall not foreclose LICENSOR from exercising any other rights it may have because any payment is late. 
  

	21.	Add the following as Section 5.6 of the License Agreement as follows: 

 Performance of BUKWANG’s Sublicensee. LICENSOR agrees that any and all reports required to be submitted by BUKWANG pursuant to this Article 5 may instead be submitted by PHARMASSET in respect of that
portion of the Licensed Territory in which the Pharmasset Sublicense Agreement is in effect and that submission of a report by PHARMASSET to LICENSOR in accordance with this Article 5 shall be deemed to satisfy BUKWANG’s obligation do to so
under this Article 5. 
  

	22.	In Section 6.2 of the License Agreement, five percent (5%) shall be changed to seven and one half percent (7.5%). 

  

	23.	Section 7.1 of the License Agreement shall be amended in its entirety as follows: 

 Prosecution and Maintenance of Licensed Patents. The prosecution and maintenance of the Licensed Patents shall be the primary responsibility of LICENSOR. LICENSOR shall keep BUKWANG informed as to all
developments with respect to Licensed Patents and shall keep PHARMASSET informed as to all developments with respect to Licensed Patents in that portion of the Licensed Territory licensed to PHARMASSET under the Pharmasset Sublicense Agreement.
BUKWANG shall be afforded reasonable opportunities to advise LICENSOR and cooperate with LICENSOR in such prosecution and maintenance and PHARMASSET, on behalf of BUKWANG, shall be afforded reasonable opportunities to advise LICENSOR and cooperate
with LICENSOR in such prosecution and maintenance with respect to Licensed Patents in that portion of the Licensed Territory licensed to PHARMASSET under the Pharmasset Sublicense Agreement. 
 If BUKWANG fails to reimburse LICENSOR for any patent prosecution expenses respecting any patent application or issued patent included in
the Licensed Patents within the time allowed therefor, upon at least thirty (30) days’ prior notice to BUKWANG, LICENSOR shall notify PHARMASSET of BUKWANG’s failure to pay such prosecution expenses if any such expenses respect a
patent application or an issued patent included in the Licensed Patents in that portion of the Licensed Territory licensed to PHARMASSET under the Pharmasset Sublicense Agreement. If PHARMASSET fails 

  

 9 

 
to reimburse LICENSOR for any such patent prosecution expenses within thirty (30) days after receipt of notice, LICENSOR may remove such patent
application or issued patent from the Licensed Patents and LICENSOR shall be free, at its election to abandon or maintain the prosecution of such patent application or issued patent or grant rights to such patent application or issued patent to
third parties. 
 BUKWANG, upon ninety (90) days advance written notice to LICENSOR, may advise LICENSOR that it no
longer wishes to pay expenses for filing, prosecuting or maintaining one or more Licensed Patents. If such Licensed Patents are in that portion of the Licensed Territory licensed to PHARMASSET under the Pharmasset Sublicense Agreement, LICENSOR
shall notify PHARMASSET of BUKWANG’s refusal to pay such expenses. If such Licensed Patents are outside of the PHARMASSET licensed territory, or if PHARMASSET does not, within thirty (30) days of such notice, pay the expenses for filing,
prosecution or maintaining the Licensed Patents in the territory licensed to PHARMASSET under the Pharmasset Sublicense Agreement, LICENSOR may, at its option, elect to pay such expenses or permit such Licensed Patents to become abandoned or lapsed.
If LICENSOR elects to pay such expenses, such patents shall not be subject to any license granted to BUKWANG hereunder and LICENSOR shall be free to grant rights to such Licensed Patents to third parties. 
  

	24.	Add the following to Section 7.3 to Article 7 of the License Agreement as follows: 

 7.3 Further Obligations. 
 (a) Except as otherwise provided in Article 8, each
party’s responsibilities for patent prosecution activities pursuant to this Article 7 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all
interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration
to the other party’s or its sublicensee’s position with respect to any such patent prosecution activities (which term, as used herein, shall include without limitation, any inter partes activities of the type described in the first
sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution
activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensee, as applicable, may initiate, pursue or assume such patent prosecution activities, as its
sole expense. 
 (b) In conducting its patent prosecution activities under this Agreement, each party may use patent attorneys
selected by it in its own discretion. In addition to the other obligations set forth in this Article 7, each party undertakes to keep the other party and, if applicable, such other party’s sublicensee throughout the term of this Agreement
regularly informed of the status and progress of the patent prosecution activities it undertakes under this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicable and as appropriate for the licensed
territory for a given sublicensee, upon reasonable request and at reasonable intervals, with all correspondence 

  

 10 

 
with the applicable patent office counterparts with respect to the applicable patents and patent applications. To the extent that a party has not previously
done so, or promptly upon request by the other party or sublicensee, in order to assist such other party or its sublicensee in connection with any of its activities or the exercise of any of its rights pursuant to Article 7, such party shall provide
the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited,
copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate any other patent prosecution activities for which it
has patent prosecution responsibility pursuant to this Article 7, it shall give the other party or its sublicensee notice thereof in a sufficiently timely manner so as to enable such other party or sublicensee to determine whether to assume patent
prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least sixty (60) days before any abandonment, lapse or any other relevant deadline. 
 (c) BUKWANG and LICENSOR agree that, during the term of the Pharmasset Sublicense Agreement, the rights of BUKWANG under this Article 7
shall be exercised, if at all, by PHARMASSET with respect to all patent prosecution activities in any portion of the Licensed Territory in which the Pharmasset Sublicense Agreement is then in effect. With respect to such patent prosecution
activities, LICENSOR shall communicate with PHARMASSET directly. 
  

	25.	Section 8.1(c) of the License Agreement shall be amended in its entirety as follows: 

 If LICENSOR shall fail within ninety (90) days after receiving notice from BUKWANG of a potential infringement, to either (i) terminate such infringement or (ii) to institute, either jointly as provided
in subparagraph (a) above or solely as provided in subparagraph (b) above and, thereafter, to prosecute such suit diligently, or (iii) if LICENSOR notifies BUKWANG that it does not plan to institute or join in such suit, BUKWANG may
institute suit, and if required by law or required in order to bring suit or other legal action, name LICENSOR as a plaintiff. BUKWANG shall bear the entire cost of such litigation, including defending any counterclaims brought against LICENSOR and
paying any judgments rendered against LICENSOR, and shall be entitled to retain the entire amount of any recovery or settlement. 
  

	26.	A new Section 8.1(d) shall be added to the License Agreement as follows: 

 In the event BUKWANG commences a suit pursuant to subparagraph (c), BUKWANG may deposit up to thirty percent (30%) of any royalties and milestone payments which are otherwise payable to LICENSOR during the
pendency of such suit in an interest-bearing escrow account. Upon final resolution of such suit, BUKWANG shall provide LICENSOR with an accounting of the amounts escrowed and BUKWANG’s expenses incurred in such infringement suit. BUKWANG shall
be entitled to offset any expenses which BUKWANG fails to recoup in such suit against the escrowed amounts. Any escrowed amounts (and interest thereon) in excess of BUKWANG’s unrecouped expenses shall be promptly paid to LICENSOR. 

 

 11 

	27.	A new Section 8.3 shall be added to the License Agreement as follows: 

 Sublicense Rights. BUKWANG and LICENSOR agree that, during the term of the Pharmasset Sublicense Agreement, the rights of BUKWANG under this Article 8 shall be exercised, if at all, by PHARMASSET with respect
to any infringements in any portion of the Licensed Territory in with the Pharmasset Sublicense Agreement is then in effect. With respect to such infringements, LICENSOR shall contact Pharmasset regarding decisions relating to whether it desires to
commence any infringement suit and, if so, whether such suit should be commenced jointly. 
  

	28.	A new Section 9.4 shall be added to the License Agreement as follows: 

 Rights to Disclose. Notwithstanding any provision of this Article 9 to the contrary, BUKWANG shall have the right to disclose any and all information and technology disclosed to it by LICENSOR to PHARMASSET.
LICENSOR agrees that PHARMASSET shall have the right to disclose such information and technology as provided in Article 13 of the Pharmasset Sublicense Agreement. 
  

	29.	Section 12.1 of the License Agreement shall be amended in its entirety as follows: 

 Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on the Operative Date and shall continue until the date of expiration of the last-to-expire of the Licensed
Patents, including any renewals or extensions thereof. 
  

	30.	Delete the first sentence of Section 12.4 of the License Agreement and replace it with the following: 

 LICENSOR may exercise its right of termination by giving BUKWANG, its trustees or receivers or assigns, sixty (60) days prior written notice of the
occurrence of an event giving cause for termination hereunder and of LICENSOR’s election to terminate. 
  

	31.	Section 14.4 of the License Agreement shall be amended in its entirety as follows: 

 BUKWANG shall mark Licensed Products Sold in the United States with United States patent numbers. Licensed Products manufactured or Sold in other countries shall be marked in compliance with the intellectual property
laws in force in such foreign countries. The foregoing obligations shall be subject to size and space limitations in accordance with any regulatory requirements and any later agreement between the parties. 
  

 12 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

	32.	A new Section 14.11 shall be added to the License Agreement as follows: 

 Third Party Beneficiary. PHARMASSET shall be deemed an intended beneficiary hereunder and have the right to enforce the rights under Sections 2.12, 4.4, 5.6, 7.1, 7.3, 8.1(c), 8.1(d), 8.3 and 9.4 of this
Agreement. 
  

	33.	Exhibit A of the License Agreement is deleted and replaced with Exhibit A attached hereto. LICENSOR warrants and represents that, with the exception of the two patent cases
identified by U.S. patent numbers [***] and [***], Exhibit A is a complete list of all patents and patent applications which LICENSOR owns as of the date hereof that relate to the development, manufacture, use, sale, offer for sale, import, export
and/or registration of the Licensed Products. The patent case identified by U.S. patent number [***] and U.S. patent application publication number [***] and all foreign counterpart patents and patent applications thereto are specifically excluded
from Exhibit A. 

  

	34.	Attached hereto as Exhibit B is a true and correct copy of the waiver obtained by LICENSOR from the United States government pursuant to 35 USC §204, pursuant to which LICENSOR
was authorized to grant the rights and license granted to BUKWANG under the License Agreement. 

  

	35.	This Amendment Number 5 shall become effective upon the Effective Date of the Pharmasset Sublicense Agreement (as defined therein). 

  

	36.	Except as amended by this Amendment Number 5, the License Agreement shall remain unchanged and continue in full force and effect. 

  

	37.	This Amendment Number 5 and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder, shall be construed under and governed by the
laws of the state of Georgia and the United States of America. 

  

	38.	This Amendment Number 5 may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 

 [Signature Page Follows] 
  

 13 

 IN WITNESS WHEREOF, LICENSOR and BUKWANG have caused this Amendment Number 5 to be signed by their duly
authorized representatives, under seal, as of the day and year indicated above. 
  

									
	LICENSOR:	 		 	BUKWANG:
			
	 UNIVERSITY OF GEORGIA
 RESEARCH
FOUNDATION, INC.
	 		 	BUKWANG PHARM. IND. CO., LTD
					
	 By: 
	 	 /s/ Robert R. Fincher
	 		 	 By: 
	 	 /s/ Sung Koo Lee

					
	 Name: 
	 	 Robert R. Fincher, Ph.D.
	 		 	 Name: 
	 	 Sung Koo Lee

					
	 Title: 
	 	 Chief Licensing Officer
	 		 	 Title: 
	 	 President & CEO

  

			
	YALE UNIVERSITY
		
	 By: 
	 	 /s/ Jon Soderstrom

		
	 Name: 
	 	 Jon Soderstrom

		
	 Title: 
	 	 Managing Director
 Office Cooperative Research

  

 14 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 Exhibit A 
 Licensed Patents 
 * UGA [***] IS ALSO UGA [***] 
  

													
	 CASE
	  	 COUNTRY
	  	 SERIAL
 NUMBER
	  	 REGISTRATION
 NUMBER
	  	 MATTER
 NUMBER
	  	 File
 Date
	  	 Status

							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

 15 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

													
	 CASE
	  	 COUNTRY
	  	 SERIAL
 NUMBER
	  	 REGISTRATION
 NUMBER
	  	 MATTER
 NUMBER
	  	 File
 Date
	  	 Status

		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

 16 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

													
	 CASE
	  	 COUNTRY
	  	 SERIAL
 NUMBER
	  	 REGISTRATION
 NUMBER
	  	 MATTER
 NUMBER
	  	 File
 Date
	  	 Status

		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]

  

 17 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

													
	 CASE
	  	 COUNTRY
	  	 SERIAL
 NUMBER
	  	 REGISTRATION
 NUMBER
	  	 MATTER
 NUMBER
	  	 File
 Date
	  	 Status

		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

 18 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

													
	 CASE
	  	 COUNTRY
	  	 SERIAL
 NUMBER
	  	 REGISTRATION
 NUMBER
	  	 MATTER
 NUMBER
	  	 File
 Date
	  	 Status

		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]

  

 19 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 EXHIBIT B 
 U.S. Government Waiver 
  

			
	 DEPARTMENT OF HEALTH & HUMAN SERVICES
	  	Public Health Service
National Institutes of Health
		
		  	Office of Technology Transfer
		  	National Institutes of Health
		  	6011 Executive Boulevard
		  	Rockville, MD 20858

  

			
	DATE:	  	March 28, 1996
		
	TO:	  	 Barbara M. McCarey, J.D.
 Deputy Director,
OTT

		
	FROM:	  	Technology Licensing Specialist, OTT
		
	SUBJECT:	  	Recommendation to Grant U.S. Manufacture Requirement Waiver on Extramural Inventions entitled “[***]” Invented by [***] / (University of Georgia and Yale University
[***])
		
		  	OTT Reference #: [***]

 The Office of Technology Transfer (OTT) has evaluated the U.S. Manufacturers Requirement waiver request by the
University of Georgia and Yale University and determined that granting the waiver would be consistent with the statutory criteria and will enable the licensee, Bukwang Pharm. Inc. Co., Ltd, to continue the manufacturing and the commercialization of
this federally supported technology. 
 The U.S. manufacturing requirements are set forth at 35 U.S.C. 204. Waivers of the U.S. manufacturing requirements
may be granted upon a showing that 1) reasonable but unsuccessful efforts have been made to license the Invention to licensees likely to manufacture substantially in the U.S.; or that 2) domestic manufacture is not commercially feasible under the
circumstances. 
 Technology Profile 
 The
federally supported ([***]) technologies resulted in the filing of a U.S. Patent Application in February of 1994, covering a method and compound for the treatment of Hepatitis B Virus (HBV). 
 The inhibitory effects of the L-analogs of nucleotides represent a new strategy in the development of potential drugs against viruses like HBV, EBV, and HIV. Lack of
toxicity of these compounds in the human systems in comparison to their D-counterparts and efficient inhibition of viral processes makes it a novel strategy to combat viral diseases. L-FMAU falls into this category and could prove to be a very
active anti viral agent against HBV and EBV. 
  

 20 

 Licensing Activities 
 The granting institutions that developed the present technology have made a substantial effort to license this invention. The following U.S. companies that manufacture and market technologies in this field have had an opportunity to review
this invention for the purpose of licensing: Abbott Laboratories, Avid Therapeutics, Inc., Bristol-Myers Squibb, Gilead Sciences, Lipitek International, Microprobe Corporation, and OncoRx. Unfortunately, no U.S. companies have sufficient interest to
license this invention. There are several competing technologies to this invention. The grantee institutions are not certain but, they believe one of the reasons they have not been successful in securing a U.S. manufacturer is due to these competing
technologies. Two of the other competing technologies are nucleoside analogs and the U.S. market for treatment of HBV is apparently too small for U.S. companies to pursue another alternative therapy. Further, it follows that if the U.S. market is
not large enough to attract a domestic manufacturer, it would not be commercially feasible to create an FDA compliant facility to manufacture the subject compounds in the U.S. 
 Recommendation 
 OTT recommends approval of the University of Georgia’s and Yale University’s request
to waive the U.S. manufacturing requirement for Bukwang Pharm. Ind. Co., Ltd. based on provisions in 35 U.S.C. 204, for the following reasons: 
 1) The
University of Georgia and Yale University have been unsuccessful in their efforts to license the present invention to a U.S. company. 
 2) There is an
exclusive license agreement between the University of Georgia and Yale University and Bukwang Pharm. Ind. Co., Ltd of South Korea that will allow this invention to be developed into a therupeutic for the treatment of HBV. 
 3) The commercial market for the present invention in the U.S. is not large enough to support the investment required to construct an FDA compliant facility in the U.S.

 Please sign below to indicate whether you concur with the recommendations to grant the waiver under these conditions, or whether you elect to deny the
waiver. 
  

					
			
	 	 		 	 /s/ J.B. Palmer-Vihtelic

		 		 	 J.B. Palmer-Vihtelic

			
	x	 		 	Approve waiver
			
	 ̈	 		 	Disapprove waiver
			
	 /s/ Barbara M. McCarey
	 		 	 March 29, 1996

	 Barbara M. McCarey, J.D.
	 		 	 Date

  

 21 

 EXHIBIT J 
 ADDITIONAL SUPPLY TERMS 
 The following sets forth an outline of the principal terms of a supply
agreement (the “Supply Agreement”) to be negotiated pursuant to Article 21 of the License Agreement. In each case, the terms hereof and of the Supply Agreement will be subject to the parties’ rights and obligations under the License
Agreement. 
 1. Delivery. Compound supplied by Bukwang to Pharmasset shall be delivered to a facility designated by Pharmasset.

 2. Shortage of Materials. 
 (a) In the event that Bukwang determines that the materials and/or resources required to manufacture and deliver Compound to Pharmasset in a timely manner are, or are reasonably anticipated to become, in short supply
such that Bukwang may be unable to provide Pharmasset with the quantities of Compound forecast by Pharmasset under the Supply Agreement, Bukwang shall notify Pharmasset of such shortage as promptly as practicable. If Bukwang so notifies Pharmasset,
Bukwang and Pharmasset shall promptly meet to discuss how to address the potential shortage. 
 (b) In the event that Bukwang,
at any time, has any information indicating that it may not be able to supply Pharmasset with all forecasted or ordered quantities of Compound (whether or not Bukwang may be at fault), Bukwang shall promptly provide Pharmasset a written notice to
that effect. 
 3. Quality Assurance. The parties shall enter into a Quality Agreement (the “Quality Agreement”)
which shall set forth certain obligations of each party regarding the manufacture and supply of Compound consistent with the current specifications which apply to current manufacture of Compound in Germany under United States standards attached
hereto as Schedule 1. As more specifically set forth in the Quality Agreement, Bukwang shall be responsible for all aspects of its supply chain regarding the Compound, including without limitation quality control, quality assurance, release testing
and stability testing until delivery thereof to Pharmasset. 
 4. Location of Manufacturing. All Compound supplied by Bukwang to
Pharmasset shall be manufactured only in a facility that has been designated as an approved manufacturing facility by the FDA in full cGMP compliance. Should Bukwang desire to change any of the manufacturing sites for Compound, or any component
thereof, to a site other than those designated in the applicable United States Registration, Bukwang shall notify Pharmasset in writing and the Parties shall thereafter meet to discuss the potential consequences of such a change. Bukwang shall not
change manufacturing sites for Compound, or any component thereof, to be supplied to Pharmasset except in accordance with the authorization of the applicable Registration and the change control procedures and applicable consent requirements set
forth in the Supply Agreement. 
  

 1 

 Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted
portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission. 
  

 5. Back-Up Manufacturing Rights. If Bukwang fails to supply at least [***] percent ([***]%) of
Pharmasset’s requirements for Compound on a rolling [***] ([***]) month cumulative basis (a “Failure to Supply”), then Pharmasset shall so notify Bukwang and Bukwang shall have thirty (30) days to cure such Failure to
Supply. If such Failure to Supply is not timely cured, then Pharmasset may, by providing written notice within one hundred ninety (90) days of the occurrence of such Failure to Supply, elect to assume, or have its designee assume, manufacturing
of Compound. If Pharmasset elects to assume, or have its designee assume, the manufacturing of Compound, the following provisions shall be applicable: 
 (a) Transfer of Manufacturing Technology. Bukwang, within thirty (30) days of receipt of Pharmasset’s notice, or during such longer period as may be reasonably necessary, shall, without undue
interference with Bukwang’s continuing operations, be responsible for providing Pharmasset or its designee, to the extent consistent with third-party rights, with the documentation, know-how and technical assistance necessary for the successful
implementation of the manufacturing process at a location to be designated by Pharmasset. To the extent practicable, Bukwang shall continue to supply Pharmasset with Compound under the terms of the Supply Agreement until Pharmasset or its designee
is capable of doing so. 
 (b) Documentation to be Provided by Bukwang. In particular, in connection with the provision
of the manufacturing technology for Compound, Bukwang shall provide the following to Pharmasset or its designee to the extent consistent with third party rights: 
 (i) Copies of flow charts of the manufacturing procedures and work instructions related to manufacturing the Compound; 
 (ii) A list of all equipment, including the source of the equipment, utilized in the production of the Compound; 
 (iii) Copies of all current specifications, including packaging, for the Compound; 
 (iv) Copies of all standard operating procedures for the manufacturing procedures to be transferred; 
 (v) All necessary environmental conditions necessary to manufacture the Compound and copies of any existing external environmental impact
studies based on the materials or methods employed in the manufacturing method to be transferred; and 
 (vi) Such other
documentation as the parties may agree. 
 (c) Audit of Bukwang Procedures. The Supply Agreement will contain
reasonable and customary provisions allowing Pharmasset or its designee to inspect and audit those portions of the sites at which the Compound is manufactured in connection with the establishment of manufacturing capability for Compound. 

 

 2 

 (d) Access to Bukwang Personnel. Bukwang shall, without undue interference with
Bukwang’s continuing operations, make available to Pharmasset or its designee, for a reasonable period of time, all manufacturing and operations personnel necessary to support the establishment of the manufacturing technology to Pharmasset or
its designee, including the personnel necessary for the validation and qualification of the transferred manufacturing protocol. These personnel shall be reasonably available to Pharmasset or its designee and shall reasonably cooperate with
Pharmasset or its designee in the implementation of the manufacturing technology until all Installation Qualification, Operation Qualification and Process Qualification procedures have been completed successfully. 
 (e) upon Pharmasset’s request, Bukwang shall, to the extent practicable, supply Pharmasset with clinical and commercial quantities of
such Compound for the shorter of (i) the period until Pharmasset or its designee has established and validated a manufacturing process for such Compound and is approved to manufacture clinical trial and commercial supplies of such Compound or
(ii) twelve (12) months from the effective date of such Pharmasset election; provided, however, that Pharmasset will reimburse Bukwang for Bukwang’s Acquisition Cost or Manufacturing Cost for such Compound. 
 6. Forecasts. No later than eighteen (18) months prior to the anticipated launch date, Pharmasset will give to Bukwang a twelve
(12) month rolling forecast of Pharmasset’s estimated monthly requirements of Compound. The first three (3) months of the forecast shall be binding and the remainder shall be a good faith estimate of Pharmasset’s requirements.
Pharmasset will provide Bukwang with rolling three-month binding purchase orders for Compound in accordance with the binding portion of the rolling forecast. 
 7. Representations and Warranties. Bukwang shall make, and shall cause its Affiliates to make, representations and warranties regarding the Compound supplied under the Supply Agreement, including, without
limitation, the following representations and warranties: 
 (a) All Compound shall (i) be manufactured in accordance
with the then-current good manufacturing practices of all applicable regulatory authorities in countries reasonably designated on not less than ninety (90) days notice by Pharmasset from time to time, and all other applicable laws, at the time
of delivery of Compound, (ii) comply with the specifications at the time of delivery. 
 (b) Bukwang will guarantee that
any Compound delivered under the Supply Agreement (i) shall not be adulterated or misbranded within the meaning of the FDA act and applicable foreign equivalents at the time of delivery to Pharmasset, and (ii) is not an article that may
not, under the FDA act (or applicable foreign equivalents), be introduced into interstate commerce. 
 8. Covenants. Bukwang shall
make, and shall cause its Affiliates to make, covenants relating to Compound supplied under the Supply Agreement, including, without limitation, the following covenants: 
 (a) Bukwang shall, and require its Affiliates and third party contract manufacturers, if any, to maintain all regulatory and governmental
permits, licenses and approvals that may be necessary to manufacture and ship Compound; 
  

 3 

 (b) Bukwang shall advise Pharmasset of any information that arises out of Bukwang’s
or its Affiliates’ or third party contract manufacturers’ activities of which it is aware, that have material adverse regulatory compliance and/or reporting consequences concerning Compound; 
 (c) Bukwang shall promptly advise Pharmasset of any requests by any regulatory authority for inspections at the premises of Bukwang or its
Affiliates or third party contract manufacturers, with respect to Compound; 
 (d) In the event Bukwang or its Affiliates or
third party contract manufacturers are inspected by any regulatory authority relating to Compound, Bukwang will use commercially reasonable efforts to ensure, subject to rights of third parties, that Pharmasset shall have the right to be present
during such inspection. Bukwang shall promptly notify Pharmasset of any alleged violations or deficiencies relating to a facility at which Compound is manufactured, packaged or stored, and shall promptly disclose to Pharmasset all relevant portions
of any notice of observations or potential violations as well as a copy of its or its Affiliates’ or third party contract manufacturers’ response thereto; 
 (e) For the purpose of permitting a quality and compliance audit, Bukwang shall grant to authorized representatives of Pharmasset (or a
third party hired on behalf of Pharmasset who is reasonably acceptable to Bukwang), upon reasonable notice, access to areas of each of its plants, and permit Pharmasset access to areas of Bukwang’s and its Affiliates’ and, to the extent
practicable and to the extent consistent with third party rights, third party contract manufacturers’ plants, at such times as Compound is being manufactured, packaged or tested; provided, that Pharmasset’s audit of any third party
facilities will be subject to reasonable and customary confidentiality and non-use obligations; 
 (f) Pharmasset shall have
the right, consistent with the rights of third parties, to examine those technical records made by Bukwang or its Affiliates or third party contract manufacturers that relate to the manufacture of Compound; provided, that such records will be
subject to reasonable and customary confidentiality and non-use obligations; and 
 (g) Bukwang shall ensure that its third
party contract manufacturers agree to provide indemnification for any third party product liability claims arising out of the failure of such third party contract manufacturer to manufacture Compound in accordance with their respective
specifications. 
 9. Additional Provisions. In addition to more detailed terms regarding the matters specified above in this
Exhibit J, the Supply Agreement shall contain such other customary supply agreement provisions as are agreed upon by the parties. 
  

 4 

 EXHIBIT A 
 PRIMARY LICENSE AGREEMENT BETWEEN BUKWANG, YALE 
 UNIVERSITY AND UNIVERSITY OF GEORGIA RESEARCH FOUNDATION,
INC. 
 DATED DECEMBER 28, 1995 AND AS AMENDED 
  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]